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Abstract 
 
In recent years, the exploitation of flow technologies as an enabling tool to access unique 
chemical reactivity has flourished. This dissertation describes the utilisation of these flow 
methods to access new sets of highly versatile, unstable diazo compounds and their 
application in coupling reactions. 
 
In the first chapter, an introduction into the structure and reactivity of diazo compounds is 
provided, as well as a discussion of currently available methods for their generation.  
 
The second chapter describes the coupling of flow-generated, semi-stabilised diazo 
compounds with terminal alkynes for the synthesis of racemic di- and trisubstituted allenes, 
using copper(I) catalysis.  
 
The third chapter follows with an account of creating chiral disubstituted allenes by 
asymmetric coupling of flow-generated, semi-stabilised aryl aldehyde-derived diazo 
compounds with terminal alkynes, using a copper(I) catalyst and a newly developed 
pyridine(bisimidazoline) ligand.  
 
The fourth chapter describes the generation of new, highly reactive non-stabilised diazo 
compounds and their reaction with arylboronic acids to allow metal-free ‘protodeboronative’ 
and ‘oxidative’ C(sp2)-C(sp3) cross-couplings.  
 
Finally, the fifth chapter describes the experimental procedures relevant for the results 
described in Chapters 2-4.  
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Structure representation 
 
This thesis uses the graphical representation of chemical structures based on the convention 
proposed by Maehr.* Solid and broken lines represent relative configuration and indicate 
compounds that are racemic, whereas solid and broken wedges are used to assign absolute 
configuration. Normal bond lines are used to describe stereocentres where the configuration 
is unspecified. 
 
. 
 
 
                                                 
* H. Maehr, J. Chem. Ed. 1985, 62, 114-120.  
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1.1. Properties and reactivity of diazo compounds 
 
The simplest member of the diazo compound family, diazomethane, was first synthesised by 
von Pechmann in 1894.
1
 Notorious for its acute toxicity and shock sensitivity, its properties 
are particularly illustrative of the dangers inherent to handling diazo compounds.
2
 Indeed, the 
high reactivity and instability exhibited by many diazo compounds has meant that general 
preparative methods for these compounds remain limited in scope.
3
 Despite these limitations, 
these species offer a myriad of unique reactivities, which are most conveniently split into 
three different types of processes: (a) nucleophilic addition; (b) 1,3-dipolar cycloaddition 
reactions; and (c) thermal or photolytic fragmentation to form singlet or triplet carbenes 
(Scheme 1). 
 
 
Scheme 1: Categories of typical reactivity pathways for diazo compounds. 
 
Diazo compounds can be represented by two resonance structures, with a formal positive 
charge on the central nitrogen atom, and either a formal negative charge on the terminal 
carbon atom or on the terminal nitrogen atom (Scheme 2).  
 
 
Scheme 2: Resonance structures of diazo compounds. 
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When considering the frontier molecular orbitals of diazomethane, the highest coefficient of 
the HOMO resides on the terminal carbon atom,
4
 explaining the observed tendency of 
diazoalkanes to react via carbon with electrophiles, such as Brønsted/Lewis acids and metal 
salts. The transient alkyl diazonium species generated can then undergo a variety of 
transformations with concomitant extrusion of nitrogen gas, such as migration reactions, 
eliminations, nucleophilic additions, and in the case of reaction with metal salts, metal 
carbenoid formation (Scheme 3).
2 
 
 
Scheme 3: Reactivity pathways of the transient alkyl diazonium cation after nucleophilic addition of diazo 
compounds. 
 
Whilst diazo compounds often act as nucleophiles via carbon, the corresponding metal 
carbenoid is electrophilic and can participate in complementary reactive pathways.
5,6
 Further 
to this, metal carbenoids act as more controllable alternatives to highly reactive free carbenes. 
In the presence of the correct metal and ligand, it is possible to direct the reaction selectively 
towards, for example, cyclopropanation and C-H or heteroatom-H insertion reactions 
(Scheme 4).
7-9
 Although free carbenes (often generated by the thermal or photolytic 
fragmentation of diazo compounds) are able to offer similar reactive pathways, the process is 
inherently less selective and often leads to a mixture of products.
10 
 
 
Scheme 4: Reactivity pathways of metal carbenoids formed from diazo compounds. 
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The ability of diazo compounds to act as nucleophiles is dependent on the electronic nature of 
two flanking groups either side of the diazo unit.
11,12
 It is convenient to classify diazo 
compounds into three main classes: stabilised diazo compounds, semi-stabilised diazo 
compounds and non-stabilised diazo compounds (Figure 1).  
 
 
Figure 1: Classification of diazo compounds and their relative reactivities. 
 
The most stable diazo compounds have an electron-withdrawing group on one or both sides 
of the diazo unit, either acting by π-conjugation (Scheme 5) and/or σ-withdrawal of electron 
density. Such stabilisation by carbonyl groups,
13,14
 nitriles (e.g. 1),
15
 phosphonates,
16
 CF3 (e.g. 
2)
17,18
 and silanes (e.g. 3)
19
 reduce the nucleophilicity of the diazo compound and are 
therefore less acid-labile. Indeed, many of these ‘stabilised diazo compounds’ are in fact 
stable to mild organic acids, such as acetic acid, and are also amenable to purification by 
silica gel column chromatography. Hence, the generation and use of these members of the 
diazo compound family is most widespread, especially for α-diazocarbonyl compounds. 
 
 
Scheme 5: Mesomeric stabilisation in α-diazocarbonyl compounds. 
 
Adjacent aromatic rings (e.g. 4),
20
 vinylic groups (e.g. 5)
21
 and acetylenic groups (e.g. 6)
22
 
can also provide partial stabilisation of negative charge (‘semi-stabilised diazo compounds’), 
though the effect is smaller compared to electron-withdrawing groups in the stabilised diazo 
compound family. Members of this family are more potent nucleophiles and are therefore 
more acid-labile, precluding their purification by silica gel column chromatography. The use 
of ‘semi-stabilised diazo compounds’ is more limited due to the difficulties in their 
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preparation and so most procedures generate the required diazo compound in situ from more 
stable precursors (Section 1.2). Vinylic diazo compounds present an additional complication 
as they are prone to cyclisation to pyrazoles (Scheme 6).
21 
 
 
Scheme 6: Cyclisation of vinylic diazo compounds to pyrazoles. 
 
The final class of diazo compounds, ‘non-stabilised diazo compounds’, have either hydrogen 
atoms or alkyl groups on both sides of the diazo moiety (e.g. 7-9).
12
 When alkyl groups are 
present, the tendency to donate electron density through hyperconjugation further increases 
the negative charge on the carbon atom attached to the diazo group, increasing 
nucleophilicity, acid-lability and instability, thus making this family of compounds highly 
challenging to prepare and utilise. A further subdivision of this family involves strained non-
stabilised diazo compounds (Chapter 4), containing a diazo group in a ring (e.g. 10-13). 
These are among some of the most elusive reactive intermediates in organic synthesis, 
particularly for small ring sizes; the highly reactive and strained diazocyclobutane (12) has 
been prepared previously and decomposes at 0 °C,
23
 whereas N-Boc-3-diazoazetidine (13) for 
example has never been observed – their intermediacy in some reactions are, however, 
implicated in various in situ protocols for aryl-alkyl cross-couplings.
24
  
 
1.2. Synthesis of diazo compounds 
 
Due to the wide variation in the stability of diazo compounds, numerous complementary 
methods have been developed to access stabilised, semi-stabilised and non-stabilised diazo 
compounds.
3,12
 Two methods (diazotisation and fragmentation of nitrosoamide derivatives) 
can be classified as functional group manipulations from alkyl amine starting materials, 
whereas four more methods (base-mediated fragmentation of sulfonylhydrazones, oxidation 
of hydrazones, Forster reaction and photolysis of 1,3,4-oxadiazolines) can be classified as 
manipulations starting from aldehydes and ketones. The remaining method, the Regitz diazo 
transfer reaction, proceeds through deprotonation of carbonyl compounds followed by 
interception of the resulting enolate with an azide. 
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1.2.1. Diazotisation 
 
A limited set of diazo compounds are accessible through the direct diazotisation of their 
corresponding amines.
3
 When conducted under aqueous conditions, the amine is typically 
treated with sodium nitrite in the presence of acid (Scheme 7). The in situ generated nitrous 
acid allows nitrosylation of the amine, followed by elimination of water to form aliphatic 
diazonium ions. Diazotisation of water-sensitive derivatives can also be conducted in non-
aqueous conditions by use of alkyl nitrite reagents and suitable organic Brønsted or Lewis 
acids (usually acetic acid or BF3•Et2O).
3
 In the case where electron-withdrawing groups are 
attached (i.e. leading to the generation of stabilised diazo compounds), deprotonation at the 
α-carbon is facile and leads to formation of the desired diazo compound. However, the 
intermediacy of the aliphatic diazonium species is a major limitation to this method and is 
therefore not generally applicable to the generation of semi-stabilised or non-stabilised diazo 
compounds. Without the presence of stabilising electron-withdrawing groups, rearrangements 
and solvolysis resulting in thermodynamically favourable expulsion of nitrogen gas is a 
predominant reaction pathway.  
 
 
Scheme 7: Mechanism of diazotisation of alkyl amines leading to formation of diazo compounds. 
 
1.2.2. Base-mediated fragmentation of nitrosoamide derivatives 
 
To circumvent the aliphatic diazonium intermediate problem posed by direct diazotisation of 
amines, it is possible to transform amines to nitrosoamide derivatives, through 
acylation/sulfonylation then subsequent nitrosylation. Various nitrosoamide derivatives 
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undergo cleavage in the presence of hydroxide ions, leading to the formation of diazo 
compounds. These derivatives are often based on carboxylic acid or sulfonic acid derivatives, 
including amides, carbamates, ureas, guanidines and sulfonamides (Figure 2).
3,12 
 
 
Figure 2: Commonly utilised nitrosoamide derivatives for the generation of diazo compounds. 
 
This method remains the preferred route to generating diazomethane (7), starting from the 
sulfonamide-based Diazald
®
 (14) (Scheme 8).
25,26
 The method can also be used for the 
generation of some of the other members of the non-stabilised diazo compound family, 
though yields after distillation become poorer with longer alkyl chain lengths due to their 
progressively higher boiling points.
21
   
 
 
Scheme 8: Base-mediated fragmentation of Diazald
®
 (14) to form diazomethane (7).
25,26 
 
1.2.3. Base-mediated fragmentation of sulfonylhydrazones 
 
Condensations of aldehydes or ketones with sulfonylhydrazides (usually p-toluenesulfonyl 
hydrazide, generating tosylhydrazones) generate the corresponding sulfonylhydrazones, 
which are potential precursors for the generation of diazo compounds via the Bamford-
Stevens reaction. On heating (usually above 70 °C) in the presence of base, these 
sulfonylhydrazones can be deprotonated at nitrogen then eliminate sulfinate, thus generating 
the desired diazo compound (Scheme 9).
3,12
  
 
 
Scheme 9: Base-mediated fragmentation of sulfonylhydrazones to form diazo compounds. 
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As diazo compounds are heat sensitive, particularly in the case of semi-stabilised and non-
stabilised diazo compounds, procedures utilising this route typically proceed using in situ 
generation and interception with suitable substrates. Alternatively, electronically activated o-
nosylhydrazones (Scheme 10),
27
 have been demonstrated to be useful for the generation of 
aryldiazoalkanes at room temperature, which were then trapped with alkynes in a silver-
catalysed cyclopropenation reaction.  
 
 
Scheme 10: Generation and use of semi-stabilised diazoalkanes from o-nosylhydrazones as reported by Bi et 
al.
27 
 
However, the generation of non-stabilised diazoalkane solutions remains elusive via this 
route and these are more commonly accessed through oxidation of hydrazones (Section 1.2.4).  
 
1.2.4. Oxidation of hydrazones 
 
A wide selection of metal-based oxidants are able to effect the dehydrogenation of 
hydrazones to diazo compounds, including HgO, Pb(OAc)4, activated MnO2, AgO and CuO. 
Of these, HgO and Pb(OAc)4 and are the most widely used oxidants, able to provide access to 
highly sensitive non-stabilised diazo compounds, although undesirably, these oxidants are 
highly toxic.
3,12
  
 
In the case of Pb(OAc)4, initial investigations revealed that the production of acetic acid as a 
byproduct of the oxidation limited the reaction scope to stabilised diazo compounds.
28-30
 The 
Pb(OAc)4 method was developed further by Holton and Shechter.
31
 Oxidations using this 
improved procedure were conducted at -78 °C in DMF using 1,1,3,3-tetramethylguanidine 
(15) as a basic additive, to prevent decomposition of semi-stabilised and non-stabilised diazo 
compounds by the acetic acid and to accelerate oxidation by forming the conjugate bases of 
the hydrazones, providing a wide variety of alkyl diazo compounds in good yields (e.g. 10, 
11, 16-18) (Scheme 11). Kingsbury et al. have subsequently disclosed that the 
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aforementioned Pb(OAc)4/tetramethylguanidine oxidative system can be modified to be 
metal-free by replacing Pb(OAc)4 with PhI(O2CCF3)2, with no deleterious effect on the yield 
of the diazo compound.
32 
 
 
Scheme 11: Oxidation of hydrazones with Pb(OAc)4 to generate semi-stabilised and non-stabilised diazo 
compounds as reported by Holton and Shechter.
31 
 
Oxidation of hydrazones with activated MnO2 generally remains limited to the formation of 
semi-stabilised diazo compounds, i.e. for the oxidation of arylhydrazones and 
vinylhydrazones. Despite the lower toxicity profile compared to mercury- and lead-based 
oxidants, a major limitation associated with MnO2 is the use of large excesses of the oxidant 
to provide synthetically useful conversions of the hydrazone to diazo compound.
3,12
 The 
process is further hampered by excess oxidant causing decomposition of diazo compounds to 
their corresponding benzyl alcohols, aldehydes/ketones and azines. 
 
 
Metal-free methods for the oxidation of hydrazones are also available. In 2007, Javed and 
Brewer described a highly useful modified Swern protocol for the generation of semi-
stabilised aryldiazomethanes (e.g. 4, 17) in excellent yields (Scheme 12).
33
 The generation of 
non-stabilised aliphatic diazo compounds is more challenging, with tert-butyldiazomethane 
(19) being produced in 51% yield and diazocyclohexane (10) being produced in capricious 
yields of 5% to 42%.  
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Scheme 12: Oxidation of hydrazones via a modified Swern protocol as reported by Javed and Brewer.
33 
 
A method described by Furrow and Myers in 2004 uses a hypervalent iodine reagent 20 to 
oxidise TBS-protected hydrazones to their corresponding diazo compounds, providing access 
to a variety of in situ generated semi-stabilised and non-stabilised diazoalkanes, which were 
subsequently intercepted with carboxylic acids for the formation of esters (Scheme 13).
34
 
However, the water-sensitivity and limited availability of the (difluoro)iodobenzene (20) 
oxidant is a significant limitation. 
 
 
Scheme 13: In situ oxidation of TBS-protected hydrazones and trapping with carboxylic acids using PhIF2 (20) 
as reported by Furrow and Myers.
34 
 
Overall, oxidative methods for the generation of diazo compounds offer some of the most 
versatile routes for the generation of all three families of diazo compounds. It should be noted, 
however, that the stability and synthesis of unprotected hydrazones via direct condensation of 
aldehydes or ketones with hydrazine is not always ideal, due to the possibility of the 
unprotected NH2 group of the hydrazone reacting further with aldehydes or ketones to 
generate azines. Furthermore, unprotected hydrazones can undergo disproportionation to 
azines and hydrazine (21) (Scheme 14), which limits their utility as stable diazo compound 
precursors.
35
  
 
1. Introduction to diazo compounds 
11 
 
 
Scheme 14: Disproportionation of unprotected hydrazones to azines and hydrazine (21). 
 
1.2.5. Forster reaction 
 
Originally discovered in 1915 by Forster, the reaction of oximes (e.g. 22) with chloramine 
allows the synthesis of a small selection of stabilised α-diazoketones (e.g. 23) (Scheme 15).36  
 
 
Scheme 15: Formation of stabilised diazo compounds via reaction with chloramine as reported by Forster.
36 
 
The Forster reaction is rarely used as a method of generating sensitive diazo compounds, 
however, due to the strong oxidising ability of chloramine, leading to incompatibility with a 
variety of functional groups. Using this method though, it is possible to generate solutions of 
diazomethane (7) from the sodium salt of formaldehyde oxime (24) (i.e. under basic 
conditions to limit acid-mediated decomposition) (Scheme 16);
37
 it has not been hitherto 
possible to generalise this method for the synthesis of other non-stabilised aliphatic diazo 
compounds. 
 
 
Scheme 16: Generation of diazomethane (7) from 24 via the Forster reaction as reported by Rundel.
37 
 
A related modification of the Forster reaction involves the use of hydroxylamine-O-sulfonic 
acid (25) as a substitute for chloramine. In the presence of aqueous base, some semi-
stabilised diazo compounds (26 and 27) were generated in moderate yields (Scheme 17).
38
 
This modified method is also limited by the lack of generality, as attempts to generate the 
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corresponding diazo compounds from acetophenone oxime and benzaldehyde oxime resulted 
only in low yields.  
 
 
Scheme 17: Modified Forster reaction using hydroxylamine-O-sulfonic acid (25).
38 
 
1.2.6. Photolysis of oxadiazolines 
 
The photolysis of 1,3,4-oxadiazolines represents an underutilised technique to generate diazo 
compounds, despite its general applicability to the synthesis of non-stabilised diazoalkanes. 
In 1989, Warkentin et al. described the fragmentation of 2-alkoxy-Δ3-1,3,4-oxadiazolines 
under irradiation with 300 nm UV light, leading to the clean formation of diazo compounds – 
homolytic cleavage of the C-N bond leads to the formation of a diradical, which can 
subsequently fragment into a diazoalkane and an ester (Scheme 18).
39
 
 
 
Scheme 18: Photolysis of oxadiazolines to form diazo compounds as reported by Warkentin et al.
39 
 
Although diazo compounds themselves are unstable to photolysis, their absorption maxima 
(ca. 220 nm and 440 nm) are significantly different to the photolytic wavelength required for 
the fragmentation of 1,3,4-oxadiazolines;
39
 hence, utilisation of light sources that provide 
irradiation at solely ca. 300 nm represents a promising method to access non-stabilised diazo 
compounds using these precursors.  
 
The 1,3,4-oxadiazoline diazo precursors are most conveniently accessed via the condensation 
of ketones with appropriate acylhydrazines to form the corresponding N-acylhydrazones. 
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Subsequent oxidation using either Pb(OAc)4
40,41
 or PhI(OAc)2
42
 in the appropriate alcoholic 
solvent allows the formation of the required precursors (Scheme 19). 
 
 
Scheme 19: Generation of oxadiazolines via condensation then oxidative cyclisation.
40-42 
 
However, it should be noted that oxidation of an aldehyde-derived hydrazone does not form 
the required oxadiazoline precursor, since aromatisation to the more stable 1,3,4-oxadiazole 
occurs, representing a major limitation of this method (Scheme 20).
42 
 
 
Scheme 20: Formation of oxadiazoles from aldehyde-derived hydrazones after oxidation. 
 
1.2.7. Regitz diazo transfer 
 
The relatively acidic methylene unit in 1,3-dicarbonyl compounds, such as 1,3-diketones and 
β-ketoesters, can be deprotonated with a mild base and the resulting enolate intercepted with 
a variety of alkyl- and arylsulfonyl azides, including mesyl azide (28), triflyl azide (29), p-
toluenesulfonyl azide (30) and p-acetamidobenzenesulfonyl azide (31) (Figure 3).
3,12
  
 
 
Figure 3: Commonly utilised azide reagents for the Regitz diazo transfer reaction. 
 
This reaction, known as the Regitz diazo transfer reaction (Scheme 21), is a popular method 
to access stabilised α-diazocarbonyl compounds. 
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Scheme 21: Mechanism of Regitz diazo transfer. 
 
In the case of less acidic methylene units in simple ketones and esters, the substrate can be 
activated towards deprotonation by means of introducing a formyl or trifluoroacetyl group 
(via Claisen reaction), then subjected to the diazo transfer reaction conditions. Deformylation 
or loss of the trifluoroacetyl group occurs in the process of diazo transfer, allowing the 
generation of various α-diazoketones and esters (Scheme 22).3  
 
 
Scheme 22: Deformylative Regitz diazo transfer. 
 
The diazo transfer method is not necessarily limited to carbonyl compounds. Starting from 32, 
the precursor 33 was formed via a Claisen reaction, then generation of the stabilised α-
diazophosphonate reagent 34 (Seyferth-Gilbert reagent) was conducted in moderate yield 
under analogous conditions to the aforementioned methods utilising carbonyl compounds as 
substrates (Scheme 23).
43 
 
 
Scheme 23: Synthesis of the Seyferth-Gilbert reagent (34) via Regitz diazo transfer.
43 
 
In addition, a Grignard reagent can be used in lieu of suitably acidic substrates; 
trimethylsilyldiazomethane (3) can be generated from the Grignard reagent (36) derived from 
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chloromethyltrimethylsilane (35), via reaction with the diazo transfer reagent diphenyl 
phosphorazidate (37) (Scheme 24).
44 
 
 
Scheme 24: Synthesis of trimethylsilyldiazomethane (3) by Regitz diazo transfer.
44 
 
1.3. Previous reports of flow-generated diazo compounds 
 
The inherent toxicity and explosive properties of diazo compounds present significant safety 
hazards for their use in chemical reactions, particularly for large-scale processes. Flow 
methods have therefore attracted substantial attention for the generation and use of diazo 
compounds.
45-47 
 
In these processes, the required diazo intermediate can be generated in small quantities from 
more stable precursors in situ and reacted in subsequent steps without any manual operator 
handling. In addition, scale up of these processes is safer as only a small amount of the 
hazardous diazo compound is present at any point in time. The desired product can be left to 
accrue over time, thus avoiding the generation of large quantities of reactive species in an 
analogous batch process.
47
 Another advantage arises from the large surface area to volume 
ratio of reaction channels in a flow system, which leads to very efficient heat transfer.
48
 This 
property can be exploited particularly for exothermic reactions, where thermal runaway could 
lead to uncontrolled decomposition or detonation of the diazo compound. 
 
A selection of reports that involve the generation of diazo compounds using flow methods are 
presented below and are split into three categories, involving the generation of: (a) stabilised 
diazo compounds; (b) semi-stabilised diazo compounds; and (c) non-stabilised diazo 
compounds. 
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1.3.1. Flow-generated stabilised diazo compounds 
 
Ethyl diazoacetate (39) represents a versatile two-carbon synthon in organic synthesis and 
hence, numerous reports have focused on its generation in a continuous flow fashion. Rutjes 
et al. investigated a method for the diazotisation of glycine ethyl ester hydrochloride (38•HCl) 
to form ethyl diazoacetate (39) in a microfluidic reactor.
49
 Optimised conditions for this 
protocol involved passage of a buffered aqueous solution of glycine ethyl ester (38•HCl), 
1.5 equiv. of sodium nitrite and CH2Cl2 through a microfluidic chip at 50 °C, followed by an 
in-line phase separation to provide solutions of 39 in 95% yield, with an overall production of 
approx. 20 g of ethyl diazoacetate per day (Scheme 25). Reports on the generation and use of 
39 have also been demonstrated subsequently by Kim et al.
50
 and Wirth et al.
51
 in 
nucleophilic additions to aldehydes. 
 
 
Scheme 25: Flow synthesis of ethyl diazoacetate (39) as reported by Rutjes et al.
49 
 
A different flow approach using the Bamford-Stevens reaction for the generation of stabilised 
α-diazoesters was reported by Hayes et al. – by passing solutions of sulfonylhydrazones and 
Et3N through a heated reactor at 80 °C or 99 °C, moderate to excellent yields of their 
corresponding α-diazoesters were obtained.52 These solutions could then be used for various 
heteroatom-H insertion reactions, for example metal-catalysed insertion into O-H, N-H, S-H 
and P-H bonds (Scheme 26).
52,53 
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Scheme 26: Flow synthesis of α-diazoesters by the Bamford-Stevens reaction and their insertion reactions into 
heteroatom-H bonds as reported by Hayes et al.
52,53
  
 
In 2015, Moody et al. showed that a polymer-supported version of N-iodo p-
toluenesulfonamide potassium salt (PS-TsNIK)
54
 could be utilised for the generation of 
various stabilised diazo compounds (α-diazocarbonyls and an α-diazophosphonate) from their 
corresponding hydrazones.
55
 The reactor output provided sufficiently pure solutions of diazo 
compounds that could be immediately used for further derivatisation, for example in O-H and 
N-H insertion reactions, as well as epoxidation reactions (Scheme 27). A following report by 
Davies et al. showed that this flow oxidation method was also useful for enantioselective 
rhodium-catalysed C-H insertion reactions.
56 
 
 
Scheme 27: Flow synthesis of stabilised diazo compounds via oxidation of hydrazones and their reactions with 
alcohols, amines and aldehydes as reported by Moody et al.
55 
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Wirth et al. disclosed that α-diazoester 41 could be formed under flow conditions by Regitz 
diazo transfer using ester 40 and p-ABSA (31) (Scheme 28).
57
 An initial analysis of 
differential scanning calorimetry data for 41 (onset temperature of 77 °C) indicated that if the 
exothermic enthalpy change associated with diazo transfer was not adequately controlled, 
thermal runaway would occur, thus highlighting the utility of a flow method for this process.  
 
 
Scheme 28: Flow synthesis of α-diazoester 41 by Regitz diazo transfer as reported by Wirth et al.57 
 
Other than α-diazocarbonyl compounds, the generation of (trifluoromethyl)diazomethane (2) 
and (difluoromethyl)diazomethane (44) in flow have also attracted interest. Pieber and 
Kappe
58
 reported the use of the tube-in-tube reactor developed by Ley et al.
59
 to access 
solutions of 2, via diazotisation of amine hydrochloride 42•HCl. Diffusion of the desired 
diazo compound 2 from the aqueous diazotisation solution in the inner tubing occurs through 
the gas-permeable membrane, into the outer tubing containing THF, thus providing solutions 
of 2 for further reactions. The use of this protocol was briefly illustrated by nucleophilic 
addition of 2 onto various aldehydes (Scheme 29).   
 
Scheme 29: Flow synthesis of (trifluoromethyl)diazomethane (2) by diazotisation as reported by Pieber and 
Kappe.
58 
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Koenigs et al.
60,61
 and Jamison et al.
62
 have extensively investigated the formation of 2 and 
44 in flow. In the first case, flow diazotisation of 42 or 43 with tert-butyl nitrite in the 
presence of acetic acid generates a solution of diazo compound 2 or 44, which was then used 
in various batch mode [3 + 2] cycloadditions with alkenes and alkynes to form pyrazolines 
and pyrazoles respectively (Scheme 30). In the second, solutions of 2 or 44 were prepared 
analogously under flow conditions, but the [3 + 2] cycloadditions were also conducted in 
flow (Scheme 31). 
 
 
Scheme 30: Flow synthesis of 2 and 44 and subsequent [3 + 2] cycloaddition in batch as reported by Koenigs et 
al.
60,61 
 
 
Scheme 31: Flow synthesis of 2 and 44 and subsequent [3 + 2] cycloaddition in flow as reported by Jamison et 
al.
62 
 
For stabilised silylated diazo compounds, a very recent report by Lebel et al. presented a 
route via diazotisation, for example using nitrite 46 to diazotise amine 45, leading to the 
generation of trimethylsilyldiazomethane (3) in 65% yield (Scheme 32).
63 
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Scheme 32: Flow synthesis of trimethylsilyldiazomethane (3) via diazotisation as reported by Lebel et al.
63 
 
1.3.2. Flow-generated semi-stabilised diazo compounds 
 
In contrast to stabilised diazo compounds, methods for the flow generation of semi-stabilised 
diazo compounds have only been recently developed. One possible flow method was 
presented by Charette et al. using the Bamford-Stevens reaction. Their report showed that 
passing a mixture of the mesitylsulfonylhydrazone with 2 equiv. of 1,1,3,3-
tetramethylguanidine (15) through a heated reactor at 65 °C, followed by an in-line aqueous 
workup, leads to solutions of various aryldiazoalkanes (Scheme 33).
64
 These precursors have 
lower decomposition temperatures than the more commonly used tosylhydrazones and thus 
facilitates the synthesis of semi-stabilised diazo compounds. 
 
 
Scheme 33: Formation of semi-stabilised aryldiazoalkanes from mesitylsulfonylhydrazones under flow 
conditions as reported by Charette et al.
64 
 
Another approach using the oxidation of hydrazones was presented Ley et al. using flow 
methods.
65
 When solutions of arylhydrazones with DIPEA were passed through columns of 
activated MnO2, this allowed for the controlled generation of a variety of arylhydrazones 
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derived from aldehydes and ketones, as well as vinylhydrazones, which could be 
subsequently trapped with carboxylic acids,
65
 boronic acids
65,66
 (Chapter 4.1.2) and electron-
deficient olefins (Scheme 34).
67 
 
 
Scheme 34: Formation of semi-stabilised diazoalkanes via oxidation of hydrazones under flow conditions as 
reported by Ley et al.
65-67 
 
1.3.3. Flow-generated non-stabilised diazo compounds 
 
In 1998, the Aerojet-General Corporation filed a patent for the continuous flow generation of 
diazomethane (7) from N-methyl-N-nitrosourea, thus providing a method to safely generate 
tonne-scale quantities of ethereal solutions of 7.
68
 A later report in 2002 by Phoenix 
Chemicals Ltd. investigated the continuous flow generation of diazomethane (7) from 
Diazald
®
 (14), to be used for the tonne-scale synthesis of α-chloroketone 49, a key 
intermediate for the synthesis of the antiviral drug nelfinavir (50).
69
 In this process, an initial 
attack of 7 on anhydride 47 leads to formation of the α-diazocarbonyl compound 48, which 
can be subsequently treated with HCl to form 49 (Scheme 35).  
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Scheme 35: Use of flow-generated diazomethane for the synthesis of intermediate 49.
69 
 
A number of equivalent smaller scale procedures for the continuous flow preparation of 
diazomethane have been described since these seminal reports,
70-72
 as well as examples 
utilising gas-permeable membranes.
73,74
 
 
Whilst these flow methods have proven useful for safe handling of diazomethane, no reports 
have been disclosed for the flow generation of any other non-stabilised diazo compounds. 
This therefore represents a major unexplored area in diazo compound synthesis using flow 
chemistry. 
 
1.4. Summary and project overview 
 
A multitude of approaches for the synthesis of diazo compounds have been reviewed and are 
summarised below (Scheme 36). Although some of these methods have existed for a number 
of decades, precedent reports have primarily focused on the generation and use of stabilised 
diazo compounds. In contrast, mild procedures to access and utilise diazo compounds from 
the semi-stabilised and non-stabilised families still remain highly underdeveloped.  
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Scheme 36: Summary of synthetic routes for generation of diazo compounds. 
 
One objective of this work thus focuses on the development of procedures that allow safe and 
mild generation of semi-stabilised and non-stabilised diazo compounds. It is hoped that the 
use of flow technologies could potentially facilitate this process. With methods in hand for 
forming these unstable species, it would then be possible to demonstrate their synthetic utility, 
with particular attention to their use in coupling reactions. Chapter 2 focuses on the synthesis 
of racemic allenes by coupling semi-stabilised diazo compounds with terminal alkynes, 
whilst Chapter 3 focuses on exploiting the mild generation of these diazo compounds for 
asymmetric allene synthesis. Finally, Chapter 4 describes the generation and use of non-
stabilised diazo compounds in metal-free C(sp
2
)-C(sp
3
) coupling reactions with arylboronic 
acids. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
2. Racemic allene synthesis using 
flow-generated aryl diazo compounds 
 
  
2. Racemic allene synthesis using flow-generated diazo compounds 
25 
 
2.1. Properties of allenes 
 
Allenes constitute the first member of the family of cumulenes, compounds containing 
consecutive carbon-carbon double bonds. Their two orthogonal cumulated double bonds have 
piqued the interest of chemists for over a hundred years, structures predicted initially by van’t 
Hoff in 1874,
75
 and then were first synthesised by Burton and von Pechmann in 1887 
(glutinic acid, 51).
76
 Since their initial discovery, allenes have been historically considered to 
be ‘chemical curiosities’. In the past few decades, however, there has been a resurgence of 
interest in their synthetic utility.
77-80
 In addition, the allene moiety has been found in various 
natural products (e.g. isolaurallene, 52) and incorporated into drugs (e.g. enprostil, 53) and 
molecular materials (e.g. 54) (Figure 4).
81,82
  
 
 
Figure 4: The allene moiety in natural products, drug molecules and functional materials.  
 
In some cases, the higher reactivity of allenes compared to their alkene and alkyne 
counterparts provides complementary reaction pathways that can occur with higher 
selectivity and under milder reaction conditions.
79
 In addition, the unique axially chiral nature 
of the allene skeleton allows the generation of multiple chiral centres under high 
stereocontrol, especially for cycloaddition and cyclisation reactions.
77-80
  
 
Structurally, allenes can be considered to simply consist of two orthogonal π-bonds, with the 
two terminal carbon atoms being sp
2
-hybridised and the central carbon atom sp-hybridised 
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(Figure 5). This simplified model, however, appears to be insufficient to explain the high 
levels of enantiocontrol in some [2 + 2] cycloaddition reactions; in reality, the frontier 
molecular orbitals of allenes are helical in nature.
83
 For achiral allenes, the two HOMOs are 
degenerate orbitals, whereas for chiral allenes, this degeneracy is broken, resulting in a left-
handed or right-handed helical HOMO depending on which enantiomer is being considered.  
 
 
Figure 5: Simplified model of molecular orbitals in allenes. 
 
2.2. Synthesis of allenes 
 
Methods to synthesise allenes can be broadly categorised into two groups (Scheme 37): (a) 
reactions of propargylic derivatives to the corresponding allenes, via deprotonation or SN2′ 
displacement reactions; and (b) the coupling of two simpler fragments that results in the 
concomitant formation of one of the two C=C bonds in the allene skeleton.   
 
 
Scheme 37: Types of methods to access allenes. 
 
2.2.1. Reactions of propargylic derivatives 
 
Isomerisation of propargylic derivatives is one of the most common methods to synthesise 
allenes. When one of the hydrogen atoms next to the alkyne is suitably acidic, it is possible to 
deprotonate this centre followed by a 1,3-protonation of the resulting anion, completing a 
formal prototropic rearrangement (Scheme 38).
77,84-86
 Thus in the case of adjacent alkenyl or 
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aryl groups, for example, it is possible to deprotonate the methylene unit using a strong base, 
and thereby create a new π-bond that is in conjugation with the existing π-systems. For 
adjacent electron-withdrawing groups, such as carbonyl groups, sulfoxides, sulfones and 
phosphonates, isomerisation can be initiated under milder basic conditions due to the high 
acidity of the hydrogen atoms in the α-position. A variety of heteroatoms, including oxygen, 
nitrogen, sulfur, phosphorus and halogens, can also provide suitable acidity for the methylene 
unit, although similarly to the alkenyl/aryl case, a strong base is required to initiate 
deprotonation.
77
 
 
 
Scheme 38: Deprotonation and reprotonation approach for allene synthesis. 
 
An alternative method to derivatise propargylic derivatives is via a metal-mediated SN2′ 
reaction (Scheme 39), when a suitable leaving group is attached to the α-carbon of the alkyne 
skeleton. In particular, copper-mediated SN2′ processes are relatively common and versatile 
methods to access allenes; the choice of leaving group is broad, ranging from acetates, 
sulfonates, ethers, halides, epoxides and aziridines.
77
 Although less popular, alternative 
processes are also viable, such as aluminium, indium, titanium, samarium and zirconium-
mediated reactions.
77,84 
 
 
Scheme 39: SN2′ approach for allene synthesis. 
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2.2.2. Coupling reactions of two simpler fragments 
 
In comparison, the synthesis of allenes by coupling two fragments that results in the 
formation of one of the constituent π-bonds of the allene framework is more rarely described 
in the literature. However, in terms of rapidly building molecular complexity, these methods 
can be more valuable compared to the propargylic derivative route, as any complex molecular 
architecture must come preinstalled in the starting material for the latter case. 
 
One approach reported by Barrett et al. involves the cross-metathesis of two mono-
substituted allenes in the presence of Grubbs’ catalyst (55), thus generating symmetrical 
disubstituted allenes (Scheme 40).
87
 However, the method also produces significant levels of 
polymeric byproducts and thus limits its utility.  
 
 
Scheme 40: Allene cross-metathesis to access symmetrical disubstituted allenes as reported by Barrett et al.
87 
 
A more general method proceeds via a Wittig reaction between phosphonium ylids and 
ketenes (formed in situ from the corresponding acyl chlorides in the presence of base), 
allowing access to allenyl esters, ketones and lactams (Scheme 41).
88
   
 
 
Scheme 41: Reaction of in situ generated ketenes with phosphonium ylids to generate allenes. 
 
In 2007, Bertrand et al. reported the gold(I)-catalysed coupling of enamines and terminal 
alkynes using 56, providing a variety of mono-, di- and trisubstituted allenes in moderate to 
excellent yields (Scheme 42).
89
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Scheme 42: Coupling of enamines with terminal alkynes using gold(I) catalysis as reported by Bertrand et al.
89 
 
One of the earliest methods to access allenes by coupling was reported in 1979 by Crabbé et 
al., which occurs via a CuBr-mediated coupling of a terminal alkyne, paraformaldehyde and 
diisopropylamine (Scheme 43).
90
  
 
 
Scheme 43: Coupling of terminal alkynes with formaldehyde in the presence of diisopropylamine under CuBr 
catalysis as reported by Crabbé et al.
90 
 
Significant limitations of the original protocol included low-yielding reactions (although the 
yields were later improved by Kuang and Ma by using CuI and dicyclohexylamine instead, 
Scheme 44),
91
 and the inability to utilise other aldehydes or ketones other than formaldehyde, 
hence only providing access to monosubstituted allenes.  
 
 
Scheme 44: Improved conditions for coupling of terminal alkynes with formaldehyde using CuI and 
dicyclohexylamine as reported by Kuang and Ma.
91 
 
Further work by Ma et al. found that by replacing the copper(I) salt with ZnI2, aldehydes 
become permissible substrates for this method, thus providing a route to disubstituted allenes, 
although the high metal salt loading is a major drawback (Scheme 45).
92
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Scheme 45: Coupling of aldehydes with terminal alkynes using substoichiometric ZnI2 for disubstituted allene 
synthesis as reported by Ma et al.
92 
 
In addition, ketones can also be utilised by replacing the metal salt with CdI2, thus providing 
access to trisubstituted allenes. Again, the high metal salt loading combined with its acute 
toxicity is problematic (Scheme 46).
93 
 
 
Scheme 46: Coupling of ketones with terminal alkynes using substoichiometric CdI2 for trisubstituted allene 
synthesis as reported by Ma et al.
93 
 
The final coupling method for allene synthesis involves the coupling of diazo compounds and 
terminal alkynes. In 2011, Fox et al. reported the generation of allenes via coupling of 
stabilised α-diazoesters and terminal alkynes in the presence of base, copper(II) catalyst 57 
and tetrazine-derived ligand 58 (Scheme 47).
94
 The reaction mechanism appears to proceed 
via generation of the corresponding alkyne-coupled product as observed in a previous report 
by Suárez and Fu,
95
 followed by a prototropic rearrangement (Section 2.2.1) of the initially 
formed alkynoate to the isomeric allenoate.  
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Scheme 47: Coupling of α-diazoesters with terminal alkynes using copper(II) catalysis as reported by Fox et 
al.
94 
 
Wang et al. have also reported various conditions for the copper-mediated coupling of 
tosylhydrazones with terminal alkynes for the generation of mono-, di- and trisubstituted 
allenes, thus expanding the scope of this method to more unstable diazo compounds (Scheme 
48).
96-98
 For the latter case, ligand 59 was required to provide good yields of trisubstituted 
allenes.
98 
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Scheme 48: Coupling of tosylhydrazones with terminal alkynes using copper(I) as reported by Wang et al.
96-98
  
 
2.3. Aims of the project 
 
Since a method to generate solutions of semi-stabilised aryldiazoalkanes under flow 
conditions was recently developed within our group,
65
 it was envisaged that these compounds 
would be highly useful for copper-catalysed allene synthesis by coupling with terminal 
alkynes. Unlike the harsh conditions employed by Wang et al. using the Bamford-Stevens 
reaction,
96-98
 these milder procedures for diazo generation could potentially allow the use of 
more sensitive substrates that do not tolerate high temperature and basic reaction conditions, 
leading to enhanced yields and substrate scope. Hence, the primary aim of this project is to 
optimise and assess the scope of such a process, coupling flow-generated semi-stabilised 
diazo compounds with terminal alkynes (Scheme 49). 
 
 
Scheme 49: Investigating the use of flow-generated semi-stabilised diazo compounds in allene synthesis. 
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2.4. Results and discussion 
 
2.4.1. Initial results using ethyl diazoacetate 
 
At the initial stage of investigations into allene formation using diazo compounds, it was 
desirable to find a set of alternative conditions to those obtained by Fox et al.
94
 that would 
allow the analogous synthesis of allenes under milder conditions (i.e. ideally at room 
temperature), thus eventually permitting the generalisation of the scope to semi-stabilised 
diazo compounds prone to decomposition under the originally disclosed conditions. Using 
ethyl diazoacetate (39) and alkyne 60 as coupling partners, a variety of copper catalysts and 
loadings were tested, at room temperature for 16 h using triethylamine as the base.  
 
Table 1: Optimisation for coupling of ethyl diazoacetate (39) and alkyne 60. 
 
Entry Copper loading Solvent Yield* / % 
1 10% CuOAc dioxane 0 
2 10% CuTC dioxane 0 
3 10% Cu(acac)2 dioxane 0 
4 10% CuF2 dioxane 0 
5 10% CuCl dioxane traces 
6 10% CuBr•SMe2 dioxane 31 
7 10% CuI dioxane 84 
8 5% CuI dioxane 63 
9 20% CuI dioxane 77 
10 40% CuI dioxane 77 
11 10% CuI PhMe 12 
12 10% CuI PhCF3 21 
13 10% CuI CH2Cl2 42 
14 10% CuI THF 67 
15 10% CuI MeCN 42 
16 10% CuI MeOH traces 
* Reactions performed on 0.2 mmol scale with respect to alkyne 60; yields stated are of isolated product. 
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The majority of copper catalysts tested resulted in no conversion of alkyne 60 and 
decomposition of diazo compound 39, including CuOAc, copper(I) thiophene-2-carboxylate 
(CuTC), Cu(acac)2 and CuF2 (Table 1, entries 1-4). With CuCl and CuBr•SMe2, 
progressively higher yields of the allene product 61 were obtained (Table 1, entries 5 and 6), 
however CuI was found to be the ideal catalyst for the reaction, furnishing desired allene 
product 61 in 84% yield (Table 1, entry 7). Higher catalyst loadings than 10% of CuI (Table 
1, entries 9 and 10) led to slightly lower yields of 61, potentially due to increased rates of 
ethyl diazoacetate (39) decomposition, whereas a lowered loading of 5% CuI again led to 
reduced yield due to poorer conversion of starting material 60 (Table 1, entry 8). 
 
The use of non-polar aprotic solvents (i.e. toluene) appeared to be vastly detrimental to the 
process (Table 1, entry 11), whereas in general increasing levels of polarity (from PhCF3, 
MeCN, CH2Cl2 and THF) aided the reaction (Table 1, entries 12-15), with dioxane appearing 
to be optimal. The use of a polar protic solvent (MeOH) led to only traces of the desired 
product, presumably due to incompatibility of the in situ generated copper(I) acetylide with 
large quantities of protic solvent (Table 1, entry 16).  
 
2.4.2. Using flow-generated aryl diazo compounds 
 
With an optimised mild protocol for the generation of allenes from ethyl diazoacetate (39) 
and alkyne 60, similar conditions were then attempted for the generalisation to semi-
stabilised diazo compounds. Using hydrazone 62, a solution of the hydrazone in CH2Cl2 with 
DIPEA as buffer was passed through a column of activated MnO2 under flow conditions as 
described in previous literature.
65-67
 This provided a solution of the corresponding diazo 
compound 63 which was added directly to the reaction mixture, using alkynes 60 and 64. A 
similar screen of copper catalysts to the ones utilised for the coupling of ethyl diazoacetate 
showed a similar reactivity pattern with most being ineffective (Table 2, entries 1-5), and 
only CuI providing useful yields of the desired allene products 65 and 66 in 93% and 91% 
yield respectively (Table 2, entry 6). In sharp contrast to the initial studies using ethyl 
diazoacetate, the reaction of semi-stabilised diazo compound 63 with the copper(I) acetylide 
occurred much more rapidly, reaching full conversion within 10 min after addition of the 
diazo compound was complete, serving as testament to the enhanced nucleophilicity of semi-
stabilised compounds when compared to stabilised ones.  
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Table 2: Copper salts tested for coupling of diazo compound 63 with alkynes 60 and 64. 
 
Entry Copper salt Yield of 65* / % Yield of 66* / % 
1 CuOAc 0 0 
2 CuTC 0 0 
3 Cu(acac)2 0 0 
4 CuF2 0 0 
5 CuCl traces traces 
6 CuI 93 91 
* Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product. 
 
Having confirmed conditions for the coupling of semi-stabilised diazo compounds with 
alkynes, the scope of the reaction was then assessed (Scheme 50). A variety of diazo 
compounds derived from a selection of arylhydrazones were tested, including electron-
deficient (65-68, 71) and electron-rich (69 and 70) aromatic rings, all proceeding smoothly in 
excellent yields. A diazo compound derived from a vinylhydrazone was also tolerated (72), 
however a lower yield of 48% was obtained due to lower yielding diazo generation arising 
from cyclisation of the diazo compound to the corresponding pyrazole.
21
 The scope of the 
alkyne component was screened extensively and revealed a vast compatibility with many 
functional groups as a result of mild coupling and diazo compound generation conditions, 
including alkyl and aryl alkynes (73-75), olefins (76), mono-protected amines (77), alkyl 
bromides and iodides (78-80), acetals (81), epoxides (82), nitriles (83), ferrocene (84) and 
unprotected alcohols (85-88), again all proceeding in high yields. For compounds with 
existing stereocentres (e.g. 82, 86 and 87), no diastereoselectivity was observed, likely due to 
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the remote nature of the new axially chiral centre with respect to existing chiral centres, thus 
highlighting the importance of establishing enantioselective methods to access chiral allenes 
(Chapter 3).  
 
Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product; 
diastereomeric ratios determined by analysis of the crude 
1
H NMR spectrum. 
 
Scheme 50: Disubstituted allene synthesis via coupling of aldehyde-derived semi-stabilised diazo compounds 
and terminal alkynes using CuI catalysis. 
 
2. Racemic allene synthesis using flow-generated diazo compounds 
37 
 
To illustrate the utility of the procedure, late-stage modification of the natural products/drug 
molecules norethindrone and a propargylated version of quinine were additionally 
investigated (Scheme 51). Coupling of diazo compound 63 with norethindrone provided the 
desired diastereomeric allenes 89 in 63% yield. Despite the presence of copper(I) 
intermediates during the reaction process, no Michael addition was observed at the enone 
functionality. Although the propargylated quinine derivative contains several functionalities 
that could pose problems (quinoline and tertiary amine leading to metal catalyst poisoning; 
terminal olefin undergoing cyclopropanation side-reactions), the desired diastereomeric 
allenes 90 were provided in a high yield of 82%.  
 
 
Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product; 
diastereomeric ratios determined by analysis of the crude 
1
H NMR spectrum. 
 
Scheme 51: Late-stage modification of natural products/drug molecules. 
 
An initial attempt at using arylhydrazones derived from ketones rather than aldehydes for 
trisubstituted allene synthesis resulted only in 25% yield of allene 92, when acetophenone 
hydrazone (91) was used as the diazo compound precursor (Table 3, entry 1). In this case, the 
major side-products observed were diazine 93 and the alkene (styrene, 94), resulting from 
metal-catalysed decomposition of diazo compound 17. Utilising a stoichiometric quantity of 
CuI provided only little benefit to the reaction, raising the yield of 92 to 38% (Table 3, entry 
2); whereas attempts at slow addition of the diazo compound over 2 h and 4 h provided 
slightly better results (44% and 43% yields respectively, Table 3, entries 3 and 4). Using NaI 
as an additive also was beneficial (Table 3, entry 5), potentially by regeneration of an active 
CuI catalyst when several turnovers of the copper(I) species have occurred. Inspired by 
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previous reports accessing trisubstituted allenes utilising ligands (Fox et al. used tetrazine 
ligand 57, whereas Wang et al. used BOX ligand 58),
94,96
 it was found that 20 mol% 2,6-
lutidine as an additive allowed the generation of allene 92 in 67% yield under analogous 
conditions to the disubstituted allene method (Table 3, entry 6), without the requirement for 
slow addition of diazo compound 17 or stoichiometric quantities of CuI.  
 
Table 3: Optimisation for coupling of ketone-derived diazo compound 17 with alkyne 60. 
 
Entry Deviation from standard conditions Yield* / % 
1 - 25 
2 1 equiv. CuI 38 
3 17 (from 1.5 equiv. of 91) added over 2 h 44 
4 17 (from 3 equiv. of 91) added over 4 h 43 
5 0.5 equiv. NaI 43 
6 20 mol% 2,6-lutidine 67 
* Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product. 
 
Thus, with a modified method for the generation of trisubstituted allenes the scope of this 
method was investigated with a similar set of diazo compounds and alkynes (Scheme 52).
†
 
Again, both electron-deficient (98-100, 104) and electron-rich (105) aromatic rings were 
suitable, including diaryl-substituted diazo compounds (101-103), providing moderate to 
excellent yields. In the case of allenes 104 and 105, more significant decomposition of the 
diazo compound to the corresponding alkenes was observed, leading to lower yields of the 
desired products. A similar level of functional group tolerance in the alkyne component was 
obtained, allowing coupling with mono-protected amines (92, 95, 98, 101 and 104), ethers 
(96), nitriles (97), thiophene (100), unprotected alcohols (102) and alkyl bromides (105). In 
                                                 
†
 This work was conducted in collaboration with Dr Duc N. Tran. 
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the case of allene 100, the presence of thiophene could slightly inhibit copper(I) catalysis, 
leading to a lower yield compared to allenes 98 and 99. Scale-up to 5 mmol of 
phenylacetylene provided 0.88 g of the allene 99, though at a slightly reduced yield of 73% 
compared to 99% for the smaller scale run. This lower yield was attributed to less efficient 
diazo generation using a larger MnO2 column, which led to greater decomposition of the 
diazo compound to its corresponding diazine and alkene.  
 
Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product. 
* Reaction conducted on 5 mmol scale with respect to terminal alkyne. 
†
 Using 2 equiv. of hydrazone. 
 
Scheme 52: Trisubstituted allene synthesis via coupling of ketone-derived semi-stabilised diazo compounds and 
terminal alkynes using CuI catalysis and 2,6-lutidine additive. 
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2.4.3. Mechanistic discussion 
 
Mechanistically, it is thought that under copper(I) catalysis and basic conditions, the 
corresponding copper(I) acetylide B is generated from the terminal alkyne starting material A, 
followed by copper carbene formation (D) with the diazo compound (C). A subsequent 
migration leads to the generation of propargyl copper species E. 1,3-Protonation of propargyl 
copper species E thereby leads to regeneration of the copper(I) catalyst, generation of the 
desired allene cross-product F and completes the catalytic cycle (Scheme 53). 
 
 
Scheme 53: Proposed mechanism for allene formation via copper-catalysed coupling of diazo compounds and 
terminal alkynes. 
 
When the coupling reaction for cyclopropylacetylene (106) and diazo compound 63 was 
conducted in the presence of 3 equiv. deuterated methanol, 37% deuterium was incorporated 
into the C3-position of allene 74 (Scheme 54), which initially appeared to be evidence for the 
allenyl copper species G. However, based on more recent results (see Section 3.3.6), it 
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appears that proton-deuterium exchange with Et3NH
+
, followed by a 1,3-deuteration of the 
propargyl copper species is a more likely pathway.  
 
 
Scheme 54: Formation of allene 74 in the presence of CD3OD. 
 
2.5. Conclusions and outlook 
 
In summary, a versatile method for the generation of both disubstituted and trisubstituted 
allenes from the coupling of terminal alkynes and semi-stabilised diazo compounds has been 
developed (Scheme 55), exhibiting broad scope on both the diazo compound component and 
the alkyne component, in addition to moderate to high yields and fast reaction times.  
 
 
Scheme 55: Summary of di- and trisubstituted allene synthesis by coupling of flow-generated semi-stabilised 
diazo compounds and terminal alkynes. 
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A variety of functional groups were tolerated under these mild reaction conditions, as well as 
being applicable to the late-stage functionalisation of two natural products/drug substances. 
Compared with previous routes towards allenes, this methodology represents a significant 
advance for allene synthesis, providing a mild, simple route to di- and trisubstituted allenes. 
This procedure should therefore enable easier access to these valuable intermediates and 
hence stimulate further research into the applications of allenes in organic synthesis.  
 
With the racemic method proceeding smoothly at room temperature and promising results 
that ligands have a significant effect on reaction outcome (as observed for 2,6-lutidine being 
useful for trisubstituted allene synthesis), these initial findings set the foundation for the 
development of a new catalytic asymmetric coupling method to access chiral disubstituted 
allenes (Chapter 3). 
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3.1. Asymmetric syntheses of allenes 
 
The first synthesis of a chiral allene 108 was conducted by Maitland and Mills in 1935 via 
dehydration of the corresponding allylic alcohol 107, in the presence of L- or D-
camphorsulfonic acid (Scheme 56).
99,100
  
 
 
Scheme 56: First synthesis of chiral allene 108 as reported by Maitland and Mills.
99,100 
 
Since this original report, various methods have now been developed to access enantiopure 
allenes.
77,85
 Like methodologies generating racemic allenes, chiral allenes can generally be 
accessed via reactions of enantiopure propargylic derivatives (using elimination or SN2′ 
displacement reactions), catalytic asymmetric reactions of racemic propargylic derivatives, or 
via asymmetric coupling reactions of two simpler fragments. In addition to these three classes, 
a fourth class can be considered, utilising racemic allene starting materials and subsequent 
asymmetric derivatisation (Scheme 57).  
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Scheme 57: Types of methods to access chiral allenes. 
 
3.1.1. Reactions of enantiopure propargylic derivatives 
 
The derivatisation of enantiopure propargylic compounds is the most popular method to 
generate chiral allenes, generally due to easily accessible chiral starting materials. In 1996, 
Myers and Zhang reported a method to access chiral disubstituted allenes via a Mitsunobu 
reaction of chiral propargyl alcohols (e.g. 109) with o-nitrobenzenesulfonylhydrazine (110) 
(Scheme 58).
101
 Spontaneous elimination from intermediate 111 results in the stereoselective 
transformation of propargyl alcohol 109 to the desired allene 112.  
 
 
Scheme 58: Stereoselective elimination of propargyl alcohols under Mitsunobu conditions as reported by Myers 
and Zhang.
101 
 
An analogous approach proceeding via elimination from propargyl alcohols utilises 
Schwartz’s reagent (113), reported by Pu and Ready in 2008.102 After deprotonation with 
EtMgCl or Et2Zn, directed hydrozirconation of the internal alkyne produces a vinylzirconium 
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species, followed by rapid elimination to form the corresponding allene stereoselectively 
(Scheme 59).  
 
 
Scheme 59: Stereoselective elimination from propargyl alcohols using Schwartz’s reagent (113) as reported by 
Pu and Ready.
102 
 
Approaches using SN2′-type reactions have held significant interest in particular and existing 
methods typically proceed under copper-, palladium- or rhodium-mediated catalysis. 
Sawamura et al. (Scheme 60) and Lalic et al. (Scheme 61) have reported complementary 
copper-catalysed processes, reacting propargylic phosphates (e.g. 115, 120, 123) with either 
aryl- (e.g. 114, 119) or alkylboron (e.g. 117, 122) derivatives to form chiral allenes (e.g. 116, 
118, 121 and 124).
103-105
  
 
 
Scheme 60: SN2′-type copper-catalysed reactions of chiral propargyl phosphonates with aryl- and alkylboron 
reagents as reported by Sawamura et al.
103,104 
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Scheme 61: SN2′-type copper-catalysed reactions of chiral propargyl phosphonates with aryl- and alkylboron 
reagents as reported by Lalic et al.
105 
 
 
In addition, in 2008, Sawamura et al. disclosed a stereoselective substitution of propargylic 
carbonates (e.g. 125) with bis(pinacolato)diboron, providing access to chiral allenylboronates 
(e.g. 126) (Scheme 62).
106
   
 
 
Scheme 62: SN2′-type copper-catalysed reaction of chiral propargyl carbonate 125 to form chiral 
allenylboronate 126 as reported by Sawamura et al.
106 
 
For palladium-mediated catalysis, Molander et al. (Scheme 63) and Yoshida et al. (Scheme 
64) have shown that propargylic phosphonates (e.g. 127) and carbonates (e.g. 128) can 
undergo SN2′-type reactions, with alkenyl trifluoroborate salts and arylboronic acids 
respectively.
107,108
 However, the scope of these two processes was limited and the degree of 
chirality transfer was highly variable. 
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Scheme 63: SN2′-type palladium-catalysed reaction of chiral propargyl phosphonate 127 with alkenyl 
trifluoroborate salts as reported by Molander et al.
107 
 
 
Scheme 64: SN2′-type palladium-catalysed reaction of chiral propargyl carbonate 128 with arylboronic acids as 
reported by Yoshida et al.
108 
 
In contrast to copper-mediated processes, methods utilising rhodium catalysis have been 
underdeveloped. In 2007, Murakami et al. described the stereoselective synthesis of α-
allenols (e.g. 131) by the SN2′-type substitution of alkynyl epoxides (e.g. 130) with 
arylboronic acids (e.g. 129) (Scheme 65).
109
  
 
 
Scheme 65: SN2′-type rhodium-catalysed reaction of chiral alkynyl epoxide 130 with phenylboronic acid (129) 
as reported by Murakami et al.
109 
 
A significant drawback of this process, however, is the difficulty in generating these starting 
materials in a chiral fashion. To circumvent this issue, Ruchti and Carreira reported a 
rhodium-catalysed synthesis of allenes using propargylic benzoates and arylboronic acids in 
the presence of phosphoramidite ligand 132, proceeding in moderate to excellent yields and 
high chirality transfer (Scheme 66).
110
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Scheme 66: SN2′-type rhodium-catalysed reactions of chiral propargylic benzoates with arylboronic acids as 
reported by Ruchti and Carreira.
110 
 
3.1.2. Reactions of racemic propargylic derivatives 
 
In the presence of appropriate chiral ligands, it is possible to utilise racemic or achiral 
propargylic starting materials instead of enantiopure ones to synthesise chiral allenes. 
Alexakis et al. established that Grignard reagents in the presence of CuBr and phosphinamine 
ligand 133 react in an SN2′ fashion with achiral propargylic dichlorides, with good yields and 
moderate to high enantioselectivities, thus providing access to a variety of chiral 
chloroallenes that could be further derivatised to form various chiral trisubstituted allenes 
(Scheme 67).
111
  
 
 
Scheme 67: Enantioselective SN2′ reactions of Grignard reagents with achiral propargylic dichlorides using 
copper catalysis and ligand 133 as reported by Alexakis et al.
111 
 
In addition, Ma et al. reported the dynamic kinetic asymmetric carbonylation of racemic 
propargylic carbonates, using allylpalladium(II) chloride dimer and diphosphine ligand 134, 
providing allenyl esters in generally good yields and enantioselectivities (Scheme 68).
112
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Scheme 68: Dynamic kinetic asymmetric carbonylation of racemic propargylic carbonates using palladium 
catalysis and ligand 134 as reported by Ma et al.
112 
 
3.1.3. Asymmetric derivatisation of racemic allenes 
 
With suitable leaving groups attached to the allene motif, it is possible to conduct 
enantioselective palladium-catalysed Tsuji-Trost alkylations and aminations to construct 
chiral allenes, as reported by Trost et al.
113
 and Imada et al.
114
 In the first case, diphosphine 
ligand 135 allowed the functionalisation of allenyl acetates using various malonates and 
amines as nucleophiles, providing generally good yields and high enantioselectivities 
(Scheme 69).  
 
 
Scheme 69: Asymmetric Tsuji-Trost reactions of racemic allenic acetates with malonates and amines using 
diphosphine 135 as reported by Trost et al.
113 
 
In the second, allenyl phosphates are utilised instead and intercepted with amines, again 
leading to generally good yields and high enantioselectivities (Scheme 70).  
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Scheme 70: Asymmetric Tsuji-Trost reactions of racemic allenic phosphates with amines as reported by Imada 
et al.
114 
 
A related approach presented by Wan and Ma uses allenyl carbamates instead; rather than 
reacting with an external nucleophile, palladium-catalysed decarboxylation of the allenyl 
carbamate generates the required nucleophile in situ (Scheme 71).
115
 Significant drawbacks to 
this methodology include the difficulty in accessing the required starting materials and long 
reaction times. 
 
 
Scheme 71: Asymmetric aminative decarboxylation of racemic allenyl carbamates as reported by Wan and 
Ma.
115 
 
In 2013, Maruoka et al. reported a different approach – by generating a cumulenoate 
nucleophile from racemic 1-alkylallene-1,3-dicarboxylates using an insoluble base and chiral 
ammonium salts 136 and 137 to act as phase-transfer catalysts, tetrasubstituted chiral allenes 
were synthesised by intercepting with imines and alkyl bromides, in high yields and 
enantioselectivities (Scheme 72).
116
 For the alkylation however, occasionally a mixture of the 
desired allene product and an alkyne byproduct is observed, the latter resulting from reacting 
as an α-alkynyl enolate instead.  
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Scheme 72: Asymmetric phase-transfer catalysis using 136 or 137 for the synthesis of tetrasubstituted allenes 
by nucleophilic attack on imines and alkyl bromides as reported by Maruoka et al.
116 
 
3.1.4. Asymmetric coupling reactions of two simpler fragments 
 
Asymmetric methods coupling two simpler fragments that result in formation of one of the 
allene C=C bonds can be split into two groups: ones utilising stoichiometric chiral mediators, 
and those that use catalytic quantities of a chiral ligand.  
 
Tang et al. showed that ketenes can be transformed into ethyl allenoates by reacting with 
ethyl diazoacetate (39), using stoichiometric PPh3 and Fe(TCP)Cl as the catalyst. By utilising 
stoichiometric chiral phosphine 138 instead, they were able to demonstrate efficient and 
highly enantioselective formation of the corresponding chiral ethyl allenoates (Scheme 73).
117
 
Although the use of stoichiometric quantities of chiral phosphine 138 is a major limitation, it 
was possible to recover chiral phosphine oxide 139, regenerate phosphine 138 by reduction, 
then subsequently reuse the material in the enantioselective process.  
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Scheme 73: Reaction of ketenes with ethyl diazoacetate (39) under iron catalysis using chiral phosphine 
mediator 138 as reported by Tang et al.
117 
 
Related to the racemic Crabbé route to generate allenes (coupling terminal alkynes with 
aldehydes), Ma et al.
118-120
 (Scheme 74) and Periasamy et al.
121
 (Scheme 75) have extensively 
investigated the use of chiral prolinol 140 to replace the dialkylamine reagent, proceeding 
under zinc(II) and/or copper(I) catalysis, or solely copper(II) catalysis.  
 
 
Scheme 74: Coupling reactions of terminal alkynes and aldehydes using prolinol 140 as reported by  
Ma et al.
118-120 
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Scheme 75: Coupling reactions of terminal alkynes and aldehydes using prolinol 140 as reported by Periasamy 
et al.
121 
 
Alternative chiral amines investigated by Periasamy et al. such as chiral amines 141 and 142 
have also shown utility (Scheme 76).
122,123
 In most of these cases, good yields and high 
enantioselectivities were observed, though most of these processes require high catalyst or 
co-catalyst loadings.  
 
 
Scheme 76: Coupling reactions of terminal alkynes and aldehydes using chiral amines 141 and 142 as reported 
by Periasamy et al.
122,123 
 
A significant step was made in 2012 by Ma et al. to transform the original Crabbé method 
into a catalytic asymmetric process.
124
 By using catalytic quantities of phosphine ligand 143 
in the first CuBr-mediated step, filtration to remove copper(I) salts and then ZnI2-mediated 
allene formation, it was possible to couple various propargyl alcohols with aldehydes, 
forming chiral disubstituted allenes (Scheme 77).  
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Scheme 77: Catalytic asymmetric coupling of propargyl alcohols with aldehydes using chiral phosphine ligand 
143 as reported by Ma et al.
124 
 
Catalytic enantioselective couplings of diazo compounds and terminal alkynes have only 
been recently developed; in 2015, Feng et al. reported the coupling of stabilised α-diazoesters 
with terminal alkynes using chiral guanidium salts of 144 and copper(I) catalysis, providing a 
selection of both di- and trisubstituted allenoates in moderate to high yields with generally 
high enantioselectivities (Scheme 78).
125
  
 
 
Scheme 78: Catalytic asymmetric coupling of terminal alkynes with stabilised α-diazoesters using chiral 
guanidium salts of 144 as reported by Feng et al.
125 
 
The first coupling of semi-stabilised aryl ketone-derived diazo compounds with terminal 
alkynes was described by Wang et al. in 2016, using Cu(MeCN)4PF6 and bidentate BOX 
ligands 145 or 146, thus leading to trisubstituted allenes in generally good yields and high 
enantioselectivities (Scheme 79).
126
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Scheme 79: Catalytic asymmetric coupling of terminal alkynes with semi-stabilised aryl ketone-derived diazo 
compounds using BOX ligands 145 or 146 as reported by Wang et al.
126 
 
3.2. Aims of the project 
 
It was envisaged that by exploiting the room temperature conditions used for the generation 
of semi-stabilised diazo compounds, it may be possible to conduct allene synthesis 
enantioselectively, in the presence of a suitable chiral ligand. At the outset of investigations 
into this potential process, the asymmetric coupling of semi-stabilised diazo compounds with 
terminal alkynes was unknown (the process described by Wang et al.
126
 was published during 
our own investigations into this method). Therefore, the aims of this project centred on two 
goals: (a) to identify a suitable ligand for conducting the coupling process enantioselectively; 
and (b) to assess the reaction scope of this process (Scheme 80). 
 
 
Scheme 80: Investigating the use of flow-generated semi-stabilised diazo compounds in asymmetric allene 
synthesis using a chiral ligand. 
 
3.3. Results and discussion 
 
3.3.1. Initial screening for chiral ligands 
 
Using our racemic allene synthesis as a starting point, we next focused on developing an 
asymmetric analogue of the diazo compound/terminal alkyne coupling. To begin, a selection 
of potential ligands were assessed (Scheme 81). Ligands were added (using 15 mol% of 
ligand) to copper(I) iodide to pre-form the required metal-ligand complex, then followed by 
base, terminal alkyne 60 and flow-generated diazo compound 63 in succession. Monodentate 
phosphine ligands 147 and 148 led to the reaction proceeding without any enantioselectivity, 
whereas the use of bidentate phosphine ligands 149 and 150 led to no conversion of the 
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alkyne starting material 60. A mixed phosphine-imidazoline ligand 151 also provided good 
reactivity but no enantioselectivity, as did the pyridine-imidazoline ligand 152. Interestingly, 
bidentate BOX ligands 153 and (3aR,8aS)-59 were similarly ineffective for the coupling of 
this aldehyde-derived diazo compound. Use of the chiral guanidine-based catalyst 144 used 
by Feng et al.
125
 also did not result in any enantioselectivity. 
 
Whilst both monodentate and bidentate ligands did not result in useful enantioselectivity, 
tridentate ligands were found to be promising leads, with pyridinebis(imidazolidine) ligand 
154 providing -63% ee and PyBOX ligand 155 providing 68% ee. In contrast to the racemic 
process where the allene product was formed exclusively, the alkyne cross-product 65′ was 
now found to be a byproduct of the reaction; a 70:30 allene:alkyne ratio was observed for 
ligand 154, whereas a 38:62 allene:alkyne ratio was found for ligand 155. For further ligand 
design studies, PyBOX ligand 155 was used as the initial lead ligand structure, due to the 
ease of access to enantiopure amino alcohols.  
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Reactions performed on 0.2 mmol scale with respect to terminal alkyne; all reactions proceeded in >95% conv.; 
allene:alkyne ratio determined by analysis of the crude 
1
H NMR spectrum; ee determined by chiral HPLC. 
 
Scheme 81: Initial ligand screening of various mono-, di- and tridentate ligands for asymmetric allene synthesis. 
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3.3.2. PyBOX ligands 
 
Three different structural variations were assessed for developing new PyBOX ligands, which 
were synthesised from the condensation of pyridine-2,6-dicarbonitriles with amino alcohols 
using catalytic Zn(OTf)2 (Scheme 82).
127
 This involved varying the substituents on the 
oxadiazoline ring (R
1
 and R
2
) and the pyridine ring (R
3
). Yields were highly variable (9-98%), 
however enough material was provided in the low-yielding cases for ligand testing and so the 
procedure was not further optimised. 
 
Reactions performed on 1.0 mmol scale with respect to the pyridine-2,6-dicarbonitrile; yields stated are of 
isolated product. 
 
Scheme 82: General route to PyBOX ligands via condensation of pyridine-2,6-dicarbonitriles with amino 
alcohols. 
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Structural variations in R
1
 were relatively simple to explore due to the wide selection of 
commercially available amino alcohols. For these substituents, a switch from 
i
Pr (155) to Me 
(156) resulted in a lower 45% ee, suggesting that the methyl group is not bulky enough to 
afford good enantioselectivity. However, an increase in steric bulk to 
t
Bu (157) and Ph (166) 
also led to decreases in ee to 50% and 46% respectively (Figure 6). 
 
 
Figure 6: Effect of variation in R
1
 of PyBOX ligands for asymmetric allene synthesis.  
 
For these cases, it could be possible that with the larger tertiary alkyl and aryl groups, binding 
to the oxygen atom of the oxazoline unit becomes more preferable compared to the 
i
Pr case, 
thus moving the steric bulk away from the reactive centre and thereby leading to poorer 
enantioselectivity (Scheme 83).  
 
 
Scheme 83: Proposed rationale for poorer enantioselectivity with PyBOX ligands when steric bulk of R
1
 is 
increased. 
 
Since secondary alkyl groups appeared to be optimal for PyBOX ligands, three more 
substituents, cyclopropyl (158), cyclohexyl (159) and benzhydryl (160), were assessed for the 
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process. Both ligand 158 and 160 were found to be less efficient for enantioselectivity, at    
50% and 3% ee respectively; for the former, the smaller bond angle in a cyclopropyl ring 
compared to an 
i
Pr substituent leads to more compact steric bulk, whereas for the latter, the 
extreme bulk of the benzhydryl substituent could limit substrate binding. In the case of ligand 
159, enantioselectivity was the same as the 
i
Pr case at 68% ee, but selectivity for the allene 
product was slightly poorer at a 32:68 allene:alkyne ratio (Figure 6). With these 
considerations, the 
i
Pr group at R
1
 was taken as optimal for further structural modifications 
on R
2
 and R
3
. 
 
Variation of R
2
 was not as facile to assess; both (1R,2S)-2-amino-1,2-diphenylethan-1-ol and 
(1S,2S)-2-amino-1,2-diphenylethan-1-ol are commercially available and allowed preparation 
of ligands 161 and 162. When these were assessed for enantioselective allene formation, 55% 
and 80% ee were obtained respectively (Figure 7).  
 
 
Figure 7: Effect of variation in R
2
 of PyBOX ligands for asymmetric allene synthesis.  
 
Of particular note, when compared to ligand 166 (R
1
 = Ph, R
2
 = H), ligand 162 (both Ph 
groups anti to each other) provided very good enantioselectivity. This appears to be 
consistent with the earlier hypothesis that for monosubstituted oxazoline PyBOX ligands, 
larger steric bulk can lead to preferable binding to the oxygen atom of an oxazoline unit; for 
the case of anti-disubstituted oxazoline PyBOX ligands such as 162, coordination to the 
oxygen atom instead maintains steric bulk at the reactive centre and thus leads to high 
enantioselectivity (Scheme 84).  
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Scheme 84: Proposed rationale for higher enantioselectivity with PyBOX ligands when anti-disubstituted 
oxazolines are present. 
 
With the 
i
Pr group appearing to be optimal for monosubstituted oxazoline PyBOX ligands, 
investigation into the equivalent anti-disubstituted-
i
Pr oxazoline PyBOX ligand 163 seemed 
prudent. The required amino alcohol 171 was synthesised in four steps from commercially 
available L-valinol (167), as depicted below (Scheme 85).  
 
 
Scheme 85: Synthetic route to chiral amino alcohol 171. 
 
Benzyl protection of 167 provided 168 in 84% yield, which was then submitted to Swern 
oxidation to give the α-chiral aldehyde 169. To obtain the correct diastereomer for the 
required anti-disubstituted oxazoline PyBOX ligand, attack on the α-chiral aldehyde must 
occur with anti-Felkin selectivity. Under normal Felkin-Anh control,
128
 when the NBn2 group 
is perpendicular to the aldehyde to provide the most reactive conformer, attack of a 
nucleophile past the smallest substituent (H atom) in the absence of chelation provides the 
anti amino alcohol.
129
 In contrast, with chelation,
128
 the NBn2 group is now held in close 
proximity to the oxygen atom of the aldehyde and thus approach of the nucleophile is 
favoured from the opposite face (Scheme 86).
129
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Scheme 86: Nucleophilic attack on α-chiral aldehyde 169 under Felkin-Anh and chelation stereocontrol. 
 
Hence, for the preparation of 170, aldehyde 169 was treated with 3 equiv. of 
i
Pr2Zn,
130
 which 
provided protected amino alcohol 170 in 95% yield with very high diastereoselectivity. A 
final removal of the benzyl protecting groups by hydrogenation gave the unprotected amino 
alcohol 171 in 67% yield, which was submitted to PyBOX ligand formation as described 
earlier (Scheme 74) to provide ligand 163. PyBOX ligand 163 was found to be slightly better 
than analogous diphenyl substituted analogue 162 at inducing enantioselectivity, providing 
allene (R)-65 in 84% ee, though unfortunately the allene:alkyne ratio remained poor at 30:70 
(Figure 8).  
 
 
Figure 8: Performance of PyBOX ligand 163 for asymmetric allene synthesis.  
 
For variation at R
3
, an electron-withdrawing substituent (CF3) and an electron-donating 
substituent (OMe) were picked to assess effects on enantioselectivity and allene:alkyne ratio. 
The required 4-substituted pyridine-2,6-dicarbonitriles were synthesised by palladium-
catalysed cyanation of the corresponding 2,6-dichloropyridines,
131
 providing 172 and 173 in 
63% and 92% yields respectively (Scheme 87). 
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Scheme 87: Synthesis of 4-substituted pyridine-2,6-dicarbonitriles 172 and 173 by palladium-catalysed 
cyanation. 
 
For asymmetric allene synthesis, the CF3-substituted ligand 164 performed worse than the 
unsubstituted ligand 155, at 47% ee compared to 68% ee, whereas the allene:alkyne ratio was 
slightly better at 48:52 (Figure 9). For this case, the CF3-substituent seems to weaken binding 
of the ligand complex to the substrate, thus potentially leading to a greater extent of racemic 
allene coupling (leading to erosion of the enantioselectivity, but better allene:alkyne ratio). In 
contrast, the OMe-substituted ligand 165 provided 70% ee and a slightly poorer 36:64 
allene:alkyne ratio, suggesting that the electron-rich nature of the pyridine ring is slightly 
enhancing complex binding.  
 
 
Figure 9: Effect of variation in R
3
 of PyBOX ligands for asymmetric allene synthesis.  
 
In all of the cases where significant enantioselectivities were observed for asymmetric allene 
formation under PyBOX/CuI catalysis, poor allene:alkyne ratios were also observed, usually 
furnishing the desired chiral allene (R)-65 as the minor product. Conditions were therefore 
screened to assess whether any improvements in both enantioselectivity and the allene:alkyne 
ratio could be realised, using commercially available ligand 155. Alternative solvents were 
found to be worse than the original dioxane/CH2Cl2 mixture: use of DMSO, MeCN and DMF 
led to complete loss in enantioselectivity, most likely due to these solvents outcompeting 
ligand 155 for binding to copper(I) (Table 4, entries 3, 6 and 8); whereas DME, CH2Cl2, THF 
and EtOAc provided 43-50% ee (Table 4, entries 2, 4, 5, and 7). Alternative metal catalysts, 
for example Cu(MeCN)4PF6, AuI and ZnI2 led to no conversion to either allene (R)-65 or 
3. Asymmetric disubstituted allene synthesis using flow-generated diazo compounds 
65 
 
alkyne 65′ cross-coupled products (Table 4, entries 9-11). Other changes in the reaction 
conditions, for example at lower concentration (Table 4, entries 12), using protic additives 
such as Et3NH
+
I
-
 or MeOH (Table 4, entries 13-14), or anhydrous conditions by addition of 
4 Å molecular sieves (Table 4, entries 15) were all ineffective at promoting both good 
enantioselectivity and allene:alkyne ratio, leading to improvements in either aspect but not 
both. Alternative bases instead of Et3N, were also found to be ineffective in improving 
enantioselectivity or allene:alkyne ratio, with TMEDA and quinine again appearing to 
outcompete ligand 155 for complexation to the copper catalyst (Table 4, entries 16-19).  
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Table 4: Screening alternative conditions for asymmetric allene coupling using PyBOX ligand 155. 
 
Entry Deviation from standard conditions Allene:alkyne ratio ee / % 
1 - 38:62 68 
2 DME instead of dioxane 50:50 45 
3 DMSO instead of dioxane >95:5 0 
4 CH2Cl2 instead of dioxane 48:52 43 
5 THF instead of dioxane 42:58 48 
6 MeCN instead of dioxane 81:19 0 
7 EtOAc instead of dioxane 38:62 50 
8 DMF instead of dioxane 81:19 0 
9 Cu(MeCN)4PF6 instead of CuI (no reaction) 
10 AuI instead of CuI (no reaction) 
11 ZnI2 instead of CuI  (no reaction) 
12 initial acetylide solution diluted 4-fold 48:52 40 
13 2 equiv. Et3NH
+
I
-
 added 88:12 7 
14 2 equiv. MeOH added 40:60 64 
15 4 Å MS added 38:62 66 
16 DIPEA instead of Et3N 38:62 62 
17 TMEDA instead of Et3N >95:5 0 
18 quinine instead of Et3N >95:5 8 
19 Cs2CO3 instead of Et3N 20:80 (n.d.) 
Reactions performed on 0.2 mmol scale with respect to terminal alkyne; all reactions proceeded in >95% conv.; 
allene:alkyne ratio determined by analysis of the crude 
1
H NMR spectrum; ee determined by chiral HPLC. 
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Since opportunities in structural variation of PyBOX ligands and changes in reaction 
conditions were becoming limited, particularly with little insight into improving 
allene:alkyne ratio independently of enantioselectivity, a change in focus to a different family 
of ligands was made, to pyridine(bisimidazoline) (PyBIM) ligands.  
 
3.3.3. PyBIM ligands 
 
With the knowledge that the oxazoline units of PyBOX appear to act as ambidentate ligands, 
it was hypothesised that an appropriate approach would be to replace the oxazoline 
substituents with imidazolines. Unlike PyBOX ligands, the imidazoline substituents are not 
ambidentate, since they lack a suitably hybridised lone pair on the 1-position nitrogen atom to 
coordinate to metal ions (Scheme 88). Furthermore, functionalisation of this particular 
position offers opportunities in uniquely tuning steric and electronic parameters of the 
flanking imidazoline units, an aspect not amenable to exploration for PyBOX ligands.  
 
 
Scheme 88: Potential advantage of PyBIM ligands over PyBOX ligands to be investigated. 
 
PyBIM ligands were generally synthesised in three steps as described by Ma and You,
132
 
starting from pyridine-2,6-dicarbonyl chloride (174). Reaction of 174 with amino alcohols 
provides the diamides (175, 176 and 177), which were then chlorinated using SOCl2/PCl5 to 
form the imidoyl dichlorides. Subsequent cyclisation using anilines or alkyl amines generate 
the desired PyBIM ligands (Scheme 89).
‡
 In general, cyclisation with unhindered, electron-
rich anilines or amines (178, 179, 181, 183 and 184) proceeded well, however lower yields 
were obtained in the cases of ligands 180 or 182 where a bulky aniline/amine was used. The 
use of electron-poor anilines required longer reaction times and/or higher temperature to 
cyclise (185-191). Again, since enough material was obtained for ligand testing, no further 
attempt was made to optimise yields.  
                                                 
‡
 This work was conducted in collaboration with Timo von Keutz and Szabolcs Makai. 
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Reactions performed on 0.5 mmol scale with respect to the respective amides; yields stated are of isolated 
product from the chlorination/cyclisation sequence. 
 
Scheme 89: General route to PyBIM ligands via amide formation, chlorination and cyclisation. 
 
For these ligands, four different structural variations were investigated at R
1
, R
2
, R
3
 and R
4
 
(Figure 10).  
 
Figure 10: Structural variations in PyBIM ligands to be investigated for asymmetric induction. 
 
For variation of R
1
, an 
i
Pr substituent for ligand 178 (with Bn as the substituent at R
3
) 
provided allene (R)-65 in similar enantioselectivity to the similar PyBOX ligand 155, but 
with a better 70:30 allene:alkyne ratio (Figure 11). A change from 
i
Pr (178) to 
t
Bu (179) gave 
an increase in ee to 86% whilst allene:alkyne selectivity fell to 47:53. This effect of 
increasing steric bulk for PyBIM ligands sharply contrasts with the trend observed with 
PyBOX ligands, consistent with the imidazoline moieties being monodentate rather than 
ambidentate like the oxazolines.  
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Figure 11: Effect of variation in R
1
 of PyBIM ligands for asymmetric allene synthesis. 
 
Substituents at R
2
 were difficult to vary extensively, though it was possible to access PyBIM 
ligands analogous to PyBOX ligand 163. For these two ligands, a different synthetic 
approach was taken as outlined below, due to the lengthy route to accessing amino alcohol 
171 (Scheme 77). As reported by Chin et al.,
133
 starting from the commercially available 
‘Mother diamine’ 194, condensation with isobutyraldehyde (195) and a subsequent diaza-
Cope rearrangement afforded 196 in 85% yield; hydrolysis of this intermediate provided 89% 
of chiral diamine dihydrochloride 197. Condensation of diamine 197 with imidate 198 
(synthesised by methanolysis of 2,6-pyridinedicarbonitrile) gave ligand 199 in 58% yield, 
and alkylation of 199 with BnBr provided ligand 200 in 62% yield (Scheme 90).  
 
 
Scheme 90: Synthetic route to PyBIM ligands 199 and 200. 
 
Ligand 199 performed marginally better for enantioselectivity than the monosubstituted 
imidazoline ligand 178, whereas for ligand 200, ee sharply decreased to 19% (Figure 12). 
Since simultaneous substitution at R
1
, R
2
 and R
3
 appeared to be detrimental to asymmetric 
induction, investigations into variation of R
2
 were halted and subsequent ligand designs were 
kept monosubstituted on the imidazoline moieties (i.e. R
2
 = H).  
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Figure 12: Effect of variation in R
2
 of PyBIM ligands for asymmetric allene synthesis. 
 
For variation of R
3
 (using R
1
 = 
t
Bu), a change from Bn to a (R)-1-phenylethyl substituent for 
ligand 180 led to a decrease in ee to 25%, whereas a change to Ph for ligand 181 pleasingly 
increased the enantioselectivity to 96% ee, with a 32:68 allene:alkyne ratio (Figure 13). An 
attempt to increase steric bulk of R
3
 using di-ortho-substituted anilines, such as for ligand 
182, only led to eroded enantioselectivity. Use of di-meta-substituted anilines reduced 
enantioselectivity slightly compared to ligand 181, with 88-89% ee for all three ligands 183, 
184 and 185. Promisingly, it appeared that variation of the electronics of R
3
 was important 
for adjusting the allene:alkyne ratio independently of enantioselectivity, with more electron-
withdrawing aromatic rings leading to higher allene:alkyne ratios, in particular with 185 
providing an allene:alkyne ratio of 68:32. Further investigation into para-substituted anilines 
revealed that enantioselectivity was maintained at high levels between 96-97% ee for ligands 
186, 187 and 188, with allene:alkyne ratios becoming better with increased electron 
deficiency, to a maximum of 62:38 for ligand 188. Further decreases in electron density by 
using a nitro (189) or triflyl (190) substituent were detrimental, probably due to weakening 
binding to the copper(I) centre. Installation of a 3,5-difluoro-4-trifluoromethylaniline 
analogue (191) was detrimental to enantioselectivity, so the 4-SF5 substituent was picked for 
the final structural variations. 
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Figure 13: Effect of variation in R
3
 of PyBIM ligands for asymmetric allene synthesis. 
 
As enantioselectivities were already high for ligand 188, a potential line of approach was to 
increase electron deficiency in the pyridine ring, in an attempt to provide better allene:alkyne 
selectivities. Ligand 208, with a CF3 substituent for R
4
 to assess the impact of this structural 
change, was synthesised using the approach below (Scheme 91). 
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Scheme 91: Synthetic route to 4-CF3 substituted ligand 208. 
 
Commercially available substituted pyridine 201 was iodinated to provide 202, then 
submitted to palladium-catalysed trifluoromethylation using 203 to provide diester 204. 
Reaction with L-tert-leucinol (205) as described by Parsons and Johnson
134
 provided diamide 
206, which was then chlorinated and cyclised with aniline 207 as described previously for 
PyBIM synthesis to provide ligand 208 in 49% yield. Unfortunately, whilst ligand 208 did 
provide better allene:alkyne selectivity at 78:22, ee was markedly decreased to 63% (Figure 
14).  
 
 
Figure 14: Performance of PyBIM ligand 208 for asymmetric allene synthesis.  
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To conclude ligand optimisation, it was decided to return to substituent R
1
 and replace 
t
Bu 
with a bulkier adamantyl substituent. Chiral amino alcohol 215 was obtained in five steps 
from 1-adamantanemethanol (209), as shown below using the route described by Hamann et 
al. (Scheme 92).
135
 Swern oxidation gave aldehyde 210 in 94% yield, which was then 
subjected to a Strecker reaction using (R)-phenylglycinol (211) as a chiral auxiliary, 
providing 212 in 22% yield with good diastereoselectivity. Hydrolysis of the nitrile group 
gave 72% of 213, then submitted to hydrogenation to give chiral amino acid 214 in 
quantitative yield. Finally, reduction using LiAlH4 gave the desired amino alcohol 215 in    
90% yield, which was smoothly utilised for PyBIM synthesis to provide ligands 192 and 193 
(Scheme 89).  
 
 
Scheme 92: Synthetic route to chiral adamantyl-substituted amino alcohol 215. 
 
Whilst these ligands had relatively high enantioselectivities at 91% and 93% ee respectively, 
these enantioselectivities were poorer than the 97% ee obtained for ligand 188, and 
allene:alkyne ratios also similar (Figure 15).   
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Figure 15: Performance of adamantyl-substituted PyBIM ligands 192 and 193 for asymmetric allene synthesis.  
 
Ligand 188, with 97% ee and 62:38 allene:alkyne selectivity, was therefore chosen for 
investigation into the scope of the asymmetric allene coupling.  
 
3.3.4. Reaction scope 
 
An early attempt to generalise the scope using cyclopropylacetylene (106) provided good 
enantioselectivity (87% ee) of allene (R)-74. However, only 30% of 106 was converted to the 
allene, with the remainder being converted to alkyne cross-coupled product 74′, i.e. much 
poorer than the results during ligand design with substrate 60 (Scheme 93). At this point it 
was postulated that the N-H of the sulfonamide group could play an important role in the 
reaction mechanism, possibly acting as an internal proton source to favour formation of the 
allene cross-coupled product (Section 3.3.6).  
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Scheme 93: Asymmetric allene coupling of diazo compound 63 with cyclopropylacetylene (106). 
 
Various substrates with suitably acidic N-H protons (e.g. sulfonamides, carbamates, amides) 
were consequently used for asymmetric allene coupling, providing moderate yields of the 
chiral allenes (R)-65, (R)-77 and 216, with the remainder of the starting material being 
converted to the corresponding alkyne cross-coupled products. A myriad of functional groups 
installed onto the propargylamine were compatible with the reaction conditions, including 
trifluoromethyl (217 and 236), ketones (218), aldehydes (219), epoxides (220), unprotected 
alcohols (223), cyclopropanes and cyclopentanes (224 and 225), esters (226 and 235), 
internal and external olefins (232-234), all with high enantioselectivities and occurring very 
rapidly, reaching full completion 10 min after addition of the diazo compound. Heterocycles 
including thiophenes (221) and furans (222) were also tolerated, although for the former the 
reaction time was slightly longer at 20 min (probably due to coordination of thiophene to the 
copper(I)/ligand complex, thus hindering binding of alkynes to the catalyst). Both electron-
donating (229 and 235) and electron-withdrawing (230 and 232) substituents for the semi-
stabilised aryl diazo compound were tolerated, along with various halide substituents (227, 
228, 231) again in moderate yields and high enantioselectivities. For more electron-
withdrawing substituents on the aryl diazo compound, slightly poorer allene:alkyne ratios 
were observed, such as for allenes 228, 230, 232 and 234 (Scheme 94). 
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Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product, 
yields in parentheses are of the alkyne cross-product; ee determined by HPLC. * Reaction stirred for 20 min 
after addition of diazo compound. 
†
 Reaction conducted on 5 mmol scale with respect to alkyne. 
 
Scheme 94: Disubstituted allene synthesis via coupling of aldehyde-derived semi-stabilised diazo compounds 
and terminal alkynes using CuI catalysis. 
 
When ketone-derived aryl diazo compound 238 was utilised, generated from hydrazone 237 
(Scheme 95), no enantioselectivity was observed in the allene cross-product 98 when reacting 
with N-Boc propargylamine (239). No alkyne cross-product also was observed in this case, 
suggesting that tridentate ligand 188 exclusively allows asymmetric allene coupling of 
aldehyde-derived aryl diazo compounds, contrasting with the bidentate BOX ligand-mediated 
process described by Wang et al.
126
 for the asymmetric coupling of ketone-derived aryl diazo 
compounds. 
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Scheme 95: Attempted asymmetric coupling of ketone-derived diazo compound 238 with N-Boc 
propargylamine (239). 
 
To further probe the effectiveness of the procedure for late-stage functionalisation, a selection 
of natural products and drug molecules were derivatised to their corresponding 
propargylamines, then subjected to asymmetric allene coupling (Scheme 96). In most cases, 
such as in the case with (S)-ibuprofen (240), aspirin (241), topiramate (243), pregabalin (244), 
indomethacin (245) and atorvastatin (246), yields and diastereoselectivities/ 
enantioselectivities were similar to the previous substrates. For penicillin G, yield of allene 
242 was slightly poorer at 30% but diastereoselectivity remained excellent at 98% de. Similar 
to the synthesis of 221 bearing a thiophene moiety (Scheme 94), the thioether functionality 
may have impeded binding of the alkyne to the catalyst, affecting yield and lengthening 
reaction time.  
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Reactions performed on 0.2 mmol scale with respect to terminal alkyne; yields stated are of isolated product, 
yields in parentheses are of the alkyne cross-product; de/ee determined by HPLC. * Reaction stirred for 20 min 
after addition of diazo compound. 
†
 Yield by 
1
H NMR using 1,4-dinitrobenzene as internal standard. 
 
Scheme 96: Late-stage modification of natural products/drug molecules via asymmetric allene coupling. 
 
Scale-up to 5 mmol of propargylamide for allene 236 provided 0.89 g of material in 47% 
yield and 95% ee, essentially identical to the smaller scale run. Recrystallisation of this 
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compound provided crystals that were suitable for analysis by X-ray diffraction (Figure 16), 
which revealed that the stereochemistry of the new axially chiral centre was (R).  
 
 
Figure 16: X-ray crystal structure of allene 236. 
 
Stereochemical assignment of the other allenes synthesised was initially assigned by analogy, 
but confirmed by the laevorotatory nature of the optical rotations. By use of the Lowe-
Brewster rule,
136,137
 the aromatic ring attached to the allene is the most polarisable group, 
leading to an anticlockwise sense (Figure 17). Allene 242 derived from penicillin G was one 
exception to the laevorotatory optical rotations, with an optical rotation of +2.2. Since the 
starting material alkyne has a highly dextrorotatory optical rotation of +228.6, it appears that 
the allene functionality contributes a strongly laevorotatory component (thus consistent with 
(R)-stereochemistry) whilst the remainder of the molecule provides a similar strongly 
dextrorotatory component. 
 
 
Figure 17: Lowe-Brewster rule as applied to disubstituted allenes. 
 
3.3.5. Pyrroline synthesis using allene (R)-65 
 
As a demonstration of the use of allenes for cyclisation reactions, various metal catalysts 
were screened for reaction of allene (R)-65 to form the corresponding 3-pyrroline 247. Gold 
catalysts such as AuCl and AuCl3 caused decomposition of the allene (Table 5, entries 1 and 
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2), whereas the majority of silver catalysts were ineffective in converting starting material 
(Table 5, entries 3-9). Fortunately, AgPF6 (Table 5, entry 10) was found to be a suitable 
soluble source of Ag
+
 ions, providing the desired pyrroline 247 in quantitative yield and good 
axial to point chirality transfer (97% to 95% ee).  
 
Table 5: Metal catalyst testing for cyclisation of allene (R)-65 to pyrroline 247. 
 
Entry Metal salt Yield* / % ee / % 
1 AuCl (dec.) 
2 AuCl3 (dec.) 
3 Ag2CO3 (no reaction) 
4 Ag2SO4 (no reaction) 
5 AgOTf (no reaction) 
6 AgOAc (no reaction) 
7 AgNO3 (no reaction) 
8 AgOCN (no reaction) 
9 AgI (no reaction) 
10 AgPF6 99 95 
* Reactions performed on ca. 0.05 mmol scale with respect to allene (R)-65; yields stated are of isolated product; 
ee determined by HPLC.  
 
However, the reaction was not found to be general when cyclisation was attempted for the 
synthesis of pyrrolines 248 and 249, using the carbamate and amide-based allenes (R)-77 and 
216 respectively, with no conversion of the starting material observed (Scheme 97). For these 
substrates, it is likely that ability of the nitrogen atom to act as a nucleophile is severely 
curtailed by conjugation into the amide π-system, thus unable to participate in cyclisation as 
observed with sulfonamide-based allene (R)-65.   
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Scheme 97: Attempted cyclisation of allenes (R)-77 and 216 under silver-catalysed conditions. 
 
3.3.6. Mechanistic discussion 
 
The mechanism of the enantioselective asymmetric allene coupling of aldehyde-derived aryl 
diazo compounds and terminal alkynes is likely to proceed as described below (Scheme 98).  
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Scheme 98: Proposed mechanism for chiral disubstituted allene formation via asymmetric copper-catalysed 
coupling of aldehyde-derived aryl diazo compounds and terminal alkynes. 
 
In the presence of the ligand-copper(I) complex A and base, the terminal alkyne (B) forms 
the copper(I) acetylide complex D. Since complex D already has 18-electrons in its valence 
orbitals, attack of diazo compound C onto the copper centre is precluded. A possible reaction 
pathway involves the concerted insertion of the diazo compound into the Cu-C bond of 
complex D, arranged such that the smaller H atom of the diazo compound approaches next to 
the bulky 
t
Bu group of the ligand, hence minimising steric clash. This process provides E, 
which can be protonated from the front face of the catalyst to form the desired allene cross-
coupled product F, with the acidic N-H bond acting as the internal proton source. Migration 
of copper to an allenylcopper species (Scheme 53) appears unlikely, since protonation of this 
species would lead to the opposite enantiomer of allene F.  
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For the alkyne cross-coupled product, this could be produced from E if dissociation from the 
ligand-copper(I) complex occurred, resulting in an anion G that would then undergo 
protonation to form F′. This appears to be supported by the poorer allene:alkyne ratios 
observed for electron-withdrawing substituents on the aryl diazo compound, as these anions 
would be more stabilised and thus lead to more formation of the alkyne cross-coupled 
product. 
 
3.4. Conclusions and outlook 
 
To summarise, a new PyBIM ligand (188) was designed that allowed the copper-catalysed 
coupling of aldehyde-derived semi-stabilised aryl diazo compounds and propargylated 
amines, providing disubstituted allenes in moderate yields and high enantioselectivities 
rapidly and with a wide functional group tolerance (Scheme 99). The versatility of the 
process was illustrated by the asymmetric allenylation of seven natural products and drug 
molecules and the utility of these molecules emphasised by converting allene (R)-65 to 
pyrroline 247 using silver(I) catalysis.  
 
 
Scheme 99: Summary of chiral disubstituted allene synthesis by asymmetric coupling of flow-generated semi-
stabilised diazo compounds and terminal alkynes. 
 
Although there are many advantages to this methodology, a major drawback lies in the 
formation of significant quantities of the alkyne cross-coupled side product, limiting the 
scope of the terminal alkyne to appropriately functionalised propargylamine derivatives, as 
well as leading to generally moderate yields. A potential future line of research could involve 
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installation of suitably acidic groups on the ligand skeleton on a variable tether length, acting 
therefore as a bifunctional catalyst that could lead to improved allene:alkyne selectivities and 
broader substrate scope (Figure 18).  
 
 
Figure 18: Potential further investigations by installation of acidic N-H moieties. 
 
Overall, the advances described in this chapter should enable chemists to easily access chiral 
disubstituted allenes using a catalytic asymmetric coupling method. Taken together with the 
complementary asymmetric route to trisubstituted allenes described by Wang et al.,
126
 it is 
envisaged that further applications of chiral allenes in organic synthesis can now be readily 
developed. Furthermore, the advantage of using PyBIM ligands over PyBOX ligands as 
observed for this methodology could be important for the development of new catalytic 
asymmetric reactions in organic synthesis. 
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4.1. C(sp
2
)-C(sp
3
) cross-couplings 
 
4.1.1. Metal-catalysed C(sp
2
)-C(sp
3
) cross-couplings 
 
Unlike the well-established metal-catalysed C(sp
2
)-C(sp
2
) cross-couplings, analogous C(sp
2
)-
C(sp
3
) cross-couplings have proven challenging to develop. These types of metal-catalysed 
couplings can be separated into two categories (Scheme 100): (a) coupling of a C(sp
3
)-based 
organometallic reagent with a C(sp
2
)-based electrophile; and (b) coupling of a C(sp
2
)-based 
organometallic reagent with a C(sp
3
)-based electrophile. By far the most common metals 
utilised for these couplings are palladium or nickel, though copper, iron and cobalt-catalysed 
couplings are also relatively prevalent.
138
  
 
 
Scheme 100: Approaches to metal-catalysed C(sp
2
)-C(sp
3
) cross-couplings. 
 
In general, metal-catalysed coupling reactions usually proceed through a three-step cycle, 
involving an oxidative addition, transmetallation, then reductive elimination. For the first 
type of C(sp
2
)-C(sp
3
) cross-couplings involving alkyl-based organometallics, oxidative 
addition and transmetallation occur smoothly with the aryl/alkenyl-based electrophile. Slow 
reductive elimination to form the new C-C bond is however a particular problem, since the 
metal complex is liable to undergo β-hydride elimination and lead to the formation of alkene 
byproducts, unlike C(sp
2
)-C(sp
2
) cross-couplings (Scheme 101).
138
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Scheme 101: Catalytic cycle and side-reactions for metal-catalysed coupling of C(sp
3
) organometallics with 
C(sp
2
) electrophiles. 
 
For the second, more challenging type of C(sp
2
)-C(sp
3
) cross-couplings involving alkyl-based 
electrophiles, the process is further exacerbated by numerous factors. Firstly, oxidative 
addition of the metal catalyst is slower on unreactive alkyl electrophiles, proceeding usually 
via SN2 or radical mechanisms rather than the concerted process observed with C(sp
2
)-based 
electrophiles. With strongly basic organometallic reagents (e.g. organolithiums, Grignards), 
direct elimination of the alkyl electrophile may become a significant side reaction. Secondly, 
with the use of an alkyl-based electrophile, β-hydride elimination is now a possible side 
reaction immediately after oxidative addition, and slow transmetallation would lead to 
significant levels of this process. Finally, as previously mentioned with alkyl-based 
organometallics, slow reductive elimination also leads to significant β-hydride elimination 
(Scheme 102).
138 
 
4. C(sp
2
)-C(sp
3
) cross-couplings using flow-generated diazo compounds 
90 
 
 
Scheme 102: Catalytic cycle and side-reactions for metal-catalysed coupling of C(sp
2
) organometallics with 
C(sp
3
) electrophiles. 
 
For palladium-based catalytic procedures, efforts have primarily focused on coupling alkyl 
organometallics with aryl/alkenyl electrophiles.
138
 A variety of procedures have been 
described for the coupling of various electrophiles (e.g. 251, 254, 257, 260, 263) with alkyl 
Grignard (e.g. 250), organozinc (e.g. 253), organoboron (e.g. 256), organosilicon (e.g. 259) 
and organoindium reagents (e.g. 262) to access C(sp
2
)-C(sp
3
) cross-coupled products (e.g. 
252, 255, 258, 261, 264) (Scheme 103).
139-143
 The level of success is primarily dependent on 
the steric nature of the alkyl organometallic reagent: coupling of primary alkyl 
organometallics is usually facile and high-yielding, whereas secondary alkyl reagents are 
more challenging to utilise. In contrast, tertiary alkyl organometallic reagents represent a 
significant unsolved problem for palladium-based catalysis as a general useful method for 
coupling these reagents is unknown. These processes require substrate-specific combinations 
of ligand, base and solvent to effect desired reactivity; in many cases, the use of electron-rich, 
bulky phosphine ligands are crucial to achieving high rates of reductive elimination, thus 
suppressing β-hydride elimination.  
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Scheme 103: Selected examples of palladium-catalysed C(sp
2
)-C(sp
3
) cross-couplings using aryl/alkenyl 
electrophiles and various alkyl organometallic reagents.
139-143 
 
The use of unactivated alkyl electrophiles for palladium-mediated analogous C(sp
2
)-C(sp
3
) 
cross-coupling remains highly underdeveloped, since only primary alkyl electrophiles (e.g. 
266, 269, 272, 275, 278) have been coupled with aryl/alkenyl Grignards (e.g. 265), 
organozincs (e.g. 268), organoborons (e.g. 271), organosilanes (e.g. 274) and 
organostannanes (e.g. 277) successfully thus far for C(sp
2
)-C(sp
3
) cross-coupled products (e.g. 
267, 270, 273, 276, 279) (Scheme 104).
144-148
 Palladium-catalysed routes are generally 
limited to the SN2 mechanism of oxidative addition, hence oxidative addition to unactivated 
secondary and tertiary alkyl electrophiles becomes too slow to allow productive coupling 
processes.  
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Scheme 104: Selected examples of palladium-catalysed C(sp
2
)-C(sp
3
) cross-couplings using unactivated alkyl 
electrophiles and various aryl/alkenyl organometallic reagents.
144-148 
 
In contrast to palladium-catalysed methods, processes using nickel catalysis for coupling 
C(sp
3
) organometallics (e.g. 280, 283) with C(sp
2
) electrophiles (e.g. 281, 284) are able to 
tolerate primary, secondary and even tertiary alkyl nucleophiles to generate cross-coupled 
products (e.g. 282, 285), although these methods are generally limited to the use of alkyl 
Grignard and organozinc reagents (Scheme 105).
149,150
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Scheme 105: Selected examples of nickel-catalysed C(sp
2
)-C(sp
3
) cross-couplings using aryl/alkenyl 
electrophiles and various alkyl organometallic reagents.
149,150 
 
Nickel-based catalytic cycles, unlike palladium-mediated processes, can proceed via radical 
mechanisms due to the ability of nickel to gain or lose single electrons, interchanging usually 
between four different oxidation states, i.e. Ni
0
, Ni
I
, Ni
II
 and Ni
III
, unlike the Pd
0
/Pd
II
 and 
Pd
II
/Pd
IV
 cycles observed for palladium catalysis. With this different mode of reactivity, 
oxidative addition is no longer limited to SN2 processes and thus unactivated alkyl halides 
spanning primary (e.g. 290), secondary (e.g. 287, 296, 299) and tertiary halides (e.g. 293) 
become permissible reagents for C(sp
2
)-C(sp
3
) cross-coupling with aryl/alkenyl 
organometallic reagents (e.g. 286, 289, 292, 295, 298) to access the corresponding cross-
coupled products (e.g. 288, 291, 294, 297, 300) (Scheme 106).
151-155
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Scheme 106: Selected examples of nickel-catalysed C(sp
2
)-C(sp
3
) cross-couplings using unactivated alkyl 
electrophiles and various aryl/alkenyl organometallic reagents.
151-155 
 
In addition, nickel catalysis has been shown to be highly useful for C(sp
2
)-C(sp
3
) cross-
coupling when utilised in tandem with methods generating carbon-centred radicals, for 
example photoredox catalysis (enabling the coupling of reagents such as oxalates, carboxylic 
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acids and organoboronates),
156-162
 redox-active esters
163-165
 and Katritzky pyridinium salts
166
 
(Figure 19).  
 
 
Figure 19: Examples of precursors to carbon-centred radicals for application in nickel-catalysed cross-coupling 
reactions. 
 
4.1.2. Metal-free C(sp
2
)-C(sp
3
) cross-couplings using diazo compounds 
 
Although developments in C-C bond-forming cross-couplings have predominantly involved 
metal catalysis, a valuable alternative approach involves the use of diazo compounds and 
their reactions with organoboron derivatives for metal-free coupling processes. In 1968, Hooz 
and Linke described the reaction of the stabilised diazo compound, diazoacetone (301), with 
trialkylboranes, thus providing a route to C(sp
3
)-C(sp
3
) coupled products in a metal-free 
fashion (Scheme 107).
167
  
 
 
Scheme 107: Coupling of diazoacetone (301) with trialkylboranes as reported by Hooz and Linke.
167 
 
Analogous processes using aryl/vinyl-based organoboronic reagents,
168
 such as utilising aryl- 
and vinyldichloroboranes and aryl/vinylboroxines were subsequently developed, coupling 
stabilised α-diazocarbonyl compounds (Scheme 108).169-171 Whilst these reports represented a 
significant development in methods for metal-free C(sp
2
)-C(sp
3
) coupling, they were limited 
to stabilised α-diazocarbonyl compounds.  
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Scheme 108: Coupling of stabilised α-diazocarbonyl compounds with aryldichloroboranes, 
vinyldichloroboranes and aryl/vinylboroxines as reported by Hooz et al.,
169
 Brown and Salunkhe,
170
 and Wang 
et al.
171
 respectively. 
 
A major first step in generalising the scope to less stabilised diazo compound partners was 
made by Kabalka et al. in 1994, when the coupling of trialkylboranes and aryl aldehyde-
derived sulfonylhydrazones was described (Scheme 109).
172
 A significant limitation of this 
process involves the use of oxygen-sensitive trialkylboranes, as well as poor atom efficiency 
arising from only one of the three alkyl groups being transferred in this process. 
 
 
Scheme 109: Coupling of aryl aldehyde-derived sulfonylhydrazones with trialkylboranes as reported by 
Kabalka et al.
172 
 
A further report by Barluenga et al. in 2009 involved the use of readily available arylboronic 
acids coupling with tosylhydrazones (Scheme 110).
173
 After this seminal publication, 
subsequent reports based on generalising this process for utilising vinylboronic acids
174
 and 
saturated heterocyclic sulfonylhydrazones,
24
 as well as application to medicinal chemistry 
programmes
175
 and flow processes,
176
 have highlighted its utility. However, major drawbacks 
of the procedure have also been identified, including protodeboronation of starting boronic 
acid material and elimination, due to the high temperature and basic conditions required for 
diazo generation from sulfonylhydrazones.   
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Scheme 110: Coupling of tosylhydrazones with arylboronic acids as reported by Barluenga et al.
173 
 
These problems were addressed to some extent by Ley et al., where a flow process for the 
mild generation of semi-stabilised aryl- and vinyl diazo compounds from their corresponding 
aryl/vinyl hydrazones was reported via activated MnO2 oxidation, thus allowing these C(sp
2
)-
C(sp
3
) cross-couplings to occur at ambient conditions (Scheme 111).
65
 Interception of the 
putative, unstable boronic acid intermediate has also been demonstrated, a key advantage that 
is not possible using the original conditions reported by Barluenga et al.; thus, treatment of 
transient intermediate with H2O2/NaOH leads to the corresponding alcohol (e.g. 302), 
whereas addition of further diazo compounds allows multiple C-C bond formation in an 
iterative fashion.
66
  
 
 
Scheme 111: Coupling of semi-stabilised aryl- and vinyl diazo compounds with arylboronic acids as reported 
by Ley et al.
65 
 
These findings represent a noteworthy milestone in the development of metal-free cross-
coupling methods. However, a major drawback still exists for this process: the generation of 
diazo compounds via this route is strictly limited to semi-stabilised diazo compounds, i.e. 
‘activated’ aryl- and vinylhydrazones that are amenable to oxidation by MnO2. The mild 
generation of non-stabilised diazo compounds is impossible using this route. Hence, a mild 
route towards these highly sought compounds would be extremely valuable, not only for 
expanding the scope of the metal-free C(sp
2
)-C(sp
3
) coupling process, but also potentially 
providing access to new alcohols, boronic acid/ester reagents and iterative coupling products.  
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4.2. Aims of the project 
 
Although methods to generate solutions of semi-stabilised diazo compounds have been 
established, as well as illustrating their use in metal-free C(sp
2
)-C(sp
3
) cross-coupling 
reactions,
65
 mild and general procedures for the generation of non-stabilised diazo 
compounds have been underdeveloped. The aim of this project thus focuses on two goals: (a) 
to identify a suitable precursor for generation of non-stabilised diazo compounds, using a 
sufficiently mild, general and simple procedure; and (b) to illustrate the use of these diazo 
compounds by reaction with arylboronic acids in metal-free C(sp
2
)-C(sp
3
) cross-coupling 
reactions (Scheme 112).  
 
 
Scheme 112: Investigating the generation of non-stabilised diazo compounds from appropriate precursors and 
their use in metal-free C(sp
2
)-C(sp
3
) cross-coupling. 
 
4.3. Results and discussion 
 
4.3.1. Optimisation results 
 
With the aim of creating a method to allow metal-free C(sp
2
)-C(sp
3
) coupling using non-
stabilised diazo compounds, an appropriate precursor was required, one that would unveil the 
desired diazo compound under mild conditions. Of the methods surveyed previously 
(Chapter 1), only three methods appeared appropriate: the base-mediated fragmentation of 
nitrosoamide derivatives, the oxidation of hydrazones and the photolysis of oxadiazolines. 
The photolysis method seemed to be the most convenient to test. The starting materials were 
generally synthesised by a simple two-step, one-pot process from readily available ketones 
(via condensation with acethydrazide then subsequent oxidation using PhI(OAc)2) to provide 
the desired, bench-stable diazo precursors (303-324) (Scheme 113).
42
 In addition, utilisation 
of flow technologies would provide a direct benefit by providing more efficient irradiation, 
arising from smaller penetration depths compared to a similar scale batch protocol.
177
 In 
contrast, the alternative two approaches for generating diazo compounds require tedious 
multi-step synthetic routes and lead to relatively unstable diazo precursors.   
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Yields stated are of isolated product for the two-step hydrazone formation/oxidation sequence; diastereomeric 
ratios determined by analysis of the crude 
1
H NMR spectrum. 
 
Scheme 113: Synthetic route towards 1,3,4-oxadiazolines for use as diazo compound precursors. 
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In general the two-step yields were moderate to excellent, except for the 4-membered ring 
precursors 307, 310 and 313 where significant hydrolysis of the hydrazones by acetic acid 
was observed in the oxidation step. Oxadiazoline 325 was obtained from the m-CPBA 
mediated oxidation of 305, whereas oxadiazolines 326 and 327 were obtained by bromination 
via an Appel reaction and Swern oxidation of 324 respectively (Scheme 114). 
 
 
Scheme 114: Synthesis of oxadiazolines 325, 326 and 327. 
 
Using diazo precursor 303, an initial attempt to produce the corresponding non-stabilised 
diazo compound 328 involved passing a 0.1 M Et2O solution of 303 through a 10 mL coil 
(FEP tubing) at a 0.125 mL min
-1
 flow rate (80 min residence time), irradiated at 310 nm by a 
9 W UV lamp on a Vapourtec E-series flow platform. Indeed, in-line IR analysis indicated 
two identifiable signals, one at 2040 cm
-1
 corresponding to the diazo stretch for compound 
328, along with one at 1746 cm
-1
 corresponding to the C=O stretch of MeOAc (Figure 20). 
The IR signal for MeOAc was particularly useful for gauging photolytic conversion of any 
oxadiazoline derived from acetic hydrazide.  
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Figure 20: Tracking photolysis of oxadiazoline 303 using in-line IR spectroscopy (top); IR spectrum of reaction 
mixture at 175 min, showing the presence of diazo compound 328 and MeOAc (bottom). 
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With the intermediacy of diazo compound 328 confirmed, the reactor output (2 equiv. with 
respect to oxadiazoline 303) was directed into a solution of 4-chlorophenylboronic acid (329, 
1 equiv.) and DIPEA (2 equiv.), then stirred at r.t. under air overnight. Tertiary alcohol 331, 
arising from spontaneous atmospheric oxidation of the putative boronic acid intermediate 330, 
was thus obtained in 46% yield (Scheme 115).  
 
 
Scheme 115: Initial attempt at ex situ generation of diazo compound 328 from photolysis of oxadiazoline 303 
and subsequent interception with 4-chlorophenylboronic acid (329). 
 
Freshly prepared solutions of diazo compound 328 appeared to lose their distinctive red 
colouration over a period of 1 to 2 hours, suggesting that conducting an in situ photolysis, i.e. 
passing a combined mixture of boronic acid 329, oxadiazoline 303 and DIPEA through the 
photolysis reactor, could be more effective. When this in situ protocol was conducted, alcohol 
331 was obtained in slightly higher yield, at 55% (Table 6, entry 2). A switch of solvent to 
CH2Cl2 provided 18% when conducted ex situ (Table 6, entry 3), but a significantly higher in 
situ yield of 76% (Table 6, entry 4); it is probable that the Et2O solvent used previously 
coordinates with the boronic acid or related species (see Section 4.3.3) and leads to poorer 
interception of highly reactive diazo compound 328, whereas use of CH2Cl2 is advantageous 
due to the absence of this effect. Variation of other parameters led to decreased yields 
compared to this entry: a decrease in residence time to 40 min led to slightly lower yield of 
331 at 68% (Table 6, entry 5), due to incomplete photolysis of oxadiazoline 303; utilisation 
of less DIPEA (1 equiv.) led to a lower 70% yield of 331 (Table 6, entry 6); whereas use of a 
different base (1,1,3,3-tetramethylguanidine (15), Table 6, entry 7) led to complete loss of 
reactivity, probably due to irreversible coordination of the base to boronic acid 329. 
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Changing the photolysis reactor temperature to lower temperatures (0 °C and -10 °C) had no 
appreciable effect on reaction yield (Table 6, entries 8 and 9), so the original temperature was 
maintained for reaction scope studies.  
 
Table 6: Optimisation for oxidative C(sp
2
)-C(sp
3
) cross-coupling of arylboronic acids with non-stabilised diazo 
compounds generated via photolysis of oxadiazolines. 
 
Entry T / °C Base Solvent tR / min Yield* / % Other comments 
1 10 DIPEA (2 equiv.) Et2O 80 46 ex situ 
2 10 DIPEA (2 equiv.) Et2O 80 55 - 
3 10 DIPEA (2 equiv.) CH2Cl2 80 18 ex situ 
4 10 DIPEA (2 equiv.) CH2Cl2 80 76 - 
5 10 DIPEA (2 equiv.) CH2Cl2 40 68 - 
6 10 DIPEA (1 equiv.) CH2Cl2 80 70 - 
7 10 TMG (2 equiv.) Et2O 80 traces - 
8 0 DIPEA (2 equiv.) CH2Cl2 80 75 - 
9 -10 DIPEA (2 equiv.) CH2Cl2 80 76 - 
* Reactions performed on 0.5 mmol scale with respect to arylboronic acid; yields stated are of isolated product. 
 
It was notable that during these optimisation studies, the obtained product was oxidised 
C(sp
2
)-C(sp
3
) coupling product 331, with no traces of the protodeboronated product. The 
sensitivity of tertiary alkyl boronic acids to atmospheric oxidation is known, as well as the 
difficulty of obtaining deboronated products from these boronic acid substrates.
178
 When 
protodeboronation of boronic acid intermediate 330 was attempted with degassed aqueous 
HCl or NaOH solutions, no protodeboronated product was observed and only the oxidised 
product was obtained on re-exposure to air. A report by Aggarwal et al. indicated that 
protodeboronation of tertiary boronic pinacol esters was possible by using TBAF;
179
 thus, 
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when the reaction output was directed into a solution of TBAF and stirred at r.t. overnight, 
protodeboronated C(sp
2
)-C(sp
3
) coupling product 332 was finally obtained in 71% yield 
(Scheme 116). 
 
 
Scheme 116: Switchable ‘workup’ procedure using TBAF for protodeboronative C(sp2)-C(sp3) cross-coupling 
of arylboronic acids with non-stabilised diazo compounds. 
 
4.3.2. Reaction scope 
 
With methods for both the oxidative and protodeboronative C(sp
2
)-C(sp
3
) coupling in hand, a 
full assessment of the reaction scope for arylboronic acids and oxadiazolines was made.
§
  
 
For the protodeboronative C(sp
2
)-C(sp
3
) coupling with respect to the oxadiazoline component 
(Scheme 117), a variety of 6-membered, 5-membered and 4-membered, saturated 
heterocyclic and carbocyclic rings were tolerated, including pyran (332), tetrahydrofuran 
(333), tetrahydrothiopyran (334), tetrahydrothiophene (335), thietane (336), N-Boc piperidine 
(337), N-Boc pyrrolidine (338), N-Boc azetidine (339), cyclohexane (340), cyclopentane  
(341) and cyclobutane (342) rings. Progressively higher yields were obtained on changing 
ring size from 4-rings to 5-rings to 6-rings, consistent with progressively more stable diazo 
compounds with larger ring sizes. The lower stability of the 4-membered diazo compounds 
can be explained by their strong tendency to react with electrophiles, leading to relief of ring 
strain by moving from a sp
2
-carbon centre to sp
3
.  
 
                                                 
§
 This work was conducted in collaboration with Dr Andreas Greb. 
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Reactions performed on 0.5 mmol scale with respect to arylboronic acid; yields stated are of isolated product.  
* Protodeboronation conducted at 75 °C. 
 
Scheme 117: Protodeboronative C(sp
2
)-C(sp
3
) coupling using oxadiazolines and arylboronic acids. 
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Despite this latent instability, it is notable that the 4-membered protodeboronated products 
(336, 339, 342) were still obtained in moderate yields, even though the instability of 
diazocyclobutane (12) has been previously reported.
23
 In addition, whilst extensive 
elimination was observed for the tetrahydrothiophene and thietane moieties when 
sulfonylhydrazones (e.g. 364) were used for coupling with boronic acids (e.g. 365), the 
milder conditions used here for diazo compound generation provided good yields of coupled 
products 335 and 336 without any of the previously reported olefinic thiol side-products (e.g. 
366) (Scheme 118).
24
  
 
 
Scheme 118: Unsuccessful C(sp
2
)-C(sp
3
) cross-coupling of tetrahydrothiophene-derived sulfonylhydrazone 364 
with boronic acid 365 due to elimination to 366 as reported by Ley et al.
24 
 
Probing further, oxadiazolines derived from 2-tetralone (314) and highly hindered 
adamantanone (315) provided excellent yields of coupling products 343 and 344 respectively. 
Use of the oxadiazoline derived from cyclopropyl methyl ketone (316) allowed the formation 
of 345 in 86% yield, suggesting that the coupling process (i.e. steps after photolysis of the 
oxadiazoline has completed) does not occur via a radical mechanism due to the absence of 
cyclopropane ring-opened products, despite the photolytic conditions used.  
 
In terms of functional group compatibility for the oxadiazolines, a myriad of moieties were 
tolerated, including terminal olefins (346), alkynes (347), acetals (348), phosphonates (349) 
and sulfones (350). The use of an epoxide was also possible, providing a 1:1 diastereomeric 
mixture of product 351 in 81% yield. The use of alkyl bromide 326 was possible, providing 
32% yield of 352, with the lower yield attributed to partial elimination of the product in the 
presence of TBAF. In contrast, use of alkyl aldehyde 327 led to extensive polymerisation, 
likely due to TBAF acting as a base and thus enabling aldol reactions. An unprotected 
primary alcohol substrate 324 was also not viable in this process (Figure 21). Heterocyclic 
compounds such as furans and pyrimidines were tolerated, providing products 353 and 354 in 
65% and 57% yields respectively.  
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Figure 21: Unsuccessful oxadiazoline examples for protodeboronative C(sp
2
)-C(sp
3
) cross-coupling. 
 
For scope of the arylboronic acid component, electron-deficient arenes performed well, with 
4-bromo (355), 4-trifluoromethyl (356), 4-cyano (357) and 4-methoxycarbonyl (358) 
substituents providing moderate to good yields of coupled products. A relatively more 
electron-rich arene substrate with 3-NHAc worked well, providing 88% yield of coupling 
product 359. In contrast, when 4-methoxybenzeneboronic acid was used, no coupling 
products were observed using the unmodified general protocol; however, on heating the 
reaction output with TBAF at 75 °C, coupling product 360 was obtained in 56% yield, 
suggesting that protodeboronation was more difficult in this particular case. A similar effect 
was observed when slightly sterically hindered 2-methylbenzeneboronic acid was utilised, 
again requiring protodeboronation at 75 °C to furnish product 361 in 69% yield. Hetero-
arylboronic acids, such as 3-pyridyl and 2-thienylboronic acids were tolerated to some extent, 
providing products 362 and 363 in 30% and 38% yields respectively. For these cases, the 
lower yields are likely due to coordination of these heterocycles to the boronic acids, 
hindering interception of the diazo compound, similar to when tetramethylguanidine was 
used as the base in optimisation studies. Utilisation of 3-thienyl (367) and 3-furanylboronic 
acids (368) did not result in any coupling products, even when protodeboronation was 
attempted at 75 °C. In addition, use of an alkylboronic acid, cyclohexylboronic acid (369), 
did not result in any observed coupling products (Figure 22).  
 
 
Figure 22: Unsuccessful boronic acid examples for cross-coupling. 
 
The analogous oxidative C(sp
2
)-C(sp
3
) coupling processes generally proceeded in 
comparable yields to the protodeboronative couplings (Scheme 119). Thus, various 6-
membered (331, 371, 374, 377), 5-membered (370, 372, 375, 378) and 4-membered rings 
(373, 376, 379) were tolerated, with the same observed trend in terms of higher diazo 
compound stability for higher sized rings. Oxidation of 4-membered substrates leading to 
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compounds 373 and 376 appeared to be less efficient compared to the analogous 
protodeboronative cases. The use of the oxadiazoline derived from 2-tetralone (314) 
proceeded analogously, providing 71% of 380; however, oxidation of the adamantane 
derivative appeared to be extremely slow, only providing traces of the desired alcohol 
product 381. Substrates with cyclopropyl (382), olefin (383), alkyne (384), acetal (385), 
phosphonate (386), sulfone (387), furan (390) and pyrimidine (391) moieties all proceeded 
analogously to their corresponding protodeboronative products. It is notable that the epoxide 
and alkyl bromide products 388 and 389 proceeded very well, both in 87% yield; no cyclised 
tetrahydrofuran product was observed in the latter case. In these particular two cases, the 
versatility of this methodology for obtaining alcohols is highlighted, since approaches 
utilising alternative organometallic routes would require installation of the reactive 
functionalities (i.e. epoxide and alkyl bromide) after the use of the Grignard/organolithium 
reagent. Electron-deficient (392, 393) and electron-rich (395) arylboronic acids also 
performed well, with the exception of 394 where protodeboronation to form 358 appeared to 
be facile and only 31% of the desired oxidised product was obtained. 
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Reactions performed on 0.5 mmol scale with respect to arylboronic acid; yields stated are of isolated product.  
 
Scheme 119: Oxidative C(sp
2
)-C(sp
3
) coupling using oxadiazolines and arylboronic acids. 
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4.3.3. Mechanistic discussion 
 
Based on recent observations about the reactivity of boronic acid species and their 
derivatives,
180
 it is anticipated that the mechanism of the C(sp
2
)-C(sp
3
) coupling process 
proceeds as described below (Scheme 120).  
 
 Scheme 120: Proposed mechanism for C(sp
2
)-C(sp
3
) coupling. 
 
On dissolution of arylboronic acids in CH2Cl2, significant formation of the boroxine occurs – 
when 4-chlorophenylboronic acid (329) was analysed by 
1
H NMR spectroscopy in CD2Cl2, a 
mixture of two different compounds were observed (Figure 23). An independent synthesis of 
the corresponding boroxine 396 (azeotropic removal of water by refluxing under Dean-Stark 
conditions) revealed that one component corresponds to the boroxine, whereas the other set 
of signals belongs to the boronic acid, in a 1:2.6 ratio of 329 to 396. 
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Figure 23: NMR spectra of 4-chlorophenylboronic acid (329) (top) and its corresponding boroxine 396 (bottom) 
in CD2Cl2. 
 
Diazo compound 328 is generated from oxadiazoline 303 as described earlier (Section 1.2.6), 
which then attacks boroxine 396, on each of the three boron atoms to give diazonium A. 
Subsequent migration of the aryl group with expulsion of nitrogen results in the organoboron 
derivative B, which then undergoes protodeboronation with TBAF or oxidation with 
atmospheric oxygen to provide the protodeboronated and oxidised C(sp
2
)-C(sp
3
) coupled 
products respectively.  
 
4.4. Conclusions and outlook 
 
To conclude, a method for the C(sp
2
)-C(sp
3
) coupling of non-stabilised diazo compounds, 
generated in situ by flow photolysis of oxadiazolines, and arylboronic acids was developed 
(Scheme 121). Changing the ‘workup’ conditions of the reaction allows generation of either 
protodeboronated C(sp
2
)-C(sp
3
) coupling products by treatment with TBAF, or oxidised 
C(sp
2
)-C(sp
3
) coupling products by stirring under air. A variety of 4-membered, 5-membered 
and 6-membered saturated heterocyclic and carbocyclic oxadiazolines were tolerated for both 
methods, as well as various reactive functional groups and arylboronic acids, in generally 
moderate to excellent yields.  
 
4. C(sp
2
)-C(sp
3
) cross-couplings using flow-generated diazo compounds 
112 
 
 
Scheme 121: Summary for C(sp
2
)-C(sp
3
) coupling using oxadiazolines and arylboronic acids. 
 
The functional group tolerance and scope of this newly developed process represents a major 
advance in metal-free C(sp
2
)-C(sp
3
) coupling, especially compared to the existing reports 
using sulfonylhydrazones as diazo precursors. An inherent limitation that comes with the use 
of oxadiazolines involves the inability to access alkyl aldehyde-derived diazo compound 
derivatives, since the required oxadiazolines for these substrates are currently inaccessible, so 
this represents a potential direction for further research. Nevertheless, by enabling a mild, 
simple route to a multitude of non-stabilised alkyl diazo compounds derived from ketones, it 
is anticipated that these compounds could find significant utility in organic synthesis, for 
example, in new cyclopropanation, cycloaddition, heteroatom-H and C-H bond insertion 
reactions. 
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5.1. General experimental details 
 
All batch reactions were performed using oven-dried glassware (200 °C) under an 
atmosphere of argon unless otherwise stated. All flow reactions were performed using a 
Uniqsis FlowSyn platform, a Vapourtec R2+R4 system or a Vapourtec E-series system. 
Solvents were freshly distilled over sodium benzophenone ketyl (THF, Et2O) or calcium 
hydride (acetone, MeCN, MeOH, CH2Cl2, CHCl3 and toluene). Additional anhydrous 
solvents were obtained from commercial sources and used directly (DMF, DMA, DMSO and 
1,4-dioxane). DIPEA and Et3N were freshly distilled over calcium hydride and stored over 
4 Å molecular sieves. All reagents were obtained from commercial sources and used without 
further purification.  
 
Flash column chromatography was performed using high-purity grade silica gel (Merck grade 
9385) with a pore size 60 Å and 230–400 mesh particle size under air pressure. Analytical 
thin layer chromatography (TLC) was performed using silica gel 60 F254 pre-coated glass 
backed plates and visualised by ultraviolet radiation (254 nm) and/or potassium 
permanganate solution as appropriate.  
 
1
H NMR spectra were recorded on a 600 MHz Avance 600 BBI Spectrometer as indicated. 
Chemical shifts are reported in ppm with the resonance resulting from incomplete deuteration 
of the solvent as the internal standard (CDCl3: 7.26 ppm; CD2Cl2: 5.32 ppm, t; DMSO-d6: 
2.50 ppm, qn; MeOD-d4: 3.31 ppm, qn). 
13
C NMR spectra were recorded the same 
spectrometer with complete proton decoupling. Chemical shifts are reported in ppm with the 
solvent resonance as the internal standard (
13
CDCl3: 77.16 ppm, t; DMSO-d6: 39.52 ppm, 
sept; MeOD-d4: 49.00 ppm, sept). 
19
F NMR spectra were recorded on a 376 MHz Avance III 
HD Spectrometer with complete proton decoupling. Chemical shifts are reported in ppm with 
CFCl3 as the external standard (CFCl3: 0.00 ppm).
 31P NMR spectra were recorded on an 
Avance 600 BBI Spectrometer with complete proton decoupling. Chemical shifts are reported 
in ppm with 85% phosphoric acid in D2O as the external standard (H3PO4: 0.00 ppm). Data 
are reported as follows: chemical shift δ/ppm, integration (1H, 19F and 31P), multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, qn = quintet, sept = septet, oct = octet, br = broad, 
m = multiplet or combinations thereof; 
13
C signals are singlets unless otherwise stated), 
coupling constants J in Hz, assignment. Spectra are assigned as fully as possible, using 
1
H-
COSY, DEPT-135, HSQC, HMBC and NOESY where appropriate to facilitate structural 
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determination. Signals that cannot be unambiguously assigned are reported with all possible 
assignments separated by a slash (e.g. H1/H2) or descriptions of their environments (e.g. ArH, 
NH, OH). Multiple signals arising from diastereotopic or (pseudo)axial/equatorial positions 
are suffixed alphabetically (e.g. H1a, H1b). Overlapping signals that cannot be resolved are 
reported with their assignments denoted in list format (e.g. H1, H2 and H3). 
1
H NMR signals 
are reported to 2 decimal places and 
13
C signals to 1 decimal place unless rounding would 
produce a value identical to another signal. In this case, an additional decimal place is 
reported for both signals concerned.  
 
Infrared spectra were recorded neat as thin films on a Perkin-Elmer Spectrum One FTIR 
spectrometer and selected peaks are reported (s = strong, m = medium, w = weak, br = broad). 
 
High resolution mass spectrometry (HRMS) was performed using positive or negative 
electrospray ionisation (ESI), on either a Waters Micromass LCT Premier spectrometer or 
performed by the Mass Spectrometry Service for the Department of Chemistry at the 
University of Cambridge. All m/z values are reported to 4 decimal places and are within ± 5 
ppm of theoretical values.  
 
Specific optical rotation was recorded on a Perkin-Elmer Model 343 digital polarimeter, 
using a Na/Hal lamp set at 589 nm and with a path length of 100 mm. [α]D values were 
measured using spectroscopy grade solvent at the specified concentration (in g/100 mL) and 
temperature, with units of deg 10
-1
 cm
2
 g
-1
.  
 
Melting points were recorded on a Stanford Research Systems OptiMelt Automated Melting 
Point System calibrated against vanillin (m.p. 83 °C), phenacetin (m.p. 136 °C) and caffeine 
(m.p. 237 °C). 
 
Chiral HPLC analysis was conducted on an Agilent 1100 Series Chromatography system 
using mixtures of hexane/isopropanol as eluent on Chiralpak AS, Chiralpak OD-H, 
ChiralART SA or ChiralART SC columns.  
 
X-ray crystallographic analysis was performed by Dr Andrew Bond for the Department of 
Chemistry at the University of Cambridge on a Bruker D8-QUEST PHOTON-100 
diffractometer.  
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5.2. Experimental data for Chapter 2 
 
5.2.1. Synthetic procedures and characterisation for alkyne starting materials 
 
 
4-Methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (60): To a solution of propargylamine 
(3.2 mL, 50.0 mmol, 1 equiv.) in CH2Cl2 (125 mL) at 0 °C was added Et3N (17.4 mL, 
125.0 mmol, 2.5 equiv.) then p-toluenesulfonyl chloride (9.53 g, 50.0 mmol, 1 equiv.) 
portionwise. The mixture was stirred at r.t. for 16 h. The reaction mixture was then diluted 
with Et2O (500 mL) and the organic phase washed with 1 M aqueous HCl solution (300 mL), 
saturated aqueous NH4Cl solution (300 mL), dried (MgSO4) and evaporated under reduced 
pressure. The residual precipitate was triturated with hexane (3 × 25 mL) to provide the title 
compound as an off-white amorphous solid (9.55 g, 45.6 mmol, 91%), m.p. 74-76 °C (lit. 
m.p.
181
 74-75 °C). Data are consistent with a reported example.
181 
 
1
H NMR (600 MHz, CDCl3): δ 7.77 (d, J = 8.2 Hz, 2 H, H5), 7.31 (d, J = 8.2 Hz, 2 H, H6), 
4.82 (br t, J = 5.8 Hz, 1 H, NH), 3.82 (dd, J = 5.8, 2.5 Hz, 2 H, H3), 2.43 (s, 3 H, H8), 2.10 (t, 
J = 2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 144.0 (C7), 136.6 (C4), 129.8 (C6), 127.5 (C5), 78.1 (C2), 
73.1 (C1), 33.0 (C3), 21.7 (C8). 
FTIR (νmax, cm
-1
): 3276 (m, NH and alkyne CH), 1598 (w), 1495 (w), 1428 (w), 1324 (m), 
1307 (m), 1292 (w), 1186 (w), 1156 (s), 1121 (w), 1093 (m), 1070 (m), 1019 (w), 993 (w), 
925 (w), 813 (m). 
HRMS (ESI): calculated for C10H12NO2S [M+H]
+
 210.0583, found 210.0586.  
 
 
(2RS,3RS)-2-Phenyl-3-((prop-2-yn-1-yloxy)methyl)oxirane: To a suspension of sodium 
hydride (88 mg, 2.40 mmol, 1.2 equiv., 60% dispersion in mineral oil) in anhydrous THF 
(5 mL) was added a solution of trans-3-phenylglycidol (300 mg, 2.00 mmol, 1.0 equiv.) in 
anhydrous THF (5 mL) slowly dropwise at 0 °C under an argon atmosphere. The mixture was 
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stirred further at this temperature for 10 min. Propargyl bromide (0.18 mL, 2.40 mmol, 
1.2 equiv.) was then added slowly dropwise at 0 °C and the mixture stirred further at r.t. for 
1 h. The reaction mixture was quenched with a few drops of EtOAc and the solvent removed 
under reduced pressure. EtOAc (25 mL) was added to the residue and the organic layer 
washed with water (2 × 25 mL), brine (25 mL), dried (MgSO4), filtered and evaporated under 
reduced pressure. The residue was purified by silica gel column chromatography (eluent:     
10% EtOAc/hexane) to provide the title compound as a colourless oil (350 mg, 1.86 mmol, 
93%). Data are consistent with a reported example.
182 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 – 7.33 (m, 2 H, H2), 7.33 – 7.29 (m, 1 H, H1), 7.29 – 
7.26 (m, 2 H, H3), 4.26 (d, J = 2.4 Hz, 2 H, H8), 3.92 (dd, J = 11.4, 3.1 Hz, 1 H, H7a), 3.82 
(dd, J = 6.3, 2.1 Hz, 1 H, H5), 3.70 (dd, J = 11.4, 5.3 Hz, 1 H, H7b), 3.24 (ddd, J = 5.3, 3.1, 
2.1 Hz, 1 H, H6), 2.47 (t, J = 2.4 Hz, 1 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 136.7 (C4), 128.6 (C2), 128.5 (C1), 125.8 (C3), 79.3 (C9), 
75.2 (C10), 69.4 (C7), 60.9 (C6), 58.7 (C8), 56.0 (C5). 
FTIR (νmax, cm
-1
): 3289 (w, alkyne CH), 2859 (w), 2118 (w, C≡C), 1743 (w), 1605 (w), 
1498 (w), 1462 (w), 1443 (w), 1359 (w), 1243 (w), 1202 (w), 1097 (s), 1027 (w), 976 (w), 
932 (w), 910 (w), 879 (m), 838 (w). 
HRMS (ESI): calculated for C12H12O2Na [M+Na]
+
 211.0730, found 211.0731.  
Rf = 0.25 (10% EtOAc/hexane). 
 
 
(1S,2S,4S,5R)-2-((R)-(6-Methoxyquinolin-4-yl)(prop-2-yn-1-yloxy)methyl)-5-vinyl-
quinuclidine: To a suspension of sodium hydride (0.40 g, 10.0 mmol, 2.0 equiv., 60% 
dispersion in mineral oil) in anhydrous DMF (15 mL) was added a solution of quinine (1.62 g, 
5.0 mmol, 1.0 equiv.) in anhydrous DMF (15 mL) slowly dropwise at 0 °C under an argon 
atmosphere. The mixture was stirred further at this temperature for 10 min. Propargyl 
bromide (0.52 mL, 6.0 mmol, 1.2 equiv.) was then added slowly dropwise at 0 °C and the 
mixture stirred further at r.t. for 3 h. The reaction mixture was quenched with water (50 mL) 
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and extracted with Et2O (3 × 25 mL). The combined organic extracts were washed with water 
(4 × 50 mL), brine (50 mL), dried (MgSO4), filtered and evaporated under reduced pressure. 
The residue was purified by silica gel column chromatography (eluent: 60% EtOAc/38% 
hexane/2% Et3N) to provide the title compound as an off-white amorphous solid (1.63 g, 
4.5 mmol, 90%), m.p. 87-89 °C (lit. m.p.
183
 88-90 °C). Data are consistent with a reported 
example.
183
 
 
1
H NMR (600 MHz, CDCl3): δ 8.75 (d, J = 4.4 Hz, 1 H, H10), 8.03 (t, J = 5.9 Hz, 1 H, H6), 
7.41 (d, J = 4.4 Hz, 1 H, H9), 7.39 – 7.34 (m, 2 H, H3 and H7), 5.83 – 5.68 (m, 1 H, H19), 
5.31 (br s, 1 H, H11), 4.95 (dt, J = 17.1, 1.4 Hz, 1 H, H20trans), 4.91 (dt, J = 10.3, 1.4 Hz, 1 H, 
H20cis), 4.21 (dd, J = 15.9, 2.4 Hz, 1 H, H21a), 3.93 (s, 3 H, H1), 3.89 (dd, J = 15.9, 2.4 Hz, 
1 H, H21b), 3.41 (br s, 1 H, H13a), 3.15 (br s, 1 H, H12), 3.07 (dd, J = 13.8, 10.1 Hz, 1 H, 
H17a), 2.72 – 2.62 (m, 1 H, H13b), 2.62 – 2.55 (m, 1 H, H17b), 2.45 (t, J = 2.4 Hz, 1 H, H23), 
2.25 (br s, 1 H, H18), 1.82 – 1.79 (m, 1 H, H15), 1.79 – 1.71 (m, 2 H, H14a and H16a), 1.67 
(br s, 1 H, H16b), 1.56 – 1.48 (m, 1 H, H14b). 
13
C NMR (150 MHz, CDCl3): δ 157.9 (C2), 147.7 (C10), 144.8 (C8), 143.9 (C5), 142.1 
(C19), 132.0 (C6), 127.6 (C4), 121.9 (C7), 120.0 – 118.0 (br, C9), 114.3 (C20), 101.5 – 101.0 
(br, C3), 79.4 (C22), 77.5 –76.7 (br, obscured by CDCl3 peak, C11), 75.1 (C23), 60.1 (C12), 
57.3 (C17), 56.3 (C21), 55.8 (C1), 43.2 (C13), 40.2 (C18), 27.87 (C14/C15), 27.86 
(C14/C15), 23.5 – 22.5 (br, C16). 
FTIR (νmax, cm
-1
): 2935 (m), 2099 (w, C≡C), 1620 (m), 1591 (w), 1506 (m), 1473 (m), 1455 
(m), 1429 (m), 1362 (m), 1306 (w), 1240 (s), 1228 (s), 1107 (m), 1082 (s), 1050 (s), 1032 (s), 
905 (m), 852 (m), 839 (m), 817 (s). 
HRMS (ESI): calculated for C23H27N2O2Na [M+H]
+
 363.2067, found 363.2077.  
Rf = 0.20 (60% EtOAc/38% hexane/2% Et3N). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -161.5 (CHCl3, c = 1.0). 
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5.2.2. Synthetic procedures and characterisation for hydrazone starting materials 
 
General procedure for aldehyde-derived hydrazone formation: To a solution of aldehyde 
(20.0 mmol, 1.0 equiv.) in methanol (20 mL) was added hydrazine hydrate (1.2 mL, 24 mmol, 
1.2 equiv.) and the mixture stirred at r.t. for 1 h. The mixture was then evaporated under 
reduced pressure to provide the desired hydrazone. The crude hydrazone was used for 
generation of the corresponding diazo compound without further purification.  
 
General procedure for ketone-derived hydrazone formation: To a solution of ketone 
(20.0 mmol, 1.0 equiv.) in methanol (20 mL) was added hydrazine hydrate (2.9 mL, 
60.0 mmol, 3.0 equiv.) and the mixture stirred at 80 °C for 3 h in a sealed vial. The solvent 
was removed under reduced pressure and the residue diluted with water (25 mL) and CH2Cl2
 
(25 mL). The mixture was separated, the aqueous layer extracted with CH2Cl2 (3 × 25 mL) 
and the combined organic extracts were dried (MgSO4), filtered and evaporated under 
reduced pressure to provide the desired hydrazone. The crude hydrazone was used for 
generation of the corresponding diazo compound without further purification.  
 
 
(4-Chlorobenzylidene)hydrazine (62): Following the general procedure for aldehyde-
derived hydrazone formation using 4-chlorobenzaldehyde (2.81 g, 20.0 mmol), provided the 
title compound as a white crystalline solid (3.08 g, 19.9 mmol, 99%), m.p. 59-61 °C (lit. 
m.p.
184
 60-61 °C). Data are consistent with a reported example.
185 
 
1
H NMR (600 MHz, CDCl3): δ 7.69 (s, 1 H, H5), 7.47 (d, J = 8.5 Hz, 2 H, H3), 7.31 (d, J = 
8.5 Hz, 2 H, H2), 5.54 (br s, 2 H, NH). 
13
C NMR (150 MHz, CDCl3): δ 141.8 (C5), 134.4 (C4), 133.7 (C1), 128.9 (C2), 127.4 (C3). 
FTIR (νmax, cm
-1
): 3357 (w, NH2), 3186 (w, NH2), 1625 (w), 1594 (w), 1486 (w), 1393 (w), 
1249 (w), 1218 (w), 1109 (w), 1090 (m), 1010 (w), 961 (w), 924 (w), 912 (w), 864 (w), 824 
(s). 
HRMS (ESI): calculated for C7H7N2ClNa [M+Na]
+
 177.0190, found 177.0188.  
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(4-Bromobenzylidene)hydrazine: Following the general procedure for aldehyde-derived 
hydrazone formation using 4-bromobenzaldehyde (3.70 g, 20.0 mmol), provided the title 
compound as an off-white crystalline solid (3.98 g, 19.9 mmol, 99%), m.p. 73-75 °C (lit. 
m.p.
184
 77-78 °C). Data are consistent with a reported example.
184 
 
1
H NMR (600 MHz, CDCl3): δ 7.67 (s, 1 H, H5), 7.47 (d, J = 8.5 Hz, 2 H, H2), 7.41 (d, J = 
8.5 Hz, 2 H, H3), 5.56 (br s, 2 H, NH). 
13
C NMR (150 MHz, CDCl3): δ 141.7 (C5), 134.3 (C4), 131.9 (C2), 127.7 (C3), 122.6 (C1). 
FTIR (νmax, cm
-1
): 3353 (w, NH2), 3194 (w, NH2), 1627 (w), 1586 (m), 1483 (w), 1391 (m), 
1069 (s), 1006 (m), 924 (m), 912 (m), 862 (m), 818 (s). 
HRMS (ESI): calculated for C7H7N2BrNa [M+Na]
+
 220.9685, found 220.9690. 
 
 
(3-Methoxybenzylidene)hydrazine: Following the general procedure for aldehyde-derived 
hydrazone formation using m-anisaldehyde (2.72 g, 20.0 mmol), provided the title compound 
as a yellow oil (2.99 g, 19.9 mmol, 99%). Data are consistent with a reported example.
186 
 
1
H NMR (600 MHz, CDCl3): δ 7.72 (s, 1 H, H8), 7.26 (t, J = 7.9 Hz, 1 H, H4), 7.16 (dd, J = 
2.5, 0.8 Hz, 1 H, H7), 7.07 (dt, J = 7.9, 0.8 Hz, 1 H, H5), 6.86 (ddd, J = 7.9, 2.5, 0.8 Hz, 1 H, 
H3), 5.51 (br s, 2 H, NH), 3.83 (s, 3 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 160.0 (C2), 143.1 (C8), 136.7 (C6), 129.7 (C4), 119.5 (C5), 
115.4 (C3), 110.2 (C7), 55.4 (C1). 
FTIR (νmax, cm
-1
): 3387 (w, NH2), 3200 (w, NH2), 2911 (w), 2835 (w), 1597 (s), 1575 (s), 
1489 (m), 1466 (m), 1455 (m), 1431 (m), 1397 (w), 1317 (w), 1288 (m), 1263 (s), 1195 (w), 
1155 (s), 1072 (w), 1038 (s), 994 (w), 967 (w), 922 (m), 862 (w). 
HRMS (ESI): calculated for C8H10N2ONa [M+Na]
+
 173.0685, found 173.0692. 
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4-(Hydrazonomethyl)benzonitrile: Following the general procedure for aldehyde-derived 
hydrazone formation using 4-formylbenzonitrile (2.62 g, 20.0 mmol) provided the title 
compound as a yellow amorphous solid (2.90 g, 20.0 mmol, 99%), m.p. 63-66 °C (lit. m.p.
187
 
64-66 °C). Data are consistent with a reported example.
188
 
 
1
H NMR (600 MHz, CDCl3): δ 7.70 (s, 1 H, H6), 7.62 (s, 4 H, H3 and H4), 5.81 (br s, 2 H, 
NH2). 
13
C NMR (150 MHz, CDCl3): δ 139.9 (C6), 139.7 (C5), 132.5 (C3), 126.5 (C4), 119.1 (C1), 
111.5 (C2). 
FTIR (νmax, cm
-1
): 3377 (w, NH2), 3198 (w, NH2), 2221 (m, C≡N), 1589 (s), 1552 (m), 1503 
(m), 1398 (m), 1244 (w), 1175 (w), 1091 (w), 909 (s), 869 (w), 824 (s). 
HRMS (ESI): calculated for C8H7N3Na [M+Na]
+
 168.0532, found 168.0530.  
 
 
((E)-3-Phenylallylidene)hydrazine: Following the general procedure for aldehyde-derived 
hydrazone formation using trans-cinnamaldehyde (2.64 g, 20.0 mmol) provided the title 
compound as a yellow waxy solid (2.91 g, 19.9 mmol, 99%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.55 (d, J = 9.1 Hz, 1 H, H7), 7.42 (d, J = 7.5 Hz, 2 H, H3), 
7.33 (t, J = 7.5 Hz, 2 H, H2), 7.28 – 7.24 (m, 1 H, H1), 6.86 (dd, J = 16.1, 9.1 Hz, 1 H, H6), 
6.66 (d, J = 16.1 Hz, 1 H, H5), 4.88 (br s, 2 H, NH2). 
13
C NMR (150 MHz, CDCl3): δ 145.3 (C7), 136.6 (C4), 134.9 (C5), 128.8 (C2), 128.3 (C1), 
126.7 (C3), 125.9 (C6). 
FTIR (νmax, cm
-1
): 3322 (w, NH2), 3177 (w, NH2), 3025 (w), 2907 (w), 1640 (w), 1578 (w), 
1485 (w), 1447 (m), 1383 (w), 1292 (w), 1257 (w), 1208 (w), 1178 (w), 1151 (w), 1127 (w), 
1088 (m), 971 (s), 933 (w), 915 (w), 842 (w).  
HRMS (ESI): calculated for C9H10N2Na [M+Na]
+
 169.0736, found 168.0735.  
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(1-Phenylethylidene)hydrazine (91): Following the general procedure for ketone-derived 
hydrazone formation using acetophenone (2.40 g, 20.0 mmol) provided the title compound as 
a yellow oil (2.00 g, 14.9 mmol, 75%). Data are consistent with a reported example.
185
 
 
1
H NMR (600 MHz, CDCl3): δ 7.67 – 7.63 (m, 2 H, H3), 7.38 – 7.33 (m, 2 H, H2), 7.32 – 
7.28 (m, 1 H, H1), 5.36 (br s, 2 H, NH2), 2.13 (s, 3 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 147.4 (C5), 139.5 (C4), 128.4 (C2), 128.1 (C1), 125.6 (C3), 
11.7 (C6). 
FTIR (νmax, cm
-1
): 3385 (w, NH2), 3214 (w, NH2), 1592 (s), 1571 (w), 1495 (s), 1444 (s), 
1369 (s), 1330 (w), 1254 (w), 1115 (m), 1079 (m), 1064 (m), 1026 (s), 951 (w), 914 (w). 
HRMS (ESI): calculated for C8H10N2Na [M+Na]
+
 157.0736, found 157.0740.  
 
 
(1-(4-Chlorophenyl)ethylidene)hydrazine (237): Following the general procedure for 
ketone-derived hydrazone formation using 4’-chloroacetophenone (3.09 g, 20.0 mmol) 
provided the title compound as an off-white crystalline solid (3.40 g, 20.0 mmol, 99%), m.p. 
48.5-49.5 °C (lit. m.p.
189
 48.4-50.1 °C). Data are consistent with a reported example.
185
 
 
1
H NMR (600 MHz, CDCl3): δ 7.57 (d, J = 8.6 Hz, 2 H, H3), 7.30 (d, J = 8.6 Hz, 2 H, H2), 
5.38 (br s, 2 H, NH2), 2.09 (s, 3 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 146.0 (C5), 137.9 (C4), 133.9 (C1), 128.5 (C2), 126.8 (C3), 
11.5 (C6). 
FTIR (νmax, cm
-1
): 3356 (w, NH2), 3215 (w, NH2), 1638 (w), 1599 (w), 1488 (m), 1395 (w), 
1369 (w), 1333 (w), 1270 (w), 1108 (w), 1092 (s), 1007 (m), 958 (w), 822 (s). 
HRMS (ESI): calculated for C8H9N2ClNa [M+Na]
+
 191.0346, found 191.0340.  
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(1-(4-(Trifluoromethyl)phenyl)pent-4-en-1-ylidene)hydrazine: Following the general 
procedure for ketone-derived hydrazone formation using 1-(4-(trifluoromethyl)phenyl)pent-
4-en-1-one (4.56 g, 20.0 mmol) provided the title compound as a yellow waxy solid (4.24 g, 
17.5 mmol, 88%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 2 H, H4), 7.58 (d, J = 8.2 Hz, 2 H, H3), 
5.86 (ddt, J = 17.0, 10.2, 6.7 Hz, 1 H, H9), 5.61 (br s, 2 H, NH2), 5.11 (dq, J = 17.0, 1.4 Hz, 
1 H, H10trans), 5.05 (dd, J = 10.2, 1.4 Hz, 1 H, H10cis), 2.74 – 2.68 (m, 2 H, H7), 2.33 – 2.27 
(m, 2 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 148.0 (q, J = 0.5 Hz, C6), 141.8 (q, J = 1.3 Hz, C5), 136.9 
(C9), 129.8 (q, J = 32.4 Hz, C2), 125.8 (C4), 125.4 (q, J = 3.9 Hz, C3), 124.3 (q, J = 271.8 
Hz, C1), 116.2 (C10), 29.2 (C8), 24.6 (C7). 
19
F NMR (376 MHz, CDCl3): -62.5 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 3311 (w, NH2), 3210 (w, NH2), 1630 (w), 1524 (w), 1502 (w), 1408 (w), 
1323 (s), 1161 (m), 1108 (s), 1067 (s), 1016 (m), 980 (w), 956 (w), 918 (w), 857 (m), 846 
(m). 
HRMS (ESI): calculated for C12H13F3N2Na [M+Na]
+
 265.0923, found 265.0926.  
 
 
(4-(5,5-Dimethyl-1,3-dioxan-2-yl)-1-(4-methoxyphenyl)butylidene)hydrazine: Following 
the general procedure for ketone-derived hydrazone formation using 4-(5,5-dimethyl-1,3-
dioxan-2-yl)-1-(4-methoxyphenyl)butan-1-one (1.46 g, 5.00 mmol) provided the title 
compound as a yellow viscous oil (1.53 g, 4.99 mmol, 99%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.57 (d, J = 9.0 Hz, 2 H, H4), 6.85 (d, J = 9.0 Hz, 2 H, H3), 
5.40 (br s, 2 H, NH2), 4.46 (t, J = 4.8 Hz, 1 H, H10), 3.80 (s, 3 H, H1), 3.59 (d, J = 11.2 Hz, 
2 H, H11a), 3.40 (d, J = 11.2 Hz, 2 H, H11b), 2.66 – 2.59 (m, 2 H, H7), 1.75 – 1.64 (m, 4 H, 
H8 and H9), 1.17 (s, 3 H, H13/H14), 0.70 (s, 3 H, H13/H14). 
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13
C NMR (150 MHz, CDCl3): δ 159.7 (C2), 150.7 (C6), 131.3 (C5), 127.0 (C4), 113.8 (C3), 
101.9 (C10), 77.3 (C11), 55.4 (C1), 34.4 (C9), 30.3 (C12), 25.3 (C7), 23.1 (C13/C14), 21.9 
(C13/C14), 20.0 (C8). 
FTIR (νmax, cm
-1
): 3401 (w, NH2), 3220 (w, NH2), 2955 (w), 2839 (w), 1675 (w), 1603 (m), 
1511 (s), 1464 (m), 1394 (m), 1363 (w), 1307 (m), 1247 (s), 1174 (m), 1131 (s), 1096 (m), 
1033 (m), 1014 (m), 969 (w), 910 (m), 833 (m), 808 (w). 
HRMS (ESI): calculated for C17H26N2O3Na [M+Na]
+
 329.1836, found 329.1842.  
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5.2.3. Synthetic procedures and characterisation for allenes 
 
General procedure for allene formation with aldehyde-derived hydrazones: 
Conditioning phase: A solution of hydrazone (0.1 M) and DIPEA (0.2 M) in CH2Cl2 was 
passed through a column reactor (Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed 
with activated MnO2 (0.86 g), at a flow rate of 0.5 mL min
-1
 for 20 min and the reactor output 
was monitored using a FlowIR
®
 device. The flow was switched to solvent (DIPEA, 0.2 M in 
CH2Cl2) for 10 min. The column was then ready for the generation of the diazo compound. 
 
Generation phase: A vial was charged with the appropriate alkyne (0.2 mmol, 1.0 equiv.), 
copper(I) iodide (3.9 mg, 0.02 mmol, 0.1 equiv.), 1,4-dioxane (2 mL) and Et3N (0.05 mL, 
0.4 mmol, 2 equiv.) and pre-mixed for 10 min. A solution of hydrazone (0.1 M) and DIPEA 
(0.2 M) in CH2Cl2 was passed through the pre-conditioned column reactor (Omnifit
®
 column, 
6.6 mm i.d. × 50 mm length), packed with activated MnO2 (0.86 g), at a flow rate of 
0.5 mL min
-1
. When the FlowIR
®
 showed that the intensity of the diazo peak was stable, 
3 mL of the output (1.5 equiv. with respect to the hydrazone) was directly added into the 
reaction vial (over 6 min) containing the copper acetylide and the reaction mixture further 
stirred at r.t. for 10 min. The mixture was then filtered through a pad of Celite, eluting with 
EtOAc, and the filtrate evaporated under reduced pressure. The residue was purified by silica 
gel column chromatography to provide the desired disubstituted allene product. Any excess 
diazo compound produced during the conditioning phase or the generation phase before 
steady-state was reached was gently quenched by directing the output of the flow reactor into 
a stirred suspension of copper(I) iodide (0.10 g) in MeOH (25 mL). 
 
General procedure for allene formation with ketone-derived hydrazones: (N.B. Diazo 
compound generation from ketone-derived hydrazones does not require a pre-conditioning 
phase for the MnO2 column reactor). A vial was charged with the appropriate alkyne 
(0.2 mmol, 1.0 equiv.), copper(I) iodide (3.9 mg, 0.02 mmol, 0.1 equiv.), 2,6-lutidine (4.6 µL, 
0.04 mmol, 0.2 equiv.), 1,4-dioxane (2 mL), Et3N (0.05 mL, 0.4 mmol, 2 equiv.) and pre-
mixed for 10 min. A solution of hydrazone (0.1 M) and DIPEA (0.2 M) in CH2Cl2 was passed 
through the column reactor (Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed with 
activated MnO2 (0.86 g), at a flow rate of 0.5 mL min
-1
. When the FlowIR
®
 showed that the 
intensity of the diazo peak was stable, 3 mL of the output (1.5 equiv. with respect to the 
hydrazone) was directly added into the reaction vial (over 6 min) containing the copper 
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acetylide and the reaction mixture further stirred at r.t. for 10 min. The mixture was then 
filtered through a pad of Celite, eluting with EtOAc, and the filtrate evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography to provide the 
desired trisubstituted allene product. Any excess diazo compound produced during the 
generation phase before steady-state was reached was gently quenched by directing the 
output of the flow reactor into a stirred suspension of copper(I) iodide (0.10 g) in MeOH 
(25 mL). 
 
 
Ethyl 5-((4-methylphenyl)sulfonamido)penta-2,3-dienoate (61): A vial was charged with 
4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol, 1.0 equiv.), 
copper(I) iodide (3.9 mg, 0.02 mmol, 0.1 equiv.), 1,4-dioxane (2 mL) and Et3N (0.05 mL, 
0.4 mmol, 2 equiv.) and pre-mixed for 10 min. To this reaction mixture was added a solution 
of ethyl diazoacetate (39) (0.03 mL, 0.3 mmol, 1.5 equiv.) in dioxane (1 mL) slowly 
dropwise over 10 min and stirred at r.t. for 16 h. The mixture was then filtered through a pad 
of Celite, eluting with EtOAc, and the filtrate evaporated under reduced pressure. The residue 
was purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to provide 
the title compound as a yellow gum (49.5 mg, 0.168 mmol, 84%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.75 (d, J = 8.2 Hz, 2 H, H9), 7.31 (d, J = 8.2 Hz, 2 H, H10), 
5.62 (dt, J = 6.1, 2.9 Hz, 1 H, H6), 5.56 (q, J = 6.1 Hz, 1 H, H4), 4.74 (br t, J = 6.2 Hz, 1 H, 
NH), 4.21 – 4.14 (m, 2 H, H2), 3.78 – 3.66 (m, 2 H, H7), 2.43 (s, 3 H, H12), 1.27 (t, J = 
7.1 Hz, 3 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 211.7 (C5), 165.2 (C3), 143.9 (C11), 137.0 (C8), 129.9 
(C10), 127.3 (C9), 93.0 (C4), 91.1 (C6), 61.4 (C2), 40.8 (C7), 21.7 (C12), 14.3 (C1). 
FTIR (νmax, cm
-1
): 3270 (br w, NH), 2982 (w), 1966 (w, C=C=C), 1714 (m, C=O), 1598 (w), 
1495 (w), 1424 (w), 1367 (w), 1330 (m), 1277 (w), 1158 (s), 1094 (m), 1034 (w), 870 (w), 
815 (w). 
HRMS (ESI): calculated for C14H17NO4SNa [M+Na]
+
 318.0770, found 318.0781. 
Rf = 0.28 (30% EtOAc/hexane). 
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N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide (65): Following 
the general procedure for allene formation with aldehyde-derived hydrazones using 4-methyl-
N-(prop-2-yn-1-yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol) and (4-
chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography (eluent:    
20% EtOAc/hexane) provided the title compound as an off-white amorphous solid (62.3 mg, 
0.187 mmol, 93%), m.p. 88-90 °C. 
 
1
H NMR (400 MHz, CDCl3): δ 7.75 (d, J = 8.2 Hz, 2 H, H10), 7.25 (d, J = 8.2 Hz, 2 H, 
H11), 7.21 (d, J = 8.5 Hz, 2 H, H2), 7.11 (d, J = 8.5 Hz, 2 H, H3), 6.15 (dt, J = 6.2, 3.2 Hz, 
1 H, H5), 5.52 (q, J = 6.2 Hz, 1 H, H7), 5.10 (t, J = 6.0 Hz, 1 H, NH), 3.73 – 3.68 (m, 2 H, 
H8), 2.40 (s, 3 H, H13). 
13
C NMR (100 MHz, CDCl3): δ 204.9 (C6), 143.7 (C12), 137.0 (C9), 133.1 (C1), 132.0 (C4), 
129.8 (C11), 128.9 (C2), 128.2 (C3), 127.2 (C10), 96.9 (C5), 92.5 (C7), 41.7 (C8), 21.6 
(C13). 
FTIR (νmax, cm
-1
): 3276 (w, NH), 2924 (w), 1957 (w, C=C=C), 1723 (w), 1597 (w), 1491 
(m), 1408 (w), 1323 (m), 1265 (w), 1155 (s), 1090 (s), 1013 (m), 874 (m), 834 (m), 812 (s).  
HRMS (ESI): calculated for C17H16NO2SClNa [M+Na]
+
 356.0482, found 356.0477. 
Rf = 0.24 (20% EtOAc/hexane). 
 
 
4-(4-Chlorophenyl)buta-2,3-dien-1-ol (66): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using propargyl alcohol (64) (11.2 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 20% EtOAc/hexane) provided the title compound as a colourless oil 
(33.0 mg, 0.183 mmol, 91%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.6 Hz, 2 H, H2), 7.23 (d, J = 8.6 Hz, 2 H, H3), 
6.29 (dt, J = 6.0, 2.9 Hz, 1 H, H5), 5.80 (q, J = 6.0 Hz, 1 H, H7), 4.27 (br s, 2 H, H8), 1.80 (br 
s, 1 H, OH). 
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13
C NMR (150 MHz, CDCl3): δ 204.4 (C6), 132.9 (C1), 132.4 (C4), 128.9 (C2), 128.1 (C3), 
96.4 (C5), 96.3 (C7), 60.3 (C8). 
FTIR (νmax, cm
-1
): 3330 (br m, OH), 2872 (w), 1951 (m, C=C=C), 1490 (s), 1428 (m), 1390 
(m), 1352 (m), 1260 (w), 1198 (w), 1089 (s), 1012 (s), 872 (s), 830 (s). 
HRMS (ESI): calculated for C10H10OCl [M+H]
+
 181.0415, found 181.0411. 
Rf = 0.31 (20% EtOAc/hexane). 
 
 
N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide (67): Following 
the general procedure for allene formation with aldehyde-derived hydrazones using 4-methyl-
N-(prop-2-yn-1-yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol) and (4-
bromobenzylidene)hydrazine, purified by silica gel column chromatography (eluent: 25% 
EtOAc/hexane) and trituration with Et2O provided the title compound as an off-white 
amorphous solid (69.9 mg, 0.185 mmol, 92%), m.p. 122-124 °C (lit. m.p.
190
 120-123 °C). 
Data are consistent with a reported example.
190 
 
1
H NMR (600 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 2 H, H10), 7.39 (d, J = 8.4 Hz, 2 H, H2), 
7.27 (d, J = 8.2 Hz, 2 H, H11), 7.05 (d, J = 8.4 Hz, 2 H, H3), 6.15 (dt, J = 6.0, 3.1 Hz, 1 H, 
H5), 5.53 (q, J = 6.0 Hz, 1 H, H7), 4.69 (t, J = 5.7 Hz, 1 H, NH), 3.73 – 3.67 (m, 2 H, H8), 
2.42 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 204.9 (C6), 143.8 (C9), 137.0 (C12), 132.4 (C1), 131.9 (C2), 
129.9 (C11), 128.6 (C3), 127.3 (C10), 121.4 (C4), 97.2 (C5), 92.7 (C7), 41.6 (C8), 21.7 
(C13). 
FTIR (νmax, cm
-1
): 3229 (m, NH), 1948 (w, C=C=C), 1597 (w), 1486 (m), 1454 (m), 1423 
(m), 1346 (m), 1318 (m), 1305 (m), 1289 (m), 1235 (w), 1155 (s), 1124 (m), 1089 (m), 1067 
(m), 1058 (m), 1008 (m), 916 (m), 877 (m), 828 (m), 817 (s), 809 (m). 
HRMS (ESI): calculated for C17H17NO2SBr [M+H]
+
 378.0158, found 378.0150. 
Rf = 0.31 (25% EtOAc/hexane). 
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4-(4-Bromophenyl)buta-2,3-dien-1-ol (68): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using propargyl alcohol (64) (11.2 mg, 
0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 25% EtOAc/hexane) provided the title compound as a colourless oil 
(44.9 mg, 0.199 mmol, 99%). Data are consistent with a reported example.
120 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.16 (d, J = 8.4 Hz, 2 H, H3), 
6.25 (dt, J = 6.0, 2.9 Hz, 1 H, H5), 5.77 (q, J = 6.0 Hz, 1 H, H7), 4.25 (br s, 2 H, H8), 1.84 (br 
s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 204.5 (C6), 133.0 (C1), 131.9 (C2), 128.5 (C3), 121.0 (C4), 
96.44 (C5/C7), 96.37 (C5/C7), 60.3 (C8). 
FTIR (νmax, cm
-1
): 3344 (br m, OH), 2876 (w), 1950 (m, C=C=C), 1698 (m), 1588 (m), 1488 
(s), 1428 (m), 1388 (m), 1264 (m), 1204 (m), 1175 (m), 1103 (m), 1069 (s), 1041 (m), 1008 
(s), 873 (m), 828 (s).  
HRMS (ESI): calculated for C10H10OBr [M+H]
+
 224.9910, found 224.9901. 
Rf = 0.27 (25% EtOAc/hexane). 
 
 
N-(4-(3-Methoxyphenyl)buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide (69): 
Following the general procedure for allene formation with aldehyde-derived hydrazones 
using 4-methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol) and (3-
methoxybenzylidene)hydrazine, purified by silica gel column chromatography (eluent: 25% 
EtOAc/hexane) provided the title compound as a colourless oil (53.5 mg, 0.162 mmol, 81%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.76 (d, J = 8.2 Hz, 2 H, H13), 7.28 (d, J = 8.2 Hz, 2 H, 
H14), 7.21 (t, J = 7.8 Hz, 1 H, H6), 6.81 (d, J = 7.8 Hz, 1 H, H7), 6.79 – 6.76 (m, 2 H, H3 
and H5), 6.18 (dt, J = 6.0, 3.0 Hz, 1 H, H8), 5.53 (q, J = 6.0 Hz, 1 H, H10), 4.96 (t, J = 
6.0 Hz, 1 H, NH), 3.80 (s, 3 H, H1), 3.69 (td, J = 6.0, 3.0 Hz, 2 H, H11), 2.42 (s, 3 H, H16). 
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13
C NMR (150 MHz, CDCl3): δ 204.8 (C9), 159.9 (C2), 143.6 (C12), 136.8 (C15), 134.7 
(C4), 129.8 (C14), 129.7 (C6), 127.2 (C13), 119.7 (C7), 113.2 (C5), 112.2 (C3), 97.8 (C8), 
92.1 (C10), 55.3 (C1), 41.7 (C11), 21.6 (C16). 
FTIR (νmax, cm
-1
): 3275 (w, NH), 1954 (w, C=C=C), 1598 (m), 1490 (m), 1454 (m), 1438 
(m), 1321 (m), 1291 (m), 1265 (m), 1153 (s), 1092 (m), 1040 (m), 876 (m), 836 (m), 813 (m). 
HRMS (ESI): calculated for C18H19NO3SNa [M+Na]
+
 352.0978, found 352.0961. 
Rf = 0.24 (25% EtOAc/hexane). 
 
 
4-(3-Methoxyphenyl)buta-2,3-dien-1-ol (70): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using propargyl alcohol (64) (11.2 mg, 
0.2 mmol) and (3-methoxybenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 25% EtOAc/hexane), provided the title compound as a colourless oil 
(32.6 mg, 0.185 mmol, 93%). Data are consistent with a reported example.
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1
H NMR (600 MHz, CDCl3): δ 7.23 (t, J = 7.9 Hz, 1 H, H6), 6.90 (d, J = 7.9 Hz, 1 H, H7), 
6.85 (m, 1 H, H3), 6.77 (dd, J = 8.9, 2.4 Hz, 1 H, H5), 6.29 (dt, J = 6.0, 2.9 Hz, 1 H, H8), 
5.78 (q, J = 6.0 Hz, 1 H, H10), 4.25 (br s, 2 H, H11), 3.80 (s, 3 H, H1), 1.94 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 204.4 (C9), 159.9 (C2), 135.3 (C4), 129.7 (C6), 119.5 (C7), 
112.9 (C5), 112.2 (C3), 97.2 (C8), 96.0 (C10), 60.4 (C11), 55.3 (C1). 
FTIR (νmax, cm
-1
): 3360 (br m, OH), 2940 (m), 2836 (w), 1950 (m, C=C=C), 1598 (s), 1584 
(s), 1490 (s), 1466 (s), 1438 (m), 1408 (m), 1317 (m), 1265 (s), 1154 (s), 1111 (w), 1041 (s), 
1011 (m), 875 (m). 
HRMS (ESI): calculated for C11H12O2Na [M+Na]
+
 199.0730, found 199.0720. 
Rf = 0.20 (25% EtOAc/hexane). 
 
 
4-(4-Hydroxybuta-1,2-dien-1-yl)benzonitrile (71): Following the general procedure for 
allene formation with aldehyde-derived hydrazones using propargyl alcohol (64) (11.2 mg, 
0.2 mmol) and 4-(hydrazonomethyl)benzonitrile, purified by silica gel column 
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chromatography (eluent: 35% EtOAc/hexane) provided the title compound as a colourless 
gum (28.4 mg, 0.166 mmol, 83%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 8.3 Hz, 2 H, H3), 7.38 (d, J = 8.3 Hz, 2 H, H4), 
6.33 (dt, J = 6.1, 2.9 Hz, 1 H, H6), 5.87 (q, J = 6.0 Hz, 1 H, H8), 4.33 – 4.27 (m, 2 H, H9), 
1.65 (t, J = 5.9 Hz, 1 H, OH). 
13
C NMR (100 MHz, CDCl3): δ 205.8 (C7), 139.3 (C5), 132.6 (C3), 127.4 (C4), 119.1 (C1), 
110.6 (C2), 96.9 (C8), 96.5 (C6), 60.1 (C9). 
FTIR (νmax, cm
-1
): 3406 (br m, OH), 2875 (w), 2227 (s, C≡N), 1948 (m, C=C=C), 1605 (s), 
1505 (m), 1415 (m), 1202 (w), 1175 (m), 1108 (m), 1016 (s), 876 (m), 844 (s). 
HRMS (ESI): calculated for C11H10NO [M+H]
+
 172.0757, found 172.0753. 
Rf = 0.22 (35% EtOAc/hexane). 
 
 
(E)-6-Phenylhexa-2,3,5-trien-1-ol (72): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using propargyl alcohol (64) (11.2 mg, 
0.2 mmol) and ((E)-3-phenylallylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 25% EtOAc/hexane), provided the title compound as a yellow oil 
(16.4 mg, 0.095 mmol, 48%). Data are consistent with a reported example.
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1
H NMR (600 MHz, CDCl3): δ 7.38 (d, J = 7.6 Hz, 2 H, H3), 7.31 (t, J = 7.6 Hz, 2 H, H2), 
7.23 (t, J = 7.6 Hz, 1 H, H1), 6.61 (dd, J = 15.7, 10.3 Hz, 1 H, H6), 6.53 (d, J = 15.7 Hz, 1 H, 
H5), 6.17 (ddd, J = 10.3, 5.7, 2.8 Hz, 1 H, H7), 5.63 (q, J = 5.7 Hz, 1 H, H9), 4.21 (dt, J = 5.7, 
2.8 Hz, 2 H, H10), 1.71 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 207.2 (C8), 137.1 (C4), 131.4 (C5), 128.7 (C2), 127.7 (C1), 
126.4 (C3), 124.1 (C6), 97.4 (C7), 93.7 (C9), 60.6 (C10). 
FTIR (νmax, cm
-1
): 3340 (m, OH), 3027 (w), 2929 (w), 1941 (m, C=C=C), 1597 (w), 1494 
(w), 1450 (m), 1071 (m), 1009 (s), 964 (s), 877 (w). 
HRMS (ESI): calculated for C12H13O [M+H]
+
 173.0961, found 173.0958. 
Rf = 0.27 (25% EtOAc/hexane). 
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1-Chloro-4-(3-cyclopentylpropa-1,2-dien-1-yl)benzene (73): Following the general 
procedure for allene formation with aldehyde-derived hydrazones using cyclopentylacetylene 
(18.8 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a colourless oil (38.6 mg, 
0.176 mmol, 88%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.6 Hz, 2 H, H2), 7.20 (d, J = 8.6 Hz, 2 H, H3), 
6.10 (dd, J = 6.4, 2.8 Hz, 1 H, H5), 5.63 (t, J = 6.4 Hz, 1 H, H7), 2.64 – 2.55 (m, 1 H, H8), 
1.88 – 1.81 (m, 2 H, H9a and H12a), 1.72 – 1.54 (m, 4 H, H10 and H11), 1.49 – 1.41 (m, 2 H, 
H9b and H12b). 
13
C NMR (150 MHz, CDCl3): δ 204.3 (C6), 133.9 (C1), 132.3 (C4), 128.8 (C2), 127.8 (C3), 
100.6 (C7), 94.6 (C5), 39.3 (C8), 33.0 (C9/C12), 32.9 (C9/C12), 25.05 (C10/C11), 25.04 
(C10/C11).  
FTIR (νmax, cm
-1
): 2953 (m), 2868 (w), 1950 (w, C=C=C), 1491 (s), 1453 (w), 1387 (w), 
1092 (m), 1013 (w), 877 (w), 833 (m). 
HRMS (ESI): calculated for C14H16Cl [M+H]
+
 219.0935, found 219.0928. 
Rf = 0.68 (hexane). 
 
 
1-Chloro-4-(3-cyclopropylpropa-1,2-dien-1-yl)benzene (74): Following the general 
procedure for allene formation with aldehyde-derived hydrazones using cyclopropylacetylene 
(106) (13.2 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel 
column chromatography (eluent: hexane) provided the title compound as a colourless oil 
(38.2 mg, 0.200 mmol, 99%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 
6.17 (d, J = 6.4 Hz, 1 H, H5), 5.45 (t, J = 6.4 Hz, 1 H, H7), 1.38 – 1.33 (m, 1 H, H8), 0.80 – 
0.74 (m, 2 H, H9a and H10a), 0.50 – 0.40 (m, 2 H, H9b and H10b). 
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13
C NMR (150 MHz, CDCl3): δ 205.1 (C6), 133.6 (C4), 132.5 (C1), 128.8 (C2), 128.0 (C3), 
100.1 (C7), 95.5 (C5), 9.5 (C8), 7.2 (C9/C10), 7.1 (C9/C10). 
FTIR (νmax, cm
-1
): 3083 (w), 3005 (w), 1950 (w, C=C=C), 1490 (s), 1398 (w), 1252 (w), 
1091 (s), 1048 (w), 1013 (m), 929 (w), 875 (m), 832 (s). 
HRMS (ESI): calculated for C12H12Cl [M+H]
+
 191.0622, found 191.0614. 
Rf = 0.60 (hexane). 
 
 
1-Chloro-4-(3-phenylpropa-1,2-dien-1-yl)benzene (75): Following the general procedure 
for allene formation with aldehyde-derived hydrazones using phenylacetylene (20.4 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a yellow oil (40.4 mg, 
0.183 mmol, 92%). Data are consistent with a reported example.
193
 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 – 7.23 (m, 9 H, ArH), 6.61 (d, J = 6.6 Hz, 1 H, H5/H7), 
6.56 (d, J = 6.6 Hz, 1 H, H5/H7). 
13
C NMR (150 MHz, CDCl3): δ 208.0 (C6), 133.4 (C1/C4/C8), 133.1 (C1/C4/C8), 132.3 
(C1/C4/C8), 129.0 (CH), 128.9 (CH), 128.3 (CH), 127.7 (C11), 127.2 (CH), 99.0 (C5/C7), 
97.7 (C5/C7). 
FTIR (νmax, cm
-1
): 3030 (w), 1937 (w, C=C=C), 1597 (w), 1489 (s), 1458 (w), 1421 (w), 
1386 (w), 1254 (w), 1193 (w), 1091 (s), 1013 (s), 964 (w), 913 (m), 878 (s), 832 (s). 
HRMS (ESI): calculated for C15H12Cl [M+H]
+
 227.0622, found 227.0614. 
Rf = 0.45 (hexane). 
 
 
1-Chloro-4-(3-(cyclohex-1-en-1-yl)propa-1,2-dien-1-yl)benzene (76): Following the 
general procedure for allene formation with aldehyde-derived hydrazones using 1-
ethynylcyclohexene (21.2 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified 
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by silica gel column chromatography (eluent: hexane) provided the title compound as a 
colourless oil (29.0 mg, 0.126 mmol, 63%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.6 Hz, 2 H, H2), 7.22 (d, J = 8.6 Hz, 2 H, H3), 
6.35 (br d, J = 6.4 Hz, 1 H, H7), 6.26 (d, J = 6.4 Hz, 1 H, H5), 5.78 (br s, 1 H, H13), 2.17 – 
2.12 (m, 2 H, H12), 2.12 – 2.06 (m, 1 H, H9a), 2.02 – 1.94 (m, 1 H, H9b), 1.68 – 1.58 (m, 
4 H, H10 and H11). 
13
C NMR (150 MHz, CDCl3): δ 206.7 (C6), 133.5 (C1), 132.6 (C4), 131.7 (C8), 128.9 (C2), 
128.0 (C3), 127.7 (C13), 102.1 (C5), 96.8 (C7), 26.1 (C9/C12), 25.9 (C9/C12), 22.6 
(C10/C11), 22.5 (C10/C11). 
FTIR (νmax, cm
-1
): 2928 (m), 2858 (w), 2833 (w), 1932 (w, C=C=C), 1703 (w), 1592 (w), 
1490 (s), 1448 (w), 1434 (w), 1386 (w), 1348 (w), 1250 (w), 1136 (w), 1092 (s), 1013 (s), 
917 (w), 884 (m), 846 (s), 831 (s). 
HRMS (ESI): calculated for C15H16Cl [M+H]
+
 231.0935, found 231.0928. 
Rf = 0.53 (hexane). 
 
 
tert-Butyl (4-(4-chlorophenyl)buta-2,3-dien-1-yl)carbamate (77): Following the general 
procedure for allene formation with aldehyde-derived hydrazones using N-Boc-
propargylamine (31.0 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by 
silica gel column chromatography (eluent: 15% EtOAc/hexane) provided the title compound 
as a colourless oil (51.8 mg, 0.185 mmol, 93%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.5 Hz, 2 H, H2), 7.20 (d, J = 8.5 Hz, 2 H, H3), 
6.23 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.64 (q, J = 6.4 Hz, 1 H, H7), 4.74 (br s, 1 H, NH), 3.92 – 
3.72 (m, 2 H, H8), 1.39 (s, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 155.8 (C9), 132.9 (C1), 132.6 (C4), 128.9 (C2), 
128.2 (C3), 96.6 (C5), 94.1 (C7), 79.7 (C10), 39.1 (C8), 28.5 (C11). 
FTIR (νmax, cm
-1
): 3344 (w, NH), 2978 (w), 2932 (w), 1953 (w, C=C=C), 1690 (s, C=O), 
1490 (s), 1455 (w), 1430 (w), 1391 (m), 1366 (m), 1273 (m), 1248 (s), 1162 (s), 1091 (m), 
1051 (w), 1013 (m), 952 (w), 912 (w), 860 (w), 831 (m).  
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HRMS (ESI): calculated for C15H18NO2ClNa [M+Na]
+
 302.0918, found 302.0907. 
Rf = 0.33 (15% EtOAc/hexane). 
 
 
1-(5-Bromopenta-1,2-dien-1-yl)-4-chlorobenzene (78): Following the general procedure 
for allene formation with aldehyde-derived hydrazones using 4-bromo-1-butyne (26.6 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a colourless oil (42.2 mg, 
0.164 mmol, 82%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H2), 7.24 (d, J = 8.6 Hz, 2 H, H3), 
6.18 (dt, J = 6.6, 2.8 Hz, 1 H, H5), 5.62 (q, J = 6.6 Hz, 1 H, H7), 3.48 (td, J = 6.6, 1.2 Hz, 2 H, 
H9), 2.75 – 2.64 (m, 2 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 206.0 (C6), 132.81 (C1/C4), 132.76 (C1/C4), 128.9 (C2), 
128.2 (C3), 95.1 (C5), 93.0 (C7), 32.2 (C8), 31.8 (C9). 
FTIR (νmax, cm
-1
): 2967 (w), 1950 (w, C=C=C), 1727 (m), 1589 (m), 1491 (s), 1402 (m), 
1267 (m), 1208 (m), 1090 (s), 1014 (m), 873 (m), 832 (s). 
HRMS (ESI): calculated for C11H11BrCl [M+H]
+
 256.9727, found 256.9720. 
Rf = 0.35 (hexane). 
 
 
1-Bromo-4-(5-bromopenta-1,2-dien-1-yl)benzene (79): Following the general procedure 
for allene formation with aldehyde-derived hydrazones using 4-bromo-1-butyne (26.6 mg, 
0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a colourless oil (56.2 mg, 
0.186 mmol, 93%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.5 Hz, 2 H, H2), 7.18 (d, J = 8.5 Hz, 2 H, H3), 
6.16 (dt, J = 6.6, 2.8 Hz, 1 H, H5), 5.61 (q, J = 6.6 Hz, 1 H, H7), 3.48 (td, J = 6.6, 1.1 Hz, 2 H, 
H9), 2.75 – 2.64 (m, 2 H, H8). 
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13
C NMR (150 MHz, CDCl3): δ 205.9 (C6), 133.2 (C1), 131.8 (C2), 128.5 (C3), 120.8 (C4), 
95.2 (C5), 93.1 (C7), 32.1 (C8), 31.8 (C9). 
FTIR (νmax, cm
-1
): 2963 (w), 1949 (w, C=C=C), 1700 (w), 1588 (w), 1487 (s), 1429 (w), 
1386 (w), 1265 (m), 1207 (m), 1102 (w), 1069 (s), 1009 (s), 964 (w), 928 (w), 871 (s), 828 
(s). 
HRMS (ESI): calculated for C11H11Br2 [M+H]
+
 300.9222, found 300.9209. 
Rf = 0.27 (hexane). 
 
 
1-Chloro-4-(7-iodohepta-1,2-dien-1-yl)benzene (80): Following the general procedure for 
allene formation with aldehyde-derived hydrazones using 6-iodo-1-hexyne (41.6 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a colourless oil (50.1 mg, 
0.151 mmol, 75%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.5 Hz, 2 H, H2), 7.20 (d, J = 8.5 Hz, 2 H, H3), 
6.11 (dt, J = 6.6, 3.0 Hz, 1 H, H5), 5.57 (q, J = 6.6 Hz, 1 H, H7), 3.19 (t, J = 7.0 Hz, 2 H, 
H11), 2.20 – 2.12 (m, 2 H, H8), 1.94 – 1.86 (m, 2 H, H10), 1.65 – 1.54 (m, 2 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 205.4 (C6), 133.5 (C1), 132.4 (C4), 128.9 (C2), 127.9 (C3), 
94.9 (C7), 94.3 (C5), 33.0 (C10), 29.9 (C9), 27.7 (C8), 6.6 (C11). 
FTIR (νmax, cm
-1
): 2934 (w), 1949 (w, C=C=C), 1723 (m), 1703 (m), 1588 (m), 1490 (s), 
1455 (m), 1427 (m), 1402 (m), 1265 (m), 1207 (m), 1169 (m), 1090 (s), 1013 (s), 878 (m), 
820 (s).  
HRMS (ESI): calculated for C13H15ClI [M+H]
+
 332.9901, found 332.9894. 
Rf = 0.33 (hexane). 
 
 
1-Chloro-4-(4,4-diethoxybuta-1,2-dien-1-yl)benzene (81): Following the general procedure 
for allene formation with aldehyde-derived hydrazones using 3,3-diethoxy-1-propyne 
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(25.6 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 4% EtOAc/hexane) provided the title compound as a colourless gum 
(47.8 mg, 0.199 mmol, 99%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H2), 7.22 (d, J = 8.6 Hz, 2 H, H3), 
6.28 (dd, J = 6.1, 1.5 Hz, 1 H, H5), 5.66 (t, J = 6.1 Hz, 1 H, H7), 5.06 (dd, J = 6.1, 1.5 Hz, 
1 H, H8), 3.71 (dq overlaps with 3.68 peak, J = 9.5, 7.1 Hz, 1 H, H9a/H11a), 3.68 (dq 
overlaps with 3.71 peak, J = 9.5, 7.1 Hz, 1 H, H9a/H11a), 3.58 (two superimposed tq, J = 9.5, 
7.1 Hz, 2 H, H9b and H11b), 1.24 (t, J = 7.1 Hz, 3 H, H10/H12), 1.23 (t, J = 7.1 Hz, 3 H, 
H10/H12). 
13
C NMR (150 MHz, CDCl3): δ 205.8 (C6), 133.0 (C4), 132.3 (C1), 128.9 (C2), 128.2 (C3), 
100.2 (C8), 96.0 (C5), 95.4 (C7), 61.7 (C9/C11), 61.5 (C9/C11), 15.31 (C10/C12), 15.28 
(C10/C12). 
FTIR (νmax, cm
-1
): 2976 (w), 2881 (w), 1956 (w, C=C=C), 1491 (m), 1432 (w), 1388 (w), 
1330 (w), 1090 (s), 1053 (s), 1013 (m), 872 (w), 833 (m). 
HRMS (ESI): calculated for C14H17OClNa [M+Na]
+
 275.0809, found 275.0800. 
Rf = 0.31 (4% EtOAc/hexane). 
 
 
(2RS,3RS)-2-(((4-(4-Chlorophenyl)buta-2,3-dien-1-yl)oxy)methyl)-3-phenyloxirane (82): 
Following the general procedure for allene formation with aldehyde-derived hydrazones 
using (2RS,3RS)-2-phenyl-3-((prop-2-yn-1-yloxy)methyl)oxirane (37.6 mg, 0.2 mmol) and 
(4-chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography (eluent: 
10% EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers 
(1:1) as a colourless oil (55.4 mg, 0.177 mmol, 89%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 – 7.33 (m, 2 H, H14), 7.33 – 7.29 (m, 1 H, H15), 7.29 – 
7.25 (m, 4 H, H2 and H13), 7.23 (two superimposed d, J = 8.3 Hz, 2 H, H3), 6.26 – 6.22 (m, 
1 H, H5), 5.72 (two superimposed q, J = 6.5 Hz, 1 H, H7), 4.26 – 4.22 (m, 2 H, H8), 3.89 
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(two superimposed ddd, J = 11.5, 8.9, 3.0 Hz, 1 H, H9a), 3.80 (two superimposed dd, J = 7.5, 
3.0 Hz, 1 H, H11), 3.68 – 3.66 (m, 1 H, H9b), 3.25 – 3.22 (m, 1 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 206.16 and 206.13 (C6), 136.87 and 136.86 (C12), 132.89 
and 132.88 (C4), 132.45 and 132.44 (C1), 128.94 and 128.93 (C2), 128.6 (C14), 128.4 (C15), 
128.16 and 128.15 (C3), 125.81 and 125.80 (C13), 95.0 (C5), 92.9 (C7), 69.92 and 69.91 
(C9), 69.03 and 69.01 (C8), 61.1 (C10), 56.04 and 56.01 (C11). 
FTIR (νmax, cm
-1
): 2990 (w), 2857 (w), 1951 (w, C=C=C), 1490 (m), 1462 (w), 1431 (w), 
1391 (w), 1352 (w), 1308 (w), 1242 (w), 1201 (w), 1090 (s), 1013 (m), 969 (w), 873 (s), 832 
(s). 
HRMS (ESI): calculated for C19H17O2ClNa [M+Na]
+
 335.0809, found 335.0804. 
Rf = 0.30 (10% EtOAc/hexane). 
 
 
7-(4-Chlorophenyl)hepta-5,6-dienenitrile (83): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using 5-hexynenitrile (18.6 mg, 0.2 mmol) and 
(4-chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography (eluent: 
15% EtOAc/hexane) provided the title compound as a colourless oil (40.7 mg, 0.187 mmol, 
93%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H2), 7.19 (d, J = 8.6 Hz, 2 H, H3), 
6.16 (dt, J = 6.4, 3.1 Hz, 1 H, H5), 5.59 (q, J = 6.4 Hz, 1 H, H7), 2.40 (t, J = 7.1 Hz, 2 H, 
H10), 2.33 – 2.26 (m, 2 H, H8), 1.90 – 1.79 (m, 2 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 205.5 (C6), 133.0 (C1), 132.7 (C4), 129.0 (C2), 127.9 (C3), 
119.4 (C11), 95.1 (C5), 93.6 (C7), 27.4 (C8), 24.6 (C9), 16.7 (C10). 
FTIR (νmax, cm
-1
): 2937 (w), 2247 (w, C≡N), 1950 (w, C=C=C), 1732 (w), 1591 (w), 1499 
(s), 1424 (w), 1390 (w), 1260 (w), 1174 (w), 1089 (s), 1013 (m), 880 (m), 832 (s). 
HRMS (ESI): calculated for C13H13NCl [M+H]
+
 218.0731, found 218.0722. 
Rf = 0.25 (15% EtOAc/hexane). 
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3-(4-Chloro)phenylpropa-1,2-dienylferrocene (84): Following the general procedure for 
allene formation with aldehyde-derived hydrazones using ethynylferrocene (42.0 mg, 
0.2 mmol) and (3-methoxybenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 4% EtOAc/hexane), provided the title compound as a red oil (61.0 
mg, 0.185 mmol, 92%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (t, J = 8.1 Hz, 1 H, H6), 6.98 (d, J = 8.1 Hz, 1 H, H5), 
6.94 (s, 1 H, H3), 6.81 (d, J = 8.1 Hz, 1 H, H7), 6.34 (d, J = 6.4 Hz, 1 H, H10), 6.31 (d, J = 
6.4 Hz, 1 H, H8), 4.36 (s, 1 H, H12/H15), 4.32 (s, 1 H, H12/H15), 4.23 (s, 2 H, H13 and 
H14), 4.21 (s, 5 H, H16), 3.83 (s, 3 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 206.2 (C9), 160.0 (C2), 135.8 (C4), 129.7 (C6), 119.6 (C5), 
112.9 (C7), 112.1 (C3), 97.2 (C8), 95.2 (C10), 79.7 (C11), 69.4 (C16), 68.8 (C13/C14), 68.7 
(C13/C14), 67.7 (C12/C15), 67.1 (C12/C15), 55.3 (C1). 
FTIR (νmax, cm
-1
): 3086 (w), 2939 (w), 2834 (w), 1936 (w, C=C=C), 1595 (m), 1581 (m), 
1488 (m), 1464 (m), 1452 (m), 1435 (m), 1410 (w), 1316 (w), 1291 (m), 1264 (s), 1224 (m), 
1152 (m), 1105 (m), 1044 (s), 1000 (m), 924 (w), 873 (m), 817 (s). 
HRMS (ESI): calculated for C20H18OFe [M]
+
 330.0702, found 330.0687. 
Rf = 0.41 (4% EtOAc/hexane). 
 
 
5-(4-Chlorophenyl)penta-3,4-dien-1-ol (85): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using 3-butyn-1-ol (14.0 mg, 0.2 mmol) and (4-
chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography (eluent:    
25% EtOAc/hexane) provided the title compound as a colourless oil (35.2 mg, 0.181 mmol, 
90%). 
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1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.6 Hz, 2 H, H2), 7.21 (d, J = 8.6 Hz, 2 H, H3), 
6.14 (dt, J = 6.6, 2.9 Hz, 1 H, H5), 5.61 (q, J = 6.6 Hz, 1 H, H7), 3.77 (t, J = 6.2 Hz, 2 H, H9), 
2.43 – 2.35 (m, 2 H, H8), 1.69 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 205.9 (C6), 133.1 (C1), 132.6 (C4), 128.9 (C2), 127.9 (C3), 
94.3 (C5), 92.0 (C7), 62.0 (C9), 32.1 (C8). 
FTIR (νmax, cm
-1
): 3319 (br w, OH), 2284 (w), 1952 (w, C=C=C), 1491 (s), 1390 (w), 1090 
(m), 1048 (m), 1013 (m), 877 (m), 834 (m). 
HRMS (ESI): calculated for C11H12OCl [M+H]
+
 195.0571, found 195.0564. 
Rf = 0.22 (25% EtOAc/hexane). 
 
 
5-(4-Chlorophenyl)penta-3,4-dien-2-ol (86): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using 3-butyn-2-ol (14.0 mg, 0.2 mmol) and (4-
chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography (eluent:    
20% EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers 
(1:1) as a colourless oil (30.2 mg, 0.165 mmol, 83%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (two superimposed d, J = 8.5 Hz, 2 H, H2), 7.21 (two d, 
J = 8.5 Hz, 2 H, H3), 6.28 – 6.25 (m, 1 H, H5), 5.74 (two t, J = 6.0 Hz, 1 H, H7), 4.52 – 4.44 
(m, 1 H, H8), 1.83 (two superimposed br s, 1 H, OH), 1.38 (two d, J = 6.4 Hz, 3 H, H9).  
13
C NMR (150 MHz, CDCl3): δ 203.40 and 203.37 (C6), 132.9 (C1), 132.63 and 132.56 
(C4), 129.0 (C2), 128.04 and 128.03 (C3), 101.38 and 101.37 (C7), 96.8 and 96.6 (C5), 66.26 
and 66.00 (C8), 23.79 and 23.71 (C9). 
FTIR (νmax, cm
-1
): 3358 (br w, OH), 2978 (w), 1951 (w, C=C=C), 1701 (m), 1590 (m), 1490 
(m), 1402 (m), 1376 (m), 1265 (m), 1207 (m), 1172 (m), 1090 (s), 1013 (s), 924 (m), 878 
(m), 821 (s). 
HRMS (ESI+): calculated for C11H12OCl [M+H]
+
 195.0571, found 195.0565. 
Rf = 0.25 (20% EtOAc/hexane). 
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4-(4-Chlorophenyl)-1-phenylbuta-2,3-dien-1-ol (87): Following the general procedure for 
allene formation with aldehyde-derived hydrazones using 3-butyn-2-ol (14.0 mg, 0.2 mmol) 
and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography 
(eluent: 15% EtOAc/hexane), provided the title compound as separable diastereomers (1:1) as 
off-white amorphous solids (A: 23.7 mg, 0.092 mmol; B: 26.3 mg, 0.102 mmol; combined 
yield 97%), m.p. 85-88 °C for diastereomer A and m.p. 92-95 °C for diastereomer B. 
 
Diastereomer A: 
1
H NMR (600 MHz, CDCl3): δ 7.44 (d, J = 7.3 Hz, 2 H, H10), 7.39 (t, J = 7.3 Hz, 2 H, H11), 
7.32 (t, J = 7.3 Hz, 1 H, H12), 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.24 (d, J = 8.5 Hz, 2 H, H3), 
6.33 (dd, J = 6.2, 2.5 Hz, 1 H, H5), 5.90 (t, J = 6.2 Hz, 1 H, H7), 5.39 – 5.35 (m, 1 H, H8), 
2.19 (br d, J = 3.7 Hz, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 203.8 (C6), 142.8 (C9), 133.1 (C4), 132.4 (C1), 129.0 (C2), 
128.8 (C11), 128.21 (C3), 128.17 (C12), 126.2 (C10), 100.6 (C7), 97.4 (C5), 72.3 (C8). 
FTIR (νmax, cm
-1
): 3295 (br m, OH), 3062 (w), 1950 (w, C=C=C), 1499 (s), 1450 (m), 1430 
(w), 1192 (w), 1090 (m), 1013 (s), 879 (m), 841 (m). 
HRMS (ESI): calculated for C16H14OCl [M+H]
+
 257.0728, found 257.0717. 
Rf = 0.25 (15% EtOAc/hexane). 
 
Diastereomer B: 
1
H NMR (600 MHz, CDCl3): δ 7.44 (d, J = 7.3 Hz, 2 H, H10), 7.38 (t, J = 7.3 Hz, 2 H, H11), 
7.32 (t, J = 7.3 Hz, 1 H, H12), 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.18 (d, J = 8.5 Hz, 2 H, H3), 
6.33 (dd, J = 6.3, 2.2 Hz, 1 H, H4), 5.89 (t, J = 6.3 Hz, 1 H, H7), 5.42 – 5.38 (m, 1 H, H8), 
2.20 (br d, J = 6.6 Hz, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 204.1 (C6), 142.9 (C9), 133.1 (C4), 132.4 (C1), 129.0 (C2), 
128.8 (C11), 128.17 (C3), 128.16 (C12), 126.1 (C10), 100.5 (C7), 97.1 (C5), 72.5 (C8). 
FTIR (νmax, cm
-1
): 3390 (br w, OH), 3066 (w), 3033 (w), 1949 (w, C=C=C), 1490 (s), 1455 
(m), 1426 (w), 1386 (w), 1254 (m), 1197 (w), 1109 (w), 1090 (s), 1045 (m), 1028 (w), 1012 
(m), 922 (w), 886 (m), 840 (s), 828 (m), 814 (w). 
5. Experimental (Appendix) 
142 
 
HRMS (ESI): calculated for C16H14OCl [M+H]
+
 257.0728, found 257.0717. 
Rf = 0.21 (15% EtOAc/hexane). 
 
 
5-(4-Chlorophenyl)-2-methylpenta-3,4-dien-2-ol (88): Following the general procedure for 
allene formation with aldehyde-derived hydrazones using 2-methyl-3-butyn-2-ol (16.8 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 20% EtOAc/hexane) provided the title compound as a colourless oil 
(34.0 mg, 0.163 mmol, 82%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.5 Hz, 2 H, H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 
6.28 (d, J = 6.4 Hz, 1 H, H5), 5.80 (d, J = 6.4 Hz, 1 H, H7), 1.83 (br s, 1 H, OH), 1.429 (s, 
3 H, H9/H10), 1.426 (s, 3 H, H9/H10). 
13
C NMR (150 MHz, CDCl3): δ 202.2 (C6), 132.9 (C4), 132.7 (C1), 129.0 (C2), 127.9 (C3), 
105.6 (C7), 97.1 (C5), 70.4 (C8), 30.3 (C9/C10), 30.2 (C9/C10). 
FTIR (νmax, cm
-1
): 3368 (br w, OH), 2976 (m), 2931 (w), 1951 (w, C=C=C), 1700 (m), 1592 
(w), 1491 (s), 1426 (w), 1375 (m), 1149 (s), 1092 (s), 1014 (s), 967 (m), 878 (m), 834 (s). 
HRMS (ESI): calculated for C12H14OCl [M+H]
+
 209.0728, found 209.0720. 
Rf = 0.26 (20% EtOAc/hexane). 
 
 
(8R,9S,10R,13S,14S,17R)-17-(3-(4-Chlorophenyl)propa-1,2-dien-1-yl)-17-hydroxy-13-
methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-
cyclopenta[a]phenanthren-3-one (89): Following the general procedure for allene 
formation with aldehyde-derived hydrazones using norethindrone (59.7 mg, 0.2 mmol) and 
(4-chlorobenzylidene)hydrazine (62), purified by silica gel column chromatography 
(diastereomer A – eluent: 40% EtOAc/hexane, then 80% Et2O/hexane; diastereomer B – 
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eluent: 40% EtOAc/hexane), provided the title compound as separable diastereomers (1.5:1) 
as off-white foams (A: 33.6 mg, 0.079 mmol; B: 20.0 mg, 0.047 mmol; combined yield 63%). 
 
Diastereomer A: 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H24), 7.23 (d, J = 8.6 Hz, 2 H, 
H23), 6.30 (d, J = 6.2 Hz, 1 H, H21), 5.84 (s, 1 H, H4), 5.80 (d, J = 6.2 Hz, 1 H, H19), 2.51 – 
2.40 (m, 2 H, steroidal H/OH), 2.31 – 2.24 (m, 3 H, steroidal H/OH), 2.14 – 2.09 (m, 1 H, 
steroidal H/OH), 2.05 – 1.99 (m, 1 H, steroidal H/OH), 1.94 – 1.83 (m, 3 H, steroidal H/OH), 
1.67 – 1.45 (m, 4 H, steroidal H/OH), 1.42 – 1.25 (m, 5 H, steroidal H/OH), 1.11 – 1.03 (m, 
1 H, steroidal H/OH), 0.99 (s, 3 H, H18), 0.91 – 0.84 (m, 1 H, steroidal H/OH). 
13
C NMR (150 MHz, CDCl3): δ 202.6 (C20), 200.0 (C3), 166.7 (C5), 133.0 (C22), 132.8 
(C25), 129.0 (C24), 128.0 (C23), 124.7 (C4), 102.8 (C21), 97.2 (C19), 83.6 (C17), 49.5 (CH), 
48.9 (C14), 47.1 (C13), 42.7 (C10), 41.2 (CH), 36.72 (CH2), 36.65 (CH2), 35.6 (CH2), 32.4 
C12), 31.0 (CH2), 26.8 (CH2), 26.3 (CH2), 23.5 (CH2), 14.2 (C18). 
FTIR (νmax, cm
-1
): 3409 (br w, OH), 2932 (m), 2867 (m), 1945 (w, C=C=C), 1660 (s, C=O), 
1491 (m), 1452 (w), 1428 (w), 1362 (w), 1332 (w), 1261 (w), 1208 (w), 1130 (w), 1091 (w), 
1063 (w), 1013 (m), 968 (w), 910 (w), 883 (w), 837 (w). 
HRMS (ESI): calculated for C27H32OCl [M+H]
+
 423.2085, found 423.2069. 
Rf = 0.29 (40% EtOAc/hexane); 0.36 (80% Et2O/hexane). 
 
Diastereomer B: 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.5 Hz, 2 H, H24), 7.19 (d, J = 8.5 Hz, 2 H, 
H23), 6.30 (d, J = 6.3 Hz, 1 H, H21), 5.85 (s, 1 H, H4), 5.81 (d, J = 6.3 Hz, 1 H, H19), 2.48 – 
2.40 (m, 2 H, steroidal H), 2.33 – 2.23 (m, 3 H, steroidal H), 2.16 – 2.09 (m, 2 H, steroidal H), 
1.95 – 1.87 (m, 2 H, steroidal H), 1.84 (br s, 1 H, OH), 1.79 – 1.74 (m, 1 H, steroidal H), 1.69 
– 1.64 (m, 1 H, steroidal H), 1.61 – 1.55 (m, 1 H, steroidal H), 1.53 – 1.47 (m, 2 H, steroidal 
H), 1.42 – 1.25 (m, 4 H, steroidal H), 0.99 (s, 3 H, H18), 0.89 – 0.80 (m, 2 H, steroidal H). 
13
C NMR (150 MHz, CDCl3): δ 203.1 (C20), 200.0 (C3), 166.5 (C5), 133.0 (C22), 132.8 
(C25), 128.9 (C24), 128.0 (C23), 124.8 (C4), 102.2 (C21), 97.0 (C19), 83.4 (C17), 49.8 (CH), 
48.7 (C14), 46.8 (C13), 42.7 (C10), 41.1 (CH), 36.7 (CH2), 36.4 (CH2), 35.5 (CH2), 32.2 
(C12), 30.9 (CH2), 26.8 (CH2), 26.2 (CH2), 23.2 (CH2), 14.1 (C18). 
FTIR (νmax, cm
-1
): 3421 (br w, OH), 2932 (m), 2866 (m), 1946 (w, C=C=C), 1660 (s, C=O), 
1491 (m), 1451 (w), 1427 (w), 1362 (w), 1332 (w), 1261 (w), 1208 (w), 1131 (w), 1091 (m), 
1060 (w), 1013 (m), 967 (w), 883 (w), 836 (w). 
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HRMS (ESI): calculated for C27H32OCl [M+H]
+
 423.2085, found 423.2069. 
Rf = 0.23 (40% EtOAc/hexane). 
 
 
4-(4-((1R)-(6-Methoxyquinolin-4-yl)((2S)-5-vinylquinuclidin-2-yl)methoxy)buta-1,2-
dien-1-yl)benzonitrile (90): Following the general procedure for allene formation with 
aldehyde-derived hydrazones using norethindrone (59.7 mg, 0.2 mmol) and 4-
(hydrazonomethyl)benzonitrile, purified by silica gel column chromatography (eluent: 30% 
EtOAc/60% hexane/10% Et3N), provided the title compound as an inseparable mixture of 
diastereomers (1:1) as a brown film (78.3 mg, 0.164 mmol, 82%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.75 – 8.68 (m, 1 H, H10), 8.01 (m, 1 H, H6), 7.57 – 7.20 (m, 
7 H, ArH), 6.21 (m, 1 H, H24), 5.82 – 5.72 (m, 1 H, H22), 5.66 (m, 1 H, H19), 5.23 (br s, 1 H, 
H11), 4.95 – 4.80 (m, 2 H, H20), 4.16 – 3.95 (m, 2 H, H21), 3.93 – 3.84 (m, 3 H, H1), 3.37 – 
3.21 (m, 1 H, H13a), 3.12 – 2.98 (m, 2 H, H12 and H17a), 2.71 – 2.53 (m, 2 H, H13b and 
H17b), 2.28 – 2.16 (m, 1 H, H18), 1.80 – 1.32 (m, 5 H, H14, H15 and H16). 
13
C NMR (150 MHz, CDCl3): δ 207.2 and 206.8 (C23), 157.9 (C2), 147.6 (C10), 144.6 (C8), 
144.3 (C5), 141.9 (C19), 139.08 and 139.05 (C25), 132.44 and 132.38 (C27), 131.9 (C6), 
127.32 and 127.22 (C26), 127.19 (C4), 121.7 and 121.6 (C7), 119.5 – 118.5 (br, C9), 119.0 
(C29), 114.4 (C20), 110.34 and 110.29 (C28), 101.2 (br, C3), 95.5 and 95.2 (C24), 93.8 and 
93.5 (C22), 77.5 – 77.0 (br, obscured by CDCl3 peak, C11), 66.4 and 66.3 (C21), 60.0 (C12), 
57.3 (C17), 55.79 and 55.71 (C1), 43.4 (C13), 40.01 and 39.95 (C18), 27.87 and 27.83 (C15), 
27.78 and 27.6 (C14), 24.0 – 20.0 (br, C16). 
FTIR (νmax, cm
-1
): 2935 (m), 2865 (w), 2225 (m, C≡N), 1950 (w, C=C=C), 1620 (s), 1605 
(m), 1507 (s), 1472 (m), 1454 (m), 1432 (m), 1355 (w), 1301 (w), 1259 (m), 1240 (s), 1227 
(s), 1174 (w), 1133 (m), 1076 (s), 1030 (s), 992 (w), 910 (s), 875 (m), 843 (s), 831 (s). 
HRMS (ESI): calculated for C31H32N3O2 [M+H]
+
 478.2489, found 478.2481. 
Rf = 0.28 (30% EtOAc/60% hexane/10% Et3N). 
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4-Methyl-N-(4-phenylpenta-2,3-dien-1-yl)benzenesulfonamide (92): Following the 
general procedure for allene formation with ketone-derived hydrazones using 4-methyl-N-
(prop-2-yn-1-yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol) and (1-
phenylethylidene)hydrazine (91), purified by silica gel column chromatography (eluent: 20% 
EtOAc/hexane) provided the title compound as a colourless oil (41.7 mg, 0.133 mmol, 67%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 2 H, H11), 7.31 (m, 4 H, H2 and H3), 
7.27 (d, J = 8.2 Hz, 2 H, H12), 7.25 – 7.21 (m, 1 H, H1), 5.42 (tq, J = 5.9, 2.9 Hz, 1 H, H8), 
4.66 (t, J = 5.9 Hz, 1 H, NH), 3.67 (t, J = 5.9 Hz, 2 H, H9), 2.41 (s, 3 H, H14), 2.05 (d, J = 
2.9 Hz, 3 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 203.6 (C7), 143.6 (C4), 137.0 (C10), 136.2 (C13), 129.9 
(C12), 128.5 (C2/C3), 127.31 (C1), 127.26 (C11), 125.9 (C2/C3), 104.4 (C6), 90.0 (C8), 42.1 
(C9), 21.7 (C14), 17.1 (C5). 
FTIR (νmax, cm
-1
): 3292 (br w, NH), 2924 (w), 1950 (w, C=C=C), 1723 (w), 1681 (w), 1598 
(w), 1494 (w), 1447 (w), 1327 (m), 1267 (w), 1155 (s), 1091 (m), 909 (m), 813 (m). 
HRMS (ESI): calculated for C18H19NO2SNa [M+Na]
+
 336.1029, found 336.1022. 
Rf = 0.26 (20% EtOAc/hexane). 
 
 
tert-Butyl (4-phenylpenta-2,3-dien-1-yl)carbamate (95): Following the general procedure 
for allene formation with ketone-derived hydrazones using N-Boc-propargylamine (239) 
(31.0 mg, 0.2 mmol) and (1-phenylethylidene)hydrazine (91), purified by silica gel column 
chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a colourless oil 
(38.2 mg, 0.147 mmol, 74%). 
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1
H NMR (600 MHz, CDCl3): δ 7.40 (d, J = 7.6 Hz, 2 H, H3), 7.32 (t, J = 7.6 Hz, 2 H, H2), 
7.22 (t, J = 7.6 Hz, 1 H, H1), 5.56 – 5.48 (m, 1 H, H8), 4.69 (s, 1 H, NH), 3.82 (br s, 2 H, H9), 
2.12 (d, J = 2.9 Hz, 3 H, H5), 1.42 (s, 9 H, H12). 
13
C NMR (150 MHz, CDCl3): δ 203.5 (C7), 155.8 (C10), 136.8 (C4), 128.5 (C2), 127.0 (C1), 
125.9 (C3), 103.6 (C6), 91.5 (C8), 79.5 (C11), 39.5 (C9), 28.5 (C12), 17.2 (C5). 
FTIR (νmax, cm
-1
): 3354 (br w, NH), 2978 (w), 2930 (w), 1952 (w, C=C=C), 1690 (s, C=O), 
1598 (w), 1495 (m), 1446 (w), 1391 (w), 1366 (m), 1247 (s), 1164 (s), 1067 (w), 1050 (w), 
1026 (w), 941 (w), 909 (w), 860 (w). 
HRMS (ESI): calculated for C16H21NO2Na [M+Na]
+
 282.1465, found 282.1454. 
Rf = 0.32 (10% EtOAc/hexane). 
 
 
(5-Methoxypenta-2,3-dien-2-yl)benzene (96): Following the general procedure for allene 
formation with ketone-derived hydrazones using methyl propargyl ether (14.0 mg, 0.2 mmol) 
and (1-phenylethylidene)hydrazine (91), purified by silica gel column chromatography 
(eluent: 5% EtOAc/hexane) provided the title compound as a colourless oil (22.8 mg, 
0.131 mmol, 65%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 7.3 Hz, 2 H, H3), 7.33 (t, J = 7.3 Hz, 2 H, H2), 
7.22 (t, J = 7.3 Hz, 1 H, H1), 5.55 (tq, J = 6.8, 2.9 Hz, 1 H, H8), 4.05 (d, J = 6.8 Hz, 2 H, H9), 
3.39 (s, 3 H, H10), 2.14 (d, J = 2.9 Hz, 3 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 205.2 (C7), 136.8 (C4), 128.5 (C2), 126.9 (C1), 125.9 (C3), 
101.5 (C6), 90.5 (C8), 70.8 (C9), 57.9 (C10), 17.2 (C5). 
FTIR (νmax, cm
-1
): 2982 (w), 2927 (w), 2817 (w), 1952 (w, C=C=C), 1741 (w), 1598 (w), 
1494 (m), 1445 (m), 1351 (w), 1262 (w), 1185 (w), 1099 (s), 1067 (m), 1027 (w), 957 (w), 
913 (m). 
HRMS (ESI): calculated for C12H15O [M+H]
+
 175.1117, found 175.1112. 
Rf = 0.33 (5% EtOAc/hexane). 
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7-Phenylocta-5,6-dienenitrile (97): Following the general procedure for allene formation 
with ketone-derived hydrazones using 5-hexynenitrile (18.6 mg, 0.2 mmol) and (1-
phenylethylidene)hydrazine (91), purified by silica gel column chromatography (eluent: 10% 
EtOAc/hexane) provided the title compound as a colourless oil (29.0 mg, 0.147 mmol, 73%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.39 (d, J = 7.4 Hz, 2 H, H3), 7.33 (t, J = 7.4 Hz, 2 H, H2), 
7.22 (t, J = 7.4 Hz, 1 H, H1), 5.46 (tq, J = 7.1, 2.9 Hz, 1 H, H8), 2.40 (t, J = 7.2 Hz, 2 H, 
H11), 2.27 (q, J = 7.1 Hz, 2 H, H9), 2.11 (d, J = 2.9 Hz, 3 H, H5), 1.90 – 1.78 (m, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.5 (C7), 137.1 (C4), 128.5 (C2), 126.9 (C1), 125.7 (C3), 
119.7 (C12), 101.9 (C6), 91.1 (C8), 27.8 (C9), 24.7 (C10), 17.3 (C5), 16.6 (C11). 
FTIR (νmax, cm
-1
): 2940 (w), 2247 (w, C≡N), 1951 (w, C=C=C), 1727 (w), 1685 (w), 1598 
(w), 1493 (s), 1445 (s), 1371 (w), 1288 (w), 1264 (w), 1183 (w), 1067 (m), 1026 (m), 912 
(w), 844 (w). 
HRMS (ESI): calculated for C14H16N [M+H]
+
 198.1277, found 198.1270. 
Rf = 0.33 (10% EtOAc/hexane). 
 
 
tert-Butyl (4-(4-chlorophenyl)penta-2,3-dien-1-yl)carbamate (98): Following the general 
procedure for allene formation with ketone-derived hydrazones using N-Boc-propargylamine 
(239) (31.0 mg, 0.2 mmol) and (1-(4-chlorophenyl)ethylidene)hydrazine (237), purified by 
silica gel column chromatography (eluent: 15% EtOAc/hexane) provided the title compound 
as a colourless oil (52.4 mg, 0.178 mmol, 89%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.30 (d, J = 8.6 Hz, 2 H, H2), 7.26 (d, J = 8.6 Hz, 2 H, H3), 
5.53 – 5.47 (m, 1 H, H8), 4.69 (br s, 1 H, NH), 3.85 – 3.73 (m, 2 H, H9), 2.07 (d, J = 2.9 Hz, 
3 H, H5), 1.40 (s, 9 H, H12). 
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13
C NMR (150 MHz, CDCl3): δ 203.5 (C7), 155.8 (C10), 135.4 (C4), 132.7 (C1), 128.5 (C3), 
127.2 (C2), 102.8 (C6), 92.0 (C8), 79.6 (C11), 39.4 (C9), 28.5 (C12), 17.2 (C5). 
FTIR (νmax, cm
-1
): 3348 (br w, NH), 2978 (w), 2931 (w), 1954 (w, C=C=C), 1690 (s, C=O), 
1490 (s), 1455 (w), 1392 (m), 1366 (m), 1249 (m), 1165 (s), 1095 (m), 1063 (w), 1012 (m), 
941 (w), 860 (w), 831 (w). 
HRMS (ESI): calculated for C16H20NO2ClNa [M+Na]
+
 316.1075, found 316.1067. 
Rf = 0.41 (15% EtOAc/hexane). 
 
 
1-Chloro-4-(4-phenylbuta-2,3-dien-2-yl)benzene (99): Following the general procedure for 
allene formation with ketone-derived hydrazones using phenylacetylene (20.4 mg, 0.2 mmol) 
and (1-(4-chlorophenyl)ethylidene)hydrazine (237), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a yellow oil (52.4 mg, 
0.178 mmol, 89%). Data are consistent with a reported example.
96 
 
Scale up to 5 mmol was possible using a slightly modified procedure as follows: A 250 mL 
round-bottomed flask was charged with phenylacetylene (0.51 g, 5.0 mmol, 1.0 equiv.), 
copper(I) iodide (95 mg, 0.5 mmol, 0.1 equiv.), 2,6-lutidine (0.12 mL, 1.0 mmol, 0.2 equiv.), 
1,4-dioxane (50 mL), Et3N (1.39 mL, 10.0 mmol, 2.0 equiv.) and pre-mixed for 10 min. A 
solution of (1-(4-chlorophenyl)ethylidene)hydrazine (237) (0.1 M) and DIPEA (0.2 M) in 
CH2Cl2 was passed through the column reactor (Omnifit
®
 column, 0.79 cm i.d. × 15.0 cm 
length), packed with activated MnO2 (12.0 g), at a flow rate of 4.5 mL min
-1
. When the 
FlowIR
®
 showed that the intensity of the diazo peak was stable, 75 mL of the output 
(1.5 equiv. with respect to the hydrazone) was directly added into the reaction flask (over 
17  min) containing the copper acetylide and the reaction mixture further stirred at r.t. for 
10 min. The mixture was then filtered through a pad of Celite, eluting with EtOAc, and the 
filtrate evaporated under reduced pressure. The residue was immediately purified by silica gel 
column chromatography (eluent: hexane) to provide the title compound as a yellow oil 
(0.88 g, 3.66 mmol, 73%).   
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1
H NMR (600 MHz, CDCl3): δ 7.38 (d, J = 8.6 Hz, 2 H, H2), 7.34 – 7.31 (m, 4 H, H10 and 
H11), 7.29 (d, J = 8.6 Hz, 2 H, H3), 7.26 – 7.21 (m, 1 H, H12), 6.49 (q, J = 2.9 Hz, 1 H, H8), 
2.21 (d, J = 2.9 Hz, 3 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 206.9 (C7), 135.0 (C4), 134.3 (C9), 132.9 (C1), 128.9 
(C10/C11), 128.7 (C3), 127.3 (C12), 127.2 (C2), 127.1 (C10/C11), 103.9 (C6), 97.1 (C8), 
16.90 (C5). 
FTIR (νmax, cm
-1
): 3028 (w), 1934 (w, C=C=C), 1689 (w), 1597 (w), 1489 (s), 1449 (w), 
1408 (w), 1257 (w), 1198 (w), 1093 (s), 1062 (w), 1012 (s), 913 (w), 833 (s), 818 (s). 
HRMS (ESI): calculated for C16H14Cl [M+H]
+
 241.0779, found 241.0770. 
Rf = 0.39 (hexane). 
 
 
3-(3-(4-Chlorophenyl)buta-1,2-dien-1-yl)thiophene (100): Following the general procedure 
for allene formation with ketone-derived hydrazones using 3-ethynylthiophene (21.6 mg, 
0.2 mmol) and (1-(4-chlorophenyl)ethylidene)hydrazine (237), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a yellow oil (26.3 mg, 
0.107 mmol, 53%).  
 
1
H NMR (600 MHz, CDCl3): δ 7.36 (d, J = 8.6 Hz, 2 H, H2), 7.28 (d, J = 8.6 Hz, 2 H, H3), 
7.27 (dd, J = 5.0, 2.9 Hz, 1 H, H11), 7.14 (dd, J = 2.9, 1.2 Hz, 1 H, H10), 7.05 (dd, J = 5.0, 
1.2 Hz, 1 H, H12), 6.55 (q, J = 2.9 Hz, 1 H, H8), 2.18 (d, J = 2.9 Hz, 3 H, H5).  
13
C NMR (150 MHz, CDCl3): δ 207.0 (C7), 135.6 (C9), 135.2 (C4), 132.9 (C1), 128.7 (C3), 
127.3 (C2), 126.5 (C12), 126.2 (C11), 121.3 (C10), 103.0 (C6), 91.6 (C8), 17.1 (C5). 
 
FTIR (νmax, cm
-1
): 3103 (w), 2986 (w), 1940 (w, C=C=C), 1688 (w), 1591 (w), 1489 (s), 
1440 (w), 1402 (w), 1370 (w), 1235 (w), 1180 (w), 1146 (w), 1092 (s), 1062 (w), 1012 (s), 
858 (w), 834 (s), 820 (s). 
HRMS (ESI): calculated for C14H12SCl [M+H]
+
 247.0343, found 247.0335. 
Rf = 0.52 (hexane). 
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tert-Butyl (4,4-diphenylbuta-2,3-dien-1-yl)carbamate (101): Following a modified version 
of the general procedure for allene formation with ketone-derived hydrazones using N-Boc-
propargylamine (239) (31.0 mg, 0.2 mmol) and (diphenylmethylene)hydrazine, utilising THF 
instead of CH2Cl2 as solvent for the diazo generation and with pumping of the diazo 
compound over 8 min (2.0 equiv. with respect to hydrazone), purified by silica gel column 
chromatography (eluent: 15% EtOAc/hexane) provided the title compound as a yellow oil 
(55.8 mg, 0.174 mmol, 87%).  
 
1
H NMR (600 MHz, CDCl3): δ 7.36 – 7.32 (m, 8 H, H2 and H3), 7.31 – 7.26 (m, 2 H, H1), 
5.75 (t, J = 5.2 Hz, 1 H, H7), 4.73 (br s, 1 H, NH), 3.90 (br s, 2 H, H8), 1.41 (s, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 204.8 (C6), 155.8 (C9), 136.5 (C4), 128.6 (C2/C3), 128.5 
(C2/C3), 127.6 (C1), 112.7 (C5), 93.0 (C7), 79.7 (C10), 39.4 (C8), 28.5 (C11). 
FTIR (νmax, cm
-1
): 3348 (br w, NH), 2976 (w), 2931 (w), 1946 (w, C=C=C), 1693 (s, C=O), 
1598 (w), 1492 (s), 1453 (m), 1391 (w), 1366 (m), 1340 (w), 1273 (w), 1247 (m), 1166 (s), 
1074 (w), 1051 (w), 1031 (w), 921 (w), 862 (w). 
HRMS (ESI): calculated for C21H23NO2Na [M+Na]
+
 344.1621, found 344.1612. 
Rf = 0.37 (15% EtOAc/hexane). 
 
 
4,4-Diphenylbuta-2,3-dien-1-ol (102): Following a modified version of the general 
procedure for allene formation with ketone-derived hydrazones using propargyl alcohol (64) 
(11.2 mg, 0.2 mmol) and (diphenylmethylene)hydrazine, utilising THF instead of CH2Cl2 as 
solvent for the diazo generation and with pumping of the diazo compound over 8 min 
(2.0 equiv. with respect to hydrazone), purified by silica gel column chromatography (eluent: 
25% EtOAc/hexane) provided the title compound as a yellow oil (35.7 mg, 0.161 mmol, 
80%). Data are consistent with a reported example.
194 
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1
H NMR (600 MHz, CDCl3): δ 7.38 – 7.33 (m, 8 H, H2 and H3), 7.32 – 7.28 (m, 2 H, H1), 
5.91 (t, J = 5.8 Hz, 1 H, H7), 4.32 (d, J = 5.8 Hz, 2 H, H8), 1.64 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 204.5 (C6), 136.5 (C4), 128.64 (C2/C3), 128.58 (C2/C3), 
127.7 (C1), 112.7 (C5), 95.3 (C7), 60.8 (C8). 
FTIR (νmax, cm
-1
): 3326 (br m, OH), 3057 (w), 2869 (w), 1942 (w, C=C=C), 1597 (m), 1492 
(s), 1452 (m), 1443 (m), 1075 (m), 1013 (s), 923 (w), 902 (w). 
HRMS (ESI): calculated for C16H15O [M+H]
+
 223.1117, found 223.1109. 
Rf = 0.30 (25% EtOAc/hexane). 
 
 
(3-Cyclopropylpropa-1,2-diene-1,1-diyl)dibenzene (103): Following a modified version of 
the general procedure for allene formation with ketone-derived hydrazones using 
cyclopropylacetylene (106) (13.2 mg, 0.2 mmol) and (diphenylmethylene)hydrazine, utilising 
THF instead of CH2Cl2 as solvent for the diazo generation and with pumping of the diazo 
compound over 8 min (2.0 equiv. with respect to hydrazone), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a yellow oil (36.2 mg, 
0.156 mmol, 78%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.38 – 7.32 (m, 8 H, H2 and H3), 7.29 – 7.26 (m, 2 H, H1), 
5.56 (d, J = 7.6 Hz, 1 H, H7), 1.48 – 1.38 (m, 1 H, H8), 0.84 – 0.75 (m, 2 H, H9a), 0.53 – 
0.45 (m, 2 H, H9b). 
13
C NMR (150 MHz, CDCl3): δ 205.4 (C6), 137.3 (C4), 128.54 (C2/C3), 128.46 (C2/C3), 
127.2 (C1), 111.4 (C5), 99.0 (C7), 9.9 (C8), 7.2 (C9). 
FTIR (νmax, cm
-1
): 3080 (w), 3057 (w), 3005 (w), 1943 (w, C=C=C), 1662 (w), 1597 (m), 
1492 (s), 1443 (m), 1277 (w), 1177 (w), 1156 (w), 1073 (w), 1048 (w), 1020 (m), 965 (w), 
937 (m), 921 (w), 901 (m), 850 (w), 807 (w). 
HRMS (ESI): calculated for C18H17 [M+H]
+
 233.1325, found 233.1317. 
Rf = 0.25 (hexane). 
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tert-Butyl (4-(4-(trifluoromethyl)phenyl)octa-2,3,7-trien-1-yl)carbamate (104): Following 
the general procedure for allene formation with ketone-derived hydrazones using N-Boc-
propargylamine (239) (31.0 mg, 0.2 mmol) and (1-(4-(trifluoromethyl)phenyl)pent-4-en-1-
ylidene)hydrazine, purified by silica gel column chromatography (eluent: 15% EtOAc/hexane) 
provided the title compound as a colourless oil (42.4 mg, 0.115 mmol, 58%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.55 (d, J = 8.2 Hz, 2 H, H3), 7.49 (d, J = 8.2 Hz, 2 H, H4), 
5.88 (ddt, J = 16.8, 10.2, 6.5 Hz, 1 H, H9), 5.67 – 5.62 (m, 1 H, H12), 5.09 – 5.01 (m, 2 H, 
H10cis and H10trans), 4.72 (br s, 1 H, NH), 3.88 (dt, J = 15.7, 5.5 Hz, 1 H, H13a/H13b), 3.79 
(dt, J = 15.7, 5.5 Hz, 1 H, H13a/H13b), 2.61 – 2.48 (m, 2 H, H7), 2.33 – 2.28 (m, 2 H, H8), 
1.40 (s, 9 H, H16). 
13
C NMR (150 MHz, CDCl3): δ 203.9 (C11), 155.8 (C14), 140.4 (C5), 137.9 (C9), 129.0 (q, 
J = 32.4 Hz, C2), 126.4 (C4), 125.4 (q, J = 3.8 Hz, C3), 124.4 (q, J = 271.7 Hz, C1), 115.5 
(C10), 107.6 (C6), 94.2 (C12), 79.7 (C15), 39.2 (C13), 31.9 (C8), 29.2 (C7), 28.5 (C16).  
19
F NMR (376 MHz, CDCl3): -62.5 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 3351 (br w, NH), 2979 (w), 2931 (w), 1949 (w, C=C=C), 1694 (m, C=O), 
1616 (w), 1504 (m), 1422 (w), 1393 (w), 1367 (w), 1325 (s), 1277 (w), 1249 (m), 1164 (s), 
1123 (s), 1069 (m), 1015 (w), 914 (w), 845 (w). 
HRMS (ESI): calculated for C20H24F3NO2Na [M+Na]
+
 390.1651, found 390.1641. 
Rf = 0.42 (15% EtOAc/hexane). 
 
 
2-(8-Bromo-4-(4-methoxyphenyl)octa-4,5-dien-1-yl)-5,5-dimethyl-1,3-dioxane (105): 
Following the general procedure for allene formation with ketone-derived hydrazones using 
4-bromo-1-butyne (26.6 mg, 0.2 mmol) and (4-(5,5-dimethyl-1,3-dioxan-2-yl)-1-(4-
methoxyphenyl)butylidene)hydrazine, purified by silica gel column chromatography (eluent: 
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5% → 10% Et2O/hexane) provided the title compound as a yellow oil (45.3 mg, 0.111 mmol, 
55%). 
 
1
H NMR (400 MHz, CDCl3): δ 7.32 (d, J = 8.8 Hz, 2 H, H4), 6.85 (d, J = 8.8 Hz, 2 H, H3), 
5.54 – 5.47 (m, 1 H, H16), 4.44 (t, J = 4.7 Hz, 1 H, H10), 3.80 (s, 3 H, H1), 3.60 (d, J = 
10.9 Hz, 2 H, H11a/H11b), 3.46 (t, J = 7.1 Hz, 2 H, H18), 3.41 (d, J = 10.9 Hz, 2 H, 
H11a/H11b), 2.65 (q, J = 7.1 Hz, 2 H, H17), 2.46 – 2.39 (m, 2 H, H7), 1.77 – 1.62 (m, 4 H, 
H8 and H9), 1.19 (s, 3 H, H13/H14), 0.71 (s, 3 H, H13/H14). 
13
C NMR (100 MHz, CDCl3): δ 204.2 (C15), 158.7 (C2), 128.9 (C5), 127.3 (C4), 114.0 (C3), 
106.4 (C6), 102.2 (C10), 92.0 (C16), 77.4 (C11), 55.4 (C1), 34.7 (C7), 32.9 (C17), 32.3 
(C18), 30.3 (C9), 30.0 (C12), 23.2 (C13/C14), 22.6 (C8), 22.0 (C13/C14). 
FTIR (νmax, cm
-1
): 2953 (m), 2836 (w), 1943 (w, C=C=C), 1607 (m), 1578 (w), 1510 (s), 
1464 (m), 1394 (m), 1363 (w), 1292 (m), 1248 (s), 1177 (m), 1131 (s), 1097 (m), 1037 (m), 
970 (w), 924 (w), 886 (w), 833 (w). 
HRMS (ESI): calculated for C21H30O3Br [M+H]
+
 409.1373, found 409.1362. 
Rf = 0.31 (15% Et2O/hexane). 
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5.2.4. Deuteration experiment 
 
 
1-Chloro-4-(3-cyclopropylpropa-1,2-dien-1-yl-3-d)benzene (74-d): Following a modified 
version of the general procedure for allene formation with aldehyde-derived hydrazones 
using cyclopropylacetylene (106) (13.2 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine 
(62), with CD3OD (25 µL, 0.6 mmol, 3.0 equiv.) being added to the mixture of alkyne, Et3N 
and 1,4-dioxane prior to pre-mixing for 10 min. Purification by silica gel column 
chromatography (eluent: hexane) provided the title compound as a 37:63 mixture of allenes 
74-d and 74 as a colourless oil (35.5 mg, 0.186 mmol, combined yield 93%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.6 Hz, 2 H, H2), 7.21 (d, J = 8.6 Hz, 2 H, H3), 
6.20 – 6.13 (m, 1 H, H5), 5.44 (dd, J = 7.5, 6.6 Hz, 0.63 H, H7 of 74), 1.44 – 1.28 (m, 1 H, 
H8), 0.81 – 0.73 (m, 2 H, H9a and H10a), 0.50 – 0.40 (m, 2 H, H9b and H10b). 
13
C NMR (150 MHz, CDCl3): δ 205.0 (C6), 133.6 (C1), 132.4 (C4), 128.8 (C2), 127.9 (C3), 
100.1 (C7), 95.5 (C5 of 74-d), 95.4 (C5 of 74), 9.6 (C8 of 74), 9.5 (C8 of 74-d), 7.21 (C9/C10 
of 74), 7.19 (C9/C10 of 74-d), 7.12 (C9/C10 of 74), 7.10 (C9/C10 of 74-d). 
HRMS (ESI): calculated for C12H11DCl [M+H]
+
 192.0685, found 192.0677. 
Rf = 0.60 (hexane). 
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5.3. Experimental data for Chapter 3 
 
5.3.1. Synthetic procedures and characterisation for PyBOX ligands 
 
General procedure for PyBOX synthesis: A solution of the appropriate 2,6-
pyridinedicarbonitrile (1.0 mmol, 1 equiv.), the appropriate amino alcohol (2.0 mmol, 
2 equiv.) and zinc(II) triflate (36 mg, 0.1 mmol, 0.1 equiv.) in toluene (15 mL) was heated 
under reflux for 48 h. The reaction mixture was then cooled to r.t. and diluted with EtOAc 
(10 mL). The organic layer was washed with brine (3 × 25 mL), saturated aqueous NaHCO3 
solution (3 × 25 mL), dried (MgSO4) and evaporated under reduced pressure. The residue 
was further purified by silica gel column chromatography or recrystallisation as appropriate. 
 
 
2,6-Bis((S)-4-methyl-4,5-dihydrooxazol-2-yl)pyridine (156): Following the general 
procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 1 equiv.) 
and (S)-2-aminopropan-1-ol (0.286 g, 2.0 mmol, 2 equiv.), purified by silica gel column 
chromatography (eluent: 5% MeOH/CH2Cl2) provided the title compound as a white 
amorphous solid (0.022 g, 0.09 mmol, 9%), m.p. 148-151 °C (lit. m.p.
195
 163.0-165.5 °C, on 
material with 0.25 mol H2O). Data are consistent with a reported example.
195 
 
1
H NMR (600 MHz, CDCl3): δ 8.17 (d, J = 7.8 Hz, 2 H, H2), 7.86 (t, J = 7.8 Hz, 1 H, H1), 
4.61 (dd, J = 9.5, 8.3 Hz, 2 H, H5a), 4.43 (ddq, J = 9.5, 8.3, 6.7 Hz, 2 H, H6), 4.07 (t, J = 
8.3 Hz, 2 H, H5b), 1.37 (d, J = 6.7 Hz, 6 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 162.4 (C4), 147.0 (C3), 137.4 (C1), 125.8 (C2), 74.9 (C5), 
62.4 (C6), 21.5 (C7). 
FTIR (νmax, cm
-1
): 2971 (m), 2900 (w), 1641 (s), 1575 (s), 1531 (w), 1459 (m), 1385 (m), 
1305 (w), 1269 (w), 1246 (w), 1171 (w), 1119 (m), 1068 (s), 973 (s), 945 (m), 831 (w). 
HRMS (ESI): calculated for C13H16N3O2 [M+H]
+
 246.1237, found 246.1231.  
Rf = 0.26 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -127.6 (CHCl3, c = 0.5); lit.
195
 [𝛂]𝑫 = -131.8 (CHCl3, c = 0.72). 
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2,6-Bis((S)-4-(tert-butyl)-4,5-dihydrooxazol-2-yl)pyridine (157): Following the general 
procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.387 g, 3.0 mmol, 
1 equiv.) and L-tert-leucinol (205) (0.703 g, 6.0 mmol, 2 equiv.), after extraction and 
evaporation provided the title compound as a white crystalline solid (0.970 g, 2.9 mmol, 
98%), m.p. 236-238 °C. Data are consistent with a reported example.
196 
 
1
H NMR (600 MHz, CDCl3): δ 8.25 (d, J = 7.8 Hz, 2 H, H2), 7.84 (t, J = 7.8 Hz, 1 H, H1), 
4.47 (dd, J = 10.3, 8.6 Hz, 2 H, H5a), 4.32 (t, J = 8.6 Hz, 2 H, H6), 4.10 (dd, J = 10.3, 8.6 Hz, 
2 H, H5b), 0.96 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 162.3 (C4), 147.1 (C3), 137.2 (C1), 126.0 (C2), 76.5 (C6), 
69.6 (C5), 34.1 (C7), 26.1 (C8). 
FTIR (νmax, cm
-1
): 2957 (m), 2902 (w), 2869 (w), 1641 (s), 1590 (w), 1569 (m), 1475 (m), 
1459 (m), 1417 (w), 1395 (m), 1377 (s), 1363 (s), 1319 (w), 1276 (m), 1212 (m), 1195 (w), 
1153 (w), 1106 (s), 1075 (m), 1057 (m), 1032 (m), 997 (m), 967 (m), 956 (m), 931 (m), 899 
(w), 865 (w), 841 (m), 757 (m). 
HRMS (ESI): calculated for C19H27N3O2Na [M+Na]
+
 352.1995, found 352.2005.  
[𝛂]𝑫
𝟐𝟒.𝟎 = -115.0 (CH2Cl2, c = 1.0); lit.
196
 [𝛂]𝑫
𝟐𝟕 = -118 (CH2Cl2, c = 0.5). 
 
 
2,6-Bis((S)-4-cyclopropyl-4,5-dihydrooxazol-2-yl)pyridine (158): Following the general 
procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 
1 equiv.) and (S)-2-amino-2-cyclopropylethan-1-ol (0.202 g, 2.0 mmol, 2 equiv.), purified by 
silica gel column chromatography (eluent: 30% acetone/CH2Cl2) provided the title compound 
as a yellow amorphous solid (0.096 g, 0.32 mmol, 32%), m.p. 82-85 °C. 
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1
H NMR (600 MHz, CDCl3): δ 8.22 (d, J = 7.8 Hz, 2 H, H2), 7.85 (t, J = 7.8 Hz, 1 H, H1), 
4.60 (dd, J = 9.8, 8.3 Hz, 2 H, H5a), 4.28 (t, J = 8.3 Hz, 2 H, H5b), 3.82 (dt, J = 9.8, 8.3 Hz, 
2 H, H6), 1.01 – 0.94 (m, 2 H, H7), 0.66 – 0.60 (m, 2 H, H8/H9), 0.57 – 0.51 (m, 2 H, 
H8/H9), 0.49 – 0.44 (m, 2 H, H8/H9), 0.36 – 0.31 (m, 2 H, H8/H9). 
13
C NMR (150 MHz, CDCl3): δ 162.9 (C4), 147.0 (C3), 137.3 (C1), 126.0 (C2), 73.4 (C5), 
71.3 (C6), 16.0 (C7), 3.3 (C8/C9), 2.3 (C8/C9). 
FTIR (νmax, cm
-1
): 3403 (w), 3084 (w), 3007 (w), 2900 (w), 1647 (m), 1573 (m), 1533 (w), 
1447 (w), 1380 (m), 1355 (m), 1331 (m), 1250 (m), 1205 (w), 1170 (m), 1147 (w), 1106 (w), 
1083 (w), 1062 (m), 1051 (m), 1025 (m), 973 (s), 939 (m), 895 (m), 828 (s), 819 (s). 
HRMS (ESI): calculated for C17H20N3O2 [M+H]
+
 298.1550, found 298.1556.  
Rf = 0.43 (30% acetone/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -189.4 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-cyclohexyl-4,5-dihydrooxazol-2-yl)pyridine (159): Following the general 
procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 1 equiv.) 
and (S)-2-amino-2-cyclohexylethan-1-ol (0.286 g, 2.0 mmol, 2 equiv.), purified by 
recrystallisation from EtOAc provided the title compound as a white flaky solid (0.123 g, 
0.32 mmol, 32%), m.p. 204-206 °C. Compound has been prepared previously,
197
 but NMR 
spectra were recorded in CD2Cl2. 
 
1
H NMR (600 MHz, CDCl3): δ 8.19 (d, J = 7.9 Hz, 2 H, H2), 7.84 (t, J = 7.9 Hz, 1 H, H1), 
4.51 (dd, J = 9.7, 8.5 Hz, 2 H, H5a), 4.24 (t, J = 8.5 Hz, 2H, H5b), 4.13 (ddd, J = 9.7, 8.5, 
7.0 Hz, 2 H, H6), 2.00 (br d, J = 12.8 Hz, 2 H, H8a/H12a), 1.80 – 1.72 (m, 4 H, H9a and 
H11a), 1.68 (br d, J = 12.1 Hz, 2 H, H10a), 1.61 (br d, J = 12.6 Hz, 2 H, H8a/H12a), 1.57 – 
1.49 (m, 2 H, H7), 1.32 – 1.16 (m, 6 H, H9b, H10b and H11b), 1.13 – 1.01 (m, 4 H, H8b and 
H12b). 
13
C NMR (150 MHz, CDCl3): δ 162.3 (C4), 147.1 (C3), 137.3 (C1), 125.8 (C2), 72.2 (C6), 
71.3 (C5), 43.0 (C7), 29.8 (C8/C12), 29.1 (C8/C12), 26.6 (C10), 26.2 (C9 and C11). 
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FTIR (νmax, cm
-1
): 2919 (m), 2850 (m), 1629 (s), 1569 (w), 1451 (w), 1414 (w), 1379 (s), 
1326 (w), 1282 (w), 1228 (w), 1101 (s), 1072 (s), 1057 (w), 998 (w), 980 (w), 962 (s), 941 
(w), 910 (w), 885 (w), 843 (w), 756 (w). 
HRMS (ESI): calculated for C23H32N3O2 [M+H]
+
 382.2489, found 382.2498.  
[𝛂]𝑫
𝟐𝟖.𝟑 = -162.8 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-benzhydryl-4,5-dihydrooxazol-2-yl)pyridine (160): Following the general 
procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 
1 equiv.) and (S)-2-amino-3,3-diphenylpropan-1-ol (0.455 g, 2.0 mmol, 2 equiv.), purified by 
recrystallisation from toluene and washed on the filter with cold EtOAc (2 mL) provided the 
title compound as an off-white flaky solid (0.195 g, 0.35 mmol, 35%), m.p. 262-264 °C.  
 
1
H NMR (600 MHz, CDCl3): δ 8.17 (d, J = 7.9 Hz, 2 H, H2), 7.78 (t, J = 7.9 Hz, 1 H, H1), 
7.37 – 7.13 (m, 20 H, ArH), 5.17 (td, J = 9.3, 8.5 Hz, 2 H, H6), 4.54 (appears t, J = 9.3 Hz, 
2 H, H5a), 4.20 (appears t, J = 8.5 Hz, 2 H, H5b), 4.07 (d, J = 9.3 Hz, 2 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 163.0 (C4), 146.9 (C3), 142.2 (C8/C12), 142.0 (C8/C12), 
137.2 (C1), 128.9 (ArCH), 128.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 127.0 (C11/C15), 
126.6 (C11/C15), 126.3 (C2), 72.3 (C5), 70.5 (C6), 57.1 (C7). 
FTIR (νmax, cm
-1
): 1638 (m), 1571 (w), 1495 (w), 1452 (w), 1379 (s), 1276 (w), 1108 (s), 
1073 (m), 1031 (w), 975 (w), 830 (w). 
HRMS (ESI): calculated for C37H32N3O2 [M+H]
+
 550.2489, found 550.2506.  
[𝛂]𝑫
𝟐𝟖.𝟑 = -93.1 (CHCl3, c = 1.0). 
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2,6-Bis((4S,5R)-4,5-diphenyl-4,5-dihydrooxazol-2-yl)pyridine (161): Following the 
general procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 
1 equiv.) and (1R,2S)-2-amino-1,2-diphenylethan-1-ol (0.427 g, 2.0 mmol, 2 equiv.), purified 
by silica gel column chromatography (eluent: 2% MeOH/CH2Cl2) and then recrystallisation 
from CH2Cl2/hexane provided the title compound as a white crystalline solid (0.091 g, 
0.18 mmol, 18%), m.p. 233-236 °C (lit. m.p.
198
 225-226 °C). Data are consistent with a 
reported example.
198 
 
1
H NMR (600 MHz, CDCl3): δ 8.44 (d, J = 7.9 Hz, 2 H, H2), 8.04 (t, J = 7.9 Hz, 1 H, H1), 
7.08 – 6.95 (m, 20 H, ArH), 6.14 (d, J = 10.3 Hz, 2 H, H5), 5.83 (d, J = 10.3 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 164.1 (C4), 147.2 (C3), 137.8 (C1), 137.3 (C6/C11), 136.1 
(C6/C11), 128.0 (C7/C8/C12/C13), 127.81 (C7/C8/C12/C13), 127.76 (C7/C8/C12/C13), 
127.6 (C9/C14), 127.2 (C9/C14), 126.7 (C7/C8/C12/C13), 126.6 (C2), 86.4 (C5), 74.5 (C10). 
FTIR (νmax, cm
-1
): 1664 (w), 1630 (m), 1572 (m), 1495 (w), 1453 (m), 1357 (w), 1321 (m), 
1261 (w), 1244 (w), 1211 (w), 1169 (m), 1141 (m), 1108 (m), 1077 (s), 1028 (w), 995 (w), 
968 (s), 921 (m), 888 (w), 859 (w), 821 (m), 765 (s). 
HRMS (ESI): calculated for C35H28N3O2 [M+H]
+
 522.2176, found 522.2181.  
Rf = 0.18 (2% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -293.7 (CHCl3, c = 1.0); lit.
198
 [𝛂]𝑫 = -305 (CHCl3, c = 0.5). 
 
 
2,6-Bis((4S,5S)-4,5-diphenyl-4,5-dihydrooxazol-2-yl)pyridine (162): Following the 
general procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 
1 equiv.) and (1S,2S)-2-amino-1,2-diphenylethan-1-ol (0.427 g, 2.0 mmol, 2 equiv.), purified 
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by silica gel column chromatography (eluent: 2% MeOH/CH2Cl2) provided the title 
compound as a white amorphous solid (0.088 g, 0.17 mmol, 17%), m.p. 200-201 °C (lit. 
m.p.
199
 201-202 °C). Data are consistent with a reported example.
199
 
 
1
H NMR (600 MHz, CDCl3): δ 8.41 (d, J = 7.9 Hz, 2 H, H2), 7.98 (t, J = 7.9 Hz, 1 H, H1), 
7.41 – 7.30 (m, 20 H, ArH), 5.56 (d, J = 8.4 Hz, 2 H, H5), 5.35 (d, J = 8.4 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 163.0 (C4), 147.1 (C3), 141.3 (C6/C11), 139.8 (C6/C11), 
137.5 (C1), 128.9 (C7/C8/C12/C13), 128.9 (C7/C8/C12/C13), 128.6 (C9/C14), 127.9 
(C9/C14), 126.9 (C7/C8/C12/C13), 126.7 (C2), 126.3 (C7/C8/C12/C13), 90.1 (C5), 79.1 
(C10). 
FTIR (νmax, cm
-1
): 1648 (m), 1600 (w), 1568 (m), 1493 (w), 1448 (m), 1341 (w), 1288 (m), 
1258 (m), 1222 (w), 1162 (m), 1123 (m), 1080 (m), 1025 (w), 1012 (w), 978 (s), 956 (s), 915 
(w), 890 (w), 846 (m), 758 (s). 
HRMS (ESI): calculated for C35H27N3O2Na [M+Na]
+
 544.1995, found 544.2006.  
Rf = 0.26 (2% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -37.8 (CHCl3, c = 1.0); lit.
199
 [𝛂]𝑫
𝟐𝟎 = -41.4 (CHCl3, c = 0.5). 
 
 
(S)-2-(Dibenzylamino)-3-methylbutan-1-ol (168): A mixture of L-valinol (167) (2.06 g, 
20.0 mmol, 1 equiv.), benzyl bromide (5.24 mL, 44.0 mmol, 2.2 equiv.), potassium carbonate 
(8.30 g, 60.0 mmol, 3 equiv.) and tetrabutylammonium iodide (2.22 g, 6.0 mmol, 0.3 equiv.) 
in acetonitrile (200 mL) was heated under reflux for 16 h. The solvent was removed under 
reduced pressure and the residue diluted with EtOAc (300 mL) and water (300 mL). The 
organic layer was separated and the aqueous layer extracted further with EtOAc (3 × 100 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure. 
The residue was then purified by silica gel column chromatography (eluent: 15% 
EtOAc/hexane) to provide the title compound as a colourless oil (4.75 g, 16.8 mmol, 84%). 
Data are consistent with a reported example.
200 
 
5. Experimental (Appendix) 
161 
 
1
H NMR (600 MHz, CDCl3): δ 7.33 – 7.28 (m, 4 H, H9), 7.26 – 7.22 (m, 6 H, H8 and H10), 
3.89 (d, J = 13.2 Hz, 2 H, H6a), 3.69 (d, J = 13.2 Hz, 2 H, H6b), 3.57 (dd, J = 10.7, 4.6 Hz, 
1 H, H1a), 3.44 (dd, J = 10.7, 9.8 Hz, 1 H, H1b), 2.95 (br s, 1 H, OH), 2.54 (ddd, J = 9.8, 7.8, 
4.6 Hz, 1 H, H2), 2.12 – 2.01 (m, 1 H, H3), 1.14 (d, J = 6.8 Hz, 3 H, H4/H5), 0.89 (d, J = 
6.7 Hz, 3 H, H4/H5). 
13
C NMR (150 MHz, CDCl3): δ 139.8 (C7), 129.4 (C8), 128.6 (C9), 127.3 (C10), 64.8 (C2), 
59.4 (C1), 54.4 (C6), 27.7 (C3), 22.9 (C4/C5), 20.3 (C4/C5). 
FTIR (νmax, cm
-1
): 3443 (br w, OH), 3064 (w), 3028 (w), 2956 (m), 2871 (m), 1703 (w), 
1603 (w), 1494 (m), 1453 (s), 1362 (m), 1322 (w), 1247 (w), 1206 (w), 1137 (w), 1099 (m), 
1064 (s), 1028 (s), 1009 (s), 910 (m), 858 (w), 827 (w), 787 (w). 
HRMS (ESI): calculated for C19H26NO [M+H]
+
 284.2009, found 284.2011.  
Rf = 0.28 (15% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟕.𝟕 = +23.1 (CHCl3, c = 1.0); lit.
200
 [𝛂]𝑫
𝟐𝟎 = +24.5 (CHCl3, c = 0.8). 
 
 
(S)-2-(Dibenzylamino)-3-methylbutanal (169): To a solution of oxalyl chloride (1.92 mL, 
22.5 mmol, 1.5 equiv.) in anhydrous CH2Cl2 (20 mL) at -78 °C was added slowly dropwise a 
solution of DMSO (2.34 mL, 33.0 mmol, 2.2 equiv.) in anhydrous CH2Cl2 (20 mL), keeping 
the internal temperature below -60 °C. The mixture was stirred further for 5 min. A solution 
of (S)-2-(dibenzylamino)-3-methylbutan-1-ol (168) (4.25 g, 15.0 mmol, 1 equiv.) in 
anhydrous CH2Cl2 (20 mL) was added slowly dropwise and stirred further for 15 min. 
Triethylamine (10.4 mL, 75.0 mmol, 5 equiv.) was then added, stirred at -78 °C for 30 min, 
warmed to r.t. and quenched with water (75 mL). The organic layer was separated and the 
aqueous layer extracted with CH2Cl2 (3 × 25 mL). The combined organic extracts were 
washed with saturated aqueous NH4Cl solution (50 mL), dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by silica gel column chromatography 
(eluent: 5% EtOAc/hexane) to provide the title compound as a pale yellow turbid oil (3.71 g, 
13.2 mmol, 88%). Data are consistent with a reported example.
201 
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1
H NMR (600 MHz, CDCl3): δ 9.86 (d, J = 3.4 Hz, 1 H, H1), 7.37 (d, J = 7.3 Hz, 4 H, H8), 
7.33 (t, J = 7.3 Hz, 4 H, H9), 7.26 (t, J = 7.3 Hz, 2 H, H10), 4.03 (d, J = 13.8 Hz, 2 H, H6a), 
3.72 (d, J = 13.8 Hz, 2 H, H6b), 2.73 (dd, J = 10.0, 3.4 Hz, 1 H, H2), 2.29 (d sept, J = 10.0, 
6.7 Hz, 1 H, H3), 1.09 (d, J = 6.7 Hz, 3 H, H4/H5), 0.88 (d, J = 6.7 Hz, 3 H, H4/H5). 
13
C NMR (150 MHz, CDCl3): δ 205.3 (C1), 139.4 (C7), 128.9 (C8), 128.5 (C9), 127.3 
(C10), 71.7 (C2), 54.7 (C6), 26.2 (C3), 20.3 (C4/C5), 20.0 (C4/C5). 
FTIR (νmax, cm
-1
): 3063 (w), 3030 (w), 2960 (w), 2809 (w), 2716 (w), 1716 (s, C=O), 1602 
(w), 1494 (m), 1454 (m), 1368 (w), 1308 (w), 1241 (w), 1208 (w), 1155 (w), 1112 (w), 1091 
(w), 1074 (m), 1049 (w), 1028 (m), 971 (w), 908 (w), 846 (w), 824 (w). 
HRMS (ESI): calculated for C19H24NO [M+H]
+
 282.1852, found 282.1850. 
Rf = 0.36 (5% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟑.𝟕 = -63.4 (CHCl3, c = 1.0); lit.
201
 [𝛂]𝑫
𝟐𝟓 = -62.2 (CHCl3, c = 1.0). 
 
 
(3S,4S)-4-(Dibenzylamino)-2,5-dimethylhexan-3-ol (170): To a solution of (S)-2-
(dibenzylamino)-3-methylbutanal (169) (2.81 g, 10.0 mmol, 1 equiv.) in anhydrous toluene 
(40 mL) was added a solution of diisopropylzinc (30 mL, 1.0 M in toluene, 30.0 mmol, 
3 equiv.) at 0 °C and the reaction mixture stirred further for 16 h. The reaction was quenched 
with saturated aqueous NH4Cl solution (50 mL) and extracted with CH2Cl2 (3 × 50 mL). The 
combined organic extracts were dried (MgSO4) and evaporated under reduced pressure. The 
residue was purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to 
provide the title compound as a yellow oil (3.08 g, 9.46 mmol, 95%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.32 – 7.29 (m, 4 H, H12), 7.27 (d, J = 7.0 Hz, 4 H, H11), 
7.26 – 7.21 (m, 2 H, H13), 4.60 (br s, 1 H, OH), 3.93 (d, J = 13.0 Hz, 2 H, H9a), 3.66 (dd, J = 
9.9, 1.5 Hz, 1 H, H4), 3.42 (d, J = 13.0 Hz, 2 H, H9b), 2.51 (dd, J = 9.9, 2.2 Hz, 1 H, H5), 
2.24 (sept d, J = 7.4, 2.2 Hz, 1 H, H6), 1.60 (sept d, J = 6.7, 1.5 Hz, 1 H, H3), 1.04 (m, 9 H, 
H1/H2, H7 and H8), 0.44 (d, J = 6.7 Hz, 3 H, H1/H2). 
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13
C NMR (150 MHz, CDCl3): δ 139.0 (C10), 129.4 (C11), 128.5 (C12), 127.3 (C13), 70.5 
(C4), 61.9 (C5), 53.8 (C9), 30.0 (C3), 25.0 (C6), 23.9 (C1/C2/C7/C8), 21.7 (C1/C2/C7/C8), 
19.3 (C1/C2/C7/C8), 13.5 (C1/C2). 
FTIR (νmax, cm
-1
): 3354 (br w, OH), 3064 (w), 3029 (w), 2959 (s), 2874 (m), 1604 (w), 1495 
(m), 1454 (s), 1414 (w), 1389 (m), 1362 (m), 1241 (w), 1208 (w), 1179 (w), 1137 (w), 1095 
(m), 1072 (s), 1028 (m), 1005 (s), 972 (s), 947 (m), 911 (w), 867 (w), 847 (w), 810 (w). 
HRMS (ESI): calculated for C22H32NO [M+H]
+
 326.2478, found 326.2483. 
Rf = 0.28 (5% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟔.𝟎 = +21.0 (CHCl3, c = 1.0). 
 
 
(3S,4S)-4-Amino-2,5-dimethylhexan-3-ol (171): A mixture of (3S,4S)-4-(dibenzylamino)-
2,5-dimethylhexan-3-ol (170) (1.63 g, 5.0 mmol, 1 equiv.), 20% palladium(II) hydroxide on 
carbon (0.5 g) and acetic acid (0.34 mL, 6.0 mmol, 1.2 equiv.) in ethanol (50 mL) was stirred 
under H2 (balloon) at 50 °C for 16 h. A further portion of 20% palladium(II) hydroxide on 
carbon (0.5 g) was added, then stirred under H2 (balloon) at 50 °C for a further 16 h. The 
mixture was filtered through a pad of Celite, eluting with ethanol, and the solvent removed 
under reduced pressure. The residue was dissolved in CH2Cl2 (25 mL) and 1 M aqueous 
NaOH solution (25 mL) was added. The organic layer was separated and the aqueous layer 
extracted further with CH2Cl2 (3 × 25 mL). The combined organic extracts were dried 
(MgSO4) and evaporated under reduced pressure to provide the title compound as a white 
amorphous solid (0.486 g, 3.3 mmol, 67%), m.p. 55-57 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 3.15 (t, J = 5.3 Hz, 1 H, H4), 2.52 (t, J = 5.3 Hz, 1 H, H5), 
1.81 (br s, 3 H, NH2 and OH), 1.76 (sept d, J = 6.8, 5.3 Hz, 1 H, H6), 1.69 (sept d, J = 6.8, 
5.3 Hz, 1 H, H3), 0.95 (d, J = 6.8 Hz, 3 H, H1/H2), 0.94 (d, J = 6.8 Hz, 3 H, H7/H8), 0.91 (d, 
J = 6.8 Hz, 3 H, H1/H2), 0.86 (d, J = 6.8 Hz, 3 H, H7/H8). 
13
C NMR (150 MHz, CDCl3): δ 75.7 (C4), 57.7 (C5), 30.8 (C3), 30.0 (C6), 20.4 (C7/C8), 
20.0 (C1/C2), 16.91 (C1/C2/C7/C8), 16.86 (C1/C2/C7/C8). 
FTIR (νmax, cm
-1
): 3348 (w, NH2), 3300 (w, NH2), 3165 (br w, OH), 2962 (m), 2932 (m), 
2910 (m), 2874 (m), 1619 (m), 1585 (w), 1470 (m), 1389 (w), 1361 (w), 1338 (w), 1315 (w), 
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1299 (w), 1252 (w), 1189 (w), 1134 (m), 1113 (w), 1057 (m), 1021 (w), 1001 (s), 960 (m), 
947 (m), 926 (m), 903 (s), 806 (m), 766 (m). 
HRMS (ESI): calculated for C8H20NO [M+H]
+
 146.1539, found 146.1534. 
[𝛂]𝑫
𝟐𝟓.𝟐 = +6.6 (CHCl3, c = 1.0). 
 
 
2,6-Bis((4S,5S)-4,5-diisopropyl-4,5-dihydrooxazol-2-yl)pyridine (163): Following the 
general procedure for PyBOX synthesis, using 2,6-pyridinedicarbonitrile (0.129 g, 1.0 mmol, 
1 equiv.) and (3S,4S)-4-amino-2,5-dimethylhexan-3-ol (0.290 g, 2.0 mmol, 2 equiv.), purified 
by silica gel column chromatography (eluent: 3% MeOH/CH2Cl2) provided the title 
compound as a yellow gum (0.065 g, 0.17 mmol, 17%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.06 (d, J = 7.8 Hz, 2 H, H2), 7.83 (t, J = 7.8 Hz, 1 H, H1), 
4.24 (t, J = 5.9 Hz, 2 H, H5), 3.82 (t, J = 5.9 Hz, 2 H, H9), 1.89 – 1.76 (m, 4 H, H6 and H10), 
0.99 – 0.94 (m, 24 H, H7, H8, H11 and H12). 
13
C NMR (150 MHz, CDCl3): δ 161.7 (C4), 147.2 (C3), 137.3 (C1), 125.5 (C2), 87.9 (C5), 
74.9 (C9), 32.9 (C6/C10), 32.7 (C6/C10), 18.8 (C7/C8/C11/C12), 18.4 (C7/C8/C11/C12), 
17.9 (C7/C8/C11/C12), 17.3 (C7/C8/C11/C12). 
FTIR (νmax, cm
-1
): 2961 (s), 2933 (m), 2875 (m), 1666 (m), 1575 (m), 1523 (w), 1465 (s), 
1386 (m), 1370 (m), 1261 (m), 1239 (m), 1170 (m), 1108 (m), 1079 (m), 979 (s), 955 (m), 
929 (w), 904 (w), 832 (w), 763 (w). 
HRMS (ESI): calculated for C23H36N3O2 [M+H]
+
 386.2802, found 386.2803. 
Rf = 0.34 (3% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -93.2 (CHCl3, c = 1.0). 
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4-(Trifluoromethyl)pyridine-2,6-dicarbonitrile (172): To a 20 mL microwave vial was 
added 2,6-dichloro-4-(trifluoromethyl)pyridine (1.080 g, 5.0 mmol, 1.0 equiv.), zinc(II) 
cyanide (0.646 g, 5.5 mmol, 1.1 equiv.), zinc powder (65 mg, 1.0 mmol, 0.2 equiv.), 
palladium(II) trifluoroacetate (83 mg, 0.25 mmol, 0.05 equiv.), rac-2-(di-tert-
butylphosphino)-1,1'-binaphthyl (0.199 g, 0.50 mmol, 0.1 equiv.) and anhydrous DMA (20 
mL). The mixture was placed under vacuum and backfilled with argon (three cycles), stirred 
at r.t. for 20 min, then subsequently heated to 95 °C for 16 h. The mixture was then cooled to 
r.t. and filtered through a pad of Celite, eluting with EtOAc. The solvents were removed by 
vacuum distillation (6-10 mmHg) and the residue purified by silica gel column 
chromatography (eluent: 10% EtOAc/hexane) to provide the title compound as a pale yellow 
amorphous solid (0.620 g, 3.1 mmol, 63%), m.p. 103-104 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 8.12 (q, J = 0.6 Hz, 2 H, H3). 
13
C NMR (150 MHz, CDCl3): δ 142.0 (q, J = 36.8 Hz, C2), 136.7 (C4), 127.0 (q, J = 3.4 Hz, 
C3), 120.9 (q, J = 274.8 Hz, C1), 114.5 (C5). 
19
F NMR (376 MHz, CDCl3): δ -64.8 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 3069 (w), 1870 (w), 1567 (w), 1416 (w), 1403 (m), 1352 (m), 1304 (w), 
1250 (w), 1222 (m), 1212 (m), 1153 (s), 1105 (m), 981 (w), 925 (m), 863 (m), 792 (w). 
HRMS (ESI): calculated for C8H3F3N3 [M+H]
+
 198.0274, found 198.0265.  
Rf = 0.27 (10% EtOAc/hexane). 
 
 
(4S,4'S)-2,2'-(4-(Trifluoromethyl)pyridine-2,6-diyl)bis(4-isopropyl-4,5-dihydrooxazole) 
(164): Following the general procedure for PyBOX synthesis, using 4-
(trifluoromethyl)pyridine-2,6-dicarbonitrile (172) (0.197 g, 1.0 mmol, 1 equiv.) and L-valinol 
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(167) (0.206 g, 2.0 mmol, 2 equiv.), purified by silica gel column chromatography (eluent:    
5% acetone/CH2Cl2) provided the title compound as an off-white amorphous solid (0.179 g, 
0.48 mmol, 48%), m.p. 90-93 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 8.42 (s, 2 H, H3), 4.55 (dd, J = 9.8, 8.5 Hz, 2 H, H6a), 4.25 
(t, J = 8.5 Hz, 2 H, H6b), 4.16 (ddd, J = 9.8, 8.5, 6.7 Hz, 2 H, H7), 1.92 – 1.82 (oct, J = 
6.7 Hz, 2 H, H8), 1.04 (d, J = 6.7 Hz, 6 H, H9/H10), 0.93 (d, J = 6.7 Hz, 6 H, H9/H10). 
13
C NMR (150 MHz, CDCl3): δ 161.5 (C5), 148.4 (C4), 139.9 (q, J = 35.0 Hz, C2), 122.3 
(q, J = 273.7 Hz, C1), 121.6 (q, J = 3.5 Hz, C3), 73.2 (C7), 71.4 (C6), 32.9 (C8), 19.1 
(C9/C10), 18.4 (C9/C10). 
19
F NMR (376 MHz, CDCl3): δ -64.6 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 2961 (w), 2874 (w), 1670 (w), 1644 (m), 1608 (w), 1574 (w), 1467 (w), 
1443 (w), 1413 (w), 1386 (w), 1368 (w), 1356 (w), 1337 (w), 1294 (m), 1277 (m), 1259 (m), 
1174 (m), 1141 (s), 1112 (m), 1041 (w), 1020 (w), 978 (m), 961 (m), 938 (m), 907 (m), 819 
(w), 768 (w), 753 (w). 
HRMS (ESI): calculated for C18H23F3N3O2 [M+H]
+
 370.1737, found 370.1742.  
Rf = 0.29 (5% acetone/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -124.8 (CHCl3, c = 1.0). 
 
 
4-Methoxypyridine-2,6-dicarbonitrile (173): To a 20 mL microwave vial was added 2,6-
dichloro-4-methoxypyridine (0.890 g, 5.0 mmol, 1.0 equiv.), zinc(II) cyanide (0.646 g, 
5.5 mmol, 1.1 equiv.), zinc powder (65 mg, 1.0 mmol, 0.2 equiv.), palladium(II) 
trifluoroacetate (83 mg, 0.25 mmol, 0.05 equiv.), rac-2-(di-tert-butylphosphino)-1,1'-
binaphthyl (0.199 g, 0.50 mmol, 0.1 equiv.) and anhydrous DMA (20 mL). The mixture was 
placed under vacuum and backfilled with argon three times, stirred at r.t. for 20 min, then 
subsequently heated to 95 °C for 16 h. The mixture was then cooled to r.t. and filtered 
through a pad of Celite, eluting with EtOAc. The solvents were removed by vacuum 
distillation (6-10 mmHg) and the residue purified by silica gel column chromatography 
(eluent: 40% EtOAc/hexane) to provide the title compound as a white amorphous solid 
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(0.730 g, 4.6 mmol, 92%), m.p. 147-149 °C. Compound has been prepared previously,
202
 but 
NMR spectra were recorded in CD2Cl2.
 
 
1
H NMR (600 MHz, CDCl3): δ 7.39 (s, 2 H, H3), 3.99 (s, 3 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 167.0 (C2), 136.3 (C4), 117.9 (C3), 115.7 (C5), 56.9 (C1). 
FTIR (νmax, cm
-1
): 3087 (w), 3074 (w), 2243 (w, C≡N), 1589 (s), 1558 (m), 1474 (m), 1437 
(m), 1338 (s), 1275 (w), 1211 (w), 1194 (m), 1172 (w), 1155 (s), 1046 (s), 984 (s), 943 (w), 
916 (m), 891 (s). 
HRMS (ESI): calculated for C8H6N3O [M+H]
+
 160.0505, found 160.0502.  
Rf = 0.43 (40% EtOAc/hexane). 
 
 
(4S,4'S)-2,2'-(4-Methoxypyridine-2,6-diyl)bis(4-isopropyl-4,5-dihydrooxazole) (165): 
Following the general procedure for PyBOX synthesis, using 4-methoxypyridine-2,6-
dicarbonitrile (173) (0.159 g, 1.0 mmol, 1 equiv.) and L-valinol (167) (0.206 g, 2.0 mmol, 
2 equiv.), purified by silica gel column chromatography (eluent: 3% MeOH/CH2Cl2) 
provided the title compound as a white amorphous solid (0.216 g, 0.65 mmol, 65%), m.p. 60-
62 °C (lit. m.p.
203
 83-84 °C, on material with 0.5 mol H2O). Data are consistent with a 
reported example.
203
  
 
1
H NMR (600 MHz, CDCl3): δ 7.72 (s, 2 H, H3), 4.50 (dd, J = 9.8, 8.5 Hz, 2 H, H6a), 4.20 
(t, J = 8.5 Hz, 2 H, H6b), 4.11 (ddd, J = 9.8, 8.5, 6.7 Hz, 2 H, H7), 3.93 (s, 3 H, H1), 1.85 
(oct, J = 6.7 Hz, 2 H, H8), 1.02 (d, J = 6.7 Hz, 6 H, H9/H10), 0.91 (d, J = 6.7 Hz, 6 H, 
H9/H10). 
13
C NMR (150 MHz, CDCl3): δ 166.6 (C2), 162.4 (C5), 148.4 (C4), 111.8 (C3), 72.9 (C7), 
71.0 (C6), 56.0 (C1), 32.9 (C8), 19.2 (C9/C10), 18.3 (C9/C10). 
FTIR (νmax, cm
-1
): 2964 (w), 2876 (w), 1673 (w), 1584 (m), 1533 (w), 1471 (w), 1443 (w), 
1380 (w), 1346 (w), 1296 (w), 1245 (m), 1214 (m), 1182 (w), 1162 (m), 1143 (w), 1106 (w), 
1082 (w), 1045 (m), 970 (s), 939 (w), 886 (w), 864 (m), 806 (w), 758 (m). 
5. Experimental (Appendix) 
168 
 
HRMS (ESI): calculated for C18H26N3O3 [M+H]
+
 332.1969, found 332.1967.  
Rf = 0.28 (3% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -99.9 (CHCl3, c = 1.0); lit.
203
 [𝛂]𝑫 = -83.6 (CH2Cl2, c = 0.53).  
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5.3.2. Synthetic procedures and characterisation for PyBIM ligands 
 
General procedure for PyBIM synthesis: To a mixture of the appropriate amide precursor 
(5.0 mmol, 1 equiv.) in anhydrous CHCl3 (35 mL) was added thionyl chloride (2.1 mL, 
28.8 mmol, 5.8 equiv.) at 0 °C. The mixture was then heated under reflux for 5 h. Phosphorus 
pentachloride (2.19 g, 10.5 mmol, 2.1 equiv.) was then added in one portion and the mixture 
stirred under reflux for 16 h. The solution was then stripped of volatiles and the residue 
redissolved in anhydrous CHCl3 (35 mL) to use as a stock solution of the imidoyl chloride 
intermediate.  
 
To a 5 mL microwave vial was added a solution of the imidoyl chloride in CHCl3 (3.5 mL, 
0.5 mmol, 1 equiv.), triethylamine (0.52 mL, 3.6 mmol, 7.2 equiv.) and the appropriate 
aniline/amine (1.1 mmol, 2.2 equiv.). The vial was sealed and stirred at r.t. or 60 °C for the 
allotted time. The mixture was diluted with CH2Cl2 (10 mL) then quenched with 1 M aqueous 
NaOH solution (10 mL). The organic layer was separated and the aqueous layer extracted 
further with CH2Cl2 (3 × 10 mL). The combined organic extracts were dried (MgSO4) and 
evaporated under reduced pressure. The residue was then purified by silica gel column 
chromatography. 
 
 
N
2
,N
6
-Bis((S)-1-hydroxy-3-methylbutan-2-yl)pyridine-2,6-dicarboxamide (175): To a 
stirred solution of L-valinol (167) (2.06 g, 20.0 mmol, 2 equiv.) and triethylamine (2.79 mL, 
20.0 mmol, 2 equiv.) in anhydrous CH2Cl2 (50 mL) was added portionwise pyridine-2,6-
dicarbonyl chloride (174) (2.04 g, 10.0 mmol, 1 equiv.) at 0 °C. The mixture was warmed to 
r.t. and stirred further for 16 h. Water (50 mL) was added and the organic layer separated. 
The aqueous layer was extracted further with CH2Cl2 (3 × 25 mL) and the combined organic 
extracts dried (MgSO4) and evaporated under reduced pressure. The residue was 
recrystallised from CH2Cl2 to provide the title compound as a white crystalline solid (2.20 g, 
6.5 mmol, 65%), m.p. 120-121 °C (lit. m.p.
204
 118-120 °C). Data are consistent with a 
reported example.
205
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1
H NMR (600 MHz, CDCl3): δ 8.36 (d, J = 7.8 Hz, 2 H, H2), 8.06 (t, J = 7.8 Hz, 1 H, H1), 
8.00 (br d, J = 8.1 Hz, 2 H, NH), 3.99 – 3.93 (m, 2 H, H5), 3.89 – 3.81 (m, 4 H, H9), 2.53 (br 
s, 2 H, OH), 2.09 (oct, J = 6.8 Hz, 2 H, H6), 1.06 (d, J = 6.8 Hz, 6 H, H7/H8), 1.04 (d, J = 
6.8 Hz, 6 H, H7/H8). 
13
C NMR (150 MHz, CDCl3): δ 164.2 (C4), 148.8 (C3), 139.4 (C1), 125.3 (C2), 64.2 (C9), 
57.4 (C5), 29.5 (C6), 19.8 (C7/C8), 18.7 (C7/C8). 
FTIR (νmax, cm
-1
): 3401 (w, NH), 3304 (br m, OH), 2964 (w), 2878 (w), 1680 (m), 1644 (s, 
C=O), 1592 (w), 1538 (s), 1477 (m), 1442 (w), 1389 (w), 1368 (w), 1341 (w), 1302 (w), 
1238 (w), 1171 (w), 1145 (w), 1094 (w), 1066 (s), 1017 (s), 1000 (w), 970 (w), 956 (w), 934 
(w), 899 (w), 872 (w), 844 (m), 800 (w). 
HRMS (ESI): calculated for C17H27N3O4Na [M+Na]
+
 360.1894, found 360.1892. 
[𝛂]𝑫
𝟐𝟓.𝟗 = -37.5 (CHCl3, c = 1.0); lit.
206
 [𝛂]𝑫
𝟐𝟓 = -82.3 (acetone, c = 0.15). 
 
 
2,6-Bis((S)-1-benzyl-4-isopropyl-4,5-dihydro-1H-imidazol-2-yl)pyridine (178): Following 
the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3-methylbutan-2-
yl)pyridine-2,6-dicarboxamide (175) and benzylamine (0.12 mL, 1.1 mmol, 2.2 equiv.) at 
60 °C for 16 h, purified by silica gel column chromatography (eluent: 10% MeOH/CH2Cl2) 
provided the title compound as a brown foam (113.1 mg, 0.236 mmol, 47%). Compound has 
been prepared previously,
132
 but NMR spectra were recorded in CD3OD. 
 
1
H NMR (600 MHz, CDCl3): δ 8.21 (d, J = 7.9 Hz, 2 H, H2), 7.95 (t, J = 7.9 Hz, 1 H, H1), 
7.28 – 7.23 (m, 6 H, H13 and H14), 7.14 – 7.09 (m, 4 H, H12), 4.57 (AB q, J = 15.3 Hz, 4 H, 
H10a and H10b), 3.96 (ddd, J = 10.7, 9.6, 6.7 Hz, 2 H, H6), 3.49 (dd, J = 10.7, 9.6 Hz, 2 H, 
H5a), 3.09 (t, J = 9.6 Hz, 2 H, H5b), 1.86 (oct, J = 6.7 Hz, 2 H, H7), 0.94 (d, J = 6.7 Hz, 6 H, 
H8/H9), 0.84 (d, J = 6.7 Hz, 6 H, H8/H9). 
13
C NMR (150 MHz, CDCl3): δ 162.2 (C4), 148.3 (C3), 138.3 (C1), 137.1 (C11), 128.6 
(C13), 127.6 (C12), 127.5 (C14), 127.1 (C2), 68.3 (C6), 53.0 (C5), 51.7 (C10), 32.9 (C7), 
18.8 (C8/C9), 17.8 (C8/C9). 
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FTIR (νmax, cm
-1
): 3030 (w), 2957 (m), 2871 (m), 1596 (s), 1563 (s), 1495 (m), 1454 (m), 
1385 (w), 1363 (m), 1312 (w), 1263 (m), 1151 (w), 1110 (w), 1077 (w), 1029 (w), 995 (w), 
925 (w), 831 (m). 
HRMS (ESI): calculated for C31H38N5 [M+H]
+
 480.3122, found 480.3138. 
Rf = 0.07 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟕.𝟖 = -130.6 (CHCl3, c = 1.0); lit.
132
 [𝛂]𝑫
𝟐𝟓 = -133.5 (CHCl3, c = 0.39). 
 
 
2,2'-((1E,1'E)-(((3S,4S)-2,5-Dimethylhexane-3,4-diyl)bis(azanylylidene))bis(methanyl-
ylidene))diphenol (196): To a solution of (R,R)-1,2-bis(2-hydroxyphenyl)-1,2-
diaminoethane (194) (6.92 g, 28.3 mmol, 1 equiv.) in anhydrous toluene (75 mL) was added 
isobutyraldehyde (195) (6.5 mL, 70.8 mmol, 2.5 equiv.). The mixture was heated under 
reflux with equipped Dean-Stark apparatus for 16 h. The mixture was then evaporated under 
reduced pressure and the residue triturated with MeOH. The product was collected by 
filtration to provide the title compound as a yellow powder (8.49 g, 24.1 mmol, 85%), m.p. 
189-191 °C (lit. m.p.
133
 188-189 °C). Data are consistent with a reported example.
133 
 
1
H NMR (600 MHz, CDCl3): δ 13.54 (s, 2 H, OH), 8.17 (s, 2 H, H7), 7.28 – 7.24 (m, 2 H, 
H3), 7.15 (dd, J = 7.5, 1.7 Hz, 2 H, H5), 6.96 – 6.93 (m, 2 H, H2), 6.79 (td, J = 7.5, 1.1 Hz, 
2 H, H4), 3.26 – 3.19 (m, 2 H, H8), 2.17 – 2.09 (m, 2 H, H9), 0.99 (d, J = 6.8 Hz, 6 H, 
H10/H11), 0.91 (d, J = 6.8 Hz, 6 H, H10/H11). 
13
C NMR (150 MHz, CDCl3): δ 165.8 (C7), 161.4 (C1), 132.3 (C3), 131.6 (C5), 118.57 (C4), 
118.56 (C6), 117.1 (C2), 76.3 (C8), 28.6 (C9), 20.7 (C10/C11), 17.5 (C10/C11). 
FTIR (νmax, cm
-1
): 2966 (w), 2927 (w), 2873 (w), 1627 (s), 1579 (m), 1499 (m), 1460 (m), 
1418 (w), 1389 (w), 1364 (w), 1337 (w), 1315 (w), 1280 (m), 1207 (w), 1175 (w), 1150 (w), 
1115 (w), 1083 (w), 1032 (w), 999 (w), 988 (w), 959 (w), 922 (w), 889 (w), 850 (w), 826 (w). 
HRMS (ESI): calculated for C22H29N2O2 [M-H]
-
 351.2078, found 351.2077.  
[𝛂]𝑫
𝟐𝟖.𝟒 = +150.0 (CHCl3, c = 1.0); lit.
133
 [𝛂]𝑫
𝟐𝟔 = +144.8 (CHCl3, c = 1.0). 
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(3S,4S)-2,5-Dimethylhexane-3,4-diammonium dichloride (197): To a solution of 2,2'-
((1E,1'E)-(((3S,4S)-2,5-dimethylhexane-3,4-diyl)bis(azanylylidene))bis(methanylylidene))-
diphenol (196) in THF (200 mL) was added 37% aqueous HCl (7.2 mL). The mixture was 
heated at 50 °C for 3 h, producing a white precipitate. The product was collected by filtration, 
providing the title compound as a white crystalline solid (4.68 g, 21.5 mmol, 89%), m.p. 284-
286 °C (sublim.) (lit. m.p.
133
 >200 °C (sublim.)). Data are consistent with a reported 
example.
133 
 
1
H NMR (600 MHz, DMSO-d6): δ 8.48 (br s, 6 H, NH), 3.21 (d, J = 5.4 Hz, 2 H, H1), 2.17 
– 2.07 (m, 2 H, H2), 1.03 – 0.94 (m, 12 H, H3 and H4). 
13
C NMR (150 MHz, DMSO-d6): δ 56.2 (C1), 27.2 (C2), 19.7 (C3/C4), 17.3 (C3/C4). 
FTIR (νmax, cm
-1
): 2824 (br m, NH), 1588 (s), 1555 (m), 1532 (m), 1497 (s), 1458 (m), 1379 
(w), 1035 (w), 983 (w). 
HRMS (ESI): calculated for C8H21N2 [of free base, M+H]
+
 145.1699, found 145.1696. 
[𝛂]𝑫
𝟐𝟖.𝟒 = -4.8 (MeOH, c = 1.0); lit.
133
 [𝛂]𝑫
𝟐𝟕 = +5.4 (MeOH, c = 1.0) (N.B. there appears to be 
a sign error in the literature optical rotation, given that their other similar (S,S)-diamine 
hydrochloride salts also have negative optical rotation values). 
 
 
Dimethyl pyridine-2,6-bis(carbimidate) (198): To a solution of 2,6-pyridinedicarbonitrile 
(2.58 g, 20.0 mmol, 1 equiv.) in anhydrous MeOH (50 mL) was added sodium (60 mg, 
2.5 mmol, 0.125 equiv.) and the mixture stirred at r.t. for 48 h. Acetic acid (0.15 mL, 
2.5 mmol, 0.125 equiv.) was then added and the solvent removed under reduced pressure, 
which provided the title compound as a yellow amorphous solid (3.86 g, 20.0 mmol, 99%), 
m.p. >200 °C (dec.). Data are consistent with a reported example.
207
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1
H NMR (600 MHz, CDCl3): δ 9.23 (br s, 2 H, NH), 7.93 – 7.91 (m, 3 H, H1 and H2), 4.03 
(s, 6 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 166.2 (C4), 147.1 (C3), 139.1 (C1), 122.7 (C2), 54.2 (C5). 
FTIR (νmax, cm
-1
): 3289 (w), 3268 (m), 3008 (w), 2956 (w), 1654 (m), 1640 (m), 1571 (s), 
1457 (m), 1434 (m), 1338 (s), 1268 (w), 1210 (m), 1194 (m), 1158 (w), 1080 (s), 998 (m), 
946 (s), 914 (s), 874 (w), 824 (s), 751 (s). 
HRMS (ESI): calculated for C9H11N3O2Na [M+Na]
+
 216.0743, found 216.0749.  
 
 
2,6-Bis((4S,5S)-4,5-diisopropyl-4,5-dihydro-1H-imidazol-2-yl)pyridine (199): To a 
suspension of (3S,4S)-2,5-dimethylhexane-3,4-diammonium dichloride (197) (1.82 g, 
8.4 mmol, 2.1 equiv.) in CH2Cl2 (25 mL) was added 3 M aqueous NaOH solution (20 mL). 
The organic layer was separated and the aqueous layer extracted further with CH2Cl2 (3 × 
10 mL). The combined organic extracts were dried (MgSO4) and evaporated under reduced 
pressure to provide the corresponding free base (ca. 1.21 g, 8.4 mmol). The free base was 
then dissolved in CH2Cl2 (20 mL) and transferred into a 20 mL microwave vial charged with 
dimethyl pyridine-2,6-bis(carbimidate) (198) (0.773 g, 4.0 mmol, 1 equiv.). The mixture was 
heated at 40 °C for 48 h. Water (20 mL) was then added and the organic layer separated. The 
aqueous layer was extracted further with CH2Cl2 (3 × 20 mL) and the combined organic 
extracts dried (MgSO4) then evaporated under reduced pressure. The residue was purified by 
silica gel column chromatography (eluent: 10% MeOH/CH2Cl2) to provide the title 
compound as a white foam (0.893 g, 2.33 mmol, 58%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.25 (d, J = 7.8 Hz, 2 H, H2), 7.80 (t, J = 7.8 Hz, 1 H, H1), 
5.90 (br s, 2 H, NH), 3.64 (br s, 4 H, H5), 1.75 (br s, 4 H, H6), 0.95 (d, J = 6.8 Hz, 24 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 160.5 (C4), 147.8 (br, C3), 137.1 (C1), 124.1 (C2), 33.4 
(C6), 18.5 (C7). (C5 too broadened to distinguish properly). 
FTIR (νmax, cm
-1
): 3204 (br w, NH), 2957 (m), 2871 (m), 1603 (m), 1565 (m), 1463 (s), 
1385 (m), 1365 (m), 1320 (w), 1261 (m), 1240 (m), 1148 (w), 1077 (w), 992 (m), 938 (w), 
832 (m). 
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HRMS (ESI): calculated for C23H38N5 [M+H]
+
 384.3122, found 384.3130.  
Rf = 0.15-0.45 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟑 = -162.4 (CHCl3, c = 1.0). 
 
 
2,6-Bis((4S,5S)-1-benzyl-4,5-diisopropyl-4,5-dihydro-1H-imidazol-2-yl)pyridine (200): 
To a suspension of sodium hydride (64 mg, 60% dispersion in mineral oil, 1.6 mmol, 4 equiv.) 
in anhydrous DMF (3 mL) was added a solution of 2,6-bis((4S,5S)-4,5-diisopropyl-4,5-
dihydro-1H-imidazol-2-yl)pyridine (199) (0.153 g, 0.4 mmol, 1 equiv.) in anhydrous DMF 
(1 mL) at 0 °C. The mixture was stirred further for 30 min. A solution of benzyl bromide 
(0.12 mL, 1.0 mmol, 2.5 equiv.) was added slowly dropwise over 30 min and then the 
mixture was warmed to r.t. and stirred for 16 h. The mixture was quenched with water 
(20 mL), extracted with CH2Cl2 (3 × 25 mL) and the combined organic extracts evaporated 
under reduced pressure. The residue was redissolved in Et2O (25 mL), washed with water 
(4 × 25 mL), brine (25 mL), dried (MgSO4) and evaporated under reduced pressure. The 
residue was purified by silica gel column chromatography (eluent: 10% MeOH/CH2Cl2) to 
provide the title compound as a colourless resin (0.140 g, 0.25 mmol, 62%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.03 (d, J = 7.8 Hz, 2 H, H2), 7.85 (t, J = 7.8 Hz, 1 H, H1), 
7.24 – 7.17 (m, 6 H, H16 and H17), 7.12 – 7.09 (m, 4 H, H15), 5.11 (d, J = 15.4 Hz, 2 H, 
H13a), 4.24 (d, J = 15.4 Hz, 2 H, H13b), 3.56 (t, J = 5.2 Hz, 2 H, H9), 3.20 (dd, J = 5.2, 
3.7 Hz, 2 H, H5), 1.93 – 1.84 (m, 2 H, H6), 1.53 – 1.43 (m, 2 H, H10), 0.83 (d, J = 6.9 Hz, 
6 H, H7/H8), 0.82 (d, J = 6.9 Hz, 6 H, H11/H12), 0.80 (d, J = 6.9 Hz, 6 H, H7/H8), 0.77 (d,  
J = 6.9 Hz, 6 H, H11/H12). 
13
C NMR (150 MHz, CDCl3): δ 161.7 (C4), 149.9 (C3), 138.0 (C14), 137.7 (C1), 128.4 
(C15/C16), 128.3 (C15/C16), 127.3 (C17), 126.0 (C2), 70.5 (C9), 66.9 (C5), 49.5 (C13), 33.8 
(C10), 29.6 (C6), 18.9 (C11/C12), 17.8 (C11/C12), 17.5 (C7/C8), 16.0 (C7/C8). 
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FTIR (νmax, cm
-1
): 2957 (m), 2870 (m), 1594 (m), 1562 (s), 1463 (s), 1399 (w), 1385 (m), 
1363 (w), 1327 (w), 1261 (w), 1210 (w), 1147 (m), 1074 (m), 1025 (w), 997 (w), 966 (m), 
930 (w), 833 (s). 
HRMS (ESI): calculated for C37H50N5 [M+H]
+
 564.4061, found 564.4071.  
Rf = 0.16 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -172.4 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-1-benzyl-4-(tert-butyl)-4,5-dihydro-1H-imidazol-2-yl)pyridine (179): 
Following the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3,3-
dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and benzylamine (0.12 mL, 1.1 mmol, 
2.2 equiv.) at 60 °C for 16 h, purified by silica gel column chromatography (eluent: 10% 
MeOH/EtOAc) provided the title compound as a brown gum (100.1 mg, 0.197 mmol, 39%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.06 (br d, J = 7.7 Hz, 2 H, H2), 7.87 (t, J = 7.7 Hz, 1 H, H1), 
7.29 – 7.23 (m, 6 H, H12 and H13), 7.17 – 7.13 (m, 4 H, H11), 4.60 (d, J = 15.2 Hz, 2 H, 
H9a), 4.53 (br d, J = 15.2 Hz, 2 H, H9b), 3.84 (appears t, J = 10.6 Hz, 2 H, H6), 3.40 (t, J = 
10.6 Hz, 2 H, H5a), 3.07 (appears t, J = 9.9 Hz, 2 H, H5b), 0.88 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 162.7 (C4), 137.9 (C1), 128.6 (C12), 127.9 (C11), 127.4 
(C10), 127.3 (C11), 126.3 – 126.0 (br, C2), 73.6 – 73.1 (br, C6), 51.9 (C5/C9), 51.8 (C5/C9), 
34.3 (C7), 26.2 (C8). (C3 too broadened to distinguish properly). 
FTIR (νmax, cm
-1
): 3029 (w), 2952 (s), 2866 (m), 1594 (m), 1565 (s), 1495 (m), 1454 (s), 
1390 (m), 1362 (s), 1275 (m), 1148 (m), 1076 (m), 1028 (m), 829 (m). 
HRMS (ESI): calculated for C33H42N5 [M+H]
+
 508.3435, found 508.3423. 
Rf = 0.14 (15% MeOH/EtOAc). 
[𝛂]𝑫
𝟐𝟓.𝟗 = -140.4 (CHCl3, c = 1.0). 
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2,6-Bis((S)-4-(tert-butyl)-1-((R)-1-phenylethyl)-4,5-dihydro-1H-imidazol-2-yl)pyridine 
(180): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-
3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and (R)-1-phenylethan-1-amine 
(0.14 mL, 1.1 mmol, 2.2 equiv.) at 60 °C for 16 h, purified by silica gel column 
chromatography (eluent: 5% MeOH/CH2Cl2) provided the title compound as a brown gum 
(26.3 mg, 0.049 mmol, 10%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.26 (br s, 2 H, H2), 8.05 (t, J = 7.7 Hz, 1 H, H1), 7.32 – 
7.25 (m, 10 H, H12, H13 and H14), 5.67 (br s, 2 H, H9), 3.86 (t, J = 10.7 Hz, 2 H, H6), 3.29 
(appears br t, J = 9.1 Hz, 2 H, H5a), 3.18 (appears t, J = 10.7 Hz, 2 H, H5b), 1.42 (d, J = 
6.8 Hz, 6 H, H10), 0.97 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 162.4 (C4), 138.9 (C1), 128.8 (C12/C13), 128.1 (br, C2), 
127.8 (C14), 127.1 (C12/C13), 53.2 (C9), 46.1 (C5), 34.6 (C7), 25.9 (C8), 16.3 (C10). (C11 
appears to be hidden behind other aromatic carbon peaks; C3, C6 too broadened to 
distinguish properly). 
FTIR (νmax, cm
-1
): 2953 (m), 2866 (w), 1592 (m), 1562 (s), 1454 (m), 1391 (w), 1362 (m), 
1279 (s), 1205 (m), 1174 (m), 1078 (w), 1024 (m), 994 (w), 827 (m), 787 (m). 
HRMS (ESI): calculated for C35H46N5 [M+H]
+
 536.3748, found 536.3737.  
Rf = 0.06 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟔.𝟏 = +37.2 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-phenyl-4,5-dihydro-1H-imidazol-2-yl)pyridine (181): Follow-
ing the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3,3-
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dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and aniline (0.10 mL, 1.1 mmol, 
2.2 equiv.) at 60 °C for 16 h, purified by silica gel column chromatography (eluent: 5% 
MeOH/CH2Cl2) provided the title compound as a pale brown gum (213.0 mg, 0.444 mmol, 
89%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.67 – 7.60 (m, 3 H, H1 and H2), 7.09 (t, J = 7.6 Hz, 4 H, 
H11), 6.92 (t, J = 7.6 Hz, 2 H, H12), 6.60 (d, J = 7.6 Hz, 4 H, H10), 4.02 (dd, J = 10.9, 
9.3 Hz, 2 H, H5a), 3.93 (dd, J = 10.9, 7.6 Hz, 2 H, H6), 3.60 (dd, J = 9.3, 7.6 Hz, 2 H, H5b), 
0.91 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 159.8 (C4), 149.9 (C3), 143.1 (C9), 136.7 (C1), 128.4 (C11), 
124.6 (C2), 123.3 (C12), 122.8 (C10), 74.1 (C6), 55.1 (C5), 34.3 (C7), 26.0 (C8). 
FTIR (νmax, cm
-1
): 2954 (w), 2868 (w), 1595 (m), 1569 (m), 1496 (s), 1480 (s), 1425 (w), 
1392 (m), 1362 (m), 1299 (w), 1280 (w), 1216 (w), 1168 (w), 1082 (w), 1049 (w), 1018 (w), 
994 (w), 931 (w), 825 (w). 
HRMS (ESI): calculated for C31H38N5 [M+H]
+
 480.3122, found 480.3109. 
Rf = 0.11 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟗 = +35.3 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-mesityl-4,5-dihydro-1H-imidazol-2-yl)pyridine (182): 
Following the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3,3-
dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 2,4,6-trimethylaniline (0.16 mL, 
1.1 mmol, 2.2 equiv.) at r.t. for 48 h, purified by silica gel column chromatography (eluent: 
10% MeOH/CH2Cl2) provided the title compound as a pale brown gum (68.9 mg, 
0.122 mmol, 24%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.58 (br t, J = 7.9 Hz, 1 H, H1), 7.51 (d, J = 7.9 Hz, 2 H, H2), 
6.82 (s, 2 H, H12/H15), 6.71 (s, 2 H, H12/H15), 4.21 (appears t, J = 11.3 Hz, 2 H, H6), 3.93 
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(t, J = 11.3 Hz, 2 H, H5a), 3.57 (appears t, J = 10.8 Hz, 2 H, H5b), 2.24 (s, 6 H, H11/H17), 
2.18 (s, 6 H, H14), 1.82 (s, 6 H, H11/H17), 1.05 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 162.5 (C4), 146.0 (C3), 138.3 (C9), 137.6 (C1), 136.1 
(C10/C16), 134.8 (C10/C16), 134.1 (C13), 130.0 (C12/C15), 129.9 (C12/C15), 126.4 (C2), 
70.7 (C6), 53.8 (C5), 34.3 (C7), 26.2 (C8), 20.9 (C14), 18.2 (C11/C17), 17.9 (C11/C17). 
FTIR (νmax, cm
-1
): 2952 (s), 2867 (m), 1612 (m), 1558 (s), 1479 (s), 1362 (w), 1280 (m), 
1172 (w), 1018 (w), 853 (w), 823 (w). 
HRMS (ESI): calculated for C37H50N5 [M+H]
+
 564.4061, found 564.4053. 
Rf = 0.11 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = +19.6 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(3,5-di-tert-butylphenyl)-4,5-dihydro-1H-imidazol-2-
yl)pyridine (183): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-
bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 3,5-di-tert-
butylaniline (0.226 g, 1.1 mmol, 2.2 equiv.) at r.t. for 16 h, purified by silica gel column 
chromatography (eluent: 10% MeOH/CH2Cl2) provided the title compound as a yellow foam 
(201.3 mg, 0.286 mmol, 57%). 
 
1
H NMR (600 MHz, MeOD-d4): δ 7.80 (t, J = 8.0 Hz, 1 H, H1), 7.41 (d, J = 8.0 Hz, 2 H, 
H2), 7.36 (t, J = 1.5 Hz, 2 H, H14), 6.94 (d, J = 1.5 Hz, 4 H, H10), 4.39 (t, J = 10.7 Hz, 2 H, 
H5a), 4.21 (dd, J = 10.7, 8.1 Hz, 2 H, H6), 4.16 (dd, J = 10.7, 8.1 Hz, 2 H, H5b), 1.24 (s, 
36 H, H13), 1.06 (s, 18 H, H8). 
13
C NMR (150 MHz, MeOD-d4): δ 162.2 (C4), 153.9 (C9), 147.3 (C3), 140.2 (C11), 139.1 
(C1), 128.4 (C2), 122.3 (C14), 120.0 (C10), 70.9 (C6), 57.4 (C5), 35.9 (C12), 35.3 (C7), 31.7 
(C13), 25.8 (C8). 
FTIR (νmax, cm
-1
): 2954 (s), 2868 (m), 1594 (s), 1567 (m), 1479 (m), 1393 (w), 1362 (m), 
1334 (w), 1248 (m), 1203 (w), 1168 (w), 1084 (w), 993 (w), 900 (w), 864 (w), 827 (w), 751 
(m).  
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HRMS (ESI): calculated for C47H70N5 [M+H]
+
 704.5626, found 704.5618. 
Rf = 0.14 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -70.6 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(3,5-dimethylphenyl)-4,5-dihydro-1H-imidazol-2-yl)pyridine 
(184): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-
3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 3,5-dimethylaniline (0.16 mL, 
1.1 mmol, 2.2 equiv.) at r.t. for 16 h, purified by silica gel column chromatography (eluent: 
10% MeOH/CH2Cl2) provided the title compound as an orange resin (206.3 mg, 0.385 mmol, 
77%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.93 (br d, J = 7.7 Hz, 2 H, H2), 7.77 (br t, J = 7.7 Hz, 1 H, 
H1), 6.71 (s, 2 H, H13), 6.34 (s, 4 H, H10), 4.12 (t, J = 10.5 Hz, 2 H, H5a), 4.04 (dd, J = 10.5, 
7.9 Hz, 2 H, H6), 3.76 (dd, J = 10.5, 7.9 Hz, 2 H, H5b), 2.16 (s, 12 H, H12), 0.94 (s, 18 H, 
H8). 
13
C NMR (150 MHz, CDCl3): δ 160.0 (C4), 146.2 – 145.8 (br, C3), 140.3 – 140.1 (C9), 
138.7 (C11), 137.8 – 137.7 (br, C1), 127.7 – 127.5 (br, C2/C13), 127.5 – 127.3 (br, C2/C13), 
121.3 (C10), 70.4 – 70.0 (br, C6), 55.7 (C5), 34.4 (C7), 25.6 (C8), 21.3 (C12). 
FTIR (νmax, cm
-1
): 2953 (m), 1595 (s), 1567 (s), 1476 (s), 1363 (w), 1337 (w), 1275 (w), 
1217 (w), 994 (w), 834 (w). 
HRMS (ESI): calculated for C35H46N5 [M+H]
+
 536.3748, found 536.3735. 
Rf = 0.05 (10% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -18.6 (CHCl3, c = 1.0). 
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2,6-Bis((S)-1-(3,5-bis(trifluoromethyl)phenyl)-4-(tert-butyl)-4,5-dihydro-1H-imidazol-2-
yl)pyridine (185): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-
bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 3,5-
bis(trifluoromethyl)aniline (0.10 mL, 0.66 mmol, 2.2 equiv.) at 60 °C for 16 h, purified by 
silica gel column chromatography (eluent: 3% MeOH/CH2Cl2) provided the title compound 
as a light brown foam (163.0 mg, 0.212 mmol, 43%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.99 (d, J = 7.8 Hz, 2 H, H2), 7.85 (t, J = 7.8 Hz, 1 H, H1), 
7.37 (s, 2 H, H13), 6.88 (q, J = 1.1 Hz, 4 H, H10), 3.98 (dd, J = 10.6, 7.4 Hz, 2 H, H6), 3.92 
(dd, J = 10.6, 8.9 Hz, 2 H, H5a), 3.65 (dd, J = 8.9, 7.4 Hz, 2 H, H5b), 0.90 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 157.3 (C4), 148.3 – 148.2 (br, C3), 143.9 (C9), 137.8 (C1), 
131.5 (q, J = 33.3 Hz, C11), 125.6 (C2), 123.1 (q, J = 272.8 Hz, C12), 121.1 – 120.09 (br, 
C10), 115.8 – 115.5 (br, C13), 74.2 (C6), 54.5 (C5), 34.4 (C7), 25.8 (C8). 
19
F NMR (376 MHz, CDCl3): δ -63.2 (s, 12 F, F12). 
FTIR (νmax, cm
-1
): 2960 (w), 2871 (w), 1685 (w), 1610 (w), 1570 (w), 1520 (w), 1475 (m), 
1396 (m), 1365 (m), 1274 (s), 1171 (m), 1126 (s), 1108 (m), 1057 (m), 1022 (w), 996 (w), 
879 (w), 846 (w), 827 (w), 756 (m). 
HRMS (ESI): calculated for C35H34F12N5 [M+H]
+
 752.2617, found 752.2640.  
Rf = 0.29 (4% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -100.1 (CHCl3, c = 1.0). 
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Dimethyl 4,4'-((4S,4'S)-pyridine-2,6-diylbis(4-(tert-butyl)-4,5-dihydro-1H-imidazole-2,1-
diyl))dibenzoate (186): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-
bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and methyl 4-
aminobenzoate (0.166 g, 1.1 mmol, 2.2 equiv.) at r.t. for 72 h, purified by silica gel column 
chromatography (eluent: 4% → 10% MeOH/CH2Cl2) provided the title compound as an 
orange foam (132.0 mg, 0.222 mmol, 44%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.80 – 7.75 (m, 3 H, H1 and H2), 7.73 (d, J = 8.8 Hz, 4 H, 
H11), 6.50 (d, J = 8.8 Hz, 4 H, H10), 3.98 – 3.91 (m, 4 H, H5a and H6), 3.85 (s, 6 H, H14), 
3.71 – 3.63 (m, 2 H, H5b), 0.89 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 166.8 (C13), 158.4 (C4), 149.7 (br, C3), 146.5 (C9), 137.5 
(C1), 130.1 (C11), 125.0 (C2), 123.7 (C12), 120.5 (C10), 74.1 (C6), 54.2 (C5), 52.0 (C14), 
34.3 (C7), 25.9 (C8). 
FTIR (νmax, cm
-1
): 2953 (m), 2869 (w), 1715 (s, C=O), 1603 (s), 1568 (m), 1516 (m), 1479 
(m), 1434 (m), 1382 (m), 1363 (m), 1332 (w), 1276 (s), 1181 (m), 1112 (m), 1048 (w), 1000 
(w), 932 (w), 847 (w), 827 (w), 769 (m), 753 (m). 
HRMS (ESI): calculated for C35H42N5O4 [M+H]
+
 596.3231, found 596.3228. 
Rf = 0.26 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟏 = -47.1 (CHCl3, c = 1.0). 
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2,6-Bis((S)-4-(tert-butyl)-1-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-imidazol-2-
yl)pyridine (187): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-
bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 4-
trifluoromethylaniline (0.14 mL, 1.1 mmol, 2.2 equiv.) at r.t. for 16 h, purified by silica gel 
column chromatography (eluent: 5% MeOH/CH2Cl2) provided the title compound as a 
yellow gum (215.1 mg, 0.349 mmol, 70%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.88 (d, J = 7.8 Hz, 2 H, H2), 7.79 (t, J = 7.8 Hz, 1 H, H1), 
7.27 (d, J = 8.5 Hz, 4 H, H11), 6.51 (d, J = 8.5 Hz, 4 H, H10), 3.96 – 3.88 (m, 4 H, H5a and 
H6), 3.66 – 3.59 (m, 2 H, H5b), 0.90 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 158.1 (C4), 149.1 (C3), 145.4 (C9), 137.5 (C1), 125.3 (q, 
J = 3.7 Hz, C11), 125.1 (C2), 124.4 (q, J = 271.3 Hz, C13), 124.1 (q, J = 32.6 Hz, C12), 
121.2 (C10), 73.9 (C6), 54.3 (C5), 34.3 (C7), 25.8 (C8). 
19
F NMR (376 MHz, CDCl3): δ -61.8 (s, 6 F, F13). 
FTIR (νmax, cm
-1
): 2953 (w), 1604 (w), 1569 (w), 1523 (w), 1481 (w), 1412 (w), 1364 (w), 
1323 (s), 1161 (m), 1114 (m), 1070 (m), 1047 (w), 1014 (w), 833 (w), 757 (w). 
HRMS (ESI): calculated for C33H36F6N5 [M+H]
+
 616.2869, found 616.2861. 
Rf = 0.07 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -44.5 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(4-(pentafluorosulfanyl)phenyl)-4,5-dihydro-1H-imidazol-2-
yl)pyridine (188): Following the general procedure for PyBIM synthesis, using N
2
,N
6
-
5. Experimental (Appendix) 
183 
 
bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 4-
(pentafluorothio)aniline (207) (0.241 g, 1.1 mmol, 2.2 equiv.) at r.t. for 72 h, purified by 
silica gel column chromatography (eluent: 3% → 5% MeOH/CH2Cl2) provided the title 
compound as an off-white foam (208.6 mg, 0.285 mmol, 57%). For scale-up to 5.0 mmol 
with respect to the imidoyl chloride, the general procedure was slightly modified, using 4-
(pentafluorothio)aniline (207) (3.29 g, 15.0 mmol, 3 equiv.), which provided the title 
compound as an off-white foam (1.54 g, 2.1 mmol, 42%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.02 (d, J = 7.8 Hz, 2 H, H2), 7.83 (t, J = 7.8 Hz, 1 H, H1), 
7.36 (d, J = 9.0 Hz, 4 H, H11), 6.41 (d, J = 9.0 Hz, 4 H, H10), 3.95 – 3.87 (m, 4 H, H5a and 
H6), 3.66 – 3.58 (m, 2 H, H5b), 0.91 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 157.4 (C4), 148.5 (C3), 147.5 (qn, J = 17.3 Hz, C12), 144.7 
(C9), 137.6 (C1), 125.7 (qn, J = 4.1 Hz, C11), 125.4 (C2), 120.4 (C10), 73.7 (C6), 54.2 (C5), 
34.3 (C7), 25.8 (C8). 
19
F NMR (376 MHz, CDCl3): δ 86.3 (qn, J = 150.1 Hz, 2 F, SFax), 63.9 (d, J = 150.1 Hz, 8 F, 
SFeq). 
FTIR (νmax, cm
-1
): 2958 (w), 1596 (m), 1570 (w), 1507 (m), 1481 (m), 1429 (w), 1393 (m), 
1365 (w), 1334 (w), 1208 (w), 1160 (w), 1103 (m), 1012 (w), 828 (s, S-F), 757 (w). 
HRMS (ESI): calculated for C31H36F10N5S2 [M+H]
+
 732.2247, found 732.2236. 
Rf = 0.09 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟏 = -63.4 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(4-nitrophenyl)-4,5-dihydro-1H-imidazol-2-yl)pyridine (189): 
Following the general procedure for PyBIM synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3,3-
dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 4-nitroaniline (0.152 g, 1.1 mmol, 
2.2 equiv.) at r.t. for 72 h, purified by silica gel column chromatography (eluent: 5% 
MeOH/CH2Cl2) provided the title compound as a yellow foam (119.7 mg, 0.210 mmol, 42%). 
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1
H NMR (600 MHz, CDCl3): δ 7.93 (d, J = 7.7 Hz, 2 H, H2), 7.91 – 7.85 (m, 5 H, H1 and 
H10), 6.46 (d, J = 9.0 Hz, 4 H, H11), 4.00 – 3.94 (m, 2 H, H6), 3.90 (appears t, J = 9.8 Hz, 
2 H, H5a), 3.69 (appears t, J = 8.4 Hz, 2 H, H5b), 0.89 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 157.2 (C4), 149.1 (C3), 147.5 (C12), 141.7 (C9), 138.1 (C1), 
125.4 (C2), 124.2 (C11), 119.8 (C10), 74.1 (C6), 53.9, (C5) 34.2 (C7), 25.8 (C8). 
FTIR (νmax, cm
-1
): 2956 (w), 1590 (m), 1504 (m, NO2), 1478 (w), 1431 (w), 1389 (w), 1364 
(w), 1325 (s, NO2), 1249 (w), 1187 (w), 1154 (w), 1113 (m), 1048 (w), 1000 (w), 854 (w), 
843 (w), 751 (m). 
HRMS (ESI): calculated for C31H36N7O4 [M+H]
+
 570.2823, found 570.2819. 
Rf = 0.08 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟏 = -95.1 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(4-((trifluoromethyl)sulfonyl)phenyl)-4,5-dihydro-1H-
imidazol-2-yl)pyridine (190): Following the general procedure for PyBIM synthesis, using 
N
2
,N
6
-bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 4-
((trifluoromethyl)sulfonyl)aniline (0.248 g, 1.1 mmol, 2.2 equiv.) at r.t. for 72 h, purified by 
silica gel column chromatography (eluent: 3% → 5% MeOH/CH2Cl2) provided the title 
compound as a yellow gum (69.6 mg, 0.094 mmol, 19%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.10 (d, J = 7.8 Hz, 2 H, H2), 7.94 (t, J = 7.8 Hz, 1 H, H1), 
7.61 (d, J = 8.8 Hz, 4 H, H11), 6.53 (d, J = 8.8 Hz, 4 H, H10), 3.99 (dd, J = 9.8, 7.7 Hz, 2 H, 
H6), 3.91 (t, J = 9.8 Hz, 2 H, H5a), 3.71 (dd, J = 9.8, 7.7 Hz, 2 H, H5b), 0.94 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 156.5 (C4), 148.8 (C9), 148.3 (C3), 138.2 (C1), 131.0 (C11), 
125.8 (C2), 121.8 (C12), 120.3 (C10), 120.1 (q, J = 325.7 Hz, C13), 74.0 (C6), 53.9 (C5), 
34.3 (C7), 25.9 (C8). 
19
F NMR (376 MHz, CDCl3): δ -78.6 (s, 6 F, F13). 
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FTIR (νmax, cm
-1
): 2958 (m), 1587 (s), 1502 (m), 1479 (m), 1412 (w), 1216 (s), 1193 (s), 
1141 (s), 1076 (s), 1003 (w), 830 (m), 768 (m). 
HRMS (ESI): calculated for C33H36F6N5O4S2 [M+H]
+
 744.2107, found 744.2117. 
Rf = 0.31 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟒 = -85.0 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(3,5-difluoro-4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-
imidazol-2-yl)pyridine (191): Following the general procedure for PyBIM synthesis, using 
N
2
,N
6
-bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)pyridine-2,6-dicarboxamide (176) and 3,5-
difluoro-4-(trifluoromethyl)aniline (0.217 g, 1.1 mmol, 2.2 equiv.) at r.t. for 72 h, purified by 
silica gel column chromatography (eluent: 3% MeOH/CH2Cl2) provided the title compound 
as a white foam (31.0 mg, 0.045 mmol, 9%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.02 (d, J = 7.8 Hz, 2 H, H2), 7.91 (t, J = 7.8 Hz, 1 H, H1), 
6.05 (d, J = 11.3 Hz, 4 H, H10), 3.99 (dd, J = 10.0, 8.2 Hz, 2 H, H6), 3.86 (t, J = 10.0 Hz, 2 H, 
H5a), 3.69 (dd, J = 10.0, 8.2 Hz, 2 H, H5b), 0.93 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 159.7 (approx. dd, J = 256.0, 7.5 Hz, C11), 156.6 (C4), 
148.2 (C3), 146.9 (t, J = 14.1 Hz, C9), 138.1 (C1), 125.8 (C2), 122.0 (q, J = 272.3 Hz, C13), 
104.3 (d, J = 28.5 Hz, C10), 101.0-100.0 (br, C12), 74.0 (C6), 54.0 (C5), 34.3 (C7), 25.8 (C8). 
19
F NMR (376 MHz, CDCl3): δ -55.5 (t, J = 21.3 Hz, 6 F, F13), -111.5 (q, J = 21.3 Hz, 4 F, 
F11). 
FTIR (νmax, cm
-1
): 2958 (w), 2873 (w), 1644 (m), 1606 (m), 1576 (m), 1514 (w), 1480 (w), 
1415 (w), 1400 (w), 1365 (w), 1301 (s), 1226 (m), 1186 (w), 1130 (m), 1083 (w), 1046 (m), 
1033 (w), 1006 (w), 834 (w), 756 (w). 
HRMS (ESI): calculated for C33H32F10N5 [M+H]
+
 688.2493, found 688.2493. 
Rf = 0.29 (3% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -53.6 (CHCl3, c = 0.5). 
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Dimethyl 4-iodopyridine-2,6-dicarboxylate (202): To a solution of dimethyl 4-chloro-
2,6,dicarboxylate (201) (4.66 g, 20.3 mmol, 1 equiv.) in anhydrous MeCN (150 mL) was 
added acetyl chloride (4.33 mL, 60.9 mmol, 3 equiv.) and then sodium iodide (60.9 g, 
406.0 mmol, 20 equiv.). The mixture was sonicated for 5 h, keeping the bath temperature 
below 30 °C. The mixture was then cooled to 0 °C and saturated aqueous Na2CO3 solution 
(75 mL) and CH2Cl2 (150 mL) were added. The organic layer was separated and then washed 
with saturated aqueous Na2S2O3 solution (100 mL), water (2 × 100 mL), dried (MgSO4) and 
evaporated under reduced pressure. The residue was recrystallised from MeOH to provide the 
title compound as white crystalline needles (4.35 g, 13.6 mmol, 67%), m.p. 175-176 °C (lit. 
m.p.
208
 174-175 °C). Data are consistent with a reported example.
208 
 
1
H NMR (600 MHz, CDCl3): δ 8.66 (s, 2 H, H2), 4.02 (s, 6 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 164.0 (C4), 148.4 (C3), 137.3 (C2), 107.1 (C1), 53.6 (C5). 
FTIR (νmax, cm
-1
): 3068 (w), 2949 (w), 1708 (s, C=O), 1566 (m), 1442 (s), 1324 (s), 1262 (s), 
1241 (m), 1194 (m), 1142 (s), 981 (m), 960 (m), 888 (m), 825 (m), 778 (s). 
HRMS (ESI): calculated for C9H9NO4I [M+H]
+
 321.9571, found 321.9578.  
 
 
Dimethyl 4-(trifluoromethyl)pyridine-2,6-dicarboxylate (204): To a mixture of dimethyl 
4-iodopyridine-2,6-dicarboxylate (202) (1.41 g, 4.4 mmol, 1 equiv.), copper(I) iodide (4.99 g, 
26.2 mmol, 6 equiv.) and (dppf)PdCl2•CH2Cl2 (0.18 g, 0.22 mmol, 0.05 equiv.) in anhydrous 
DMF (70 mL) was added a solution of methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (203) 
(5.03 g, 26.2 mmol, 6 equiv.) in anhydrous DMF (20 mL). The mixture was stirred at 100 °C 
for 16 h. The mixture was cooled to r.t. then diluted with CH2Cl2 (150 mL). The mixture was 
filtered through a pad of Celite, eluting with CH2Cl2, then the filtrate was washed with water 
(2 × 250 mL), brine/water (1:1, 250 mL), brine (250 mL), dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by silica gel column chromatography 
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(eluent: 40% EtOAc/hexane) to provide the title compound as a yellow amorphous solid 
(1.03 g, 3.93 mmol, 89%), m.p. 122-123 °C (lit. m.p.
134
 122-124 °C). Data are consistent with 
a reported example.
134 
 
1
H NMR (600 MHz, CDCl3): δ 8.52 (s, 2 H, H3), 4.07 (s, 6 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 164.1 (C5), 149.8 (C4), 141.3 (q, J = 35.6 Hz, C2), 123.9 (q, 
J = 3.5 Hz, C3), 122.1 (q, J = 273.8 Hz, C1), 53.8 (C6). 
19
F NMR (376 MHz, CDCl3): δ -64.7 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 3083 (w), 2964 (w), 1718 (s, C=O), 1630 (w), 1448 (m), 1435 (w), 1383 
(w), 1274 (s), 1252 (s), 1198 (m), 1168 (s), 1129 (s), 985 (m), 970 (m), 936 (m), 891 (m), 851 
(m), 784 (m). 
HRMS (ESI): calculated for C10H9F3NO4 [M+H]
+
 264.0478, found 264.0482.  
Rf = 0.51 (40% EtOAc/hexane). 
 
 
N
2
,N
6
-Bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)-4-(trifluoromethyl)pyridine-2,6-
dicarboxamide (206): To a 5 mL microwave vial was added dimethyl 4-
(trifluoromethyl)pyridine-2,6-dicarboxylate (204) (0.526 g, 2.0 mmol, 1 equiv.) and L-tert-
leucinol (205) (0.516 g, 4.4 mmol, 2.2 equiv.). The neat mixture was stirred at 120 °C for 
2.5 h, whereupon a precipitate formed. The residue was purified by silica gel column 
chromatography (60% EtOAc/hexane → EtOAc) to provide the title compound as a white 
amorphous solid (0.837 g, 1.93 mmol, 96%), m.p. 186-188 °C (lit. m.p.
134
 178-180 °C). 
Compound has been prepared previously,
134
 but NMR spectra were recorded in DMSO-d6. 
 
1
H NMR (600 MHz, CDCl3): δ 8.60 (s, 2 H, H3), 8.04 (br d, J = 9.1 Hz, 2 H, NH), 4.05 – 
3.99 (m, 2 H, H6), 3.99 – 3.94 (m, 2 H, H9a), 3.82 – 3.75 (m, 2 H, H9b), 2.23 (br s, 2 H, OH), 
1.06 (s, 18 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 163.0 (C5), 150.4 (C4), 142.2 (q, J = 35.3 Hz, C2), 122.3 (q, 
J = 274.0 Hz, C1), 121.4 (q, J = 3.4 Hz, C3), 63.2 (C9), 59.9 (C6), 34.2 (C7), 27.2 (C8). 
19
F NMR (376 MHz, CDCl3): δ -64.8 (s, 3 F, F1). 
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FTIR (νmax, cm
-1
): 3390 (br w, OH), 3324 (w, NH), 2967 (w), 1741 (w), 1664 (s, C=O), 
1609 (w), 1539 (s), 1478 (w), 1435 (w), 1412 (w), 1366 (w), 1334 (w), 1283 (m), 1239 (w), 
1220 (w), 1178 (m), 1151 (m), 1140 (s), 1096 (m), 1058 (w), 1046 (m), 1023 (w), 999 (w), 
933 (w), 903 (w), 797 (w), 778 (w). 
HRMS (ESI): calculated for C20H29F3N3O4 [M-H]
-
 432.2116, found 432.2114.  
Rf = 0.20 (50% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -5.2 (CHCl3, c = 0.25); lit.
134
 [𝛂]𝑫
𝟐𝟖 = +6.32 (MeOH, c = 0.27). 
 
 
2,6-Bis((S)-4-(tert-butyl)-1-(4-(pentafluorosulfanyl)phenyl)-4,5-dihydro-1H-imidazol-2-
yl)-4-(trifluoromethyl)pyridine (208): Following the general procedure for PyBIM 
synthesis, using N
2
,N
6
-bis((S)-1-hydroxy-3,3-dimethylbutan-2-yl)-4-(trifluoromethyl)-
pyridine-2,6-dicarboxamide (206) and 4-(pentafluorothio)aniline (207) (0.241 g, 1.1 mmol, 
2.2 equiv.) at 60 °C for 5 d, purified by silica gel column chromatography (eluent: 1% →   
1.5% MeOH/CH2Cl2) provided the title compound as an off-white amorphous solid 
(196.0 mg, 0.245 mmol, 49%), m.p. 201-202 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 8.33 (s, 2 H, H3), 7.38 (d, J = 8.9 Hz, 4 H, H12), 6.36 (d, J = 
8.9 Hz, 4 H, H11), 3.95 (dd, J = 10.7, 7.7 Hz, 2 H, H7), 3.88 (dd, J = 10.7, 9.2 Hz, 2 H, H6a), 
3.64 (dd, J = 9.2, 7.7 Hz, 2 H, H6b), 0.94 (s, 18 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 156.4 (C5), 149.5 (C4), 147.9 (qn, J = 17.1 Hz, C13), 144.5 
(C10), 140.1 (q, J = 34.8 Hz, C2), 125.8 (qn, J = 4.2 Hz, C12), 122.4 (q, J = 273.9 Hz, C1), 
121.3 (q, J = 3.5 Hz, C3), 120.8 (C11), 73.9 (C7), 54.5 (C6), 34.4 (C8), 25.9 (C9). 
19
F NMR (376 MHz, CDCl3): δ 86.1 (qn, J = 150.1 Hz, 2 F, SFax), 63.9 (d, J = 150.1 Hz, 8 F, 
SFeq), -64.5 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 2959 (w), 2871 (w), 1594 (m), 1571 (m), 1506 (m), 1481 (m), 1448 (w), 
1412 (w), 1395 (w), 1364 (m), 1327 (m), 1288 (m), 1269 (m), 1179 (m), 1147 (m), 1103 (m), 
1024 (w), 907 (w), 826 (s, S-F), 790 (m), 755 (m). 
HRMS (ESI): calculated for C32H35N5F13S2 [M+H]
+
 800.2121, found 800.2103. 
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Rf = 0.20 (1% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟒 = -84.2 (CHCl3, c = 1.0). 
 
 
1-Adamantanecarboxaldehyde (210): To a solution of anhydrous DMSO (3.55 mL, 
50.0 mmol, 2.5 equiv.) in anhydrous CH2Cl2 (50 mL) at -78 °C was added oxalyl chloride 
(2.20 mL, 26.0 mmol, 1.3 equiv.) slowly dropwise, keeping the internal temperature below -
60 °C. The mixture was stirred further for 15 min. A solution of 1-adamantanemethanol (209) 
(3.35 g, 20.0 mmol, 1 equiv.) in anhydrous CH2Cl2 (25 mL) was added slowly dropwise and 
the mixture then stirred for 1 h. Triethylamine (13.9 mL, 100.0 mmol, 5 equiv.) was then 
added and stirred for 30 min. The mixture was warmed to r.t., quenched with 10% aqueous 
KH2PO4 (50 mL) and diluted with Et2O (50 mL). The organic layer was separated, washed 
with 10% aqueous KH2PO4 (3 × 50 mL), dried (MgSO4) and evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography (eluent: CH2Cl2) to 
provide the title compound as a white amorphous solid (3.07 g, 18.7 mmol, 94%), m.p. 147-
148 °C (lit. m.p.
209
 146-148 °C). Data are consistent with a reported example.
209 
 
1
H NMR (600 MHz, CDCl3): δ 9.28 (s, 1 H, H1), 2.04 (s, 3 H, H4), 1.74 (d, J = 12.3 Hz, 
3 H, H5a), 1.69 (s, 6 H, H3), 1.66 (d, J = 12.3 Hz, 3 H, H5b).
  
13
C NMR (150 MHz, CDCl3): δ 206.1 (C1), 44.9 (C2), 36.6 (C5), 35.8 (C3), 27.4 (C4). 
FTIR (νmax, cm
-1
): 2904 (s), 2850 (m), 2696 (w), 1802 (w), 1721 (s, C=O), 1451 (m), 1344 
(w), 1264 (w), 1193 (w), 1143 (w), 1105 (w), 1052 (w), 988 (w), 905 (m). 
HRMS (ESI): calculated for C11H17O [M+H]
+
 165.1274, found 165.1279.  
Rf = 0.76 (CH2Cl2). 
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(S)-2-(Adamantan-1-yl)-2-(((R)-2-hydroxy-1-phenylethyl)amino)acetonitrile (212): To a 
mixture of 1-adamantanecarboxaldehyde (210) (5.72 g, 34.8 mmol, 1 equiv.) in water (90 mL) 
was added sodium bisulfite (3.62 g, 34.8 mmol, 1 equiv.), then potassium cyanide (2.27 g, 
34.8 mmol, 1 equiv.) at 0 °C. A solution of (R)-phenylglycinol (211) (4.78 g, 34.8 mmol, 
1 equiv.) in MeOH (9 mL) was then added dropwise. The mixture was stirred at r.t. for 2 h 
then under reflux for 16 h. The mixture was cooled to r.t. and extracted with EtOAc (2 × 
100 mL). The combined organic extracts were washed with brine (50 mL), dried (MgSO4) 
and evaporated under reduced pressure. The residue was purified by silica gel column 
chromatography (eluent: 20% EtOAc/hexane) to provide the title compound as a white 
amorphous solid (2.41 g, 7.8 mmol, 22%), m.p. 122-124 °C (lit. m.p.
210
 118-120 °C). Data 
are consistent with a reported example.
210
 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 – 7.33 (m, 4 H, H2 and H3), 7.33 – 7.29 (m, 1 H, H1), 
4.07 (dd, J = 9.2, 3.8 Hz, 1 H, H5), 3.80 (dt, J = 10.8, 3.8 Hz, 1 H, H6a), 3.61 – 3.54 (m, 1 H, 
H6b), 2.87 (s, 1 H, H7), 2.19 (br s, 1 H, OH), 2.04 (s, 3 H, H11), 1.80 – 1.70 (m, 6 H, H10a 
and H12a), 1.70 – 1.62 (m, 4 H, H12b and NH), 1.61 – 1.54 (m, 3 H, H10b). 
13
C NMR (150 MHz, CDCl3): δ 138.7 (C4), 128.9 (C2/C3), 128.4 (C1), 128.0 (C2/C3), 
119.3 (C8), 67.8 (C6), 63.3 (C5), 59.3 (C7), 38.9 (C10), 36.9 (C12), 35.9 (C9), 28.3 (C11). 
FTIR (νmax, cm
-1
): 3454 (br w, OH and NH), 2906 (s), 2850 (m), 2359 (w, C≡N), 1454 (m), 
1057 (m), 758 (m). 
HRMS (ESI): calculated for C20H27N2O [M+H]
+
 311.2118, found 311.2111.  
Rf = 0.32 (20% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟕.𝟕  = -140.4 (CHCl3, c = 1.0); lit.
210
 [𝛂]𝑫
𝟐𝟓  = +136.0 (MeOH, c = 0.25, for opposite 
enantiomer). 
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(R)-N-((S)-(Adamantan-1-yl)(carboxy)methyl)-2-hydroxy-1-phenylethan-1-ammonium 
chloride (213): A mixture of (S)-2-(adamantan-1-yl)-2-(((R)-2-hydroxy-1-
phenylethyl)amino)acetonitrile (212) (2.41 g, 7.8 mmol) in 37% aqueous HCl (52 mL) and 
acetic acid (13 mL) was heated at 80 °C for 16 h. The mixture was then cooled to r.t. then at 
0 °C, which resulted in the formation of a white precipitate after several hours. The 
precipitate was collected by vacuum filtration to provide the title compound as a white 
crystalline solid (2.06 g, 5.6 mmol, 72%), m.p. >220 °C (dec.) (lit. m.p.
210
 228-230 °C for 
opposite enantiomer). Data are consistent with a reported example.
210 
 
1
H NMR (600 MHz, MeOD-d4): δ 7.57 – 7.48 (m, 5 H, H1, H2 and H3), 4.27 (dd, J = 9.0, 
4.7 Hz, 1 H, H5), 4.25 – 4.19 (m, 1 H, H6a), 3.98 (dd, J = 11.3, 4.7 Hz, 1 H, H6b), 3.20 (s, 
1 H, H7), 2.01 (s, 3 H, H11), 1.77 – 1.71 (m, 6 H, H10a and H12a), 1.67 (d, J = 11.9 Hz, 3 H, 
H12b), 1.51 (d, J = 11.4 Hz, 3 H, H10b). 
13
C NMR (150 MHz, MeOD-d4): δ 169.5 (C8), 132.1 (C4), 131.7 (C1), 130.7 (C2/C3), 
130.2 (C2/C3), 69.4 (C7), 67.0 (C5), 62.3 (C6), 39.1 (C10), 37.0 (C12), 36.3 (C9), 29.4 
(C11). 
FTIR (νmax, cm
-1
): 3600-2400 (br w, OH and NH), 3386 (br w), 2906 (s), 2851 (m), 1730 (m, 
C=O), 1556 (m), 1424 (m), 1207 (m), 1052 (m), 763 (m). 
HRMS (ESI): calculated for C20H26NO3 [of free base, M-H]
-
 328.1918, found 328.1918.  
[𝛂]𝑫
𝟐𝟕.𝟕  = -5.7 (MeOH, c = 1.0); lit.
210
 [𝛂]𝑫
𝟐𝟓  = +100.9 (pyridine, c = 0.5, for opposite 
enantiomer). 
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(S)-(Adamantan-1-yl)(carboxy)methanammonium chloride (214): A mixture of (R)-N-
((S)-(adamantan-1-yl)(carboxy)methyl)-2-hydroxy-1-phenylethan-1-ammonium chloride 
(213) (2.06 g, 5.6 mmol), 20% palladium(II) hydroxide on carbon (0.40 g) and acetic acid 
(4 mL) in methanol (20 mL) was stirred under H2 (balloon) at r.t. for 4 d. The mixture was 
filtered through a pad of Celite, eluting with methanol, then the filtrate evaporated under 
reduced pressure. The residue was triturated with Et2O and filtered to provide the title 
compound as a white crystalline solid (1.40 g, 5.6 mmol, 99%), m.p. >250 °C (dec.) (lit. 
m.p.
211
 247-292 °C (dec.)). Data are consistent with a reported example.
211 
 
1
H NMR (600 MHz, MeOD-d4): δ 3.53 (s, 1 H, H2), 2.06 (s, 3 H, H5), 1.85 – 1.76 (m, 6 H, 
H4a and H6a), 1.71 (d, J = 11.8 Hz, 3 H, H6b), 1.65 (d, J = 12.1 Hz, 3 H, H4b). 
13
C NMR (150 MHz, MeOD-d4): δ 170.4 (C1), 63.5 (C2), 39.3 (C4), 37.3 (C6), 35.7 (C3), 
29.5 (C5). 
FTIR (νmax, cm
-1
): 3300-2400 (br w, OH and NH), 2890 (s), 2847 (s), 1741 (s, C=O), 1597 
(m), 1582 (m), 1499 (s), 1454 (m), 1420 (m), 1374 (w), 1344 (w), 1316 (w), 1291 (w), 1256 
(w), 1218 (s), 1201 (m), 1184 (w), 1140 (m), 1118 (m), 1107 (w), 1085 (m), 1035 (m), 976 
(w), 938 (w), 911 (w), 858 (m), 832 (m), 815 (m). 
HRMS (ESI): calculated for C12H18NO2 [of free base, M-H]
-
 208.1343, found 208.1343.  
[𝛂]𝑫
𝟐𝟕.𝟕 = +20.8 (MeOH, c = 1.0); lit.
211
 [𝛂]𝑫
𝟐𝟎 = +20.9 (MeOH, c = 0.93). 
 
 
(S)-2-(Adamantan-1-yl)-2-aminoethan-1-ol (215): To a solution of LiAlH4 (12.3 mL, 
1.0 M in THF, 12.3 mmol, 2.2 equiv.) at 0 °C was added slowly portionwise (S)-(adamantan-
1-yl)(carboxy)methanammonium chloride (214) (1.40 g, 5.6 mmol, 1 equiv.). The mixture 
was then stirred under reflux for 16 h. The mixture was cooled to r.t., quenched slowly with 
5. Experimental (Appendix) 
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Na2SO4•10H2O (6 g) and stirred vigorously for 1 h. The mixture was filtered through a pad of 
Celite, eluting copiously with EtOAc (150 mL). The filtrate was evaporated under reduced 
pressure to provide the title compound as a white amorphous solid (0.98 g, 5.0 mmol, 90%), 
m.p. 98-100 °C. Data are consistent with a reported example.
135 
 
1
H NMR (600 MHz, CDCl3): δ 3.69 (dd, J = 10.2, 3.8 Hz, 1 H, H1a), 3.24 (t, J = 10.2 Hz, 
1 H, H1b), 2.32 (dd, J = 10.2, 3.8 Hz, 1 H, H2), 2.09 (br s, 3 H, OH and NH2), 1.96 (s, 3 H, 
H5), 1.69 (d, J = 11.8 Hz, 3 H, H4a), 1.61 (d, J = 11.8 Hz, 3 H, H6a), 1.50 (s, 6 H, H4b and 
H6b). 
13
C NMR (150 MHz, CDCl3): δ 62.2 (C1), 61.3 (C2), 38.8 (C4), 37.3 (C6), 35.2 (C3), 28.4 
(C5). 
FTIR (νmax, cm
-1
): 3310 (br w, OH and NH), 2904 (m), 2849 (w), 1583 (w), 1450 (w), 1345 
(w), 1047 (w), 986 (w), 905 (s), 858 (w). 
HRMS (ESI): calculated for C12H22NO [M+H]
+
 196.1696, found 196.1702.  
[𝛂]𝑫
𝟐𝟕.𝟕 = +17.6 (CHCl3, c = 1.0). 
 
 
N
2
,N
6
-Bis((S)-1-(adamantan-1-yl)-2-hydroxyethyl)pyridine-2,6-dicarboxamide (177): To 
a stirred solution of (S)-2-(adamantan-1-yl)-2-aminoethan-1-ol (215) (0.488 g, 2.5 mmol, 
2 equiv.) and triethylamine (0.35 mL, 2.5 mmol, 2 equiv.) in anhydrous CH2Cl2 (13 mL) was 
added portionwise pyridine-2,6-dicarbonyl chloride (174) (0.255 g, 1.25 mmol, 1 equiv.) at 
0 °C. The mixture was warmed to r.t. and stirred further for 16 h. Water (10 mL) was added 
and the organic layer separated. The aqueous layer was extracted further with CH2Cl2 (3 × 
10 mL) and the combined organic extracts dried (MgSO4) and evaporated under reduced 
pressure. The residue was purified by silica gel column chromatography (eluent: 3% → 4% 
MeOH/CH2Cl2) to provide the title compound as a white foam (0.522 g, 1.0 mmol, 80%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.21 (d, J = 7.8 Hz, 2 H, H2), 8.07 (br d, J = 9.5 Hz, 2 H, 
NH), 7.93 (t, J = 7.8 Hz, 1 H, H1), 3.92 (dd, J = 11.0, 3.4 Hz, 2 H, H10a), 3.84 – 3.77 (m, 
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2 H, H5), 3.73 (dd, J = 11.0, 7.1 Hz, 2 H, H10b), 3.16 (br s, 2 H, OH), 1.95 (s, 6 H, H8), 1.70 
– 1.58 (m, 24 H, H7 and H9). 
13
C NMR (150 MHz, CDCl3): δ 164.4 (C4), 148.7 (C3), 139.2 (C1), 125.1 (C2), 61.7 (C10), 
60.3 (C5), 39.3 (C7), 36.9 (C6), 36.0 (C9), 28.3 (C8). 
FTIR (νmax, cm
-1
): 3401 (br w, OH and NH), 2902 (s), 2849 (m), 1727 (w), 1665 (s, C=O), 
1528 (s), 1446 (m), 1343 (w), 1316 (w), 1238 (w), 1172 (w), 1105 (w), 1073 (w), 1052 (w), 
1031 (w), 1001 (w), 970 (w), 843 (w), 753 (s). 
HRMS (ESI): calculated for C31H44N3O4 [M+H]
+
 522.3326, found 522.3309. 
Rf = 0.04 (3% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟕 = -72.3 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(adamantan-1-yl)-1-(4-(pentafluorosulfanyl)phenyl)-4,5-dihydro-1H-
imidazol-2-yl)pyridine (192): Following the general procedure for PyBIM synthesis, using 
N
2
,N
6
-bis((S)-1-(adamantan-1-yl)-2-hydroxyethyl)pyridine-2,6-dicarboxamide (177) and 4-
(pentafluorothio)aniline (207) (0.241 g, 1.1 mmol, 2.2 equiv.) at 60 °C for 16 h, purified by 
silica gel column chromatography (eluent: 3% → 5% MeOH/CH2Cl2) provided the title 
compound as a pale yellow gum (319.0 mg, 0.359 mmol, 72%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.04 (d, J = 7.8 Hz, 2 H, H2), 7.85 (t, J = 7.8 Hz, 1 H, H1), 
7.36 (d, J = 9.0 Hz, 4 H, H13), 6.39 (d, J = 9.0 Hz, 4 H, H12), 3.86 (dd, J = 10.5, 9.2 Hz, 2 H, 
H5a), 3.75 (dd, J = 10.5, 6.6 Hz, 2 H, H6), 3.66 (dd, J = 9.2, 6.6 Hz, 2 H, H5b), 1.97 (s, 6 H, 
H9), 1.70 (d, J = 12.0 Hz, 6 H, H10a), 1.66 – 1.59 (m, 12 H, H8a and H10b), 1.45 (d, J = 
11.8 Hz, 6 H, H8b). 
13
C NMR (150 MHz, CDCl3): δ 157.3 (C4), 148.4 (C3), 147.5 – 147.1 (m, C14), 144.6 
(C11), 137.5 (C1), 125.7 (br, C13), 125.5 (C2), 120.3 (C12), 73.7 (C6), 52.7 (C5), 38.3 (C8), 
37.2 (C10), 36.2 (C7), 28.3 (C9). 
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19
F NMR (376 MHz, CDCl3): δ 86.4 (qn, J = 150.2 Hz, 2 F, SFax), 64.0 (d, J = 150.2 Hz, 8 F, 
SFeq). 
FTIR (νmax, cm
-1
): 2902 (m), 2849 (w), 1595 (m), 1568 (m), 1506 (m), 1479 (m), 1451 (w), 
1430 (w), 1411 (w), 1392 (m), 1334 (w), 1316 (w), 1276 (w), 1245 (w), 1200 (w), 1163 (w), 
1136 (w), 1103 (m), 1081 (w), 1008 (w), 907 (m), 822 (s, S-F), 778 (m). 
HRMS (ESI): calculated for C43H48F10N5S2 [M+H]
+
 888.3186, found 888.3177. 
Rf = 0.28 (5% MeOH/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟓 = -126.4 (CHCl3, c = 1.0). 
 
 
2,6-Bis((S)-4-(adamantan-1-yl)-1-(4-((trifluoromethyl)sulfonyl)phenyl)-4,5-dihydro-1H-
imidazol-2-yl)pyridine (193): Following the general procedure for PyBIM synthesis, using 
N
2
,N
6
-bis((S)-1-(adamantan-1-yl)-2-hydroxyethyl)pyridine-2,6-dicarboxamide (177) and 4-
((trifluoromethyl)sulfonyl)aniline (0.248 g, 1.1 mmol, 2.2 equiv.) at 60 °C for 16 h, purified 
by silica gel column chromatography (eluent: 50% EtOAc/hexane) provided the title 
compound as a pale yellow foam (284.2 mg, 0.316 mmol, 63%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.08 (d, J = 7.9 Hz, 2 H, H2), 7.92 (t, J = 7.9 Hz, 1 H, H1), 
7.58 (d, J = 8.9 Hz, 4 H, H13), 6.50 (d, J = 8.9 Hz, 4 H, H12), 3.83 (dd, J = 9.8, 8.0 Hz, 2 H, 
H5a), 3.81 – 3.77 (m, 2 H, H6), 3.74 (dd, J = 8.0, 6.3 Hz, 2 H, H5b), 1.96 (s, 6 H, H9), 1.68 
(d, J = 11.9 Hz, 6 H, H10a), 1.65 – 1.56 (m, 12 H, H8a and H10b), 1.44 (d, J = 12.0 Hz, 6 H, 
H8b). 
13
C NMR (150 MHz, CDCl3): δ 156.2 (C4), 148.6 (C11), 148.1 (C3), 138.0 (C1), 130.8 
(C13), 125.7 (C2), 121.3 (C14), 120.2 (C12), 119.9 (q, J = 325.7 Hz, C15), 73.9 (C6), 52.2 
(C5), 38.3 (C8), 37.0 (C10), 36.1 (C7), 28.1 (C9). 
19
F NMR (376 MHz, CDCl3): δ -78.7 (s, 6 F, F15). 
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FTIR (νmax, cm
-1
): 2904 (m), 2850 (w), 1586 (m), 1568 (w), 1501 (w), 1476 (w), 1411 (w), 
1363 (m), 1315 (w), 1303 (w), 1276 (w), 1246 (w), 1215 (s), 1193 (m), 1140 (s), 1076 (m), 
1039 (w), 1005 (w), 905 (s), 830 (m), 792 (w), 764 (w). 
HRMS (ESI): calculated for C45H48F6N5O4S2 [M+H]
+
 900.3046, found 900.3045. 
Rf = 0.37 (50% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟖.𝟓 = -136.3 (CHCl3, c = 1.0). 
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5.3.3. Synthetic procedures and characterisation for alkyne starting materials 
 
General procedure for propargylamide synthesis via EDC coupling: To a solution of the 
appropriate carboxylic acid (5.0 mmol, 1.0 equiv.) in CH2Cl2 (20 mL) was added, if stated, 
DIPEA (1.05 mL, 6.0 mmol, 1.2 equiv.). EDC hydrochloride (1.15 g, 6.0 mmol, 1.2 equiv.) 
was added and stirred for 2 min, then HOBt (0.743 g, 5.5 mmol, 1.1 equiv.) was added and 
stirred for a further 2 min. Propargylamine (0.35 mL, 5.5 mmol, 1.1 equiv.) was then added 
and the mixture stirred at r.t. for 16 h. The mixture was diluted with CH2Cl2 (20 mL), washed 
with saturated aqueous Na2CO3 solution (25 mL) then 1 M aqueous HCl solution (20 mL). 
The organic phase was then dried (MgSO4) and evaporated under reduced pressure. The 
residue was purified by silica gel column chromatography to provide the desired 
propargylamide. 
 
General procedure for propargylamide synthesis via acyl chlorides: To a solution of the 
propargylamine (0.35 mL, 5.5 mmol, 1.1 equiv.) in CH2Cl2 (10 mL) was added Et3N 
(0.77 mL, 5.5 mmol, 1.1 equiv.) and DMAP (61.1 mg, 0.5 mmol, 0.1 equiv.). The appropriate 
acyl chloride (5.0 mmol, 1.0 equiv.) was then added (dropwise if liquid, as a solution in 2 mL 
CH2Cl2 if solid) and the mixture stirred at r.t. for 16 h. The mixture was diluted with CH2Cl2 
(10 mL) and treated with 1 M aqueous NaOH solution (20 mL). The organic layer was 
separated and the aqueous layer extracted further with CH2Cl2 (3 × 10 mL). The combined 
organic extracts were dried (MgSO4) then evaporated under reduced pressure. The residue 
was purified by silica gel column chromatography to provide the desired propargylamide. 
 
4-Methyl-N-(prop-2-yn-1-yl)benzenesulfonamide (60): Prepared as described previously 
(Section 5.2.1). 
 
 
N-(Prop-2-yn-1-yl)acetamide: Following the general procedure for propargylamide 
synthesis via acyl chlorides using acetyl chloride (0.35 mL, 5.0 mmol), purified by silica gel 
column chromatography (eluent: 35% EtOAc/CH2Cl2) provided the title compound as a 
yellow crystalline solid (0.271 g, 2.79 mmol, 56%), m.p. 89-90 °C (lit. m.p.
212
 83-85 °C). 
Data are consistent with a reported example.
213 
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1
H NMR (600 MHz, CDCl3): δ 5.97 (br s, 1 H, NH), 4.03 (dd, J = 5.3, 2.5 Hz, 2 H, H3), 
2.22 (t, J = 2.6 Hz, 1 H, H1), 2.00 (s, 3 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 170.0 (C4), 79.7 (C2), 71.6 (C1), 29.4 (C3), 23.1 (C5). 
FTIR (νmax, cm
-1
): 3293 (m, NH and alkyne CH), 3072 (w), 2922 (m), 2851 (w), 1644 (s, 
C=O), 1544 (s), 1423 (m), 1374 (m), 1287 (m), 1099 (w), 1029 (w), 927 (w). 
HRMS (ESI): calculated for C5H7NONa [M+Na]
+
 120.0420, found 120.0425.  
Rf = 0.23 (35% EtOAc/CH2Cl2). 
 
 
3,3,3-Trifluoro-N-(prop-2-yn-1-yl)propanamide: Following the general procedure for 
propargylamide synthesis via acyl chlorides using 3,3,3-trifluoropropionyl chloride (1.54 mL, 
15.0 mmol), purified by silica gel column chromatography (eluent: 35% EtOAc/hexane) 
provided the title compound as a white crystalline solid (1.66 g, 10.1 mmol, 67%), m.p. 76-
77 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 6.89 (br s, 1 H, NH), 4.06 (dd, J = 5.3, 2.6 Hz, 2 H, H3), 
3.13 (q, J = 10.5 Hz, 2 H, H5), 2.25 (t, J = 2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 163.2 (q, J = 3.5 Hz, C4), 124.0 (q, J = 276.7 Hz, C6), 78.7 
(C2), 72.1 (C1), 41.2 (q, J = 29.6 Hz, C5), 29.6 (C3). 
19
F NMR (376 MHz, CDCl3): δ -63.1 (s, 3 F, F6). 
FTIR (νmax, cm
-1
): 3317 (m, NH), 3302 (m, alkyne CH), 3098 (w), 1661 (s, C=O), 1567 (m), 
1427 (m), 1373 (m), 1349 (w), 1311 (w), 1262 (s), 1242 (s), 1132 (m), 1106 (m), 1057 (m), 
1035 (w), 928 (m), 854 (w), 778 (w). 
HRMS (ESI): calculated for C6H7F3NO [M+H]
+
 166.0474, found 166.0468. 
Rf = 0.32 (35% EtOAc/hexane). 
 
 
6-Oxo-N-(prop-2-yn-1-yl)heptanamide: Following the general procedure for 
propargylamide synthesis via EDC coupling using 6-oxoheptanoic acid (0.800 g, 5.0 mmol, 
90% purity), purified by silica gel column chromatography (eluent: 90% EtOAc/hexane) 
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provided the title compound as a white crystalline solid (0.471 g, 2.60 mmol, 52%), m.p. 89-
91 °C (lit. m.p.
214
 88-90 °C). Data are consistent with a reported example.
214 
 
1
H NMR (600 MHz, CDCl3): δ 5.83 (br s, 1 H, NH), 4.05 (dd, J = 5.2, 2.5 Hz, 2 H, H3), 
2.47 (t, J = 6.7 Hz, 2 H, H8), 2.23 – 2.19 (m, 3 H, H1 and H5), 2.14 (s, 3 H, H10), 1.67 – 
1.56 (m, 4 H, H6 and H7). 
13
C NMR (150 MHz, CDCl3): δ 209.0 (C9), 172.3 (C4), 79.7 (C2), 71.7 (C1), 43.4 (C8), 
36.2 (C5), 30.1 (C10), 29.3 (C3), 25.0 (C6/C7), 23.2 (C6/C7). 
FTIR (νmax, cm
-1
): 3284 (s, NH and alkyne CH), 3078 (w), 2933 (w), 2862 (w), 1711 (m, 
C=O), 1703 (m), 1640 (s, C=O), 1556 (w), 1466 (w), 1424 (w), 1376 (w), 1358 (w), 1272 (w), 
1241 (w), 1168 (w), 1106 (w), 1017 (w), 924 (w), 880 (w). 
HRMS (ESI): calculated for C10H16NO2 [M+H]
+
 188.1176, found 188.1183.  
Rf = 0.45 (90% EtOAc/hexane). 
 
 
4-Formyl-N-(prop-2-yn-1-yl)benzamide: Following the general procedure for 
propargylamide synthesis via EDC coupling using 4-formylbenzoic acid (0.751 g, 5.0 mmol), 
purified by silica gel column chromatography (eluent: 50% EtOAc/hexane) provided the title 
compound as a white amorphous solid (0.444 g, 2.37 mmol, 47%), m.p. 171-172 °C. Data are 
consistent with a reported example.
215 
 
1
H NMR (600 MHz, CDCl3): δ 10.08 (s, 1 H, H9), 7.96 (d, J = 8.5 Hz, 2 H, H7), 7.94 (d, J = 
8.5 Hz, 2 H, H6), 6.39 (br s, 1 H, NH), 4.28 (dd, J = 5.2, 2.6 Hz, 2 H, H3), 2.31 (t, J = 2.6 Hz, 
1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 191.6 (C9), 166.1 (C4), 138.9 (C5), 138.6 (C8), 130.0 (C7), 
127.9 (C6), 79.1 (C2), 72.5 (C1), 30.2 (C3). 
FTIR (νmax, cm
-1
): 3316 (m, NH and alkyne CH), 3247 (w), 1712 (m, C=O), 1642 (s, C=O), 
1540 (m), 1501 (w), 1416 (w), 1299 (w), 1259 (w), 1210 (w), 850 (w), 757 (w). 
HRMS (ESI): calculated for C11H10NO2 [M+H]
+
 188.0706, found 188.0704.  
Rf = 0.41 (50% EtOAc/hexane). 
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N-(Prop-2-yn-1-yl)cyclopent-3-ene-1-carboxamide: Following the general procedure for 
propargylamide synthesis via EDC coupling using 3-cyclopentene-1-carboxylic acid (0.561 g, 
5.0 mmol), purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) 
provided the title compound as a white amorphous solid (0.518 g, 3.47 mmol, 69%), m.p. 
102-104 °C (lit. m.p.
216
 105-107 °C). Data are consistent with a reported example.
216 
 
1
H NMR (600 MHz, CDCl3): δ 5.69 (s, 2 H, H7), 5.63 (br s, 1 H, NH), 4.07 (dd, J = 5.2, 
2.5 Hz, 2 H, H3), 2.96 (qn, J = 8.0 Hz, 1 H, H5), 2.64 (d, J = 8.0 Hz, 4 H, H6), 2.23 (t, J = 
2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 175.6 (C4), 129.4 (C7), 79.8 (C2), 71.7 (C1), 43.4 (C5), 
37.0 (C6), 29.5 (C3). 
FTIR (νmax, cm
-1
): 3278 (m, NH and alkyne CH), 3062 (w), 2914 (w), 2848 (w), 1634 (s, 
C=O), 1618 (m), 1538 (m), 1440 (w), 1388 (w), 1343 (w), 1299 (w), 1234 (m), 1182 (w), 
1039 (w), 948 (w), 847 (w).  
HRMS (ESI): calculated for C9H12NO [M+H]
+
 150.0913, found 150.0919.  
Rf = 0.39 (40% EtOAc/hexane). 
 
 
(1R,3s,5S)-N-(Prop-2-yn-1-yl)-6-oxabicyclo[3.1.0]hexane-3-carboxamide: To a solution of 
N-(prop-2-yn-1-yl)cyclopent-3-ene-1-carboxamide (0.298 g, 2.0 mmol, 1 equiv.) in CH2Cl2 
(4 mL) at 0 °C was added m-CPBA (0.583 g, 2.6 mmol, 1.3 equiv., 77% purity) portionwise. 
The mixture was then stirred at r.t. for 4 h. The mixture was filtered to remove precipitated 
m-chlorobenzoic acid, washed once on the filter with CH2Cl2 (1 mL), then the filtrate washed 
with saturated aqueous Na2CO3 solution. The organic phase was dried (MgSO4), evaporated 
under reduced pressure and purified by silica gel column chromatography (eluent: 80% 
EtOAc/hexane) to provide the title compound trans-epoxide as a white amorphous solid 
(0.143 g, 0.87 mmol, 43%), m.p. 133-135 °C.  
 
5. Experimental (Appendix) 
201 
 
1
H NMR (600 MHz, CDCl3): δ 5.71 (br s, 1 H, NH), 4.04 (dd, J = 5.2, 2.6 Hz, 2 H, H3), 
3.53 (s, 2 H, H7), 2.40 (tt, J = 9.6, 7.9 Hz, 1 H, H5), 2.26 (dd, J = 14.0, 7.9 Hz, 2 H, H6a), 
2.23 (t, J = 2.6 Hz, 1 H, H1), 1.96 (dd, J = 14.0, 9.6 Hz, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 173.7 (C4), 79.5 (C2), 71.9 (C1), 56.6 (C7), 38.9 (C5), 31.9 
(C6), 29.5 (C3). 
FTIR (νmax, cm
-1
): 3286 (m, NH), 3230 (m, alkyne CH), 3050 (w), 2926 (w), 1635 (s, C=O), 
1544 (m), 1446 (w), 1391 (w), 1294 (w), 1243 (w), 1224 (w), 1059 (w), 1035 (w), 958 (w), 
832 (m). 
HRMS (ESI): calculated for C9H12NO2 [M+H]
+
 166.0863, found 166.0871.  
Rf = 0.52 (80% EtOAc/hexane). 
 
 
(1R,3r,5S)-N-(Prop-2-yn-1-yl)-6-oxabicyclo[3.1.0]hexane-3-carboxamide: Following the 
epoxidation of N-(prop-2-yn-1-yl)cyclopent-3-ene-1-carboxamide, the cis-epoxide was also 
isolated as a white amorphous solid (0.149 g, 0.90 mmol, 45%), m.p. 114-116 °C.  
 
1
H NMR (600 MHz, CDCl3): δ 7.16 (br s, 1 H, NH), 3.95 (dd, J = 5.3, 2.5 Hz, 2 H, H3), 
3.64 (s, 2 H, H7), 2.96 (tt, J = 10.3, 1.3 Hz, 1 H, H5), 2.23 (dd, J = 15.5, 1.3 Hz, 2 H, H6a), 
2.19 (t, J = 2.5 Hz, 1 H, H1), 2.15 (dd, J = 15.5, 10.3 Hz, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 176.2 (C4), 80.1 (C2), 71.2 (C1), 59.1 (C7), 42.5 (C5), 32.1 
(C6), 29.3 (C3). 
FTIR (νmax, cm
-1
): 3287 (m, NH and alkyne CH), 3038 (w), 2929 (w), 1652 (s, C=O), 1528 
(s), 1431 (w), 1402 (w), 1352 (w), 1306 (w), 1243 (m), 1195 (w), 1100 (w), 1063 (w), 1010 
(w), 948 (w), 921 (w), 889 (w), 841 (s). 
HRMS (ESI): calculated for C9H12NO2 [M+H]
+
 166.0863, found 166.0870. 
Rf = 0.30 (80% EtOAc/hexane). 
 
 
N-(Prop-2-yn-1-yl)thiophene-2-carboxamide: Following the general procedure for 
propargylamide synthesis via EDC coupling using 2-thiophenecarboxylic acid (0.641 g, 
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5.0 mmol), purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) 
provided the title compound as an off-white amorphous solid (0.690 g, 4.17 mmol, 83%), m.p. 
117-119 °C (lit. m.p.
216
 109-111 °C). Data are consistent with a reported example.
217 
 
1
H NMR (600 MHz, CDCl3): δ 7.54 (dd, J = 3.8, 1.0 Hz, 1 H, H6), 7.49 (dd, J = 5.0, 1.0 Hz, 
1 H, H8), 7.08 (dd, J = 5.0, 3.8 Hz, 1 H, H7), 6.21 (br s, 1 H, NH), 4.24 (dd, J = 5.3, 2.5 Hz, 
2 H, H3), 2.28 (t, J = 2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 161.6 (C4), 138.1 (C5), 130.5 (C8), 128.7 (C6), 127.8 (C7), 
79.4 (C2), 72.1 (C1), 29.8 (C3). 
FTIR (νmax, cm
-1
): 3289 (s, NH and alkyne CH), 3108 (w), 3085 (w), 3051 (w), 1626 (s, 
C=O), 1549 (s), 1516 (w), 1414 (m), 1358 (w), 1344 (w), 1310 (m), 1264 (w), 1248 (w), 
1148 (w), 1062 (w), 1041 (w), 963 (w), 911 (w), 860 (w), 790 (w), 752 (w). 
HRMS (ESI): calculated for C8H8NOS [M+H]
+
 166.0321, found 166.0324.  
Rf = 0.40 (40% EtOAc/hexane). 
 
 
5-Bromo-N-(prop-2-yn-1-yl)furan-2-carboxamide: Following the general procedure for 
propargylamide synthesis via EDC coupling using 5-bromo-2-furoic acid (0.995 g, 5.0 mmol), 
purified by silica gel column chromatography (eluent: 40% EtOAc/hexane) provided the title 
compound as a white crystalline solid (0.900 g, 3.95 mmol, 79%), m.p. 105-107 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.09 (d, J = 3.5 Hz, 1 H, H6), 6.47 (br s, 1 H, NH), 6.45 (d, 
J = 3.5 Hz, 1 H, H7), 4.21 (dd, J = 5.5, 2.5 Hz, 2 H, H3), 2.28 (t, J = 2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 156.8 (C4), 149.1 (C5), 124.9 (C8), 117.3 (C6), 114.4 (C7), 
79.1 (C2), 72.2 (C1), 29.1 (C3). 
FTIR (νmax, cm
-1
): 3299 (m, NH and alkyne CH), 3122 (w), 1650 (s, C=O), 1596 (m), 1574 
(w), 1523 (s), 1469 (s), 1422 (w), 1352 (w), 1298 (m), 1204 (w), 1172 (w), 1126 (w), 1054 
(w), 1014 (w), 938 (w), 925 (w), 799 (w), 753 (w). 
HRMS (ESI): calculated for C8H7NO2Br [M+H]
+
 227.9655, found 227.9650.  
Rf = 0.53 (40% EtOAc/hexane). 
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4-Hydroxy-N-(prop-2-yn-1-yl)butanamide: A neat mixture of γ-butyrolactone (0.77 mL, 
10.0 mmol, 1 equiv.) and propargylamine (0.96 mL, 15.0 mmol, 1.5 equiv.) in a 5 mL 
microwave vial were heated at 120 °C for 3 h. The mixture was then purified directly by 
silica gel column chromatography (eluent: EtOAc) to provide the title compound as a pale 
orange amorphous solid (0.994 g, 7.03 mmol, 70%), m.p. 37-40 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 6.11 (br s, 1 H, NH), 4.05 (dd, J = 5.3, 2.6 Hz, 2 H, H3), 
3.72 – 3.68 (m, 2 H, H7), 2.77 (br s, 1 H, OH), 2.37 (t, J = 6.9 Hz, 2 H, H5), 2.23 (t, J = 
2.6 Hz, 1 H, H1), 1.93 – 1.86 (m, 2 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 173.2 (C4), 79.6 (C2), 71.8 (C1), 62.3 (C7), 33.6 (C5), 29.4 
(C3), 28.0 (C6). 
FTIR (νmax, cm
-1
): 3600-3200 (br m, OH), 3276 (m, NH and alkyne CH), 2941 (w), 1634 (s, 
C=O), 1544 (s), 1423 (m), 1339 (w), 1262 (m), 1168 (w), 1038 (m), 928 (w). 
HRMS (ESI): calculated for C7H12NO2 [M+H]
+
 142.0863, found 142.0868.  
Rf = 0.19 (EtOAc). 
 
 
N-(Prop-2-yn-1-yl)cyclopropanecarboxamide: Following the general procedure for 
propargylamide synthesis via acyl chlorides using cyclopropanecarbonyl chloride (0.14 mL, 
1.5 mmol), purified by silica gel column chromatography (eluent: 35% EtOAc/hexane) 
provided the title compound as a white crystalline solid (85.8 mg, 0.697 mmol, 46%), m.p. 
70-71 °C (lit. m.p.
216
 64-66 °C). Data are consistent with a reported example.
216 
 
1
H NMR (600 MHz, CDCl3): δ 5.83 (br s, 1 H, NH), 4.08 (dd, J = 5.3, 2.5 Hz, 2 H, H3), 
2.23 (t, J = 2.5 Hz, 1 H, H1), 1.39 – 1.32 (m, 1 H, H5), 1.02 – 0.97 (m, 2 H, H6a), 0.80 – 0.73 
(m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 173.8 and 173.7 (rotameric, C4), 79.9 (C2), 71.31 and 71.29 
(rotameric, C1), 29.3 (C3), 14.48 and 14.46 (rotameric, C5), 7.4 (C6). 
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FTIR (νmax, cm
-1
): 3293 (m, NH and alkyne CH), 3064 (w), 3013 (w), 2924 (w), 1799 (w), 
1727 (w), 1643 (s, C=O), 1537 (w), 1449 (m), 1421 (m), 1401 (m), 1349 (m), 1237 (s), 1197 
(m), 1104 (m), 1061 (m), 1032 (m), 1012 (m), 931 (m), 896 (m), 825 (w). 
HRMS (ESI): calculated for C7H10NO [M+H]
+
 124.0757, found 124.0754. 
Rf = 0.26 (35% EtOAc/hexane). 
 
 
1-(4-Chlorophenyl)-N-(prop-2-yn-1-yl)cyclopentane-1-carboxamide: Following the 
general procedure for propargylamide synthesis via acyl chlorides using 1-(4-chlorophenyl)-
1-cyclopentanecarbonyl chloride (1.22 g, 5.0 mmol), purified by silica gel column 
chromatography (eluent: 30% EtOAc/hexane) provided the title compound as a white 
amorphous solid (0.909 g, 3.47 mmol, 69%), m.p. 123-124 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.30 (d, J = 8.7 Hz, 2 H, H10), 7.27 (d, J = 8.7 Hz, 2 H, H9), 
5.40 (br s, 1 H, NH), 3.92 (dd, J = 5.3, 2.5 Hz, 2 H, H3), 2.47 – 2.40 (m, 2 H, H6a), 2.14 (t, 
J = 2.5 Hz, 1 H, H1), 2.00 – 1.93 (m, 2 H, H6b), 1.83 – 1.77 (m, 2 H, H7a), 1.69 – 1.62 (m, 
2 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 175.7 (C4), 142.3 (C11), 133.0 (C8), 129.0 (C10), 128.3 
(C9), 79.5 (C2), 71.6 (C1), 58.8 (C5), 36.9 (C6), 29.7 (C3), 23.9 (C7). 
FTIR (νmax, cm
-1
): 3306 (m, NH), 3286 (m, alkyne CH), 2957 (m), 2925 (m), 2874 (m), 1694 
(m), 1637 (s, C=O), 1594 (w), 1526 (s), 1491 (m), 1462 (m), 1416 (m), 1401 (w), 1343 (w), 
1275 (m), 1256 (m), 1219 (w), 1177 (w), 1093 (m), 1013 (m), 949 (w), 920 (w), 898 (w), 875 
(w), 831 (m), 773 (w), 761 (w). 
HRMS (ESI): calculated for C15H17NOCl [M+H]
+
 262.0993, found 262.0990.  
Rf = 0.38 (30% EtOAc/hexane). 
 
 
Methyl 4-oxo-4-(prop-2-yn-1-ylamino)butanoate: Following the general procedure for 
propargylamide synthesis via acyl chlorides using methyl 4-chloro-4-oxobutyrate (0.37 mL, 
3.0 mmol), purified by silica gel column chromatography (eluent: 35% → 50% 
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EtOAc/hexane) provided the title compound as a yellow crystalline solid (0.334 g, 1.97 mmol, 
66%), m.p. 48-49 °C (lit. m.p.
218
 44-46 °C). Data are consistent with a reported example.
218 
 
1
H NMR (600 MHz, CDCl3): δ 7.00 (br s, 1 H, NH), 3.89 (dd, J = 5.5, 2.6 Hz, 2 H, H3), 
3.54 (s, 3 H, H8), 2.53 (t, J = 7.1 Hz, 2 H, H6), 2.42 (t, J = 7.1 Hz, 2 H, H5), 2.14 (t, J = 
2.6 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 173.2 (C7), 171.4 (C4), 79.6 (C2), 71.1 (C1), 51.6 (C8), 
30.3 (C6), 29.0 (C3/C5), 28.9 (C3/C5). 
FTIR (νmax, cm
-1
): 3287 (m, NH and alkyne CH), 2955 (w), 2924 (w), 2851 (w), 1732 (s, 
C=O), 1651 (s, C=O), 1535 (s), 1438 (m), 1363 (m), 1201 (s), 1167 (s), 1089 (w), 1026 (m), 
992 (w), 922 (w), 847 (w), 801 (w). 
HRMS (ESI): calculated for C8H12NO3 [M+H]
+
 170.0812, found 170.0816.  
Rf = 0.10 (35% EtOAc/hexane). 
 
 
N-(Prop-2-yn-1-yl)pent-4-enamide: Following the general procedure for propargylamide 
synthesis via EDC coupling using 4-pentenoic acid (0.20 mL, 2.0 mmol), purified by silica 
gel column chromatography (eluent: 35% EtOAc/hexane) provided the title compound as a 
yellow oil (0.149 g, 1.09 mmol, 54%). 
 
1
H NMR (600 MHz, CDCl3): δ 6.82 (br s, 1 H, NH), 5.75 (ddt, J = 17.1, 10.2, 6.3 Hz, 1 H, 
H7), 4.99 (dd, J = 17.1, 1.5 Hz, 1 H, H8trans), 4.92 (dd, J = 10.2, 1.5 Hz, 1 H, H8cis), 3.96 (dd, 
J = 5.4, 2.6 Hz, 2 H, H3), 2.35 – 2.29 (m, 2 H, H6), 2.29 – 2.24 (m, 2 H, H5), 2.16 (t, J = 
2.6 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 172.6 (C4), 136.8 (C7), 115.5 (C8), 79.7 (C2), 71.2 (C1), 
35.3 (C5), 29.4 (C6), 29.0 (C3). 
FTIR (νmax, cm
-1
): 3293 (m, NH and alkyne CH), 3078 (w), 2924 (w), 2855 (w), 1639 (s, 
C=O), 1536 (s), 1421 (m), 1343 (w), 1266 (m), 1194 (w), 1117 (w), 1031 (w), 996 (w), 915 
(m). 
HRMS (ESI): calculated for C8H12NO [M+H]
+
 138.0913, found 138.0914.  
Rf = 0.22 (35% EtOAc/hexane). 
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(S)-2-(4-Isobutylphenyl)-N-(prop-2-yn-1-yl)propanamide: Following the general 
procedure for propargylamide synthesis via EDC coupling using (S)-ibuprofen (1.072 g, 
5.2 mmol), purified by silica gel column chromatography (eluent: 25% EtOAc/hexane) 
provided the title compound as a white crystalline solid (1.071 g, 4.40 mmol, 85%), m.p. 75-
76 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.18 (d, J = 8.0 Hz, 2 H, H8), 7.12 (d, J = 8.0 Hz, 2 H, H9), 
5.66 (br s, 1 H, NH), 4.03 (ddd, J = 17.6, 5.5, 2.5 Hz, 1 H, H3a), 3.92 (ddd, J = 17.6, 5.1, 
2.5 Hz, 1 H, H3b), 3.55 (q, J = 7.2 Hz, 1 H, H5), 2.45 (d, J = 7.2 Hz, 2 H, H11), 2.16 (t, J = 
2.5 Hz, 1 H, H1), 1.89 – 1.81 (m, 1 H, H12), 1.51 (d, J = 7.2 Hz, 3 H, H6), 0.90 (d, J = 
6.7 Hz, 6 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 174.2 (C4), 141.0 (C10), 138.2 (C7), 129.8 (C9), 127.5 (C8), 
79.7 (C2), 71.5 (C1), 46.6 (C5), 45.1 (C11), 30.3 (C12), 29.5 (C3), 22.5 (C13), 18.6 (C6). 
FTIR (νmax, cm
-1
): 3292 (m, NH and alkyne CH), 2955 (m), 2928 (m), 2869 (w), 1650 (s, 
C=O), 1537 (m), 1512 (m), 1465 (w), 1421 (w), 1366 (w), 1230 (w), 1073 (w), 1016 (w), 923 
(w), 851 (w). 
HRMS (ESI): calculated for C16H21NONa [M+Na]
+
 266.1515, found 266.1502.  
Rf = 0.29 (25% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = +3.0 (CHCl3, c = 1.0). 
 
 
2-(Prop-2-yn-1-ylcarbamoyl)phenyl acetate: Following the general procedure for 
propargylamide synthesis via EDC coupling using aspirin (0.901 g, 5.0 mmol), purified by 
silica gel column chromatography (eluent: 30% EtOAc/hexane) then trituration with Et2O 
(1 mL) provided the title compound as a white crystalline solid (0.408 g, 1.88 mmol, 38%), 
m.p. 91-92 °C (lit. m.p.
219
 86-88 °C). Data are consistent with a reported example.
219 
 
5. Experimental (Appendix) 
207 
 
1
H NMR (600 MHz, CDCl3): δ 7.79 (dd, J = 8.0, 1.6 Hz, 1 H, H6), 7.47 (td, J = 8.0, 1.6 Hz, 
1 H, H8), 7.30 (td, J = 8.0, 1.0 Hz, 1 H, H7), 7.11 (dd, J = 8.0, 1.0 Hz, 1 H, H9), 6.58 (br s, 
1 H, NH), 4.19 (dd, J = 5.2, 2.6 Hz, 2 H, H3), 2.35 (s, 3 H, H12), 2.28 (t, J = 2.6 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 169.1 (C11), 165.1 (C4), 148.1 (C10), 132.2 (C8), 130.2 
(C6), 127.5 (C5), 126.5 (C7), 123.4 (C9), 79.5 (C2), 72.1 (C1), 29.7 (C3), 21.1 (C12). 
FTIR (νmax, cm
-1
): 3287 (w, NH and alkyne CH), 1766 (m, C=O), 1649 (m, C=O), 1608 (m), 
1521 (m), 1481 (m), 1448 (w), 1424 (w), 1370 (m), 1302 (m), 1191 (s), 1101 (m), 1046 (w), 
1012 (w), 988 (w), 955 (w), 913 (w), 874 (w), 833 (w), 788 (w), 751 (w). 
HRMS (ESI): calculated for C12H11NO3Na [M+Na]
+
 240.0631, found 240.0621.  
Rf = 0.14 (30% EtOAc/hexane). 
 
 
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-(2-phenylacetamido)-N-(prop-2-yn-1-yl)-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxamide: Penicillin G sodium salt (1.43 g, 4.0 mmol) was 
dissolved in 1 M HCl aqueous solution (30 mL) and then extracted with CH2Cl2 (3 × 25 mL). 
The combined organic extracts were dried (MgSO4) and evaporated under reduced pressure 
to provide the carboxylic acid. Then, following the general procedure for propargylamide 
synthesis via EDC coupling using penicillin G (1.34 g, 4.0 mmol) and DMAP (48.9 mg, 
0.4 mmol) as additive, purified by silica gel column chromatography (eluent: 40% 
EtOAc/hexane) provided the title compound as a pale yellow amorphous solid (0.570 g, 
1.53 mmol, 38%), m.p. 140-142 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.36 (t, J = 7.4 Hz, 2 H, H16), 7.30 (t, J = 7.4 Hz, 1 H, H17), 
7.24 (d, J = 7.4 Hz, 2 H, H15), 6.79 (br t, J = 5.2 Hz, 1 H, C3-NH), 6.24 (br d, J = 9.2 Hz, 
1 H, C10-NH), 5.73 (dd, J = 9.2, 4.5 Hz, 1 H, H10), 5.36 (d, J = 4.5 Hz, 1 H, H9), 4.11 (s, 
1 H, H5), 4.07 (ddd, J = 17.6, 5.9, 2.5 Hz, 1 H, H3a), 3.92 (ddd, J = 17.6, 5.0, 2.5 Hz, 1 H, 
H3b), 3.64 – 3.56 (m, 2 H, H13), 2.23 (t, J = 2.5 Hz, 1 H, H1), 1.66 (s, 3 H, H7/H8), 1.48 (s, 
3 H, H7/H8). 
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13
C NMR (150 MHz, CDCl3): δ 176.4 (C11), 170.7 (C12), 167.2 (C4), 133.7 (C14), 129.5 
(C15), 129.2 (C16), 127.8 (C17), 78.9 (C2), 72.4 (C5), 72.1 (C1), 66.4 (C9), 65.0 (C6), 57.4 
(C10), 43.3 (C13), 29.1 (C3), 28.5 (C7/C8), 26.6 (C7/C8). 
FTIR (νmax, cm
-1
): 3287 (m, NH and alkyne CH), 3061 (w), 2969 (w), 2932 (w), 1781 (m, 
C=O), 1654 (s, C=O), 1605 (w), 1525 (m), 1455 (w), 1422 (w), 1390 (w), 1371 (w), 1292 
(m), 1238 (m), 1160 (w), 1130 (w), 1058 (w), 1031 (w), 939 (w), 893 (w). 
HRMS (ESI): calculated for C19H22N3O3S [M+H]
+
 372.1376, found 372.1387.  
Rf = 0.24 (50% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = +228.6 (CHCl3, c = 1.0). 
 
 
((3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-3a-yl)methyl prop-2-yn-1-ylsulfamate: To a solution of topiramate (1.12 g, 
3.3 mmol, 1 equiv.) in CH2Cl2 (6 mL) was added DMAP (4.0 mg, 0.033 mmol, 0.01 equiv.), 
Et3N (0.51 mL, 3.63 mmol, 1.1 equiv.) and Boc anhydride (0.83 mL, 3.63 mmol, 1.1 equiv.). 
The mixture was stirred at r.t. for 16 h, then evaporated under reduced pressure to provide 
crude mono-Boc protected topiramate. The residue was redissolved in anhydrous THF 
(20 mL), then cooled to 0 °C. Triphenylphosphine (1.57 g, 6.0 mmol, 1.8 equiv.) and 
propargyl alcohol (0.35 mL, 6.0 mmol, 1.8 equiv.) were added, followed by dropwise 
addition of diisopropyl azodicarboxylate (1.18 mL, 6.0 mmol, 1.8 equiv.) over ca. 15 min. 
The mixture was warmed to r.t. and stirred further for 16 h. The mixture was then evaporated 
under reduced pressure then the residue triturated with Et2O (25 mL). The triphenylphosphine 
oxide byproduct was filtered off, washed on the filter with Et2O (25 mL) then the filtrate 
evaporated under reduced pressure. The residue was redissolved in CH2Cl2 (20 mL) then 
trifluoroacetic acid (4.8 mL, 50.0 mmol, 15.0 equiv.) was added and the mixture stirred at r.t. 
for 16 h. The reaction mixture was quenched with saturated aqueous NaHCO3 solution 
(40 mL) and the organic layer separated. The aqueous layer was further extracted with 
CH2Cl2 (3 × 20 mL) and the combined organic extracts dried (MgSO4) and evaporated under 
reduced pressure. The residue was purified by silica gel column chromatography (eluent:     
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10% Et2O/CH2Cl2) to provide the title compound as a colourless gum (0.375 g, 0.99 mmol, 
30% over three steps). 
 
1
H NMR (600 MHz, CDCl3): δ 4.84 (br t, J = 5.7 Hz, 1 H, NH), 4.61 (dd, J = 7.9, 2.6 Hz, 
1 H, H10), 4.33 (d, J = 2.6 Hz, 1 H, H9), 4.26 (d, J = 10.6 Hz, 1 H, H4a), 4.24 (ddd, J = 7.9, 
1.9, 0.7 Hz, 1 H, H14), 4.18 (d, J = 10.6 Hz, 1 H, H4b), 4.00 – 3.91 (m, 2 H, H3), 3.91 (dd, 
J = 13.0, 1.9 Hz, 1 H, H15a), 3.78 (dd, J = 13.0, 0.7 Hz, 1 H, H15b), 2.37 (t, J = 2.5 Hz, 1 H, 
H1), 1.55 (s, 3 H, H7/H8), 1.48 (s, 3 H, H12/H13), 1.42 (s, 3 H, H7/H8), 1.34 (s, 3 H, 
H12/H13). 
13
C NMR (150 MHz, CDCl3): δ 109.5 (C6), 109.4 (C11), 100.9 (C5), 78.0 (C2), 73.8 (C1), 
70.9 (C14), 70.7 (C4), 70.5 (C9), 70.0 (C10), 61.5 (C15), 33.7 (C3), 26.6 (C7/C8), 26.0 
(C12/C13), 25.3 (C7/C8), 24.2 (C12/C13). 
FTIR (νmax, cm
-1
): 3276 (w, NH and alkyne CH), 2992 (w), 2941 (w), 1450 (w), 1371 (m), 
1320 (w), 1252 (m), 1205 (m), 1176 (s), 1068 (s), 995 (s), 980 (s), 912 (m), 885 (s), 865 (s), 
845 (m), 802 (m), 756 (m). 
HRMS (ESI): calculated for C15H24NO8S [M+H]
+
 378.1217, found 378.1216.  
Rf = 0.36 (10% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -24.4 (CHCl3, c = 1.0). 
 
 
tert-Butyl (S)-(4-methyl-2-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)pentyl)carbamate: 
Following the general procedure for propargylamide synthesis via EDC coupling in the 
presence of DIPEA using N-Boc-pregabalin (1.037 g, 4.0 mmol), purified by silica gel 
column chromatography (eluent: 40% EtOAc/hexane) provided the title compound as a white 
amorphous solid (0.617 g, 2.08 mmol, 52%), m.p. 81-83 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 6.92 (br s, 1 H, C3-NH), 4.82 (br s, 1 H, C7-NH), 4.09 – 
3.99 (m, 2 H, H3), 3.23 (ddd, J = 14.1, 6.5, 3.9 Hz, 1 H, H7a), 3.01 (dt, J = 14.1, 6.5 Hz, 1 H, 
H7b), 2.21 (t, J = 2.5 Hz, 1 H, H1), 2.17 – 2.08 (m, 2 H, H5), 2.07 – 2.00 (m, 1 H, H6), 1.68 
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– 1.60 (m, 1 H, H12), 1.44 (s, 9 H, H10), 1.13 (t, J = 7.2 Hz, 2 H, H11), 0.93 – 0.85 (m, 6 H, 
H13 and H14). 
13
C NMR (150 MHz, CDCl3): δ 172.3 (br, C4), 157.1 (br, C8), 79.9 (br, C2), 79.7 (br, C9), 
71.3 (br, C1), 43.5 (br, C7), 41.7 (br, C11), 39.2 (C5), 34.6 (br, C6), 29.3 (C3), 28.5 (C10), 
25.3 (C12), 22.9 (C13/C14), 22.8 (C13/C14). 
FTIR (νmax, cm
-1
): 3313 (m, NH and alkyne CH), 2958 (m), 2931 (m), 2870 (w), 1691 (s, 
C=O), 1647 (s, C=O), 1531 (s), 1452 (w), 1391 (w), 1366 (m), 1272 (m), 1251 (m), 1169 (s), 
1023 (w), 856 (w). 
HRMS (ESI): calculated for C16H28N2O3Na [M+Na]
+
 319.1992, found 319.1980.  
Rf = 0.34 (40% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -10.2 (CHCl3, c = 1.0). 
 
 
2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(prop-2-yn-1-
yl)acetamide: Following the general procedure for propargylamide synthesis via EDC 
coupling using indomethacin (1.79 g, 5.0 mmol), purified by silica gel column 
chromatography (eluent: 50% EtOAc/hexane) provided the title compound as a pale-yellow 
amorphous solid (0.636 g, 1.61 mmol, 32%), m.p. 171-173 °C. (N.B. Product is highly 
insoluble and the reaction mixture was diluted/extracted with copious CH2Cl2). 
 
1
H NMR (600 MHz, CDCl3): δ 7.67 (d, J = 8.7 Hz, 2 H, H18), 7.49 (d, J = 8.7 Hz, 2 H, 
H19), 6.89 – 6.86 (m, 2 H, H8 and H12), 6.71 (dd, J = 9.0, 2.5 Hz, 1 H, H11), 5.77 (br s, 1 H, 
NH), 4.01 (dd, J = 5.5, 2.5 Hz, 2 H, H3), 3.83 (s, 3 H, H9), 3.67 (s, 2 H, H5), 2.39 (s, 3 H, 
H15), 2.16 (t, J = 2.5 Hz, 1 H, H1). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C4), 168.5 (C16), 156.5 (C10), 139.8 (C20), 136.6 
(C14), 133.7 (C17), 131.4 (C18), 131.0 (C13), 130.3 (C7), 129.4 (C19), 115.3 (C12), 112.6 
(C11), 112.4 (C6), 100.9 (C8), 79.5 (C2), 71.7 (C1), 55.9 (C9), 32.2 (C5), 29.4 (C3), 13.4 
(C15). 
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FTIR (νmax, cm
-1
): 3297 (m, NH and alkyne CH), 2930 (w), 1679 (s, C=O), 1641 (s, C=O), 
1596 (m), 1532 (m), 1477 (s), 1401 (w), 1355 (s), 1322 (s), 1290 (w), 1265 (w), 1222 (s), 
1179 (w), 1150 (m), 1089 (m), 1069 (m), 1038 (w), 1012 (w), 992 (w), 927 (w), 868 (w), 835 
(w), 801 (w), 755 (m). 
HRMS (ESI): calculated for C22H20N2O3Cl [M+H]
+
 395.1157, found 395.1169.  
Rf = 0.42 (5% EtOAc/hexane). 
 
 
1-(2-((4R,6R)-2,2-Dimethyl-6-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-1,3-dioxan-4-
yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide: 
Atorvastatin calcium salt (0.994 g, 1.66 mmol with respect to one atorvastatin equivalent, 
1 equiv.) was dissolved in 1 M HCl aqueous solution (25 mL). The mixture was extracted 
with CH2Cl2 (3 × 25 mL) and the combined organic extracts were dried (MgSO4) and 
evaporated under reduced pressure to provide the carboxylic acid. The residual foam was 
redissolved in acetone (8 mL) and 2,2-dimethoxypropane (2 mL), then (±)-camphorsulfonic 
acid (77.1 mg, 0.33 mmol, 0.2 equiv.) was added. The mixture was stirred at r.t. for 16 h. The 
reaction mixture was quenched with Et3N (0.05 mL) and evaporated under reduced pressure 
to provide crude acetonide-protected atorvastatin. Then, following the general procedure for 
propargylamide synthesis via EDC coupling in the presence of DIPEA using crude acetonide-
protected atorvastatin, purified by silica gel column chromatography (eluent: 50% 
EtOAc/hexane) provided the title compound as a white foam (0.470 g, 0.74 mmol, 45% over 
three steps).  
 
1
H NMR (600 MHz, CDCl3): δ 7.22 – 7.13 (m, 9 H, H22, H26, H27, H28 and H31), 7.06 (d, 
J = 7.9 Hz, 2 H, H21), 7.02 – 6.96 (m, 3 H, H23 and H32), 6.86 (br s, 1 H, C19-NH), 6.40 (br 
t, J = 4.9 Hz, 1 H, C3-NH), 4.17 – 4.11 (m, 1 H, H6), 4.11 – 4.04 (m, 1 H, H13a), 4.04 – 4.00 
(m, 2 H, H3), 3.86 – 3.79 (m, 1 H, H13b), 3.72 – 3.65 (m, 1 H, H11), 3.62 – 3.53 (m, 1 H, 
H15), 2.34 (dd, J = 15.1, 7.4 Hz, 1 H, H5a), 2.29 (dd, J = 15.1, 4.1 Hz, 1 H, H5b), 2.21 (t, J = 
2.5 Hz, 1 H, H1), 1.71 – 1.61 (m, 2 H, H12), 1.53 (superimposed d, J = 7.1 Hz, 6 H, H16 and 
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H17), 1.38 (s, 3 H, H8/H9), 1.34 (s, 3 H, H8/H9), 1.31 (dt, J = 12.8, 2.3 Hz, 1 H, H10a), 1.09 
(dt, J = 12.8, 11.7 Hz, 1 H, H10b). 
13
C NMR (150 MHz, CDCl3): δ 170.1 (C4), 164.9 (C19), 162.4 (d, J = 247.8 Hz, C33), 
141.6 (C14), 138.5 (C20), 134.7 (C25), 133.3 (d, J = 8.1 Hz, C31), 130.6 (C26), 128.9 (C29), 
128.8 (C27), 128.5 (C22), 128.4 (d, J = 3.3 Hz, C30), 126.7 (C28), 123.7 (C23), 122.0 (C24), 
119.7 (C21), 115.52 (d, J = 21.5 Hz, C32), 115.50 (C18), 99.1 (C7), 79.6 (C2), 71.6 (C1), 
66.5 (C11), 66.2 (C6), 42.8 (C5), 40.9 (C13), 38.1 (C12), 35.8 (C10), 30.1 (C8/C9), 29.2 
(C3), 26.2 (C15), 21.9 (C16/C17), 21.7 (C16/C17), 19.9 (C8/C9). 
19
F NMR (376 MHz, CDCl3): δ -113.6 (s, 1 F, F33). 
FTIR (νmax, cm
-1
): 3302 (w, NH and alkyne CH), 3051 (w), 2960 (w), 1652 (m, C=O), 1595 
(m), 1526 (s), 1508 (s), 1436 (m), 1381 (m), 1313 (m), 1265 (m), 1222 (m), 1201 (m), 1169 
(m), 1156 (s), 1114 (w), 1094 (w), 1032 (w), 994 (w), 964 (w), 942 (w), 918 (w), 886 (w), 
841 (w), 809 (w). 
HRMS (ESI): calculated for C39H43FN3O4 [M+H]
+
 636.3232, found 636.3236.  
Rf = 0.35 (50% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -4.3 (CHCl3, c = 1.0). 
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5.3.4. Synthetic procedures and characterisation for hydrazone starting materials 
 
General procedure for aldehyde-derived hydrazone formation: General procedure is as 
described previously (Section 5.2.2). 
 
(4-Chlorobenzylidene)hydrazine (62): Prepared as described previously (Section 5.2.2). 
 
(4-Bromobenzylidene)hydrazine: Prepared as described previously (Section 5.2.2). 
 
(3-Methoxybenzylidene)hydrazine: Prepared as described previously (Section 5.2.2). 
 
 
(4-Fluorobenzylidene)hydrazine: Following the general procedure for aldehyde-derived 
hydrazone formation using 4-fluorobenzaldehyde (2.48 g, 20.0 mmol), provided the title 
compound as a colourless oil (2.75 g, 19.9 mmol, 99%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.72 (s, 1 H, H5), 7.52 (dd, J = 8.7, 5.5 Hz, 2 H, H3), 7.04 (t, 
J = 8.7 Hz, 2 H, H4), 5.47 (br s, 2 H, NH). 
13
C NMR (150 MHz, CDCl3): δ 163.1 (d, J = 248.2 Hz, C1), 142.0 (C5), 131.5 (d, J = 
3.2 Hz, C4), 127.9 (d, J = 8.2 Hz, C3), 115.7 (d, J = 21.9 Hz, C2). 
19
F NMR (376 MHz, CDCl3): δ -112.6 (s, 1 F, F1). 
FTIR (νmax, cm
-1
): 3379 (w, NH2), 3192 (w, NH2), 2905 (w), 1604 (m), 1508 (s), 1398 (w), 
1300 (w), 1228 (s), 1154 (m), 1080 (w), 1012 (w), 947 (w), 919 (w), 875 (w), 832 (s), 797 
(m). 
HRMS (ESI): calculated for C7H7FN2Na [M+Na]
+
 161.0485, found 161.0484. 
 
 
3-(Hydrazonomethyl)benzonitrile: Following the general procedure for aldehyde-derived 
hydrazone formation using 3-formylbenzonitrile (2.62 g, 20.0 mmol), provided the title 
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compound as a pale yellow amorphous solid (2.90 g, 19.9 mmol, 99%), m.p. 74-77 °C (lit. 
m.p.
184
 83-84°C). Data are consistent with a reported example.
184 
 
1
H NMR (600 MHz, CDCl3): δ 7.81 (t, J = 1.3 Hz, 1 H, H7), 7.74 (dt, J = 7.8 Hz, 1.3 Hz, 
1 H, H5), 7.68 (s, 1 H, H8), 7.54 (dt, J = 7.8, 1.3 Hz, 1 H, H3), 7.43 (t, J = 7.8 Hz, 1 H, H4), 
5.73 (br s, 2 H, NH). 
13
C NMR (150 MHz, CDCl3): δ 139.6 (C8), 136.7 (C6), 131.6 (C3), 130.1 (C5), 129.55 (C7), 
129.47 (C4), 118.8 (C1), 112.9 (C2). 
FTIR (νmax, cm
-1
): 3402 (m, NH2), 3292 (w, NH2), 3215 (w), 2917 (w), 2231 (s, C≡N), 1590 
(m), 1573 (m), 1481 (w), 1434 (w), 1388 (w), 1284 (w), 1245 (w), 1157 (w), 1088 (w), 918 
(m), 798 (s). 
HRMS (ESI): calculated for C8H7N3Na [M+Na]
+
 168.0532, found 168.0535.  
 
 
(4-Iodobenzylidene)hydrazine: Following the general procedure for aldehyde-derived 
hydrazone formation using 4-iodobenzaldehyde (9.28 g, 40.0 mmol), provided the title 
compound as a pale yellow amorphous solid (9.82 g, 39.9 mmol, 99%), m.p. 96-98 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.67 (d, J = 8.4 Hz, 2 H, H2), 7.65 (s, 1 H, H5), 7.27 (d, J = 
8.4 Hz, 2 H, H3), 5.57 (br s, 2 H, NH). 
13
C NMR (150 MHz, CDCl3): δ 141.8 (C5), 137.8 (C2), 134.8 (C4), 127.9 (C3), 94.3 (C1). 
FTIR (νmax, cm
-1
): 3360 (m, NH2), 3196 (w, NH2), 2912 (w), 1594 (w), 1483 (w), 1389 (m), 
1080 (w), 1059 (w), 1004 (w), 925 (w), 912 (w), 863 (w), 818 (s). 
HRMS (ESI): calculated for C7H7N2INa [M+Na]
+
 268.9546, found 268.9555. 
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5.3.5. Synthetic procedures and characterisation for asymmetric allenylation 
 
Stock solution of 188-CuI: To a mixture of 2,6-bis((S)-4-(tert-butyl)-1-(4-
(pentafluorosulfanyl)phenyl)-4,5-dihydro-1H-imidazol-2-yl)pyridine (188) (0.549 g, 
0.75 mmol) and copper(I) iodide (95.2 mg, 0.50 mmol) was added 1,4-dioxane (50 mL) and 
Et3N (1.39 mL, 10.0 mmol). The mixture was stirred at r.t. for 2 h, resulting in a brown-red 
solution of the ligand/copper complex. The solution was stored at -20 °C under Ar as a 
precaution. 
 
General procedure for racemic allenylation: 
Conditioning phase: A solution of hydrazone (0.1 M) and DIPEA (0.2 M) in CH2Cl2 was 
passed through a column reactor (Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed 
with activated MnO2 (0.86 g), at a flow rate of 0.5 mL min
-1
 for 20 min and the reactor output 
was monitored using a FlowIR
®
 device (SiComp head, 2100-2000 cm
-1
). The flow was 
switched to solvent (DIPEA, 0.2 M in CH2Cl2) for 10 min. The column was then ready for the 
generation of the diazo compound. 
 
Generation phase: A 5 mL microwave vial was charged with the appropriate alkyne 
(0.2 mmol, 1.0 equiv.), copper(I) iodide (3.9 mg, 0.02 mmol, 0.1 equiv.), 1,4-dioxane (2 mL) 
and Et3N (0.05 mL, 0.4 mmol, 2 equiv.) and pre-mixed for 10 min. A solution of hydrazone 
(0.1 M) and DIPEA (0.2 M) in CH2Cl2 was passed through the pre-conditioned column reactor 
(Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed with activated MnO2 (0.86 g), at a 
flow rate of 0.5 mL min
-1
. When the FlowIR
®
 showed that the intensity of the diazo peak was 
stable, 3 mL of the output (1.5 equiv. with respect to the hydrazone) was directly added into 
the reaction vial (over 6 min) containing the copper acetylide and the reaction mixture further 
stirred at r.t. for 10 min. The mixture was then filtered through a pad of Celite, eluting with 
Et2O, and the filtrate evaporated under reduced pressure. The residue was immediately 
purified by silica gel column chromatography to provide the desired disubstituted allene 
product. Any excess diazo compound produced during the conditioning phase or the 
generation phase before steady-state was reached was gently quenched by directing the 
output of the flow reactor into a stirred suspension of copper(I) iodide (0.10 g) in MeOH 
(25 mL). 
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General procedure for asymmetric allenylation:  
Conditioning phase: A solution of hydrazone (0.1 M) and DIPEA (0.2 M) in CH2Cl2 was 
passed through a column reactor (Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed 
with activated MnO2 (0.86 g), at a flow rate of 0.5 mL min
-1
 for 20 min and the reactor output 
was monitored using a FlowIR
®
 device (SiComp head, 2100-2000 cm
-1
). The flow was 
switched to solvent (DIPEA, 0.2 M in CH2Cl2) for 10 min. The column was then ready for the 
generation of the diazo compound. 
 
Generation phase: To a 5 mL microwave vial was added the appropriate alkyne (0.2 mmol, 
1.0 equiv.), then an aliquot of the vigorously stirred 188-CuI stock solution (2.05 mL, 
containing 0.15 equiv. ligand, 0.1 equiv. CuI and 2 equiv. Et3N) was added. The mixture was 
pre-mixed at r.t. for 10 min, forming a clear red-orange homogeneous solution of the copper 
acetylide-ligand complex. A solution of hydrazone (0.1 M) and DIPEA (0.2 M) in CH2Cl2 was 
passed through the pre-conditioned column reactor (Omnifit
®
 column, 6.6 mm i.d. × 50 mm 
length), packed with activated MnO2 (0.86 g), at a flow rate of 0.5 mL min
-1
. When the 
FlowIR
®
 showed that the intensity of the diazo peak was stable, 4 mL of the output (2.0 equiv. 
with respect to the hydrazone) was directly added into the reaction vial (over 8 min) 
containing the copper acetylide-ligand complex and the reaction mixture further stirred at r.t. 
for 10 min. The solution was evaporated under reduced pressure and the residue taken up in 
Et2O (5 mL). The mixture was then filtered through a pad of Celite, eluting with Et2O, and 
the filtrate evaporated under reduced pressure. The residue was immediately purified by silica 
gel column chromatography to provide the desired allene (and alkyne) cross-products. Any 
excess diazo compound produced during the conditioning phase or the generation phase 
before steady-state was reached was gently quenched by directing the output of the flow 
reactor into a stirred suspension of copper(I) iodide (0.10 g) in MeOH (25 mL). 
 
 
(R)-1-Chloro-4-(3-cyclopropylpropa-1,2-dien-1-yl)benzene ((R)-74): Following the 
general procedure for asymmetric allenylation using cyclopropylacetylene (106) (13.2 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a colourless oil (11.3 mg, 
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0.059 mmol, 30%, 87% ee). Data are consistent with racemic spectra as reported in Section 
5.2.3. 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 
6.16 (d, J = 6.4 Hz, 1 H, H5), 5.45 (t, 1 H, J = 6.4 Hz, H7), 1.39 – 1.31 (m, 1 H, H8), 0.81 – 
0.73 (m, 2 H, H9a and H10a), 0.50 – 0.39 (m, 2 H, H9b and H10b). 
13
C NMR (150 MHz, CDCl3): δ 205.1 (C6), 133.6 (C4), 132.5 (C1), 128.8 (C2), 128.0 (C3), 
100.1 (C7), 95.5 (C5), 9.5 (C8), 7.2 (C9/C10), 7.1 (C9/C10). 
FTIR (νmax, cm
-1
): 3083 (w), 3005 (w), 2923 (w), 1948 (w, C=C=C), 1593 (w), 1573 (w), 
1490 (s), 1457 (w), 1427 (w), 1397 (w), 1354 (w), 1296 (w), 1273 (w), 1251 (w), 1198 (w), 
1174 (w), 1090 (s), 1047 (w), 1013 (m), 963 (w), 928 (w), 889 (w), 874 (m), 831 (s), 811 (s), 
751 (m). 
HRMS (ESI): calculated for C12H12Cl [M+H]
+
 191.0622, found 191.0620. 
Rf = 0.52 (hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -183.9 (CHCl3, c = 1.0, 87% ee). 
HPLC: Chiralpak OD-H, hexane, 1.0 mL/min flow rate, T = 25 °C, λmax = 254 nm; tR (min) 
= 6.7 (minor), 9.9 (major). 
 
 
1-Chloro-4-(3-cyclopropylprop-2-yn-1-yl)benzene (74′): Isolated as the alkyne cross-
product from asymmetric allenylation of cyclopropylacetylene (106) and (4-
chlorobenzylidene)hydrazine (62), which provided the title compound as a colourless oil 
(26.7 mg, 0.140 mmol, 70%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.29 – 7.22 (m, 4 H, H2 and H3), 3.51 (d, J = 2.0 Hz, 2 H, 
H5), 1.33 – 1.16 (m, 1 H, H8), 0.78 – 0.72 (m, 2 H, H9a), 0.68 – 0.64 (m, 2 H, H9b). 
13
C NMR (150 MHz, CDCl3): δ 136.1 (C4), 132.3 (C1), 129.3 (C3), 128.6 (C2), 86.2 (C7), 
72.5 (C6), 24.7 (C5), 8.2 (C8), -0.3 (C9). 
FTIR (νmax, cm
-1
): 3010 (w), 2921 (w), 2853 (w), 1703 (w), 1596 (w), 1578 (w), 1490 (s), 
1421 (m), 1406 (m), 1360 (w), 1291 (w), 1202 (w), 1177 (w), 1088 (m), 1052 (w), 1035 (w), 
1016 (s), 914 (w), 886 (m), 798 (s). 
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HRMS (ESI): calculated for C12H12Cl [M+H]
+
 191.0622, found 191.0628.  
Rf = 0.24 (hexane). 
 
 
(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide ((R)-65): 
Following the general procedure for asymmetric allenylation using 4-methyl-N-(prop-2-yn-1-
yl)benzenesulfonamide (60) (41.8 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), 
purified by silica gel column chromatography (eluent: 1% Et2O/CH2Cl2) provided the title 
compound as an off-white amorphous solid (33.7 mg, 0.101 mmol, 51%, 97% ee), m.p. 86-
88 °C. Data are consistent with racemic spectra as reported in Section 5.2.3.
 
 
1
H NMR (600 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 2 H, H10), 7.27 (d, J = 8.2 Hz, 2 H, 
H11), 7.24 (d, J = 8.4 Hz, 2 H, H2), 7.12 (d, J = 8.4 Hz, 2 H, H3), 6.17 (dt, J = 6.2, 3.0 Hz, 
1 H, H5), 5.55 (q, J = 6.2 Hz, 1 H, H7), 4.68 (br s, 1 H, NH), 3.73 – 3.68 (m, 2 H, H8), 2.42 
(s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 204.8 (C6), 143.8 (C12), 137.0 (C9), 133.3 (C1), 131.9 (C4), 
129.9 (C11), 129.0 (C2), 128.2 (C3), 127.3 (C10), 97.1 (C5), 92.6 (C7), 41.7 (C8), 21.7 
(C13). 
FTIR (νmax, cm
-1
): 3276 (w, NH), 2924 (w), 1957 (w, C=C=C), 1723 (w), 1597 (w), 1491 
(m), 1408 (w), 1323 (m), 1265 (w), 1155 (s), 1090 (s), 1013 (m), 874 (m), 834 (m), 812 (s). 
HRMS (ESI): calculated for C17H15NO2SCl [M-H]
-
 332.0518, found 332.0517.  
Rf = 0.56 (1% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -205.7 (CHCl3, c = 1.0, 97% ee). 
HPLC: Chiralpak AS, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 58.4 (minor), 75.5 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)-4-methylbenzenesulfonamide (65′): Isolated as the 
alkyne cross-product from asymmetric allenylation of 4-methyl-N-(prop-2-yn-1-
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yl)benzenesulfonamide (60) and (4-chlorobenzylidene)hydrazine (62), which provided the 
title compound as an off-white amorphous solid (18.8 mg, 0.056 mmol, 28%), m.p. 81-83 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.76 (d, J = 8.3 Hz, 2 H, H10), 7.26 – 7.22 (m, 4 H, H2 and 
H11), 7.07 (d, J = 8.4 Hz, 2 H, H3), 4.63 (br s, 1 H, NH), 3.88 (dt, J = 5.9, 2.2 Hz, 2 H, H8), 
3.35 (t, J = 2.2 Hz, 2 H, H5), 2.38 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 143.8 (C12), 136.9 (C9), 134.6 (C4), 132.7 (C1), 129.7 
(C11), 129.2 (C3), 128.7 (C2), 127.5 (C10), 82.5 (C6), 76.8 (C7), 33.5 (C8), 24.4 (C5), 21.7 
(C13). 
FTIR (νmax, cm
-1
): 3268 (w, NH), 3033 (w), 2925 (w), 1723 (w), 1597 (w), 1491 (m), 1408 
(m), 1325 (m), 1306 (m), 1291 (m), 1215 (w), 1120 (w), 1186 (m), 1156 (s), 1090 (s), 1058 
(m), 1015 (m), 812 (s), 751 (s). 
HRMS (ESI): calculated for C17H16NO2SClNa [M+Na]
+
 356.0482, found 356.0486.  
Rf = 0.48 (1% Et2O/CH2Cl2). 
 
 
tert-Butyl (R)-(4-(4-chlorophenyl)buta-2,3-dien-1-yl)carbamate ((R)-77): Following the 
general procedure for asymmetric allenylation using N-Boc-propargylamine (239) (31.0 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: CH2Cl2) provided the title compound as a pale yellow gum (27.6 mg, 
0.099 mmol, 47%, 93% ee). Data are consistent with racemic spectra as reported in Section 
5.2.3.
 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 
6.24 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.65 (q, J = 6.4 Hz, 1 H, H7), 4.70 (br s, 1 H, NH), 3.92 – 
3.75 (m, 2 H, H8), 1.40 (s, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 155.8 (C9), 132.9 (C1), 132.7 (C4), 128.9 (C2), 
128.2 (C3), 96.7 (C5), 94.1 (C7), 79.7 (C10), 39.1 (C8), 28.5 (C11). 
FTIR (νmax, cm
-1
): 3350 (w, NH), 2979 (w), 2929 (w), 1952 (w, C=C=C), 1693 (s, C=O), 
1592 (w), 1491 (s), 1455 (m), 1392 (m), 1367 (m), 1249 (s), 1161 (s), 1091 (s), 1049 (w), 
1014 (m), 952 (w), 858 (w), 834 (m), 781 (w), 760 (m). 
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HRMS (ESI): calculated for C15H18NO2ClNa [M+Na]
+
 302.0918, found 302.0909.  
Rf = 0.42 (CH2Cl2). 
[𝛂]𝑫
𝟐𝟔.𝟕 = -101.0 (CHCl3, c = 1.0, 93% ee). 
HPLC: Chiralpak OD-H, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 7.7 (minor), 8.6 (major). 
 
 
tert-Butyl (R)-(4-(4-chlorophenyl)buta-2,3-dien-1-yl)carbamate: Isolated as the alkyne 
cross-product from asymmetric allenylation of N-Boc-propargylamine (239) and (4-
chlorobenzylidene)hydrazine (62), which provided the title compound as a colourless gum 
(19.8 mg, 0.071 mmol, 35%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.25 (d, J = 8.5 Hz, 2 H, H3), 
4.70 (br s, 1 H, NH), 3.95 (br s, 2 H, H8), 3.55 (t, J = 2.1 Hz, 2 H, H5), 1.45 (s, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 155.5 (C9), 135.2 (C4), 132.6 (C1), 129.4 (C3), 128.7 (C2), 
80.6 (C6), 80.2 – 80.0 (br, C10), 78.9 (C7), 31.0 – 30.9 (br, C8), 28.5 (C11), 24.6 (C5). 
FTIR (νmax, cm
-1
): 3338 (w, NH), 2978 (w), 2934 (w), 1692 (s, C=O), 1491 (s), 1455 (w), 
1421 (w), 1408 (w), 1392 (w), 1366 (m), 1330 (w), 1275 (m), 1249 (m), 1163 (s), 1090 (m), 
1048 (w), 1016 (m), 931 (w), 916 (w), 862 (w), 806 (w). 
HRMS (ESI): calculated for C15H17NO2Cl [M-H]
-
 278.0953, found 278.0960.  
Rf = 0.46 (CH2Cl2). 
 
 
(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)acetamide (216): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 50% Et2O/CH2Cl2) provided the title compound as an off-white 
amorphous solid (20.8 mg, 0.094 mmol, 47%, 94% ee), m.p. 81-82 °C. 
 
5. Experimental (Appendix) 
221 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H2), 7.20 (d, J = 8.6 Hz, 2 H, H3), 
6.25 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.74 (br s, 1 H, NH), 5.67 (q, J = 6.4 Hz, 1 H, H7), 4.02 – 
3.89 (m, 2 H, H8), 1.95 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.6 (C6), 170.1 (C9), 133.1 (C1), 132.4 (C4), 129.0 (C2), 
128.1 (C3), 96.8 (C5), 93.5 (C7), 38.0 (C8), 23.3 (C10). 
FTIR (νmax, cm
-1
): 3278 (m, NH), 3072 (w), 2928 (w), 1954 (w, C=C=C), 1651 (s, C=O), 
1549 (s), 1491 (s), 1431 (m), 1390 (w), 1372 (m), 1344 (w), 1292 (m), 1234 (w), 1091 (m), 
1042 (w), 1013 (m), 877 (w), 833 (m). 
HRMS (ESI): calculated for C12H13NOCl [M+H]
+
 222.0680, found 222.0676.  
Rf = 0.32 (50% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟐 = -234.5 (CHCl3, c = 1.0, 94% ee). 
HPLC: ChiralART SA, 97:3 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 50.9 (minor), 54.1 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product from 
asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and (4-chlorobenzylidene)-
hydrazine (62), which provided the title compound as a white amorphous solid (14.1 mg, 
0.064 mmol, 32%), m.p. 71-73 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.24 (d, J = 8.5 Hz, 2 H, H3), 
5.71 (br s, 1 H, NH), 4.07 (dt, J = 4.9, 2.2 Hz, 2 H, H8), 3.55 (t, J = 2.2 Hz, 2 H, H5), 1.99 (s, 
3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C9), 135.0 (C4), 132.7 (C1), 129.4 (C3), 128.8 (C2), 
81.0 (C6), 78.2 (C7), 29.9 (C8), 24.6 (C5), 23.2 (C10). 
FTIR (νmax, cm
-1
): 3277 (m, NH), 3074 (w), 1651 (s, C=O), 1549 (m), 1492 (s), 1422 (m), 
1373 (m), 1350 (m), 1289 (m), 1140 (w), 1090 (m), 1016 (m), 914 (w), 805 (w). 
HRMS (ESI): calculated for C12H12NOClNa [M+Na]
+
 244.0500, found 244.0496. 
Rf = 0.34 (50% Et2O/CH2Cl2). 
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(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-3,3,3-trifluoropropanamide (217): 
Following the general procedure for asymmetric allenylation using 3,3,3-trifluoro-N-(prop-2-
yn-1-yl)propanamide (33.0 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified 
by silica gel column chromatography (eluent: 25% EtOAc/hexane) provided the title 
compound as a yellow amorphous solid (29.9 mg, 0.103 mmol, 52%, 91% ee), m.p. 86-87 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
6.28 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 6.05 (br s, 1 H, NH), 5.67 (q, J = 6.4 Hz, 1 H, H7), 4.09 – 
3.91 (m, 2 H, H8), 3.04 (q, J = 10.6 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.5 (C6), 162.6 (q, J = 3.5 Hz, C9), 133.2 (C1), 132.1 
(C4), 129.0 (C2), 128.2 (C3), 124.0 (q, J = 276.7 Hz, C11), 97.3 (C5), 92.8 (C7), 41.7 (q, J = 
29.6 Hz, C10), 38.2 (C8). 
19
F NMR (376 MHz, CDCl3): δ -63.0 (s, 3 F, F11). 
FTIR (νmax, cm
-1
): 3309 (m, NH), 2921 (w), 1953 (w, C=C=C), 1651 (s, C=O), 1556 (m), 
1492 (m), 1390 (m), 1341 (w), 1264 (m), 1235 (m), 1141 (m), 1107 (m), 1093 (m), 1063 (w), 
1014 (w), 920 (w), 880 (w), 851 (w), 836 (m), 752 (w). 
HRMS (ESI): calculated for C13H10F3NOCl [M-H]
-
 288.0408, found 288.0407.  
Rf = 0.23 (25% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟕.𝟎 = -160.5 (CHCl3, c = 1.0, 91% ee). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 15.2 (minor), 16.6 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)-3,3,3-trifluoropropanamide: Isolated as the alkyne 
cross-product from asymmetric allenylation of 3,3,3-trifluoro-N-(prop-2-yn-1-
yl)propanamide and (4-chlorobenzylidene)hydrazine (62), which provided the title compound 
as an off-white amorphous solid (14.8 mg, 0.051 mmol, 26%), m.p. 96-99 °C. 
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1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.4 Hz, 2 H, H2), 7.23 (d, J = 8.4 Hz, 2 H, H3), 
5.98 (br s, 1 H, NH), 4.12 (dt, J = 4.8, 2.3 Hz, 2 H, H8), 3.56 (t, J = 2.3 Hz, 2 H, H5), 3.08 (q, 
J = 10.5 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 162.2 (q, J = 3.6 Hz, C9), 134.8 (C4), 132.7 (C1), 129.3 
(C3), 128.8 (C2), 124.0 (q, J = 276.7 Hz, C11), 81.8 (C6), 77.3 (C7), 41.7 (q, J = 29.8 Hz, 
C10), 30.3 (C8), 24.6 (C5). 
19
F NMR (376 MHz, CDCl3): δ -62.9 (s, 3 F, F11). 
FTIR (νmax, cm
-1
): 3304 (m, NH), 2970 (w), 2903 (w), 1651 (s, C=O), 1554 (m), 1492 (w), 
1452 (w), 1424 (w), 1393 (m), 1351 (m), 1304 (w), 1264 (m), 1236 (m), 1129 (m), 1101 (m), 
1092 (m), 1057 (m), 1016 (w), 927 (w), 854 (w), 841 (w), 796 (w), 760 (w). 
HRMS (ESI): calculated for C13H11F3NOClNa [M+Na]
+
 312.0373, found 312.0375.  
Rf = 0.28 (25% EtOAc/hexane). 
 
 
(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-6-oxoheptanamide (218): Following the 
general procedure for asymmetric allenylation using 6-oxo-N-(prop-2-yn-1-yl)heptanamide 
(36.2 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 30% Et2O/CH2Cl2) provided the title compound as a white 
crystalline solid (30.0 mg, 0.098 mmol, 49%, 96% ee), m.p. 94-95 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.20 (d, J = 8.5 Hz, 2 H, H3), 
6.25 (dt, J = 6.5, 3.3 Hz, 1 H, H5), 5.85 (br s, 1 H, NH), 5.67 (q, J = 6.5 Hz, 1 H, H7), 4.05 – 
3.99 (m, 1 H, H8a), 3.96 – 3.90 (m, 1 H, H8b), 2.39 – 2.34 (m, 2 H, H13), 2.18 – 2.14 (m, 
2 H, H10), 2.10 (s, 3 H, H15), 1.56 – 1.49 (m, 4 H, H11 and H12). 
13
C NMR (150 MHz, CDCl3): δ 208.9 (C14), 204.6 (C6), 172.6 (C9), 133.0 (C1), 132.5 (C4), 
128.9 (C2), 128.2 (C3), 96.9 (C5), 93.8 (C7), 43.3 (C13), 37.7 (C8), 36.4 (C10), 30.1 (C15), 
25.1 (C11/C12), 23.2 (C11/C12). 
FTIR (νmax, cm
-1
): 3312 (m, NH), 3062 (w), 2943 (w), 1950 (w, C=C=C), 1708 (s, C=O), 
1640 (s, C=O), 1538 (s), 1492 (s), 1461 (w), 1422 (w), 1361 (w), 1263 (w), 1236 (w), 1161 
(w), 1092 (m), 1014 (w), 876 (w), 835 (m), 812 (w). 
HRMS (ESI): calculated for C17H20NO2ClNa [M+Na]
+
 328.1075, found 328.1080.  
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Rf = 0.28 (30% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -210.9 (CHCl3, c = 1.0, 96% ee). 
HPLC: ChiralART SC, 85:15 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 33.8 (minor), 38.8 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)-6-oxoheptanamide: Isolated as the alkyne cross-
product from asymmetric allenylation of 6-oxo-N-(prop-2-yn-1-yl)heptanamide and (4-
chlorobenzylidene)hydrazine (62), which provided the title compound as a white amorphous 
solid (23.3 mg, 0.076 mmol, 38%), m.p. 79-80 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.6 Hz, 2 H, H2), 7.23 (d, J = 8.6 Hz, 2 H, H3), 
5.88 (br s, 1 H, NH), 4.07 (dt, J = 4.9, 2.2 Hz, 2 H, H8), 3.54 (t, J = 2.2 Hz, 2 H, H5), 2.44 (t, 
J = 6.8 Hz, 2 H, H13), 2.19 (t, J = 7.1 Hz, 2 H, H10), 2.12 (s, 3 H, H15), 1.65 – 1.54 (m, 4 H, 
H11 and H12). 
13
C NMR (150 MHz, CDCl3): δ 209.0 (C14), 172.3 (C9), 135.1 (C4), 132.6 (C1), 129.4 (C3), 
128.7 (C2), 80.8 (C6), 78.3 (C7), 43.4 (C13), 36.2 (C10), 30.1 (C15), 29.7 (C8), 25.0 
(C11/C12), 24.6 (C5), 23.2 (C11/C12). 
FTIR (νmax, cm
-1
): 3287 (m, NH), 3056 (w), 2933 (w), 2866 (w), 1702 (s, C=O), 1635 (s, 
C=O), 1542 (m), 1492 (m), 1463 (w), 1419 (w), 1377 (w), 1360 (w), 1265 (w), 1237 (w), 
1167 (w), 1097 (w), 1017 (w), 814 (w), 792 (w). 
HRMS (ESI): calculated for C17H19NO2Cl [M-H]
-
 304.1110, found 304.1110. 
Rf = 0.38 (30% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-4-formylbenzamide (219): Following the 
general procedure for asymmetric allenylation using 4-formyl-N-(prop-2-yn-1-yl)benzamide 
(37.4 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
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chromatography (eluent: 5% Et2O/CH2Cl2) provided the title compound as a pale yellow 
crystalline solid (29.2 mg, 0.094 mmol, 47%, 97% ee), m.p. 128-130 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 10.05 (s, 1 H, H14), 7.90 (d, J = 8.2 Hz, 2 H, H12), 7.83 (d, 
J = 8.2 Hz, 2 H, H11), 7.27 (d, J = 8.5 Hz, 2 H, H2), 7.22 (d, J = 8.5 Hz, 2 H, H3), 6.40 (br s, 
1 H, NH), 6.30 (dt, J = 6.4, 3.3 Hz, 1 H, H5), 5.79 (q, J = 6.4 Hz, 1 H, H7), 4.26 – 4.13 (m, 
2 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 204.8 – 204.7 (br, C6), 191.6 (C14), 166.5 (C9), 139.6 
(C10), 138.4 (C13), 133.3 (C1), 132.2 (C4), 130.0 (C12), 129.1 (C2), 128.2 (C3), 127.7 
(C11), 97.3 (C5), 93.3 (C7), 38.4 (C8). 
FTIR (νmax, cm
-1
): 3325 (w, NH), 3060 (w), 2838 (w), 1955 (w, C=C=C), 1705 (s, C=O), 
1645 (s, C=O), 1610 (w), 1572 (w), 1537 (s), 1491 (s), 1430 (w), 1389 (w), 1346 (w), 1294 
(m), 1207 (m), 1149 (w), 1090 (m), 1014 (w), 876 (w), 835 (m), 759 (w). 
HRMS (ESI): calculated for C18H14NO2ClNa [M+Na]
+
 334.0605, found 334.0610. 
Rf = 0.29 (5% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -473.6 (CHCl3, c = 1.0, 97% ee). 
HPLC: ChiralART SA, 93:7 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 43.3 (minor), 45.0 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)-4-formylbenzamide: Isolated as the alkyne cross-
product from asymmetric allenylation of 4-formyl-N-(prop-2-yn-1-yl)benzamide and (4-
chlorobenzylidene)hydrazine (62), after repurification by silica gel column chromatography 
(eluent: 40% EtOAc/hexane) of the alkyne-containing fractions, which provided the title 
compound as a white amorphous solid (20.8 mg, 0.067 mmol, 33%), m.p. 117-120 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 10.07 (s, 1 H, H14), 7.96 – 7.92 (m, 4 H, H11 and H12), 
7.28 (d, J = 8.6 Hz, 2 H, H2), 7.25 (d, J = 8.6 Hz, 2 H, H3), 6.40 (br s, 1 H, NH), 4.31 (dt, J = 
4.9, 2.2 Hz, 2 H, H8), 3.58 (t, J = 2.2 Hz, 2 H, H5). 
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13
C NMR (150 MHz, CDCl3): δ 191.6 (C14), 166.1 (C9), 139.1 (C10), 138.5 (C13), 134.9 
(C4), 132.8 (C1), 130.0 (C12), 129.4 (C3), 128.8 (C2), 127.9 (C11), 81.7 (C6), 77.7 (C7), 
30.6 (C8), 24.7 (C5). 
FTIR (νmax, cm
-1
): 3312 (w, NH), 3064 (w), 2835 (w), 1704 (s, C=O), 1647 (s, C=O), 1610 
(w), 1572 (w), 1538 (s), 1491 (s), 1419 (w), 1408 (w), 1386 (w), 1355 (w), 1291 (m), 1207 
(m), 1154 (w), 1090 (m), 1016 (m), 977 (w), 848 (m), 801 (m), 757 (m). 
HRMS (ESI): calculated for C18H13NO2Cl [M-H]
-
 310.0640, found 310.0639.  
Rf = 0.35 (5% Et2O/CH2Cl2). 
 
 
(1R,3s,5S)-N-((R)-4-(4-Chlorophenyl)buta-2,3-dien-1-yl)-6-oxabicyclo[3.1.0]hexane-3-
carboxamide (220): Following the general procedure for asymmetric allenylation using 
(1R,3s,5S)-N-(prop-2-yn-1-yl)-6-oxabicyclo[3.1.0]hexane-3-carboxamide (33.0 mg, 
0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by silica gel column 
chromatography (eluent: 30% Et2O/CH2Cl2) provided the title compound as a white 
crystalline solid (32.0 mg, 0.110 mmol, 55%, 95% ee), m.p. 134-136 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.5 Hz, 2 H, H2), 7.18 (d, J = 8.5 Hz, 2 H, H3), 
6.24 (dt, J = 6.6, 3.4 Hz, 1 H, H5), 5.75 (br s, 1 H, NH), 5.65 (q, J = 6.6 Hz, 1 H, H7), 4.04 – 
3.98 (m, 1 H, H8a), 3.92 – 3.85 (m, 1 H, H8b), 3.49 – 3.44 (m, 2 H, H12 and H13), 2.32 (tt, 
J = 9.6, 7.8 Hz, 1 H, H10), 2.18 (dd, J = 13.9, 7.8 Hz, 1 H, H11a/H14a), 2.08 (dd, J = 14.0, 
7.8 Hz, 1 H, H11a/H14a), 1.92 (ddd, J = 13.9, 9.6, 1.3 Hz, 1 H, H11b/H14b), 1.82 (ddd, J = 
14.0, 9.6, 1.3 Hz, 1 H, H11b/H14b). 
13
C NMR (150 MHz, CDCl3): δ 204.5 (C6), 173.9 (C9), 133.1 (C1), 132.3 (C4), 129.0 (C2), 
128.1 (C3), 97.1 (C5), 93.7 (C7), 56.6 (C12 and C13), 39.0 (C10), 37.7 (C8), 31.93 
(C11/C14), 31.86 (C11/C14). 
FTIR (νmax, cm
-1
): 3298 (m, NH), 3045 (w), 2925 (w), 1955 (w, C=C=C), 1649 (s, C=O), 
1540 (m), 1491 (s), 1434 (w), 1391 (w), 1340 (w), 1294 (m), 1244 (w), 1220 (m), 1091 (m), 
1060 (w), 1013 (w), 958 (w), 876 (w), 836 (s). 
HRMS (ESI): calculated for C16H17NO2Cl [M+H]
+
 290.0942, found 290.0946.  
Rf = 0.37 (30% Et2O/CH2Cl2). 
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[𝛂]𝑫
𝟐𝟓.𝟎 = -230.6 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 31.3 (minor), 36.1 (major). 
 
 
(1R,3s,5S)-N-(4-(4-Chlorophenyl)but-2-yn-1-yl)-6-oxabicyclo[3.1.0]hexane-3-
carboxamide: Isolated as the alkyne cross-product from asymmetric allenylation of 
(1R,3s,5S)-N-(prop-2-yn-1-yl)-6-oxabicyclo[3.1.0]hexane-3-carboxamide and (4-chloro-
benzylidene)hydrazine (62), which provided the title compound as a white amorphous solid 
(21.7 mg, 0.075 mmol, 37%), m.p. 131-132 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.23 (d, J = 8.5 Hz, 2 H, H3), 
5.76 (br s, 1 H, NH), 4.06 (dt, J = 5.0, 2.3 Hz, 2 H, H8), 3.54 (t, J = 2.3 Hz, 2 H, H5), 3.52 (s, 
2 H, H12), 2.39 (tt, J = 9.6, 7.8 Hz, 1 H, H10), 2.24 (dd, J = 14.0, 7.8 Hz, 2 H, H11a), 1.95 
(dd, J = 14.0, 9.6 Hz, 2 H, H11b). 
13
C NMR (150 MHz, CDCl3): δ 173.7 (C9), 135.0 (C4), 132.7 (C1), 129.3 (C3), 128.8 (C2), 
81.1 (C6), 78.1 (C7), 56.6 (C12), 38.9 (C10), 31.9 (C11), 30.0 (C8), 24.6 (C5). 
FTIR (νmax, cm
-1
): 3283 (m, NH), 3031 (w), 2924 (w), 1649 (s, C=O), 1537 (s), 1491 (s), 
1422 (w), 1408 (w), 1396 (w), 1348 (w), 1293 (m), 1243 (w), 1220 (m), 1090 (m), 1060 (w), 
1016 (m), 958 (w), 838 (s), 807 (w). 
HRMS (ESI): calculated for C16H16NO2ClNa [M+Na]
+
 312.0762, found 312.0770. 
Rf = 0.46 (30% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Chlorophenyl)buta-2,3-dien-1-yl)thiophene-2-carboxamide (221): Following 
the general procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)thiophene-2-
carboxamide (33.0 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), stirred for 
20 min after addition of diazo compound, purified by silica gel column chromatography 
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(eluent: CH2Cl2) provided the title compound as a yellow amorphous solid (30.7 mg, 
0.106 mmol, 53%, 95% ee), m.p. 86-88 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.46 – 7.43 (m, 2 H, H11 and H13), 7.26 (d, J = 8.5 Hz, 2 H, 
H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 7.03 (dd, J = 4.9, 3.8 Hz, 1 H, H12), 6.28 (dt 
superimposed on br s, J = 6.0, 3.2 Hz, 2 H, H5 and NH), 5.76 (q, J = 6.0 Hz, 1 H, H7), 4.15 
(td, J = 6.0, 3.2 Hz, 2 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 204.8 (C6), 161.9 (C9), 138.7 (C10), 133.1 (C1), 132.3 (C4), 
130.1 (C11), 129.0 (C2), 128.3 (C13), 128.2 (C3), 127.8 (C12), 97.0 (C5), 93.4 (C7), 38.3 
(C8). 
FTIR (νmax, cm
-1
): 3310 (w, NH), 3085 (w), 2921 (w), 1953 (w, C=C=C), 1626 (s, C=O), 
1542 (s), 1510 (m), 1491 (s), 1420 (m), 1389 (w), 1358 (w), 1341 (w), 1297 (m), 1140 (w), 
1090 (m), 1058 (w), 1013 (w), 875 (w), 859 (w), 833 (m). 
HRMS (ESI): calculated for C15H12NOSClNa [M+Na]
+
 312.0220, found 312.0226.  
Rf = 0.34 (CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -290.4 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 30.6 (minor), 35.0 (major). 
 
 
N-(4-(4-Chlorophenyl)but-2-yn-1-yl)thiophene-2-carboxamide: Isolated as the alkyne 
cross-product from asymmetric allenylation of N-(prop-2-yn-1-yl)thiophene-2-carboxamide 
and (4-chlorobenzylidene)hydrazine (62), which provided the title compound as a yellow 
gum (22.2 mg, 0.077 mmol, 38%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.53 (dd, J = 3.7, 1.1 Hz, 1 H, H11), 7.48 (dd, J = 5.0, 
1.1 Hz, 1 H, H13), 7.28 (d, J = 8.6 Hz, 2 H, H2), 7.25 (d, J = 8.6 Hz, 2 H, H3), 7.07 (dd, J = 
5.0, 3.7 Hz, 1 H, H12), 6.17 (br s, 1 H, NH), 4.27 (dt, J = 5.3, 2.2 Hz, 2 H, H8), 3.57 (t, J = 
2.2 Hz, 2 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 161.6 (C9), 138.3 (C10), 135.0 (C4), 132.7 (C1), 130.4 
(C13), 129.4 (C3), 128.8 (C2), 128.6 (C11), 127.8 (C12), 81.4 (C6), 78.0 (C7), 30.2 (C8), 
24.7 (C5). 
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FTIR (νmax, cm
-1
): 3301 (w, NH), 3090 (w), 2924 (w), 1626 (s, C=O), 1539 (s), 1509 (m), 
1490 (s), 1419 (m), 1360 (w), 1347 (w), 1291 (m), 1246 (w), 1151 (w), 1122 (w), 1089 (m), 
1057 (w), 1035 (w), 1016 (w), 949 (w), 913 (w), 858 (w), 799 (m). 
HRMS (ESI): calculated for C15H12NOSClNa [M+Na]
+
 312.0220, found 312.0229.  
Rf = 0.40 (CH2Cl2). 
 
 
(R)-5-Bromo-N-(4-(4-bromophenyl)buta-2,3-dien-1-yl)furan-2-carboxamide (222): 
Following the general procedure for asymmetric allenylation using 5-bromo-N-(prop-2-yn-1-
yl)furan-2-carboxamide (45.6 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, purified 
by silica gel column chromatography (eluent: 2% Et2O/CH2Cl2) provided the title compound 
as an orange amorphous solid (42.3 mg, 0.107 mmol, 53%, 96% ee), m.p. 108-110 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.15 (d, J = 8.4 Hz, 2 H, H3), 
7.04 (d, J = 3.5 Hz, 1 H, H11), 6.50 (br s, 1 H, NH), 6.41 (d, J = 3.5 Hz, 1 H, H12), 6.26 (dt, 
J = 6.1, 3.0 Hz, 1 H, H5), 5.71 (q, J = 6.1 Hz, 1 H, H7), 4.18 – 4.08 (m, 2 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 205.2 (C6), 157.2 (C9), 149.5 (C10), 132.8 (C4), 131.9 (C2), 
128.6 (C3), 124.6 (C13), 121.2 (C1), 116.9 (C11), 114.3 (C12), 96.8 (C5), 93.1 (C7), 37.8 
(C8). 
FTIR (νmax, cm
-1
): 3295 (w, NH), 1954 (w, C=C=C), 1647 (s, C=O), 1596 (m), 1575 (m), 
1523 (s), 1488 (m), 1471 (s), 1430 (w), 1388 (w), 1342 (w), 1297 (m), 1221 (w), 1202 (w), 
1171 (w), 1125 (w), 1070 (w), 1010 (m), 926 (w), 874 (w), 831 (m), 798 (m), 753 (w). 
HRMS (ESI): calculated for C15H12NO2Br2 [M+H]
+
 395.9229, found 395.9234. 
Rf = 0.37 (2% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -238.4 (CHCl3, c = 1.0, 96% ee). 
HPLC: ChiralART SC, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 19.8 (minor), 21.8 (major). 
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5-Bromo-N-(4-(4-bromophenyl)but-2-yn-1-yl)furan-2-carboxamide: Isolated as the 
alkyne cross-product from asymmetric allenylation of 5-bromo-N-(prop-2-yn-1-yl)furan-2-
carboxamide and (4-bromobenzylidene)hydrazine, which provided the title compound as an 
orange amorphous solid (31.0 mg, 0.078 mmol, 39%), m.p. 128-130 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.44 (d, J = 8.4 Hz, 2 H, H2), 7.20 (d, J = 8.4 Hz, 2 H, H3), 
7.09 (d, J = 3.5 Hz, 1 H, H11), 6.44 (d superimposed on br s, J = 3.5 Hz, 2 H, H12 and NH), 
4.25 (dt, J = 5.2, 2.3 Hz, 2 H, H8), 3.56 (t, J = 2.3 Hz, 2 H, H5). 
13
C NMR (150 MHz, CDCl3): δ 156.8 (C9), 149.2 (C10), 135.5 (C4), 131.8 (C2), 129.8 (C3), 
124.8 (C13), 120.7 (C1), 117.1 (C11), 114.4 (C12), 81.3 (C6), 77.8 (C7), 29.5 (C8), 24.7 
(C5). 
FTIR (νmax, cm
-1
): 3286 (w, NH), 1650 (s, C=O), 1596 (m), 1574 (m), 1520 (s), 1487 (m), 
1470 (s), 1419 (w), 1354 (w), 1295 (m), 1203 (w), 1172 (w), 1123 (w), 1071 (w), 1012 (m), 
927 (w), 796 (m), 752 (w). 
HRMS (ESI): calculated for C15H12NO2Br2 [M+H]
+
 395.9229, found 395.9230.  
Rf = 0.44 (2% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)-4-hydroxybutanamide (223): Following 
the general procedure for asymmetric allenylation using 4-hydroxy-N-(prop-2-yn-1-
yl)butanamide (28.2 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica 
gel column chromatography (eluent: 20% THF/Et2O) provided the title compound as a white 
amorphous solid (30.3 mg, 0.098 mmol, 49%, 91% ee), m.p. 89-91 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.3 Hz, 2 H, H2), 7.14 (d, J = 8.3 Hz, 2 H, H3), 
6.24 (dt, J = 6.2, 3.0 Hz, 1 H, H5), 5.97 (br s, 1 H, NH), 5.65 (q, J = 6.2 Hz, 1 H, H7), 4.04 – 
3.89 (m, 2 H, H8), 3.66 – 3.30 (m, 2 H, H12), 2.79 (br s, 1 H, OH), 2.34 – 2.29 (m, 2 H, H10), 
1.84 – 1.79 (m, 2 H, H11). 
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13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 173.5 (C9), 132.9 (C4), 131.9 (C2), 128.5 (C3), 
121.2 (C1), 97.0 (C5), 93.6 (C7), 62.4 (C12), 37.9 (C8), 33.9 (C10), 28.1 (C11). 
FTIR (νmax, cm
-1
): 3285 (br m, NH and OH), 2928 (w), 2876 (w), 1952 (w, C=C=C), 1637 (s, 
C=O), 1544 (m), 1488 (m), 1428 (w), 1380 (w), 1249 (w), 1217 (w), 1163 (w), 1070 (m), 
1058 (m), 1010 (m), 918 (w), 881 (w), 832 (m), 810 (w). 
HRMS (ESI): calculated for C14H16NO2BrNa [M+Na]
+
 332.0257, found 332.0262.  
Rf = 0.20 (20% THF/Et2O). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -237.5 (CHCl3, c = 0.2, 91% ee). 
HPLC: ChiralART SA, 93:7 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 16.7 (minor), 18.2 (major). 
 
 
N-(4-(4-Bromophenyl)but-2-yn-1-yl)-4-hydroxybutanamide: Isolated as the alkyne cross-
product from asymmetric allenylation of 4-hydroxy-N-(prop-2-yn-1-yl)butanamide and (4-
bromobenzylidene)hydrazine, which provided the title compound as a white amorphous solid 
(23.0 mg, 0.074 mmol, 37%), m.p. 73-74 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
5.89 (br s, 1 H, NH), 4.08 (dt, J = 4.9, 2.3 Hz, 2 H, H8), 3.69 (t, J = 5.7 Hz, 2 H, H12), 3.53 (t, 
J = 2.3 Hz, 2 H, H5), 2.62 (br s, 1 H, OH), 2.36 (t, J = 6.5 Hz, 2 H, H10), 1.88 (tt, J = 6.5, 
5.7 Hz, 2 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 173.1 (C9), 135.6 (C4), 131.8 (C2), 129.8 (C3), 120.7 (C1), 
81.0 (C6), 78.2 (C7), 62.4 (C12), 33.7 (C10), 29.9 (C8), 28.0 (C11), 24.7 (C5). 
FTIR (νmax, cm
-1
): 3272 (br m, NH and OH), 2937 (w), 1643 (s, C=O), 1542 (m), 1487 (s), 
1420 (m), 1347 (w), 1259 (m), 1070 (m), 1012 (s), 916 (w), 801 (w). 
HRMS (ESI): calculated for C14H16NO2BrNa [M+Na]
+
 332.0257, found 332.0268. 
Rf = 0.26 (20% THF/Et2O). 
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(R)-N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)cyclopropanecarboxamide (224): Following 
the general procedure for asymmetric allenylation using N-(prop-2-yn-1-
yl)cyclopropanecarboxamide (24.6 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, 
purified by silica gel column chromatography (eluent: 70% Et2O/hexane) provided the title 
compound as an orange amorphous solid (30.0 mg, 0.103 mmol, 51%, 95% ee), m.p. 119-
121 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.15 (d, J = 8.4 Hz, 2 H, H3), 
6.24 (dt, J = 6.3, 3.1 Hz, 1 H, H5), 5.85 (br s, 1 H, NH), 5.67 (q, J = 6.3 Hz, 1 H, H7), 4.06 – 
3.91 (m, 2 H, H8), 1.34 – 1.28 (m, 1 H, H10), 0.99 – 0.86 (m, 2 H, H11/H12), 0.74 – 0.64 (m, 
2 H, H11/H12). 
13
C NMR (150 MHz, CDCl3): δ 204.7 – 204.6 (br, C6), 173.6 (C9), 133.0 (C4), 131.9 (C2), 
128.5 (C3), 121.1 (C1), 96.8 (C5), 93.8 (C7), 38.0 (C8), 14.8 (C10), 7.37 (C11/C12), 7.36 
(C11/C12).  
FTIR (νmax, cm
-1
): 3277 (m, NH), 3070 (w), 3011 (w), 2914 (w), 1954 (w, C=C=C), 1638 (s, 
C=O), 1545 (m), 1487 (m), 1451 (w), 1404 (w), 1336 (w), 1239 (m), 1196 (w), 1106 (w), 
1070 (w), 1035 (w), 1010 (w), 991 (w), 912 (w), 879 (w), 830 (w). 
HRMS (ESI): calculated for C14H14NOBrNa [M+Na]
+
 314.0151, found 314.0136. 
Rf = 0.29 (70% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟕.𝟕 = -198.8 (CHCl3, c = 0.5, 95% ee). 
HPLC: ChiralART SA, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 20.1 (major), 28.3 (minor). 
 
 
N-(4-(4-Bromophenyl)but-2-yn-1-yl)cyclopropanecarboxamide: Isolated as the alkyne 
cross-product from asymmetric allenylation of N-(prop-2-yn-1-yl)cyclopropanecarboxamide 
and (4-bromobenzylidene)hydrazine, which provided the title compound as an orange 
amorphous solid (20.4 mg, 0.070 mmol, 35%), m.p. 135-136 °C. 
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1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
5.85 (br s, 1 H, NH), 4.10 (dt, J = 4.9, 2.3 Hz, 2 H, H8), 3.54 (t, J = 2.3 Hz, 2 H, H5), 1.37 – 
1.32 (m, 1 H, H10), 1.00 – 0.96 (m, 2 H, H11a), 0.77 – 0.73 (m, 2 H, H11b). 
13
C NMR (150 MHz, CDCl3): δ 173.3 (C9), 135.6 (C4), 131.7 (C2), 129.8 (C3), 120.7 (C1), 
80.8 (C6), 78.6 (C7), 29.9 (C8), 24.7 (C5), 14.8 (C10), 7.5 (C11). 
FTIR (νmax, cm
-1
): 3278 (m, NH), 3098 (w), 3010 (w), 2942 (w), 2859 (w), 1637 (s, C=O), 
1589 (w), 1551 (s), 1486 (m), 1447 (w), 1426 (w), 1403 (m), 1335 (m), 1243 (m), 1230 (m), 
1109 (w), 1074 (w), 1055 (w), 1034 (w), 1011 (m), 1002 (w), 937 (w), 908 (m), 840 (m), 823 
(w), 806 (w), 788 (m), 770 (w). 
HRMS (ESI): calculated for C14H14NOBrNa [M+Na]
+
 314.0151, found 314.0160.  
Rf = 0.36 (70% Et2O/hexane). 
 
 
(R)-N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)-1-(4-chlorophenyl)cyclopentane-1-
carboxamide (225): Following the general procedure for asymmetric allenylation using 1-(4-
chlorophenyl)-N-(prop-2-yn-1-yl)cyclopentane-1-carboxamide (52.4 mg, 0.2 mmol) and (4-
bromobenzylidene)hydrazine, purified by silica gel column chromatography (eluent: 40% 
EtOAc/hexane) provided the title compound as a yellow gum (40.5 mg, 0.094 mmol, 47%, 
95% ee). 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.15 (d, J = 8.7 Hz, 2 H, H17), 
7.11 (d, J = 8.7 Hz, 2 H, H16), 7.05 (d, J = 8.4 Hz, 2 H, H3), 6.06 (dt, J = 6.3, 3.7 Hz, 1 H, 
H5), 5.58 (dt, J = 6.3, 4.8 Hz, 1 H, H7), 5.30 (br s, 1 H, NH), 3.95 – 3.85 (m, 1 H, H8a), 3.85 
– 3.75 (m, 1 H, H8b), 2.44 – 2.33 (m, 2 H, H10/H13), 1.98 – 1.84 (m, 2 H, H10/H13), 1.84 – 
1.71 (m, 2 H, H11/H12), 1.62 – 1.56 (m, 2 H, H11/H12). 
13
C NMR (150 MHz, CDCl3): δ 203.8 (C6), 175.9 (C9), 142.5 (C18), 132.9 (C4 and C15), 
131.9 (C2), 128.8 (C16), 128.5 (C17), 128.4 (C3), 121.2 (C1), 97.5 (C5), 93.9 (C7), 58.9 
(C14), 37.5 (C8), 37.1 (C10/C13), 37.0 (C10/C13), 24.01 (C11/C12), 24.00 (C11/C12). 
FTIR (νmax, cm
-1
): 3339 (w, NH), 2958 (w), 2873 (w), 1955 (w, C=C=C), 1646 (m, C=O), 
1593 (w), 1488 (s), 1428 (w), 1401 (w), 1343 (w), 1262 (w), 1094 (m), 1070 (m), 1010 (s), 
830 (s), 794 (m). 
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HRMS (ESI): calculated for C22H22NOBrCl [M+H]
+
 430.0568, found 430.0550.  
Rf = 0.33 (25% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -216.0 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 19.1 (minor), 19.9 (major). 
 
N-(4-(4-Bromophenyl)but-2-yn-1-yl)-1-(4-chlorophenyl)cyclopentane-1-carboxamide: 
Isolated as the alkyne cross-product from asymmetric allenylation of 1-(4-chlorophenyl)-N-
(prop-2-yn-1-yl)cyclopentane-1-carboxamide and (4-bromobenzylidene)-hydrazine, which 
provided the title compound as a white crystalline solid (25.1 mg, 0.058 mmol, 29%), m.p. 
116-119 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.29 (d, J = 8.9 Hz, 2 H, H15), 
7.27 (d, J = 8.9 Hz, 2 H, H14), 7.12 (d, J = 8.4 Hz, 2 H, H3), 5.29 (br s, 1 H, NH), 3.96 (dt, 
J = 5.3, 2.3 Hz, 2 H, H8), 3.48 (t, J = 2.3 Hz, 2 H, H5), 2.48 – 2.41 (m, 2 H, H10a), 2.00 – 
1.93 (m, 2 H, H10b), 1.85 – 1.77 (m, 2 H, H11a), 1.70 – 1.64 (m, 2 H, H11b). 
13
C NMR (150 MHz, CDCl3): δ 175.6 (C9), 142.5 (C13), 135.6 (C4), 133.0 (C16), 131.7 
(C2), 129.7 (C3), 129.0 (C15), 128.4 (C14), 120.6 (C1), 80.7 (C6), 78.3 (C7), 58.9 (C12), 
37.0 (C10), 30.2 (C8), 24.7 (C5), 24.0 (C11). 
FTIR (νmax, cm
-1
): 3339 (w, NH), 2954 (w), 2874 (w), 1646 (m, C=O), 1593 (w), 1487 (s), 
1454 (w), 1419 (w), 1401 (w), 1349 (w), 1327 (w), 1268 (m), 1184 (w), 1135 (w), 1093 (m), 
1071 (m), 1012 (s), 963 (w), 907 (m), 825 (m), 799 (m), 762 (w). 
HRMS (ESI): calculated for C22H22NOBrCl [M+H]
+
 430.0568, found 430.0565. 
Rf = 0.42 (25% EtOAc/hexane). 
 
 
Methyl (R)-4-((4-(4-bromophenyl)buta-2,3-dien-1-yl)amino)-4-oxobutanoate (226): 
Following the general procedure for asymmetric allenylation using methyl 4-oxo-4-(prop-2-
yn-1-ylamino)butanoate (33.8 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, purified 
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by silica gel column chromatography (eluent: 5% Et2O/CH2Cl2) provided the title compound 
as an orange amorphous solid (29.4 mg, 0.087 mmol, 43%, 91% ee), m.p. 90-92 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.14 (d, J = 8.4 Hz, 2 H, H3), 
6.23 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.90 (br s, 1 H, NH), 5.65 (q, J = 6.4 Hz, 1 H, H7), 4.04 – 
3.89 (m, 2 H, H8), 3.64 (s, 3 H, H13), 2.65 – 2.58 (m, 2 H, H11), 2.48 – 2.42 (m, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 173.6 (C12), 171.4 (C9), 132.9 (C4), 131.9 (C2), 
128.5 (C3), 121.1 (C1), 96.9 (C5), 93.6 (C7), 52.0 (C13), 37.9 (C8), 31.1 (C10), 29.4 (C11). 
FTIR (νmax, cm
-1
): 3305 (w, NH), 2922 (w), 2851 (w), 1951 (w, C=C=C), 1734 (s, C=O), 
1648 (s, C=O), 1538 (m), 1488 (s), 1436 (m), 1362 (m), 1199 (m), 1166 (s), 1069 (m), 1028 
(w), 1009 (s), 913 (w), 876 (m), 830 (m). 
HRMS (ESI): calculated for C15H16NO3BrNa [M+Na]
+
 360.0206, found 360.0195.  
Rf = 0.15 (5% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟖.𝟎 = -157.9 (CHCl3, c = 1.0, 91% ee). 
HPLC: ChiralART SA, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 23.1 (minor), 26.3 (major). 
 
 
Methyl 4-((4-(4-bromophenyl)but-2-yn-1-yl)amino)-4-oxobutanoate: Isolated as the 
alkyne cross-product from asymmetric allenylation of methyl 4-oxo-4-(prop-2-yn-1-
ylamino)butanoate and (4-bromobenzylidene)hydrazine, which provided the title compound 
as an off-white amorphous solid (25.2 mg, 0.075 mmol, 37%), m.p. 75-76 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
5.87 (br s, 1 H, NH), 4.08 (dt, J = 4.9, 2.2 Hz, 2 H, H8), 3.68 (s, 3 H, H13), 3.53 (t, J = 
2.2 Hz, 2 H, H5), 2.68 (t, J = 6.8 Hz, 2 H, H11), 2.49 (t, J = 6.8 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 173.5 (C12), 171.1 (C9), 135.6 (C4), 131.7 (C2), 129.8 (C3), 
120.7 (C1), 80.9 (C6), 78.2 (C7), 52.0 (C13), 30.9 (C10), 29.9 (C8), 29.3 (C11), 24.7 (C5). 
FTIR (νmax, cm
-1
): 3292 (w, NH), 3061 (w), 2950 (w), 2925 (w), 1735 (s, C=O), 1649 (s, 
C=O), 1535 (m), 1487 (s), 1437 (m), 1420 (m), 1363 (m), 1200 (m), 1168 (s), 1071 (m), 1012 
(s), 915 (w), 845 (m), 802 (m). 
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HRMS (ESI): calculated for C15H16NO3BrNa [M+Na]
+
 360.0206, found 360.0200.  
Rf = 0.20 (5% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)acetamide (227): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 2% Et2O/CH2Cl2) provided the title compound as an off-white 
amorphous solid (27.4 mg, 0.103 mmol, 51%, 96% ee), m.p. 92-94 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.14 (d, J = 8.4 Hz, 2 H, H3), 
6.24 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.70 (br s, 1 H, NH), 5.66 (q, J = 6.4 Hz, 1 H, H7), 4.03 – 
3.89 (m, 2 H, H8), 1.95 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.7 – 204.6 (br, C6), 170.1 (C9), 132.9 (C4), 131.9 (C2), 
128.5 (C3), 121.1 (C1), 96.9 (C5), 93.6 (C7), 37.9 (C8), 23.3 (10). 
FTIR (νmax, cm
-1
): 3275 (m, NH), 3079 (w), 2930 (w), 1954 (w, C=C=C), 1651 (s, C=O), 
1548 (s), 1488 (s), 1429 (m), 1372 (m), 1343 (w), 1291 (m), 1099 (w), 1070 (m), 1010 (m), 
877 (w), 830 (m). 
HRMS (ESI): calculated for C12H12NOBrNa [M+Na]
+
 287.9994, found 287.9986. 
Rf = 0.33 (50% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -233.0 (CHCl3, c = 1.0, 96% ee). 
HPLC: ChiralART SA, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 24.2 (minor), 25.5 (major). 
 
 
N-(4-(4-Bromophenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product from 
asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and (4-bromobenzylidene)hydrazine, 
which provided the title compound as an off-white amorphous solid (20.0 mg, 0.075 mmol, 
38%), m.p. 82-84 °C. 
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1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
5.67 (br s, 1 H, NH), 4.07 (dt, J = 4.9, 2.2 Hz, 2 H, H8), 3.53 (t, J = 2.2 Hz, 2 H, H5), 1.99 (s, 
3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C9), 135.6 (C4), 131.7 (C2), 129.8 (C3), 120.7 (C1), 
80.9 (C6), 78.3 (C7), 29.9 (C8), 24.7 (C5), 23.2 (C10). 
FTIR (νmax, cm
-1
): 3273 (m, NH), 3079 (w), 1652 (s, C=O), 1548 (m), 1487 (s), 1421 (m), 
1373 (m), 1350 (m), 1288 (m), 1184 (w), 1141 (w), 1070 (m), 1027 (w), 1012 (m), 914 (w), 
801 (w). 
HRMS (ESI): calculated for C12H12NOBrNa [M+Na]
+
 287.9994, found 287.9985. 
Rf = 0.39 (50% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Fluorophenyl)buta-2,3-dien-1-yl)acetamide (228): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and (4-fluorobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 50% Et2O/CH2Cl2) provided the title compound as an off-white 
amorphous solid (18.3 mg, 0.089 mmol, 45%, 91% ee), m.p. 75-78 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.24 (dd, J = 8.7, 5.4 Hz, 2 H, H3), 7.00 (t, J = 8.7 Hz, 2 H, 
H2), 6.27 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.66 (q, J = 6.4 Hz, 1 H, H7), 4.05 – 3.87 (m, 2 H, 
H8), 1.96 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.3 (C6), 170.1 (C9), 162.2 (d, J = 246.7 Hz, C1), 129.8 
(d, J = 3.3 Hz, C4), 128.4 (d, J = 8.0 Hz, C3), 115.8 (d, J = 21.8 Hz, C2), 96.8 (C5), 93.3 
(C7), 38.0 (C8), 23.4 (C10).  
19
F NMR (376 MHz, CDCl3): δ -114.7 (s, 1 F, F1). 
FTIR (νmax, cm
-1
): 3277 (w, NH), 3074 (w), 2925 (w), 1953 (w, C=C=C), 1651 (m, C=O), 
1603 (w), 1548 (m), 1507 (s), 1432 (w), 1394 (w), 1373 (m), 1345 (w), 1285 (m), 1223 (s), 
1156 (m), 1096 (w), 1041 (w), 1014 (w), 877 (w), 837 (m), 765 (w). 
HRMS (ESI): calculated for C12H12FNONa [M+Na]
+
 228.0795, found 228.0802.  
Rf = 0.35 (50% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -201.5 (CHCl3, c = 1.0, 91% ee). 
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HPLC: ChiralART SA, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 22.0 (minor), 22.9 (major). 
 
 
N-(4-(4-Fluorophenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product from 
asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and (4-fluorobenzylidene)hydrazine, 
which provided the title compound as a white amorphous solid (14.2 mg, 0.069 mmol, 35%), 
m.p. 56-57 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (dd, J = 8.7, 5.4 Hz, 2 H, H3), 7.00 (t, J = 8.7 Hz, 2 H, 
H2), 5.67 (br s, 1 H, NH), 4.08 (dt, J = 4.8, 2.2 Hz, 2 H, H8), 3.55 (t, J = 2.2 Hz, 2 H, H5), 
1.99 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C9), 161.9 (d, J = 244.7 Hz, C1), 132.2 (d, J = 
3.2 Hz, C4), 129.5 (d, J = 8.0 Hz, C3), 115.5 (d, J = 21.5 Hz, C2), 81.4 (C6), 78.0 (C7), 29.9 
(C8), 24.4 (C5), 23.2 (C10). 
19
F NMR (376 MHz, CDCl3): δ -116.4 (s, 1 F, F1). 
FTIR (νmax, cm
-1
): 3278 (w, NH), 3073 (w), 2925 (w), 1651 (m, C=O), 1604 (w), 1548 (m), 
1508 (s), 1424 (w), 1374 (w), 1350 (w), 1287 (w), 1221 (m), 1158 (w), 1094 (w), 1017 (w), 
912 (w), 820 (w), 758 (w). 
HRMS (ESI): calculated for C12H13FNO [M+H]
+
 206.0976, found 206.0976. 
Rf = 0.42 (50% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(3-Methoxyphenyl)buta-2,3-dien-1-yl)acetamide (229): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and (3-methoxybenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 40% Et2O/CH2Cl2) provided the title compound as a colourless gum 
(19.4 mg, 0.089 mmol, 45%, 95% ee). 
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1
H NMR (600 MHz, CDCl3): δ 7.22 (t, J = 7.9 Hz, 1 H, H4), 6.87 (d, J = 7.9 Hz, 1 H, H5), 
6.84 – 6.82 (m, 1 H, H7), 6.77 (dd, J = 7.9, 2.5 Hz, 1 H, H3), 6.27 (dt, J = 6.5, 3.3 Hz, 1 H, 
H8), 5.70 (br s, 1 H, NH), 5.67 (q, J = 6.5 Hz, 1 H, H10), 4.02 – 3.91 (m, 2 H, H11), 3.81 (s, 
3 H, H1), 1.96 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 204.6 (C9), 170.1 (C12), 160.1 (C2), 135.3 (C6), 129.8 (C4), 
119.6 (C5), 113.2 (C3), 112.2 (C7), 97.7 (C8), 93.1 (C10), 55.4 (C1), 38.0 (C11), 23.4 (C13). 
FTIR (νmax, cm
-1
): 3289 (m, NH), 3068 (w), 2938 (w), 2835 (w), 1951 (w, C=C=C), 1652 (s, 
C=O), 1598 (m), 1582 (m), 1549 (m), 1490 (m), 1467 (m), 1439 (m), 1408 (w), 1372 (w), 
1344 (w), 1264 (m), 1155 (m), 1092 (w), 1043 (m), 995 (w), 883 (w), 787 (m). 
HRMS (ESI): calculated for C13H15NO2Na [M+Na]
+
 240.0995, found 240.1000.  
Rf = 0.31 (40% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -218.1 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 85:15 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 16.3 (minor), 21.1 (major). 
 
 
N-(4-(3-Methoxyphenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product 
from asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and (3-
methoxybenzylidene)hydrazine, which provided the title compound as a colourless gum 
(15.9 mg, 0.073 mmol, 37%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.23 (t, J = 8.0 Hz, 1 H, H4), 6.91 – 6.86 (m, 2 H, H5 and 
H7), 6.78 (dd, J = 8.0, 2.3 Hz, 1 H, H3), 5.69 (br s, 1 H, NH), 4.07 (dt, J = 4.8, 2.2 Hz, 2 H, 
H11), 3.81 (s, 3 H, H1), 3.56 (t, J = 2.2 Hz, 2 H, H8), 1.99 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C12), 159.9 (C2), 138.1 (C6), 129.7 (C4), 120.4 (C5), 
113.9 (C3), 112.1 (C7), 81.5 (C9), 77.8 (C10), 55.4 (C1), 30.0 (C11), 25.2 (C8), 23.2 (C13). 
FTIR (νmax, cm
-1
): 3283 (m, NH), 3070 (w), 2837 (w), 1651 (s, C=O), 1601 (m), 1586 (m), 
1546 (m), 1489 (m), 1455 (m), 1436 (m), 1373 (w), 1351 (w), 1317 (w), 1283 (m), 1260 (s), 
1155 (m), 1136 (w), 1090 (w), 1047 (m), 852 (w), 775 (m). 
HRMS (ESI): calculated for C13H15NO2Na [M+Na]
+
 240.0995, found 240.1000. 
Rf = 0.38 (40% Et2O/CH2Cl2). 
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(R)-N-(4-(3-Cyanophenyl)buta-2,3-dien-1-yl)acetamide (230): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and 3-(hydrazonomethyl)benzonitrile, purified by silica gel column 
chromatography (eluent: 50% Et2O/CH2Cl2) provided the title compound as a colourless gum 
(17.0 mg, 0.080 mmol, 40%, 89% ee). 
 
1
H NMR (600 MHz, CDCl3): δ 7.55 (s, 1 H, H7), 7.52 – 7.47 (m, 2 H, H3 and H5), 7.41 (t, 
J = 7.8 Hz, 1 H, H4), 6.27 (dt, J = 6.3, 3.1 Hz, 1 H, H8), 5.74 (q superimposed on br s, J = 
6.3 Hz, 2 H, H10 and NH), 4.07 – 3.92 (m, 2 H, H11), 1.98 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 205.3 (C9), 170.2 (C12), 135.6 (C6), 131.1 (C5), 130.7 (C3), 
130.3 (C7), 129.6 (C4), 118.8 (C1), 113.0 (C2), 96.1 (C8), 94.2 (C10), 38.0 (C11), 23.3 
(C13). 
FTIR (νmax, cm
-1
): 3281 (m, NH), 3072 (w), 2929 (w), 2231 (m, C≡N), 1954 (w, C=C=C), 
1651 (s, C=O), 1599 (w), 1543 (s), 1483 (m), 1432 (m), 1372 (m), 1344 (w), 1283 (m), 1228 
(w), 1096 (w), 1043 (w), 999 (w), 898 (w), 801 (m). 
HRMS (ESI): calculated for C13H13N2O [M+H]
+
 213.1022, found 213.1017.  
Rf = 0.25 (50% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -194.4 (CHCl3, c = 1.0, 89% ee). 
HPLC: ChiralART SA, 93:7 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 30.5 (minor), 32.8 (major). 
 
 
N-(4-(3-Cyanophenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product from 
asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and 3-(hydrazonomethyl)-
benzonitrile, which provided the title compound as a yellow amorphous solid (23.4 mg, 
0.110 mmol, 55%), m.p. 87-90 °C. 
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1
H NMR (600 MHz, CDCl3): δ 7.62 (s, 1 H, H7), 7.56 – 7.51 (m, 2 H, H3 and H5), 7.41 (t, 
J = 7.8 Hz, 1 H, H4), 5.88 (br s, 1 H, NH), 4.08 (dt, J = 5.3, 2.2 Hz, 2 H, H11), 3.62 (t, J = 
2.2 Hz, 2 H, H8), 2.00 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 169.9 (C12), 138.1 (C6), 132.6 (C5), 131.5 (C7), 130.6 (C3), 
129.4 (C4), 118.8 (C1), 112.7 (C2), 79.6 (C9), 79.2 (C10), 29.7 (C11), 24.8 (C8), 23.2 (C13). 
FTIR (νmax, cm
-1
): 3290 (m, NH), 3065 (w), 2923 (w), 2231 (m, C≡N), 1652 (s, C=O), 1543 
(s), 1483 (m), 1432 (m), 1374 (m), 1351 (w), 1285 (m), 1093 (w), 1027 (w), 788 (m). 
HRMS (ESI): calculated for C13H13N2O [M+H]
+
 213.1022, found 213.1028. 
Rf = 0.32 (50% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(4-Iodophenyl)buta-2,3-dien-1-yl)acetamide (231): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)acetamide (19.4 mg, 
0.2 mmol) and (4-iodobenzylidene)hydrazine, purified by silica gel column chromatography 
(eluent: 50% Et2O/CH2Cl2) provided the title compound as an off-white amorphous solid 
(27.6 mg, 0.088 mmol, 44%, 95% ee), m.p. 118-119 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.62 (d, J = 8.3 Hz, 2 H, H2), 7.01 (d, J = 8.3 Hz, 2 H, H3), 
6.22 (dt, J = 6.3, 3.2 Hz, 1 H, H5), 5.70 (br s, 1 H, NH), 5.66 (q, J = 6.3 Hz, 1 H, H7), 4.03 – 
3.87 (m, 2 H, H8), 1.95 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.7 – 204.6 (br, C6), 170.1 (C9), 137.9 (C2), 133.5 (C4), 
128.7 (C3), 97.0 (C5), 93.6 (C7), 92.5 (C1), 37.9 (C8), 23.3 (C10). 
FTIR (νmax, cm
-1
): 3280 (m, NH), 3068 (w), 2925 (w), 1951 (w, C=C=C), 1651 (s, C=O), 
1551 (s), 1484 (s), 1429 (w), 1372 (m), 1343 (w), 1291 (m), 1108 (w), 1058 (w), 1006 (m), 
876 (w), 826 (m). 
HRMS (ESI): calculated for C12H12NOINa [M+Na]
+
 335.9856, found 335.9862.  
Rf = 0.38 (50% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -198.4 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SA, 97:3 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 58.0 (minor), 62.4 (major). 
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N-(4-(4-Iodophenyl)but-2-yn-1-yl)acetamide: Isolated as the alkyne cross-product from 
asymmetric allenylation of N-(prop-2-yn-1-yl)acetamide and (4-iodobenzylidene)hydrazine, 
which provided the title compound as a yellow amorphous solid (22.4 mg, 0.072 mmol, 36%), 
m.p. 103-104 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.63 (d, J = 8.3 Hz, 2 H, H2), 7.06 (d, J = 8.3 Hz, 2 H, H3), 
5.72 (br s, 1 H, NH), 4.07 (dt, J = 5.2, 2.1 Hz, 2 H, H8), 3.52 (t, J = 2.1 Hz, 2 H, H5), 1.99 (s, 
3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 169.7 (C9), 137.7 (C2), 136.3 (C4), 130.1 (C3), 92.0 (C1), 
80.8 (C6), 78.3 (C7), 29.9 (C8), 24.8 (C5), 23.2 (C10). 
FTIR (νmax, cm
-1
): 3283 (m, NH), 3069 (w), 2919 (w), 1648 (s, C=O), 1544 (s), 1483 (s), 
1420 (m), 1400 (m), 1373 (m), 1350 (m), 1287 (m), 1187 (w), 1140 (w), 1110 (w), 1087 (w), 
1060 (w), 1027 (w), 1008 (s), 918 (w), 778 (m). 
HRMS (ESI): calculated for C12H13NOI [M+H]
+
 314.0036, found 314.0049.  
Rf = 0.45 (50% Et2O/CH2Cl2). 
 
 
(R)-N-(4-(3-Cyanophenyl)buta-2,3-dien-1-yl)cyclopent-3-ene-1-carboxamide (232): 
Following the general procedure for asymmetric allenylation using N-(prop-2-yn-1-
yl)cyclopent-3-ene-1-carboxamide (29.8 mg, 0.2 mmol) and 3-
(hydrazonomethyl)benzonitrile, purified by silica gel column chromatography (eluent: 80% 
Et2O/hexane) provided the title compound as a yellow amorphous solid (21.2 mg, 
0.080 mmol, 40%, 92% ee), m.p. 95-96 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.53 (s, 1 H, H7), 7.51 – 7.46 (m, 2 H, H3 and H5), 7.40 (t, 
J = 7.7 Hz, 1 H, H4), 6.26 (dt, J = 6.4, 3.2 Hz, 1 H, H8), 5.79 (br s, 1 H, NH), 5.74 (q, J = 
6.4 Hz, 1 H, H10), 5.64 – 5.58 (m, 2 H, H15 and H16), 4.07 – 4.00 (m, 1 H, H11a), 3.99 – 
3.92 (m, 1 H, H11b), 2.92 (qn, J = 7.9 Hz, 1 H, H13), 2.59 – 2.52 (m, 4 H, H14 and H17). 
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13
C NMR (150 MHz, CDCl3): δ 205.2 (C9), 176.1 (C12), 135.6 (C6), 131.1 (C5), 130.7 (C3), 
130.2 (C7), 129.6 (C4), 129.35 (C15/C16), 129.33 (C15/C16), 118.8 (C1), 112.9 (C2), 96.2 
(C8), 94.6 (C10), 43.6 (C13), 37.6 (C11), 37.11 (C14/C17), 37.05 (C14/C17). 
FTIR (νmax, cm
-1
): 3286 (m, NH), 3058 (w), 2926 (m), 2852 (w), 2231 (m, C≡N), 1956 (w, 
C=C=C), 1649 (s, C=O), 1536 (s), 1483 (m), 1438 (m), 1340 (w), 1296 (w), 1228 (m), 1181 
(w), 899 (w), 871 (w), 842 (w), 801 (m). 
HRMS (ESI): calculated for C17H17N2O [M+H]
+
 265.1335, found 265.1340.  
Rf = 0.29 (80% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -213.1 (CHCl3, c = 1.0, 92% ee). 
HPLC: ChiralART SC, 80:20 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 20.4 (minor), 22.4 (major). 
 
 
N-(4-(3-Cyanophenyl)but-2-yn-1-yl)cyclopent-3-ene-1-carboxamide: Isolated as the 
alkyne cross-product from asymmetric allenylation of N-(prop-2-yn-1-yl)cyclopent-3-ene-1-
carboxamide and 3-(hydrazonomethyl)benzonitrile, which provided the title compound as an 
off-white amorphous solid (31.7 mg, 0.120 mmol, 60%), m.p. 91-93 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.62 (s, 1 H, H7), 7.56 – 7.51 (m, 2 H, H3 and H5), 7.42 (t, 
J = 7.8 Hz, 1 H, H4), 5.82 (br s, 1 H, NH), 5.67 (s, 2 H, H15), 4.10 (dt, J = 5.3, 2.1 Hz, 2 H, 
H11), 3.62 (t, J = 2.1 Hz, 2 H, H8), 2.97 (qn, J = 8.1 Hz, 1 H, H13), 2.63 (d, J = 8.1 Hz, 4 H, 
H14). 
13
C NMR (150 MHz, CDCl3): δ 175.7 (C12), 138.1 (C6), 132.6 (C5), 131.5 (C7), 130.6 (C3), 
129.4 (C4), 129.3 (C15), 118.8 (C1), 112.7 (C2), 79.6 (C9), 79.4 (C10), 43.4 (C13), 37.0 
(C14), 29.7 (C11), 24.9 (C8). 
FTIR (νmax, cm
-1
): 3287 (m, NH), 3058 (w), 2922 (w), 2851 (w), 2231 (m, C≡N), 1648 (s, 
C=O), 1584 (w), 1532 (s), 1483 (m), 1435 (m), 1342 (w), 1297 (w), 1228 (m), 1180 (w), 
1094 (w), 1038 (w), 946 (w), 900 (w), 844 (m), 788 (m). 
HRMS (ESI): calculated for C17H17N2O [M+H]
+
 265.1335, found 265.1344. 
Rf = 0.36 (80% Et2O/hexane). 
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(R)-N-(4-(4-Bromophenyl)buta-2,3-dien-1-yl)pent-4-enamide (233): Following the 
general procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)pent-4-enamide (27.4 
mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 40% EtOAc/hexane) provided the title compound as an off-white 
crystalline solid (25.1 mg, 0.082 mmol, 41%, 92% ee), m.p. 97-99 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.14 (d, J = 8.4 Hz, 2 H, H3), 
6.23 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.81 – 5.69 (m, 2 H, H12 and NH), 5.65 (q, J = 6.4 Hz, 
1 H, H7), 5.01 (dq, J = 17.2, 1.2 Hz, 1 H, H13trans), 4.94 (dq, J = 10.2, 1.2 Hz, 1 H, H13cis), 
4.04 – 3.89 (m, 2 H, H8), 2.36 – 2.30 (m, 2 H, H11), 2.27 – 2.22 (m, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.6 – 204.5 (br, C6), 172.3 (C9), 137.1 (C12), 132.9 (C4), 
131.9 (C2), 128.5 (C3), 121.1 (C1), 115.7 (C13), 96.9 (C5), 93.7 (C7), 37.7 (C8), 35.9 (C10), 
29.6 (C11). 
FTIR (νmax, cm
-1
): 3294 (m, NH), 3079 (w), 2920 (w), 2851 (w), 1952 (w, C=C=C), 1638 (s, 
C=O), 1538 (s), 1488 (s), 1431 (m), 1381 (w), 1339 (w), 1264 (m), 1230 (m), 1196 (w), 1111 
(w), 1070 (m), 1010 (s), 912 (m), 877 (m), 832 (s), 811 (m), 750 (w). 
HRMS (ESI): calculated for C15H16NOBrNa [M+Na]
+
 328.0307, found 328.0309.  
Rf = 0.28 (40% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟒.𝟖 = -172.5 (CHCl3, c = 1.0, 92% ee). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 32.1 (minor), 33.1 (major). 
 
 
N-(4-(4-Bromophenyl)but-2-yn-1-yl)pent-4-enamide: Isolated as the alkyne cross-product 
from asymmetric allenylation of N-(prop-2-yn-1-yl)pent-4-enamide and (4-
bromobenzylidene)hydrazine, which provided the title compound as an orange amorphous 
solid (19.1 mg, 0.062 mmol, 31%), m.p. 68-70 °C. 
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1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.19 (d, J = 8.4 Hz, 2 H, H3), 
5.82 (ddt, J = 17.0, 10.2, 6.5 Hz, 1 H, H12), 5.65 (br s, 1 H, NH), 5.07 (dq, J = 17.0, 1.4 Hz, 
1 H, H13trans), 5.01 (dq, J = 10.2, 1.4 Hz, 1 H, H13cis), 4.08 (dt, J = 4.8, 2.2 Hz, 2 H, H8), 
3.53 (t, J = 2.2 Hz, 2 H, H5), 2.43 – 2.36 (m, 2 H, H11), 2.28 (t, J = 7.5 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 171.9 (C9), 137.0 (C12), 135.6 (C4), 131.7 (C2), 129.8 (C3), 
120.7 (C1), 115.9 (C13), 80.9 (C6), 78.3 (C7), 35.7 (C10), 29.8 (C8), 29.6 (C11), 24.7 (C5). 
FTIR (νmax, cm
-1
): 3290 (w, NH), 3078 (w), 2920 (m), 2851 (w), 1641 (s, C=O), 1539 (s), 
1487 (s), 1419 (m), 1345 (w), 1266 (m), 1184 (w), 1139 (w), 1110 (w), 1071 (m), 1030 (w), 
1012 (s), 914 (m), 840 (m), 801 (m). 
HRMS (ESI): calculated for C15H17NOBr [M+H]
+
 306.0488, found 306.0485. 
Rf = 0.36 (40% EtOAc/hexane). 
 
 
(R)-N-(4-(4-Fluorophenyl)buta-2,3-dien-1-yl)pent-4-enamide (234): Following the general 
procedure for asymmetric allenylation using N-(prop-2-yn-1-yl)pent-4-enamide (27.4 mg, 
0.2 mmol) and (4-fluorobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 60% Et2O/hexane) provided the title compound as a yellow 
amorphous solid (21.8 mg, 0.089 mmol, 44%, 95% ee), m.p. 66-68 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.24 (dd, J = 8.7, 5.4 Hz, 2 H, H3), 7.00 (t, J = 8.7 Hz, 2 H, 
H2), 6.27 (dt, J = 6.5, 3.3 Hz, 1 H, H5), 5.77 (ddt, J = 17.1, 10.2, 6.5 Hz, 1 H, H12), 5.69 (br 
s, 1 H, NH), 5.66 (q, J = 6.5 Hz, 1 H, H7), 5.01 (dd, J = 17.1, 1.4 Hz, 1 H, H13trans), 4.94 (dd, 
J = 10.2, 1.4 Hz, 1 H, H13cis), 4.05 – 3.89 (m, 2 H, H8), 2.36 – 2.30 (m, 2 H, H11), 2.29 – 
2.18 (m, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.3 – 204.2 (br, C6), 172.3 (C9), 162.3 (d, J = 246.7 Hz, 
C1), 137.1 (C12), 129.8 (d, J = 3.3 Hz, C4), 128.5 (d, J = 8.1 Hz, C3), 115.8 (d, J = 22.0 Hz, 
C2), 115.7 (C13), 96.8 (C5), 93.4 (C7), 37.8 (C8), 35.9 (C10), 29.6 (C11). 
19
F NMR (376 MHz, CDCl3): δ -114.7 (s, 1 F, F1). 
FTIR (νmax, cm
-1
): 3284 (w, NH), 3072 (w), 2921 (w), 1951 (w, C=C=C), 1643 (m, C=O), 
1604 (w), 1543 (m), 1508 (s), 1436 (w), 1394 (w), 1341 (w), 1263 (w), 1225 (m), 1156 (w), 
1094 (w), 1014 (w), 996 (w), 916 (w), 876 (w), 838 (m), 765 (w). 
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HRMS (ESI): calculated for C15H16FNONa [M+Na]
+
 268.1108, found 268.1115.  
Rf = 0.21 (60% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -212.4 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SA, 97:3 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 35.4 (major), 38.0 (minor). 
 
 
N-(4-(4-Fluorophenyl)but-2-yn-1-yl)pent-4-enamide: Isolated as the alkyne cross-product 
from asymmetric allenylation of N-(prop-2-yn-1-yl)pent-4-enamide and (4-
fluorobenzylidene)hydrazine, which provided the title compound as a yellow amorphous 
solid (21.3 mg, 0.087 mmol, 43%), m.p. 49-50 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (dd, J = 8.7, 5.4 Hz, 2 H, H3), 7.00 (t, J = 8.7 Hz, 2 H, 
H2), 5.82 (ddt, J = 17.0, 10.2, 6.5 Hz, 1 H, H12), 5.67 (br s, 1 H, NH), 5.07 (dd, J = 17.0, 
1.4 Hz, 1 H, H13trans), 5.00 (dd, J = 10.2, 1.4 Hz, 1 H, H13cis), 4.08 (dt, J = 4.8, 2.2 Hz, 2 H, 
H8), 3.55 (t, J = 2.2 Hz, 2 H, H5), 2.43 – 2.36 (m, 2 H, H11), 2.28 (t, J = 7.5 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 171.9 (C9), 161.9 (d, J = 244.8 Hz, C1), 137.0 (C12), 132.2 
(d, J = 3.2 Hz, C4), 129.5 (d, J = 8.0 Hz, C3), 115.8 (C13), 115.5 (d, J = 21.5 Hz, C2), 81.4 
(C6), 78.1 (C7), 35.7 (C10), 29.8 (C8), 29.6 (C11), 24.5 (C5). 
19
F NMR (376 MHz, CDCl3): δ -116.4 (s, 1 F, F1). 
FTIR (νmax, cm
-1
): 3281 (w, NH), 3069 (w), 2918 (w), 1642 (m, C=O), 1604 (w), 1539 (m), 
1508 (s), 1423 (w), 1345 (w), 1268 (w), 1222 (m), 1158 (w), 1094 (w), 1016 (w), 996 (w), 
914 (w), 838 (w), 756 (w). 
HRMS (ESI): calculated for C15H16FNONa [M+Na]
+
 268.1108, found 268.1114. 
Rf = 0.29 (60% Et2O/hexane). 
 
 
Methyl (R)-4-((4-(3-methoxyphenyl)buta-2,3-dien-1-yl)amino)-4-oxobutanoate (235): 
Following the general procedure for asymmetric allenylation using methyl 4-oxo-4-(prop-2-
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yn-1-ylamino)butanoate (33.8 mg, 0.2 mmol) and (3-methoxybenzylidene)hydrazine, purified 
by silica gel column chromatography (eluent: 15% Et2O/CH2Cl2) provided the title 
compound as a colourless gum (26.2 mg, 0.091 mmol, 45%, 95% ee). 
 
1
H NMR (600 MHz, CDCl3): δ 7.22 (t, J = 7.9 Hz, 1 H, H4), 6.87 (d, J = 7.9 Hz, 1 H, H5), 
6.84 – 6.82 (m, 1 H, H7), 6.77 (dd, J = 7.9, 2.4 Hz, 1 H, H3), 6.26 (dt, J = 6.5, 3.3 Hz, 1 H, 
H8), 5.89 (br s, 1 H, NH), 5.65 (q, J = 6.5 Hz, 1 H, H10), 4.03 – 3.90 (m, 2 H, H11), 3.81 (s, 
3 H, H1), 3.64 (s, 3 H, H16), 2.66 – 2.58 (m, 2 H, H14), 2.48 – 2.41 (m, 2 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 204.6 (C9), 173.6 (C15), 171.4 (C12), 160.0 (C2), 135.3 
(C6), 129.8 (C4), 119.6 (C5), 113.2 (C3), 112.2 (C7), 97.8 (C8), 93.1 (C10), 55.4 (C1), 51.9 
(C16), 38.0 (C11), 31.1 (C13), 29.4 (C14). 
FTIR (νmax, cm
-1
): 3313 (w, NH), 2953 (w), 2838 (w), 1954 (w, C=C=C), 1735 (m, C=O), 
1649 (m, C=O), 1597 (m), 1581 (m), 1536 (m), 1490 (m), 1454 (m), 1437 (m), 1408 (w), 
1363 (w), 1319 (w), 1260 (s), 1154 (s), 1083 (w), 1039 (m), 994 (w), 946 (w), 875 (m), 846 
(m), 785 (m), 754 (m). 
HRMS (ESI): calculated for C16H19NO4Na [M+Na]
+
 312.1206, found 312.1213.  
Rf = 0.30 (15% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -190.1 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 80:20 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 36.1 (minor), 40.2 (major). 
 
 
Methyl 4-((4-(3-methoxyphenyl)but-2-yn-1-yl)amino)-4-oxobutanoate: Isolated as the 
alkyne cross-product from asymmetric allenylation of methyl 4-oxo-4-(prop-2-yn-1-
ylamino)butanoate and (3-methoxybenzylidene)hydrazine, which provided the title 
compound as a colourless gum (22.4 mg, 0.077 mmol, 39%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.23 (t, J = 8.0 Hz, 1 H, H4), 6.91 – 6.85 (m, 2 H, H5 and 
H7), 6.78 (dd, J = 8.0, 2.4 Hz, 1 H, H3), 5.88 (br s, 1 H, NH), 4.08 (dt, J = 4.8, 2.3 Hz, 2 H, 
H11), 3.81 (s, 3 H, H1), 3.68 (s, 3 H, H16), 3.56 (t, J = 2.3 Hz, 2 H, H8), 2.67 (t, J = 6.8 Hz, 
2 H, H14), 2.48 (t, J = 6.8 Hz, 2 H, H13). 
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13
C NMR (150 MHz, CDCl3): δ 173.5 (C15), 171.0 (C12), 159.9 (C2), 138.1 (C6), 129.7 
(C4), 120.4 (C5), 113.9 (C3), 112.1 (C7), 81.5 (C9), 77.8 (C10), 55.4 (C1), 52.0 (C16), 30.9 
(C13), 30.0 (C11), 29.3 (C14), 25.2 (C8). 
FTIR (νmax, cm
-1
): 3304 (w, NH), 2951 (w), 2837 (w), 1735 (s, C=O), 1649 (s, C=O), 1601 
(m), 1586 (m), 1533 (m), 1489 (s), 1453 (m), 1436 (s), 1317 (m), 1257 (s), 1201 (m), 1161 
(s), 1080 (w), 1040 (s), 995 (w), 933 (w), 879 (w), 846 (m), 775 (m). 
HRMS (ESI): calculated for C16H19NO4Na [M+Na]
+
 312.1206, found 312.1216. 
Rf = 0.38 (15% Et2O/CH2Cl2). 
 
 
(R)-3,3,3-Trifluoro-N-(4-(4-iodophenyl)buta-2,3-dien-1-yl)propanamide (236): Following 
the general procedure for asymmetric allenylation using 3,3,3-trifluoro-N-(prop-2-yn-1-
yl)propanamide (37.1 mg, 0.2 mmol) and (4-iodobenzylidene)hydrazine, purified by silica gel 
column chromatography (eluent: 70% Et2O/hexane) provided the title compound as an off-
white amorphous solid (37.1 mg, 0.097 mmol, 49%, 95% ee), m.p. 131-132 °C.  
 
Scale up to 5 mmol was possible using a slightly modified procedure as follows: To a stirred 
188-CuI solution in a 250 mL round-bottomed flask (prepared on the same scale as stated for 
the stock solution – 51.4 mL, containing 0.15 equiv. ligand, 0.1 equiv. CuI and 2 equiv. Et3N) 
was added was added 3,3,3-trifluoro-N-(prop-2-yn-1-yl)propanamide (0.825 g, 5.0 mmol, 
1.0 equiv.). The mixture was pre-mixed at r.t. for 10 min, forming a clear red-orange 
homogeneous solution of the copper acetylide-ligand complex. Solutions of hydrazone (0.1 M) 
and DIPEA (0.2 M) in CH2Cl2 were passed through eight pre-conditioned column reactors 
concurrently (Omnifit
®
 column, 6.6 mm i.d. × 50 mm length), packed with activated MnO2 
(0.86 g), at a flow rate of 0.5 mL min
-1
 each. When the FlowIR
®
 showed that the intensity of 
the diazo peak was stable, 12.5 mL of each output stream from the eight columns (2.0 equiv. 
total with respect to the hydrazone) was directly added into the reaction vial (over 25 min) 
containing the copper acetylide-ligand complex and the reaction mixture further stirred at r.t. 
for 10 min. The solution was evaporated under reduced pressure and the residue taken up in 
CH2Cl2 (50 mL). The mixture was washed with concentrated ammonium hydroxide/saturated 
aqueous NH4Cl solution (1:9, 50 mL), then the organic layer dried (MgSO4) and evaporated 
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under reduced pressure. The residue was immediately purified by silica gel column 
chromatography (eluent: 70% Et2O/hexane) to provide the title compound as an off-white 
amorphous solid (0.889 g, 2.33 mmol, 47%, 95% ee). 
 
1
H NMR (600 MHz, CDCl3): δ 7.62 (d, J = 8.3 Hz, 2 H, H2), 7.00 (d, J = 8.3 Hz, 2 H, H3), 
6.25 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 6.04 (br s, 1 H, NH), 5.66 (q, J = 6.4 Hz, 1 H, H7), 4.07 – 
3.92 (m, 2 H, H8), 3.04 (q, J = 10.6 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 162.6 (q, J = 3.4 Hz, C9), 137.9 (C2), 133.2 
(C4), 128.8 (C3), 124.0 (d, J = 276.8 Hz, C11), 97.5 (C5), 92.9 (C7), 92.7 (C1), 41.7 (q, J = 
29.6 Hz, C10), 38.1 (C8). 
19
F NMR (376 MHz, CDCl3): δ -63.0 (s, 3 F, F11). 
FTIR (νmax, cm
-1
): 3308 (m, NH), 1958 (m, C=C=C), 1652 (s, C=O), 1556 (m), 1486 (w), 
1385 (w), 1337 (w), 1268 (w), 1238 (m), 1140 (m), 1107 (m), 1061 (w), 1006 (w), 923 (w), 
879 (w), 851 (w), 833 (w). 
HRMS (ESI): calculated for C13H12F3NOI [M+H]
+
 381.9910, found 381.9927.  
Rf = 0.30 (70% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -176.5 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 16.9 (minor), 18.3 (major). 
 
 
Slow diffusion of hexane into a saturated solution of 236 in CH2Cl2 provided white needle-
like crystals suitable for X-ray diffraction analysis. The absolute stereochemistry of the 
structure was unambiguously confirmed by X-ray crystallography and deposited at the 
Cambridge Crystallographic Data Centre, deposition number CCDC 1514945; space group: 
P21; unit cell data: a = 4.8751(2) Å, b = 8.3827(4) Å, c = 34.4135(12) Å, α = 90°, β = 
90.295(2)°, γ = 90°; Flack parameter = 0.047(9). 
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3,3,3-Trifluoro-N-(4-(4-iodophenyl)but-2-yn-1-yl)propanamide: Isolated as the alkyne 
cross-product from asymmetric allenylation of 3,3,3-trifluoro-N-(prop-2-yn-1-
yl)propanamide and (4-iodobenzylidene)hydrazine, which provided the title compound as an 
orange amorphous solid (34.4 mg, 0.090 mmol, 45%), m.p. 136-137 °C. During the scale up 
of 236, the title compound was also isolated as an off-white amorphous solid (0.821 g, 
2.15 mmol, 43%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.63 (d, J = 8.3 Hz, 2 H, H2), 7.05 (d, J = 8.3 Hz, 2 H, H3), 
6.02 (br s, 1 H, NH), 4.12 (dt, J = 4.8, 2.2 Hz, 2 H, H8), 3.53 (t, J = 2.2 Hz, 2 H, H5), 3.08 (q, 
J = 10.5 Hz, 2 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 162.3 (q, J = 3.4 Hz, C9), 137.8 (C2), 136.1 (C4), 130.0 
(C3), 124.0 (q, J = 276.8 Hz, C11), 92.1 (C1), 81.6 (C6), 77.3 (C7), 41.6 (q, J = 29.7 Hz, 
C10), 30.3 (C8), 24.8 (C5). 
19
F NMR (376 MHz, CDCl3): δ -62.9 (s, 3 F, F11). 
FTIR (νmax, cm
-1
): 3305 (m, NH), 1654 (s, C=O), 1555 (m), 1483 (w), 1451 (w), 1399 (w), 
1352 (w), 1278 (w), 1234 (m), 1128 (m), 1111 (m), 1060 (w), 1007 (w), 920 (w), 851 (w), 
785 (w). 
HRMS (ESI): calculated for C13H12F3NOI [M+H]
+
 381.9910, found 381.9904.  
Rf = 0.38 (70% Et2O/hexane). 
 
 
(S)-N-((R)-4-(4-Bromophenyl)buta-2,3-dien-1-yl)-2-(4-isobutylphenyl)propanamide 
(240): Following the general procedure for asymmetric allenylation using (S)-2-(4-
isobutylphenyl)-N-(prop-2-yn-1-yl)propanamide (48.7 mg, 0.2 mmol) and (4-
bromobenzylidene)hydrazine, purified by silica gel column chromatography (eluent: 50% 
Et2O/hexane) provided the title compound as a pale yellow gum (42.2 mg, 0.102 mmol, 51%, 
96% de). 
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1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.09 – 7.05 (m, 4 H, H3 and 
H13), 6.96 (d, J = 8.0 Hz, 2 H, H14), 6.11 (dt, J = 6.5, 3.7 Hz, 1 H, H5), 5.59 (dt, J = 6.5, 
5.2 Hz, 1 H, H7), 5.50 (br s, 1 H, NH), 3.90 (td, J = 5.2, 3.7 Hz, 2 H, H8), 3.48 (q, J = 7.3 Hz, 
1 H, H10), 2.39 (d, J = 7.2 Hz, 2 H, H16), 1.85 – 1.76 (m, 1 H, H17), 1.48 (d, J = 7.3 Hz, 3 H, 
H11), 0.89 (d, J = 6.6 Hz, 6 H, H18). 
13
C NMR (150 MHz, CDCl3): δ 204.2 (C6), 174.5 (C9), 140.9 (C15), 138.1 (C12), 133.0 
(C4), 131.9 (C2), 129.7 (C14), 128.4 (C3), 127.6 (C13), 121.1 (C1), 97.3 (C5), 93.9 (C7), 
46.9 (C10), 45.1 (C16), 37.4 (C8), 30.3 (C17), 22.5 (C18), 18.5 (C11). 
FTIR (νmax, cm
-1
): 3290 (w, NH), 2954 (m), 2926 (w), 2868 (w), 1953 (w, C=C=C), 1647 (s, 
C=O), 1541 (m), 1512 (m), 1488 (m), 1464 (w), 1422 (w), 1384 (w), 1366 (w), 1339 (w), 
1231 (w), 1192 (w), 1070 (m), 1010 (m), 876 (w), 830 (m). 
HRMS (ESI): calculated for C23H26NOBrNa [M+Na]
+
 434.1090, found 434.1099.  
Rf = 0.23 (50% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -229.6 (CHCl3, c = 0.5, 96% de). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 26.8 (minor), 28.6 (major). 
 
 
(S)-N-(4-(4-Bromophenyl)but-2-yn-1-yl)-2-(4-isobutylphenyl)propanamide: Isolated as 
the alkyne cross-product from asymmetric allenylation of (S)-2-(4-isobutylphenyl)-N-(prop-
2-yn-1-yl) and (4-bromobenzylidene)hydrazine, after repurification by silica gel column 
chromatography (eluent: 10% Et2O/CH2Cl2) of the alkyne-containing fractions, which 
provided the title compound as a pale yellow gum (23.7 mg, 0.057 mmol, 29%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.41 (d, J = 8.4 Hz, 2 H, H2), 7.18 (d, J = 8.0 Hz, 2 H, H13), 
7.14 (d, J = 8.4 Hz, 2 H, H3), 7.11 (d, J = 8.0 Hz, 2 H, H14), 5.51 (br s, 1 H, NH), 4.09 – 
4.02 (m, 1 H, H8a), 4.01 – 3.94 (m, 1 H, H8b), 3.54 (q, J = 7.2 Hz, 1 H, H10), 3.48 (t, J = 
2.2 Hz, 2 H, H5), 2.46 (d, J = 7.2 Hz, 2 H, H16), 1.90 – 1.80 (m, 1 H, H17), 1.51 (d, J = 7.2 
Hz, 3 H, H11), 0.90 (d, J = 6.6 Hz, 6 H, H18). 
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13
C NMR (150 MHz, CDCl3): δ 174.2 (C9), 141.0 (C15), 138.3 (C12), 135.6 (C4), 131.7 
(C2), 129.8 (C3/C14), 129.7 (C3/C14), 127.5 (C13), 120.6 (C1), 80.7 (C6), 78.4 (C7), 46.7 
(C10), 45.1 (C16), 30.3 (C17), 29.9 (C8), 24.7 (C5), 22.5 (C18), 18.6 (C11). 
FTIR (νmax, cm
-1
): 3279 (w, NH), 2955 (m), 2926 (w), 2868 (w), 1647 (s, C=O), 1534 (m), 
1511 (m), 1487 (s), 1465 (m), 1420 (m), 1383 (w), 1366 (m), 1263 (w), 1230 (m), 1189 (w), 
1071 (m), 1012 (s), 911 (w), 848 (w), 800 (m). 
HRMS (ESI): calculated for C23H26NOBrNa [M+Na]
+
 434.1090, found 434.1096.  
Rf = 0.34 (50% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -5.5 (CHCl3, c = 1.0). 
 
 
(R)-2-((4-(4-Bromophenyl)buta-2,3-dien-1-yl)carbamoyl)phenyl acetate (241): Following 
the general procedure for asymmetric allenylation using 2-(prop-2-yn-1-ylcarbamoyl)phenyl 
acetate (43.4 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel 
column chromatography (eluent: 65% Et2O/hexane) provided the title compound as an off-
white amorphous solid (39.6 mg, 0.103 mmol, 51%, 96% ee), m.p. 111-113 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.65 (dd, J = 7.7, 1.6 Hz, 1 H, H11), 7.47 – 7.43 (m, 1 H, 
H13), 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.27 – 7.23 (m, 1 H, H12), 7.16 (d, J = 8.4 Hz, 2 H, H3), 
7.08 (dd, J = 8.2, 0.8 Hz, 1 H, H14), 6.44 (br s, 1 H, NH), 6.26 (dt, J = 6.2, 3.1 Hz, 1 H, H5), 
5.73 (q, J = 6.2 Hz, 1 H, H7), 4.18 – 4.07 (m, 2 H, H8), 2.26 (s, 3 H, H17). 
13
C NMR (150 MHz, CDCl3): δ 205.0 – 204.9 (br, C6), 169.3 (C16), 165.8 (C9), 148.1 
(C15), 132.8 (C4), 132.0 (C13), 131.9 (C2), 129.7 (C11), 128.6 (C3), 128.3 (C10), 126.4 
(C12), 123.3 (C14), 121.2 (C1), 96.9 (C5), 93.2 (C7), 38.3 (C8), 21.2 (C17). 
FTIR (νmax, cm
-1
): 3309 (w, NH), 3073 (w), 2929 (w), 1953 (w, C=C=C), 1767 (m, C=O), 
1649 (m, C=O), 1608 (m), 1522 (m), 1487 (m), 1448 (w), 1430 (w), 1368 (m), 1295 (m), 
1194 (s), 1099 (w), 1070 (w), 1010 (m), 951 (w), 913 (w), 875 (w), 833 (m), 787 (w), 752 
(w). 
HRMS (ESI): calculated for C19H16NO3BrNa [M+Na]
+
 408.0206, found 408.0213.  
Rf = 0.22 (65% Et2O/hexane). 
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[𝛂]𝑫
𝟐𝟓.𝟎 = -194.2 (CHCl3, c = 0.5, 96% ee). 
HPLC: ChiralART SA, 93:7 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 26.2 (minor), 28.6 (major). 
 
 
2-((4-(4-Bromophenyl)but-2-yn-1-yl)carbamoyl)phenyl acetate: Isolated as the alkyne 
cross-product from asymmetric allenylation of 2-(prop-2-yn-1-ylcarbamoyl)phenyl acetate 
and (4-bromobenzylidene)hydrazine, which provided the title compound as an orange 
amorphous solid (29.4 mg, 0.076 mmol, 38%), m.p. 105-107 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.80 (dd, J = 7.9, 1.6 Hz, 1 H, H11), 7.48 (td, J = 7.9, 1.6 Hz, 
1 H, H13), 7.44 (d, J = 8.4 Hz, 2 H, H2), 7.31 (td, J = 7.9, 1.0 Hz, 1 H, H12), 7.20 (d, J = 
8.4 Hz, 2 H, H3), 7.11 (dd, J = 7.9, 1.0 Hz, 1 H, H14), 6.49 (br s, 1 H, NH), 4.25 (dt, J = 4.8, 
2.3 Hz, 2 H, H8), 3.56 (t, J = 2.3 Hz, 2 H, H5), 2.25 (s, 3 H, H17). 
13
C NMR (150 MHz, CDCl3): δ 169.1 (C16), 165.1 (C9), 148.1 (C15), 135.5 (C4), 132.2 
(C13), 131.8 (C2), 130.2 (C11), 129.8 (C3), 127.7 (C10), 126.5 (C12), 123.4 (C14), 120.7 
(C1), 81.3 (C6), 78.1 (C7), 30.3 (C8), 24.7 (C5), 21.0 (C17). 
FTIR (νmax, cm
-1
): 3303 (w, NH), 3064 (w), 2929 (w), 1768 (m, C=O), 1650 (m, C=O), 1608 
(m), 1520 (m), 1486 (m), 1448 (w), 1421 (w), 1368 (m), 1292 (m), 1194 (s), 1099 (m), 1071 
(w), 1045 (w), 1012 (m), 978 (w), 954 (w), 913 (w), 836 (m), 799 (m), 751 (m). 
HRMS (ESI): calculated for C19H16NO3BrNa [M+Na]
+
 408.0206, found 408.0210. 
Rf = 0.27 (65% Et2O/hexane). 
 
 
(2S,5R,6R)-N-((R)-4-(4-Bromophenyl)buta-2,3-dien-1-yl)-3,3-dimethyl-7-oxo-6-(2-
phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamide (242): Following the 
general procedure for asymmetric allenylation using (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-
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phenylacetamido)-N-(prop-2-yn-1-yl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamide 
(74.3 mg, 0.2 mmol) and (4-bromobenzylidene)hydrazine, stirred for 20 min after addition of 
diazo compound, purified by silica gel column chromatography (eluent: 90% Et2O/hexane) 
provided the title compound as an off-white foam (32.0 mg, 0.059 mmol, 30%, 98% de).  
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.36 (t, J = 7.3 Hz, 2 H, H21), 
7.31 (t, J = 7.3 Hz, 1 H, H22), 7.23 (d, J = 7.3 Hz, 2 H, H20), 7.13 (d, J = 8.4 Hz, 2 H, H3), 
6.59 (br t, J = 5.7 Hz, 1 H, C8-NH), 6.23 (dt, J = 6.3, 3.2 Hz, 1 H, H5), 6.03 (br d, J = 9.2 Hz, 
1 H, C15-NH), 5.66 – 5.59 (m, 2 H, H7 and H15), 5.19 (d, J = 4.5 Hz, 1 H, H14), 4.02 (s, 1 H, 
H10), 4.02 – 3.97 (m, 1 H, H8a), 3.94 – 3.87 (m, 1 H, H8b), 3.63 – 3.56 (m, 2 H, H18), 1.66 
(s, 3 H, H12/H13), 1.46 (s, 3 H, H12/H13). 
13
C NMR (150 MHz, CDCl3): δ 204.9 (C6), 176.4 (C16), 170.5 (C17), 167.2 (C9), 133.7 
(C19), 132.6 (C4), 132.0 (C2), 129.5 (C20), 129.3 (C21), 128.5 (C3), 127.9 (C22), 121.4 
(C1), 97.3 (C5), 93.1 (C7), 72.8 (C10), 66.2 (C14), 64.7 (C11), 57.2 (C15), 43.4 (C18), 37.6 
(C8), 28.4 (C12/C13), 26.7 (C12/C13). 
FTIR (νmax, cm
-1
): 3294 (w, NH), 3031 (w), 2964 (w), 1956 (w, C=C=C), 1782 (m, C=O), 
1655 (s, C=O), 1598 (w), 1508 (m), 1489 (m), 1455 (w), 1431 (w), 1390 (w), 1368 (w), 1288 
(m), 1234 (w), 1159 (w), 1129 (w), 1102 (w), 1070 (m), 1031 (w), 1010 (m), 909 (m), 833 (s). 
HRMS (ESI): calculated for C26H26N3O3SBrNa [M+Na]
+
 562.0770, found 562.0782.  
Rf = 0.24 (90% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = +2.2 (CHCl3, c = 0.2, 98% de). 
HPLC: ChiralART SC, 85:15 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 30.3 (major), 33.3 (minor). 
 
 
(2S,5R,6R)-N-(4-(4-Bromophenyl)but-2-yn-1-yl)-3,3-dimethyl-7-oxo-6-(2-
phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamide: Isolated as the 
alkyne cross-product from asymmetric allenylation of (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-
phenylacetamido)-N-(prop-2-yn-1-yl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxamide and 
5. Experimental (Appendix) 
255 
 
(4-bromobenzylidene)hydrazine, which provided the title compound as an orange foam 
(30.3 mg, 0.056 mmol, 28%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.38 (t, J = 7.4 Hz, 2 H, H21), 
7.32 (t, J = 7.4 Hz, 1 H, H22), 7.25 (d, J = 7.4 Hz, 2 H, H20), 7.18 (d, J = 8.4 Hz, 2 H, H3), 
6.59 (br t, J = 5.2 Hz, 1 H, C8-NH), 6.11 (br d, J = 9.3 Hz, 1 H, C15-NH), 5.77 (dd, J = 9.3, 
4.5 Hz, 1 H, H15), 5.35 (d, J = 4.5 Hz, 1 H, H14), 4.14 – 4.08 (m, 2 H, H8a and H10), 4.00 
(ddt, J = 17.5, 4.8, 2.2 Hz, 1 H, H8b), 3.66 – 3.58 (m, 2 H, H18), 3.53 (t, J = 2.2 Hz, 2 H, H5), 
1.69 (s, 3 H, H12/H13), 1.47 (s, 3 H, H12/H13). 
13
C NMR (150 MHz, CDCl3): δ 176.6 (C16), 170.6 (C17), 167.1 (C9), 135.4 (C4), 133.7 
(C19), 131.8 (C2), 129.7 (C3), 129.5 (C20), 129.3 (C21), 127.9 (C22), 120.7 (C1), 81.3 (C6), 
77.6 (C7), 72.6 (C10), 66.3 (C14), 64.9 (C11), 57.3 (C15), 43.4 (C18), 29.6 (C8), 28.3 
(C12/C13), 26.6 (C12/C13), 24.7 (C5). 
FTIR (νmax, cm
-1
): 3295 (w, NH), 3061 (w), 2967 (w), 1785 (m, C=O), 1657 (s, C=O), 1520 
(m), 1488 (m), 1455 (w), 1420 (w), 1293 (w), 1238 (w), 1129 (w), 1071 (w), 1030 (w), 1012 
(w), 910 (w), 841 (w). 
HRMS (ESI): calculated for C26H26N3O3SBrNa [M+Na]
+
 562.0770, found 562.0774. 
Rf = 0.30 (90% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = +145.0 (CHCl3, c = 0.2). 
 
 
((3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-3a-yl)methyl ((R)-4-(4-chlorophenyl)buta-2,3-dien-1-yl)sulfamate (243): 
Following the general procedure for asymmetric allenylation using ((3aS,5aR,8aR,8bS)-
2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl prop-2-
yn-1-ylsulfamate (75.5 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine (62), purified by 
silica gel column chromatography (eluent: 60% Et2O/hexane) provided a nearly inseparable 
mixture of the title compound and the alkyne cross-product as a colourless gum (96.5 mg 
containing 56.8 mg of the allene, 0.113 mmol, 57%, 96% de). An analytical sample of the 
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allene could be obtained by repeated purification by silica gel column chromatography 
(eluent: 50% Et2O/hexane). 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.21 (d, J = 8.5 Hz, 2 H, H3), 
6.31 (dt, J = 6.1, 3.0 Hz, 1 H, H5), 5.74 (q, J = 6.1 Hz, 1 H, H7), 4.70 (br t, J = 5.9 Hz, 1 H, 
NH), 4.61 (dd, J = 7.9, 2.6 Hz, 1 H, H15), 4.32 (d, J = 2.6 Hz, 1 H, H14), 4.25 – 4.23 (m, 1 H, 
H19), 4.22 (d, J = 10.5 Hz, 1 H, H9a), 4.15 (d, J = 10.5 Hz, 1 H, H9b), 3.91 – 3.86 (m, 3 H, 
H8 and H20a), 3.76 (d, J = 13.0 Hz, 1 H, H20b), 1.53 (s, 3 H, H12/H13), 1.47 (s, 3 H, 
H17/H18), 1.41 (s, 3 H, H12/H13), 1.34 (s, 3 H, H17/H18). 
13
C NMR (150 MHz, CDCl3): δ 205.1 (C6), 133.4 (C1), 131.8 (C4), 129.1 (C2), 128.3 (C3), 
109.40 (C11), 109.36 (C16), 101.0 (C10), 97.3 (C5), 92.3 (C7), 70.7 (C14), 70.6 (C9), 70.5 
(C19), 70.0 (C15), 61.5 (C20), 42.3 (C8), 26.6 (C12/C13), 26.0 (C17/C18), 25.3 (C12/C13), 
24.1 (C17/C18). 
FTIR (νmax, cm
-1
): 3286 (br w, NH), 2991 (w), 2937 (w), 1954 (w, C=C=C), 1492 (w), 1455 
(w), 1371 (m), 1319 (w), 1252 (m), 1205 (m), 1172 (s), 1070 (s), 1012 (s), 980 (m), 912 (m), 
885 (s), 865 (s), 833 (s), 803 (s), 755 (s). 
HRMS (ESI): calculated for C22H28NO8SClNa [M+Na]
+
 524.1116, found 524.1123. 
Rf = 0.38 (60% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -124.6 (CHCl3, c = 1.0, 96% de). 
HPLC: ChiralART SC, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 32.5 (minor), 34.4 (major). 
 
 
((3aS,5aR,8aR,8bS)-2,2,7,7-Tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran-3a-yl)methyl (4-(4-chlorophenyl)but-2-yn-1-yl)sulfamate: Isolated as the alkyne 
cross-product from asymmetric allenylation of ((3aS,5aR,8aR,8bS)-2,2,7,7-
tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl prop-2-yn-1-
ylsulfamate and (4-chlorobenzylidene)hydrazine (62) as part of the colourless gum (96.5 mg 
containing 39.7 mg of the alkyne, 0.079 mmol, 40%). An analytical sample of the alkyne 
could be obtained by purification by AgNO3-impregnated silica gel (10% w/w AgNO3/SiO2, 
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eluent: 50% Et2O/hexane). (N.B. The allene decomposes during purification with AgNO3-
impregnated silica gel). 
 
1
H NMR (600 MHz, CDCl3): δ 7.29 (d, J = 8.4 Hz, 2 H, H2), 7.24 (d, J = 8.4 Hz, 2 H, H3), 
4.72 (br t, J = 5.7 Hz, 1 H, NH), 4.59 (dd, J = 7.9, 2.6 Hz, 1 H, H15), 4.32 (d, J = 2.6 Hz, 1 H, 
H14), 4.25 (d, J = 10.5 Hz, 1 H, H9a), 4.24 – 4.22 (m, 1 H, H19), 4.17 (d, J = 10.5 Hz, 1 H, 
H9b), 4.01 – 3.98 (m, 2 H, H8), 3.89 (dd, J = 13.0, 1.8 Hz, 1 H, H20a), 3.76 (d, J = 13.0 Hz, 
1 H, H20b), 3.58 (t, J = 2.0 Hz, 2 H, H5), 1.53 (s, 3 H, H12/H13), 1.47 (s, 3 H, H17/H18), 
1.41 (s, 3 H, H12/H13), 1.34 (s, 3 H, H17/H18). 
13
C NMR (150 MHz, CDCl3): δ 134.6 (C4), 132.8 (C1), 129.4 (C3), 128.9 (C2), 109.40 
(C11), 109.36 (C16), 101.0 (C10), 83.1 (C6), 76.7 (C7), 70.8 (C9), 70.7 (C19), 70.5 (C14), 
70.0 (C15), 61.5 (C20), 34.2 (C8), 26.6 (C12/C13), 26.0 (C17/C18), 25.3 (C12/C13), 24.6 
(C5), 24.2 (C17/C18). 
FTIR (νmax, cm
-1
): 3288 (w, NH), 2989 (w), 2937 (w), 1492 (w), 1456 (w), 1372 (m), 1319 
(w), 1252 (m), 1206 (m), 1176 (s), 1101 (m), 1070 (s), 1014 (s), 948 (w), 913 (m), 885 (m), 
865 (m), 831 (m), 804 (m), 754 (s). 
HRMS (ESI): calculated for C22H28NO8SClNa [M+Na]
+
 524.1116, found 524.1122.  
Rf = 0.39 (60% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟗.𝟓 = -34.8 (CHCl3, c = 1.0). 
 
(Procedure for generation of AgNO3-impregnated silica gel: To a solution of AgNO3 
(2.0 g) in 75% aqueous EtOH (80 mL) in an amber glass 100 mL round-bottomed flask was 
added silica gel (20 g, 230-400 mesh, pore size 60 Å). The mixture was sonicated for 10 min 
with manual stirring. The solvent was then removed under reduced pressure on a rotary 
evaporator (60 °C water bath temperature, 40 mmHg), then dried at 140 °C for 2 h.) 
 
 
tert-Butyl ((S)-2-(2-(((R)-4-(4-chlorophenyl)buta-2,3-dien-1-yl)amino)-2-oxoethyl)-4-
methylpentyl)carbamate (244): Following the general procedure for asymmetric 
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allenylation using tert-butyl (S)-(4-methyl-2-(2-oxo-2-(prop-2-yn-1-
ylamino)ethyl)pentyl)carbamate (59.3 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine 
(62), purified by silica gel column chromatography (eluent: 10% Et2O/CH2Cl2) provided the 
title compound as a colourless gum (38.7 mg, 0.092 mmol, 46%, 96% de). 
 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.6 Hz, 2 H, H2), 7.20 (d, J = 8.6 Hz, 2 H, H3), 
6.87 (br s, 1 H, C8-NH), 6.23 (dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.68 (q, J = 6.4 Hz, 1 H, H7), 
4.79 (br s, 1 H, C12-NH), 4.07 – 4.00 (m, 1 H, H8a), 3.97 – 3.89 (m, 1 H, H8b), 3.19 (ddd, 
J = 14.2, 6.6, 3.9 Hz, 1 H, H12a), 2.96 (dt, J = 14.2, 6.6 Hz, 1 H, H12b), 2.12 – 2.03 (m, 2 H, 
H10), 2.01 – 1.93 (m, 1 H, H11), 1.62 – 1.55 (m, 1 H, H17), 1.42 (s, 9 H, H15), 1.10 – 1.05 
(m, 2 H, H16), 0.87 – 0.81 (m, 6 H, H18 and H19). 
13
C NMR (150 MHz, CDCl3): δ 204.9 (C6), 172.4 (C9), 157.1 (C13), 132.9 (C1), 132.7 (C4), 
128.9 (C2), 128.2 (C3), 96.6 (C5), 93.7 (C7), 79.6 (C14), 43.5 (C12), 41.7 (C16), 39.4 (C10), 
37.9 (C8), 34.6 (C11), 28.5 (C15), 25.3 (C17), 22.8 (C18/C19), 22.7 (C18/C19). 
FTIR (νmax, cm
-1
): 3300 (m, NH), 2957 (m), 2930 (m), 2871 (m), 1953 (w, C=C=C), 1691 (s, 
C=O), 1648 (s, C=O), 1535 (s), 1492 (s), 1453 (m), 1391 (m), 1366 (m), 1251 (m), 1169 (s), 
1091 (m), 1014 (w), 874 (w), 834 (m). 
HRMS (ESI): calculated for C23H34N2O3Cl [M+H]
+
 421.2252, found 421.2255. 
Rf = 0.30 (10% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -175.2 (CHCl3, c = 1.0, 96% de). 
HPLC: ChiralART SA, 95:5 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 15.9 (minor), 16.8 (major). 
 
 
tert-Butyl (S)-(2-(2-((4-(4-chlorophenyl)but-2-yn-1-yl)amino)-2-oxoethyl)-4-methyl-
pentyl)carbamate: Isolated as the alkyne cross-product from asymmetric allenylation of tert-
butyl (S)-(4-methyl-2-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)pentyl)carbamate and (4-
chlorobenzylidene)hydrazine (62), which provided the title compound as a colourless gum 
(34.6 mg, 0.082 mmol, 41%). 
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1
H NMR (600 MHz, CDCl3): δ 7.28 – 7.24 (m, 4 H, H2 and H3), 6.90 (br s, 1 H, C8-NH), 
4.84 (br s, 1 H, C12-NH), 4.13 – 4.03 (m, 2 H, H8), 3.55 (t, J = 2.0 Hz, 2 H, H5), 3.23 (ddd, 
J = 14.2, 6.5, 3.9 Hz, 1 H, H12a), 3.00 (dt, J = 14.2, 6.5 Hz, 1 H, H12b), 2.17 – 2.09 (m, 2 H, 
H10), 2.07 – 1.99 (m, 1 H, H11), 1.68 – 1.60 (m, 1 H, H17), 1.43 (s, 9 H, H15), 1.13 (t, J = 
7.1 Hz, 2 H, H16), 0.90 – 0.87 (m, 6 H, H18 and H19). 
13
C NMR (150 MHz, CDCl3): δ 172.3 (C9), 157.1 (C13), 135.2 (C4), 132.5 (C1), 129.4 (C3), 
128.7 (C2), 80.5 (C6), 79.7 (C14), 78.6 (C7), 43.5 (C12), 41.7 (C16), 39.2 (C10), 34.6 (C11), 
29.7 (C8), 28.5 (C15), 25.3 (C17), 24.6 (C5), 22.9 (C18/C19), 22.8 (C18/C19). 
FTIR (νmax, cm
-1
): 3323 (m, NH), 2958 (m), 2930 (m), 1691 (s, C=O), 1649 (s, C=O), 1531 
(s), 1492 (s), 1453 (m), 1391 (m), 1366 (m), 1251 (m), 1169 (s), 1091 (m), 1016 (m), 806 (w). 
HRMS (ESI): calculated for C23H33N2O3ClNa [M+Na]
+
 443.2072, found 443.2069.  
Rf = 0.39 (10% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -12.2 (CHCl3, c = 1.0). 
 
 
(R)-2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(4-(4-chlorophenyl)-
buta-2,3-dien-1-yl)acetamide (245): Following the general procedure for asymmetric 
allenylation using 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(prop-2-yn-
1-yl)acetamide (79.0 mg, 0.2 mmol) and (4-chlorobenzylidene)hydrazine, purified by silica 
gel column chromatography (eluent: 5% Et2O/CH2Cl2) provided the title compound as a 
yellow foam (41.8 mg, 0.080 mmol, 40%, 95% ee). (N.B. The starting material is sparingly 
soluble in reaction mixture at the start and thus the reaction mixture appears as a yellow-
orange suspension, but solubilises over time as the diazo compound is added). 
 
1
H NMR (600 MHz, CDCl3): δ 7.57 (d, J = 8.5 Hz, 2 H, H23), 7.46 (d, J = 8.5 Hz, 2 H, 
H24), 7.16 (d, J = 8.4 Hz, 2 H, H2), 6.99 (d, J = 8.4 Hz, 2 H, H3), 6.82 (d, J = 2.4 Hz, 1 H, 
H13), 6.73 (d, J = 9.0 Hz, 1 H, H17), 6.65 (dd, J = 9.0, 2.4 Hz, 1 H, H16), 6.02 (dt, J = 6.3, 
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3.6 Hz, 1 H, H5), 5.80 (br t, J = 5.1 Hz, 1 H, NH), 5.61 (q, J = 6.3 Hz, 1 H, H7), 3.98 – 3.85 
(m, 2 H, H8), 3.78 (s, 3 H, H14), 3.60 (AB q, J = 17.4 Hz, 2 H, H10), 2.25 (s, 3 H, H20). 
13
C NMR (150 MHz, CDCl3): δ 203.8 (C6), 169.8 (C21), 168.2 (C9), 156.3 (C15), 139.7 
(C25), 136.5 (C19), 133.5 (C22), 133.0 (C1), 132.0 (C4), 131.3 (C23), 130.9 (C18), 130.3 
(C12), 129.3 (C24), 128.9 (C2), 128.0 (C3), 115.2 (C17), 112.6 (C11), 112.2 (C16), 100.9 
(C13), 97.4 (C5), 93.4 (C7), 55.9 (C14), 37.5 (C8), 32.2 (C10), 13.2 (C20). 
FTIR (νmax, cm
-1
): 3304 (w, NH), 3062 (w), 2930 (w), 2834 (w), 1953 (w, C=C=C), 1674 (s, 
C=O), 1651 (s, C=O), 1591 (m), 1521 (m), 1490 (m), 1477 (s), 1456 (m), 1436 (m), 1401 (w), 
1357 (s), 1317 (s), 1289 (m), 1260 (m), 1223 (s), 1179 (m), 1149 (m), 1089 (s), 1070 (m), 
1037 (m), 1014 (m), 993 (w), 925 (m), 909 (m), 877 (w), 832 (s), 754 (m). 
HRMS (ESI): calculated for C29H24N2O3Cl2Na [M+Na]
+
 541.1056, found 541.1065. 
Rf = 0.27 (5% Et2O/CH2Cl2). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -171.8 (CHCl3, c = 1.0, 95% ee). 
HPLC: ChiralART SA, 85:15 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 21.2 (major), 30.1 (minor). 
 
 
2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(4-(4-chlorophenyl)but-2-
yn-1-yl)acetamide: Isolated as the alkyne cross-product from asymmetric allenylation of 2-
(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(prop-2-yn-1-yl)acetamide and 
(4-chlorobenzylidene)hydrazine, which provided the title compound as a pale yellow 
amorphous solid (39.6 mg, 0.076 mmol, 38%), m.p. 195-197 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.66 (d, J = 8.6 Hz, 2 H, H23), 7.48 (d, J = 8.6 Hz, 2 H, 
H24), 7.24 (d, J = 8.5 Hz, 2 H, H2), 7.16 (d, J = 8.5 Hz, 2 H, H3), 6.88 (d, J = 2.5 Hz, 1 H, 
H13), 6.86 (d, J = 9.1 Hz, 1 H, H17), 6.71 (dd, J = 9.1, 2.5 Hz, 1 H, H16), 5.74 (br t, J = 5.3 
Hz, 1 H, NH), 4.05 (dt, J = 5.3, 2.2 Hz, 2 H, H8), 3.79 (s, 3 H, H14), 3.66 (s, 2 H, H10), 3.49 
(t, J = 2.2 Hz, 2 H, H5), 2.38 (s, 3 H, H20). 
5. Experimental (Appendix) 
261 
 
13
C NMR (150 MHz, CDCl3): δ 169.6 (C21), 168.5 (C9), 156.4 (C15), 139.8 (C25), 136.6 
(C19), 134.9 (C4), 133.6 (C22), 132.6 (C1), 131.3 (C23), 131.0 (C18), 130.3 (C12), 129.4 
(C24), 129.3 (C3), 128.8 (C2), 115.2 (C17), 112.54 (C11), 112.46 (C16), 101.0 (C13), 80.9 
(C6), 78.1 (C7), 55.9 (C14), 32.2 (C10), 29.8 (C8), 24.6 (C5), 13.4 (C20). 
FTIR (νmax, cm
-1
): 3296 (m, NH), 2930 (w), 1670 (m), 1628 (s, C=O), 1538 (m), 1490 (m), 
1477 (m), 1438 (m), 1400 (m), 1361 (s), 1326 (s), 1288 (m), 1259 (m), 1221 (s), 1177 (w), 
1151 (m), 1089 (s), 1073 (m), 1035 (m), 1013 (m), 992 (w), 914 (w), 833 (m), 792 (m), 754 
(m). 
HRMS (ESI): calculated for C29H24N2O3Cl2Na [M+Na]
+
 541.1056, found 541.1067.  
Rf = 0.41 (5% Et2O/CH2Cl2). 
 
 
1-(2-((4R,6R)-6-(2-(((R)-4-(4-Bromophenyl)buta-2,3-dien-1-yl)amino)-2-oxoethyl)-2,2-
dimethyl-1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-
pyrrole-3-carboxamide (246): Following the general procedure for asymmetric allenylation 
using 1-(2-((4R,6R)-2,2-dimethyl-6-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-1,3-dioxan-4-
yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide (127.2 mg, 
0.2 mmol) and (4-bromobenzylidene)hydrazine, purified by silica gel column 
chromatography (eluent: 85% Et2O/hexane) provided the title compound as an off-white 
foam (64.8 mg, 0.081 mmol, 40%, 94% de). 
 
1
H NMR (600 MHz, CDCl3): δ 7.41 (d, J = 8.4 Hz, 2 H, H2), 7.22 – 7.14 (m, 9 H, H27, H31, 
H32, H33 and H36), 7.13 (d, J = 8.4 Hz, 2 H, H3), 7.07 (d, J = 7.9 Hz, 2 H, H26), 7.01 – 6.96 
(m, 3 H, H28 and H37), 6.87 (br s, 1 H, C24-NH), 6.29 (br t, J = 5.7 Hz, 1 H, C8-NH), 6.21 
(dt, J = 6.4, 3.2 Hz, 1 H, H5), 5.65 (q, J = 6.4 Hz, 1 H, H7), 4.09 – 3.99 (m, 3 H, H8a, H11 
and H18a), 3.92 – 3.86 (m, 1 H, H8b), 3.84 – 3.77 (m, 1 H, H18b), 3.65 – 3.59 (m, 1 H, H16), 
3.59 – 3.53 (m, 1 H, H20), 2.32 (dd, J = 15.1, 7.6 Hz, 1 H, H10a), 2.23 (dd, J = 15.1, 4.1 Hz, 
1 H, H10b), 1.69 – 1.59 (m, 2 H, H17), 1.52 (superimposed d, J = 7.1 Hz, 6 H, H21 and H22), 
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1.30 – 1.27 (s superimposed on m, 4 H, H13/H14 and H15a), 1.26 (s, 3 H, H13/H14), 1.04 (dt, 
J = 12.8, 11.7 Hz, 1 H, H15b). 
13
C NMR (150 MHz, CDCl3): δ 204.7 (C6), 170.4 (C9), 164.9 (C24), 162.4 (d, J = 247.9 Hz, 
C38), 141.6 (C19), 138.5 (C25), 134.7 (C30), 133.3 (d, J = 8.1 Hz, C36), 132.9 (C4), 131.9 
(C2), 130.6 (C31), 128.9 (C34), 128.8 (C32), 128.49 (C3/C27), 128.48 (C3/C27), 128.4 (d, 
J = 3.2 Hz, C35), 126.7 (C33), 123.6 (C28), 121.9 (C29), 121.1 (C1), 119.7 (C26), 115.50 (d, 
J = 21.4 Hz, C37), 115.49 (C23), 99.0 (C12), 96.8 (C5), 93.6 (C7), 66.4 (C16), 66.2 (C11), 
43.3 (C10), 40.9 (C18), 38.1 (C17), 37.7 (C8), 36.0 (C15), 30.0 (C13/C14), 26.2 (C20), 21.9 
(C21/C22), 21.7 (C21/C22), 19.8 (C13/C14). 
19
F NMR (376 MHz, CDCl3): δ -113.6 (s, 1 F, F38). 
FTIR (νmax, cm
-1
): 3301 (w, NH), 2961 (w), 1957 (w, C=C=C), 1652 (s, C=O), 1595 (m), 
1526 (s), 1509 (s), 1488 (s), 1436 (s), 1381 (m), 1313 (s), 1224 (m), 1201 (m), 1170 (m), 
1157 (s), 1115 (w), 1070 (w), 1032 (w), 1010 (w), 942 (w), 909 (m), 838 (m), 753 (m). 
HRMS (ESI): calculated for C46H48FN3O4Br [M+H]
+
 804.2807, found 804.2822. 
Rf = 0.31 (85% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -78.7 (CHCl3, c = 1.0, 94% de). 
HPLC: ChiralART SC, 85:15 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
254 nm; tR (min) = 32.8 (minor), 38.0 (major). 
 
 
1-(2-((4R,6R)-6-(2-((4-(4-Bromophenyl)but-2-yn-1-yl)amino)-2-oxoethyl)-2,2-dimethyl-
1,3-dioxan-4-yl)ethyl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-
carboxamide: Isolated as the alkyne cross-product from asymmetric allenylation of 1-(2-
((4R,6R)-2,2-dimethyl-6-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-1,3-dioxan-4-yl)ethyl)-5-(4-
fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide and (4-bromobenzyl-
idene)hydrazine, which provided the title compound as an orange foam (65.1 mg, 
0.081 mmol, 40%). 
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1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.4 Hz, 2 H, H2), 7.21 – 7.13 (m, 11 H, H3, H27, 
H31, H32, H33 and H36), 7.07 (d, J = 7.8 Hz, 2 H, H26), 7.01 – 6.96 (m, 3 H, H28 and H37), 
6.87 (br s, 1 H, C24-NH), 6.37 (br t, J = 5.0 Hz, 1 H, C8-NH), 4.16 – 4.10 (m, 1 H, H11), 
4.10 – 4.00 (m, 3 H, H8 and H18a), 3.86 – 3.78 (m, 1 H, H18b), 3.70 – 3.64 (m, 1 H, H16), 
3.60 – 3.54 (m, 1 H, H20), 3.52 (t, J = 2.1 Hz, 2 H, H5), 2.33 (dd, J = 15.1, 7.6 Hz, 1 H, 
H10a), 2.26 (dd, J = 15.1, 4.0 Hz, 1 H, H10b), 1.70 – 1.60 (m, 2 H, H17), 1.53 (superimposed 
d, J = 7.1 Hz, 6 H, H21 and H22), 1.33 (s, 3 H, H13/H14), 1.32 – 1.27 (s superimposed on m, 
4 H, H13/H14 and H15a), 1.07 (dt, J = 12.8, 11.7 Hz, 1 H, H15b). 
13
C NMR (150 MHz, CDCl3): δ 170.0 (C9), 164.9 (C24), 162.4 (d, J = 247.9 Hz, C38), 
141.6 (C19), 138.5 (C25), 135.6 (C4), 134.7 (C30), 133.3 (d, J = 8.1 Hz, C36), 131.7 (C2), 
130.6 (C31), 129.7 (C3), 128.9 (C34), 128.8 (C32), 128.5 (C27), 128.4 (d, J = 3.3 Hz, C35), 
126.7 (C33), 123.6 (C28), 121.9 (C29), 120.6 (C1), 119.7 (C26), 115.49 (d, J = 21.4 Hz, 
C37), 115.48 (C23), 99.0 (C12), 80.7 (C6), 78.3 (C7), 66.5 (C16), 66.2 (C11), 42.9 (C10), 
40.9 (C18), 38.0 (C17), 35.9 (C15), 30.0 (C13/C14), 29.6 (C8), 26.2 (C20), 24.7 (C5), 21.9 
(C21/C22), 21.7 (C21/C22), 19.9 (C13/C14). 
19
F NMR (376 MHz, CDCl3): δ -113.6 (s, 1 F, F38). 
FTIR (νmax, cm
-1
): 3301 (w, NH), 2960 (w), 1654 (s, C=O), 1596 (m), 1527 (s), 1509 (s), 
1488 (s), 1437 (m), 1381 (m), 1314 (m), 1224 (m), 1201 (m), 1157 (m), 1073 (w), 1032 (w), 
1013 (m), 942 (w), 910 (m), 886 (w), 841 (m), 805 (w), 754 (m). 
HRMS (ESI): calculated for C46H48FN3O4Br [M+H]
+
 804.2807, found 804.2817.  
Rf = 0.40 (85% Et2O/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -7.8 (CHCl3, c = 1.0). 
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5.3.6. Synthetic procedure and characterisation for silver-mediated cyclisation 
 
 
(S)-2-(4-Chlorophenyl)-1-tosyl-2,5-dihydro-1H-pyrrole (247): In the dark, to a solution of 
(R)-N-(4-(4-chlorophenyl)buta-2,3-dien-1-yl)-4-methylbenzenesulfonamide ((R)-65) 
(12.3 mg, 0.037 mmol, 1 equiv., 97% ee) in CH2Cl2 (0.3 mL) was added a solution of AgPF6 
(1.0 mg, 0.004 mmol, 0.1 equiv.) in CH2Cl2 (0.05 mL). The mixture was stirred at r.t. for 16 h. 
The reaction mixture was then evaporated under reduced pressure and purified by silica gel 
column chromatography (eluent: 20% EtOAc/hexane) to provide the title compound as a 
white amorphous solid (12.2 mg, 0.037 mmol, 99%, 95% ee), m.p. 131-133 °C. Data are 
consistent with a reported example.
220 
 
1
H NMR (600 MHz, CDCl3): δ 7.52 (d, J = 8.1 Hz, 2 H, H10), 7.24 (d, J = 8.4 Hz, 2 H, H2), 
7.21 (d, J = 8.1 Hz, 2 H, H11), 7.18 (d, J = 8.4 Hz, 2 H, H3), 5.81 (dq, J = 6.3, 2.0 Hz, 1 H, 
H6), 5.61 (dq, J = 6.3, 2.3 Hz, 1 H, H7), 5.50 – 5.46 (m, 1 H, H5), 4.34 (ddd, J = 14.6, 4.7, 
2.3 Hz, 1 H, H8a), 4.26 – 4.23 (m, 1 H, H8b), 2.40 (s, 3 H, H13). 
13
C NMR (150 MHz, CDCl3): δ 143.5 (C12), 139.2 (C4), 135.5 (C9), 133.8 (C1), 130.3 (C7), 
129.7 (C11), 128.8 (C3), 128.7 (C2), 127.4 (C10), 125.1 (C6), 69.7 (C5), 55.6 (C8), 21.6 
(C13). 
FTIR (νmax, cm
-1
): 2921 (w), 1597 (w), 1491 (w), 1411 (w), 1346 (m), 1305 (w), 1162 (s), 
1089 (m), 1059 (w), 1015 (w), 815 (m). 
HRMS (ESI): calculated for C17H17NO2SCl [M+H]
+
 334.0663, found 334.0674.  
Rf = 0.30 (20% EtOAc/hexane). 
[𝛂]𝑫
𝟐𝟓.𝟎 = -268.2 (CHCl3, c = 0.5, 95% ee); lit.
220
 [𝛂]𝑫
𝟐𝟎  = +215.2 (CHCl3, c = 0.955, for 
opposite enantiomer; ee not stated, but at most 91% ee). 
HPLC: ChiralART SC, 90:10 hexane/isopropanol, 1.0 mL/min flow rate, T = 25 °C, λmax = 
210 nm; tR (min) = 33.7 (minor), 36.7 (major). 
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5.4. Experimental data for Chapter 4 
 
5.4.1. Synthetic procedures and characterisation for oxadiazolines 
 
General procedure for oxadiazoline synthesis: A solution of the appropriate ketone 
(20.0 mmol, 1 equiv.) and acetic hydrazide (1.63 g, 22.0 mmol, 1.1 equiv.) in toluene (60 mL) 
was heated under reflux with equipped Dean-Stark apparatus for 2 h. The mixture was then 
evaporated under reduced pressure and the residue redissolved in MeOH (60 mL) and cooled 
to 0 °C. (Diacetoxyiodo)benzene (7.09 g, 22.0 mmol, 1.1 equiv.) was added portionwise, then 
the mixture stirred further at this temperature for 1 h. The mixture was evaporated under 
reduced pressure and the residue purified by silica gel column chromatography. 
 
 
3-Methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-ene (303): Following the general 
procedure for oxadiazoline synthesis using tetrahydro-4H-pyran-4-one (4.00 g, 40.0 mmol), 
purified by silica gel column chromatography (eluent: hexane → 10% EtOAc/hexane) 
provided the title compound as a colourless oil (6.39 g, 34.3 mmol, 86%). 
 
1
H NMR (600 MHz, CDCl3): δ 4.12 – 4.06 (m, 1 H, H6/H7), 4.06 – 4.00 (m, 1 H, H6/H7), 
3.91 – 3.83 (m, 2 H, H6/H7), 3.13 (s, 3 H, H1), 2.26 – 2.18 (m, 1 H, H5/H8), 2.08 – 2.01 (m, 
1 H, H5/H8), 1.79 – 1.72 (m, 1 H, H5/H8), 1.66 (s, 3 H, H2), 1.61 – 1.54 (m, 1 H, H5/H8). 
13
C NMR (150 MHz, CDCl3): δ 133.2 (C3), 118.8 (C4), 65.1 (C6 and C7), 50.7 (C1), 35.2 
(C5/C8), 34.1 (C5/C8), 23.9 (C2). 
FTIR (νmax, cm
-1
): 2963 (w), 2865 (w), 1739 (w), 1575 (w), 1470 (w), 1436 (w), 1378 (m), 
1350 (w), 1304 (w), 1234 (m), 1200 (s), 1152 (s), 1119 (m), 1098 (s), 1054 (s), 1029 (m), 
1019 (m), 1008 (m), 990 (m), 941 (m), 906 (s), 868 (s), 842 (w), 807 (w), 770 (w).  
HRMS (ESI): calculated for C8H15N2O3 [M+H]
+
 187.1077, found 187.1070. 
Rf = 0.13 (10% EtOAc/hexane). 
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3-Methoxy-3-methyl-4,7-dioxa-1,2-diazaspiro[4.4]non-1-ene (304): Following the general 
procedure for oxadiazoline synthesis using tetrahydrofuran-3-one (3.44 g, 40.0 mmol), 
purified by silica gel column chromatography (eluent: hexane → 10% EtOAc/hexane) 
provided the title compound as an inseparable mixture of diastereomers (1:1) as a colourless 
oil (4.90 g, 28.5 mmol, 71%). 
 
1
H NMR (600 MHz, CDCl3): δ 4.25 – 4.17 (m, 1.5 H, H6a of diastereomers A and B, H7a 
of diastereomer A), 4.12 (dt, J = 8.8, 7.2 Hz, 0.5 H, H6b of diastereomer B), 4.10 – 4.04 (m, 
0.5 H, H6b of diastereomer A), 4.00 (d, J = 10.0 Hz, 0.5 H, H7a of diastereomer B), 3.76 (d, 
J = 10.3 Hz, 0.5 H, H7b of diastereomer A), 3.64 (d, J = 10.0 Hz, 0.5 H, H7b of diastereomer 
B), 3.08 and 3.03 (two s, 3 H, H1), 2.65 – 2.57 (m, 0.5 H, H5a of diastereomer B), 2.43 (dt, J 
= 13.2, 7.7 Hz, 0.5 H, H5a of diastereomer A), 2.17 (ddd, J = 13.3, 7.2, 6.1 Hz, 0.5 H, H5b of 
diastereomer B), 2.03 – 1.97 (m, 0.5 H, H5b of diastereomer A), 1.63 and 1.59 (two s, 3 H, 
H2). 
13
C NMR (150 MHz, CDCl3): δ 134.4 and 134.2 (C3), 126.7 and 126.6 (C4), 73.4 and 73.1 
(C7), 68.9 and 68.8 (C6), 50.5 and 50.2 (C1), 36.8 and 36.2 (C5), 22.9 and 22.6 (C2). 
FTIR (νmax, cm
-1
): 2993 (w), 2947 (w), 2867 (w), 1571 (w), 1459 (w), 1435 (w), 1380 (m), 
1334 (w), 1206 (s), 1148 (s), 1105 (m), 1051 (s), 965 (w), 911 (s), 869 (m), 764 (w). 
HRMS (ESI): calculated for C7H13N2O3 [M+H]
+
 173.0921, found 173.0928. 
Rf = 0.23 (10% EtOAc/hexane). 
 
 
3-Methoxy-3-methyl-4-oxa-8-thia-1,2-diazaspiro[4.5]dec-1-ene (305): Following the 
general procedure for oxadiazoline synthesis using tetrahydro-4H-thiopyran-4-one (2.32 g, 
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20.0 mmol), purified by silica gel column chromatography (eluent: hexane → 10% 
EtOAc/hexane) provided the title compound as a colourless oil (3.15 g, 15.6 mmol, 78%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.14 (s, 3 H, H1), 2.95 – 2.79 (m, 4 H, H6 and H7), 2.41 
(ddd, J = 13.8, 10.0, 4.0 Hz, 1 H, H5/H8), 2.26 (ddd, J = 13.8, 10.4, 3.6 Hz, 1 H, H5/H8), 
1.94 – 1.88 (m, 1 H, H5/H8), 1.69 (ddd, J = 13.8, 6.1, 2.8 Hz, 1 H, H5/H8), 1.66 (s, 3 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 133.5 (C3), 120.2 (C4), 50.8 (C1), 35.8 (C5/C8), 34.8 
(C5/C8), 25.4 (C6/C7), 25.3 (C6/C7), 23.9 (C2). 
FTIR (νmax, cm
-1
): 2998 (w), 2947 (w), 2920 (w), 2836 (w), 1574 (w), 1430 (m), 1377 (m), 
1353 (w), 1321 (w), 1275 (w), 1226 (m), 1200 (s), 1156 (s), 1093 (m), 1083 (s), 1048 (s), 
1010 (w), 986 (w), 946 (s), 901 (s), 850 (m), 786 (w), 767 (w). 
HRMS (ESI): calculated for C8H15N2O2S [M+H]
+
 203.0849, found 203.0851. 
Rf = 0.39 (10% EtOAc/hexane). 
 
 
3-Methoxy-3-methyl-4-oxa-7-thia-1,2-diazaspiro[4.4]non-1-ene (306): Following the 
general procedure for oxadiazoline synthesis using 4,5-dihydro-3(2H)-thiophenone (2.04 g, 
20.0 mmol), purified by silica gel column chromatography (eluent: hexane → 10% 
EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers (1:1) 
as a pale yellow oil (2.30 g, 12.2 mmol, 61%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.44 (d, J = 12.0 Hz, 0.5 H, H7a of diastereomer A), 3.27 (d, 
J = 11.8 Hz, 0.5 H, H7a of diastereomer B), 3.23 – 3.14 (m, 1 H, H6a of diastereomers A and 
B), 3.12 and 3.11 (two s, 3 H, H1), 3.11 – 3.06 (m, 1 H, H6b of diastereomers A and B), 2.94 
(dd, J = 12.0, 0.9 Hz, 0.5 H, H7b of diastereomer A), 2.75 (dd, J = 11.8, 0.9 Hz, 0.5 H, H7b 
of diastereomer B), 2.59 (dt, J = 13.2, 7.7 Hz, 0.5 H, H5a of diastereomer A), 2.44 – 2.36 (m, 
0.5 H, H5a of diastereomer B), 2.28 – 2.20 (m, 0.5 H, H5b of diastereomer A), 2.09 – 2.03 (m, 
0.5 H, H5b of diastereomer B), 1.643 and 1.642 (two s, 3 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 134.6 and 134.5 (C3), 128.45 and 128.39 (C4), 50.73 and 
50.69 (C1), 39.8 and 39.0 (C5), 37.6 and 36.8 (C7), 29.49 and 29.48 (C6), 23.1 and 22.9 (C2). 
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FTIR (νmax, cm
-1
): 2972 (w), 2941 (w), 1738 (w), 1570 (w), 1456 (w), 1435 (w), 1378 (m), 
1315 (w), 1225 (m), 1204 (s), 1153 (s), 1124 (m), 1088 (m), 1051 (s), 1017 (w), 977 (w), 947 
(m), 908 (s), 866 (m), 834 (w), 770 (w). 
HRMS (ESI): calculated for C7H13N2O2S [M+H]
+
 189.0692, found 189.0690. 
Rf = 0.37 (10% EtOAc/hexane). 
 
 
7-Methoxy-7-methyl-8-oxa-2-thia-5,6-diazaspiro[3.4]oct-5-ene (307): Following the 
general procedure for oxadiazoline synthesis using 3-thietanone (0.97 g, 11.0 mmol), purified 
by silica gel column chromatography (eluent: hexane → 40% CH2Cl2/hexane) provided the 
title compound as a pale yellow oil (0.57 g, 3.26 mmol, 30%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.84 (d, J = 10.2 Hz, 1 H, H5a), 3.77 (d, J = 10.2 Hz, 1 H, 
H6a), 3.45 (dd, J = 10.2, 1.8 Hz, 1 H, H5b), 3.29 (dd, J = 10.2, 1.8 Hz, 1 H, H6b), 2.92 (s, 
3 H, H1), 1.57 (s, 3 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 136.1 (C3), 117.8 (C4), 50.2 (C1), 37.3 (C5/C6), 37.1 
(C5/C6), 23.3 (C2). 
FTIR (νmax, cm
-1
): 2999 (w), 2942 (w), 2837 (w), 1568 (w), 1459 (w), 1437 (w), 1418 (w), 
1380 (m), 1237 (m), 1204 (s), 1174 (m), 1158 (m), 1134 (m), 1097 (s), 1049 (s), 959 (w), 909 
(s), 862 (m), 776 (w). 
HRMS (ESI): calculated for C6H11N2O2S [M+H]
+
 175.0536, found 175.0540. 
Rf = 0.29 (40% CH2Cl2/hexane). 
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tert-Butyl 3-methoxy-3-methyl-4-oxa-1,2,8-triazaspiro[4.5]dec-1-ene-8-carboxylate (308): 
Following the general procedure for oxadiazoline synthesis using N-Boc-4-piperidone (4.28 g, 
25.0 mmol), purified by silica gel column chromatography (eluent: hexane → 20% 
EtOAc/hexane) provided the title compound as a white amorphous solid (5.43 g, 19.0 mmol, 
76%), m.p. 60-62 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 4.02 – 3.79 (m, 2 H, H6/H7), 3.51 – 3.41 (m, 2 H, H6/H7), 
3.14 (s, 3 H, H1), 2.19 – 2.09 (m, 1 H, H5/H8), 2.04 – 1.92 (m, 1 H, H5/H8), 1.73 – 1.62 (m, 
1 H, H5/H8), 1.66 (s, 3 H, H2), 1.52 – 1.46 (m, 1 H, H5/H8), 1.48 (s, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 154.7 (C9), 133.4 (C3), 119.7 (C4), 80.2 (C10), 50.8 (C1), 
41.8 – 41.1 (br, C6/C7), 41.1 – 40.5 (br, C6/C7), 34.4 – 34.3 (br, C5/C8), 33.4 – 33.2 (br, 
C5/C8), 28.6 (C11), 23.8 (C2). 
FTIR (νmax, cm
-1
): 2973 (w), 1693 (s, C=O), 1574 (w), 1468 (w), 1418 (m), 1378 (w), 1366 
(m), 1351 (w), 1278 (w), 1246 (m), 1223 (m), 1202 (m), 1154 (s), 1097 (s), 1055 (s), 1003 
(w), 966 (w), 933 (m), 906 (s), 867 (m), 825 (w), 804 (w), 769 (w). 
HRMS (ESI): calculated for C13H23N3O4Na [M+Na]
+
 308.1581, found 308.1590. 
Rf = 0.37 (20% EtOAc/hexane). 
 
 
tert-Butyl 3-methoxy-3-methyl-4-oxa-1,2,7-triazaspiro[4.4]non-1-ene-7-carboxylate 
(309): Following the general procedure for oxadiazoline synthesis using N-Boc-3-
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pyrrolidinone (3.70 g, 20.0 mmol), purified by silica gel column chromatography (eluent: 
hexane → 20% EtOAc/hexane) provided the title compound as an inseparable mixture of 
diastereomers (1:1) as a yellow oil (4.19 g, 15.4 mmol, 77%). 
 
1
H NMR (600 MHz, MeOD-d4): δ 3.82 (d, J = 12.2 Hz, 0.5 H, H7a of diastereomer A), 3.79 
– 3.60 (m, 2.5 H, H6 of diastereomers A and B, H7a of diastereomer B), 3.49 (d, J = 12.2 Hz, 
0.5 H, H7b of diastereomer A), 3.40 – 3.32 (m, 0.5 H, H7b of diastereomer B), 3.07 and 3.04 
(two s, 3 H, H1), 2.47 (m, 0.5 H, H5a of diastereomer A), 2.33 – 2.20 (m, 1 H, H5b of 
diastereomer A, H5a of diastereomer B), 2.18 – 2.08 (m, 0.5 H, H5b of diastereomer B), 1.60 
and 1.58 (two s, 3 H, H2), 1.50 (br s, 9 H, H10). 
13
C NMR (150 MHz, MeOD-d4): δ 154.5 (C8), 134.6 and 134.3 (C3), 124.1 and 124.00 and 
123.3 (rotameric, C4), 80.1 (C9), 52.0 and 51.7 and 51.5 and 51.2 (rotameric, C7), 49.6 and 
49.3 (C1), 44.8 and 44.7 and 44.3 and 44.2 (rotameric, C6), 34.3 and 33.55 and 33.51 and 
32.8 (rotameric, C5), 27.4 (C10), 21.7 (C2). 
FTIR (νmax, cm
-1
): 2976 (w), 2889 (w), 1740 (w), 1696 (s, C=O), 1479 (w), 1457 (w), 1399 
(s), 1366 (m), 1236 (m), 1207 (m), 1145 (s), 1095 (s), 1052 (s), 995 (w), 913 (s), 880 (m), 
868 (m), 771 (m). 
HRMS (ESI): calculated for C12H21N3O4Na [M+Na]
+
 294.1424, found 294.1421. 
Rf = 0.36 (20% EtOAc/hexane). 
 
 
tert-Butyl 7-methoxy-7-methyl-8-oxa-2,5,6-triazaspiro[3.4]oct-5-ene-2-carboxylate (310): 
Following the general procedure for oxadiazoline synthesis using N-Boc-3-azetidinone 
(2.57 g, 15.0 mmol), purified by silica gel column chromatography (eluent: 10% → 20% 
EtOAc/hexane) provided the title compound as a white amorphous solid (0.98 g, 3.81 mmol, 
25%), m.p. 64-66 °C. 
 
5. Experimental (Appendix) 
271 
 
1
H NMR (600 MHz, CDCl3): δ 4.49 (dd, J = 9.8, 1.1 Hz, 1 H, H5a), 4.38 (dd, J = 9.7, 
1.1 Hz, 1 H, H6a), 4.20 (dd, J = 9.8, 0.9 Hz, 1 H, H5b), 4.14 (dd, J = 9.7, 0.9 Hz, 1 H, H6b), 
2.93 (s, 3 H, H1), 1.62 (s, 3 H, H2), 1.47 (s, 9 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 156.0 (C7), 135.8 (C3), 111.7 (C4), 80.7 (C8), 59.4 – 58.0 
(br, C5 and C6), 50.1 (C1), 28.4 (C9), 22.7 (C2). 
FTIR (νmax, cm
-1
): 2976 (w), 2946 (w), 1706 (s, C=O), 1564 (w), 1457 (w), 1392 (s), 1382 
(s), 1368 (s), 1322 (w), 1248 (m), 1204 (m), 1157 (m), 1098 (s), 1059 (s), 910 (m), 865 (m), 
806 (w), 772 (w). 
HRMS (ESI): calculated for C11H19N3O4Na [M+Na]
+
 280.1268, found 280.1265. 
Rf = 0.44 (20% EtOAc/hexane). 
 
 
3-Methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.5]dec-1-ene (311): Following the general 
procedure for oxadiazoline synthesis using cyclohexanone (3.93 g, 40.0 mmol), purified by 
silica gel column chromatography (eluent: hexane → 5% EtOAc/hexane) provided the title 
compound as a colourless oil (5.89 g, 32.0 mmol, 80%). Data are consistent with a reported 
example.
39 
 
1
H NMR (600 MHz, CDCl3): δ 3.11 (s, 3 H, H1), 2.10 – 2.01 (m, 1 H, H5/H9), 1.95 – 1.80 
(m, 3 H, H5/H9 and H6/H7/H8), 1.73 – 1.60 (m, 4 H, H5/H9 and H6/H7/H8), 1.64 (s, 3 H, 
H2), 1.58 – 1.50 (m, 1 H, H6/H7/H8), 1.47 – 1.39 (m, 1 H, H5/H9). 
13
C NMR (150 MHz, CDCl3): δ 132.5 (C3), 122.0 (C4), 50.6 (C1), 34.9 (C5/C9), 33.6 
(C5/C9), 25.0 (C6/C7/C8), 24.2 (C2), 23.1 (C6/C7/C8), 22.9 (C6/C7/C8). 
FTIR (νmax, cm
-1
): 2999 (w), 2940 (m), 2864 (w), 1572 (w), 1450 (m), 1376 (m), 1345 (w), 
1233 (m), 1198 (s), 1156 (m), 1127 (m), 1092 (m), 1083 (m), 1056 (s), 1037 (w), 982 (m), 
920 (m), 904 (s), 868 (m), 831 (w), 817 (w), 766 (w).  
HRMS (ESI): calculated for C9H17N2O2 [M+H]
+
 185.1285, found 185.1289. 
Rf = 0.35 (5% EtOAc/hexane). 
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3-Methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.4]non-1-ene (312): Following the general 
procedure for oxadiazoline synthesis using cyclopentanone (3.36 g, 40.0 mmol), purified by 
silica gel column chromatography (eluent: hexane → 5% EtOAc/hexane) provided the title 
compound as a colourless oil (6.41 g, 37.7 mmol, 94%). Data are consistent with a reported 
example.
39
 
 
1
H NMR (600 MHz, CDCl3): δ 3.01 (s, 3 H, H1), 2.29 – 2.20 (m, 1 H, H5/H8), 2.05 – 1.97 
(m, 1 H, H5/H8), 1.97 – 1.81 (m, 5 H, H6 and H7, H5/H8), 1.72 – 1.64 (m, 1 H, H5/H8), 1.55 
(s, 3 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 133.1 (C3), 128.8 (C4), 50.2 (C1), 36.5 (C5/C8), 35.6 
(C5/C8), 25.4 (C6/C7), 25.2 (C6/C7), 23.1 (C2). 
FTIR (νmax, cm
-1
): 2966 (w), 2878 (w), 2837 (w), 1570 (w), 1455 (w), 1435 (w), 1377 (m), 
1329 (w), 1238 (m), 1201 (s), 1155 (s), 1132 (m), 1095 (m), 1055 (s), 1018 (w), 973 (w), 950 
(w), 911 (s), 870 (m), 760 (w). 
HRMS (ESI): calculated for C8H15N2O2 [M+H]
+
 171.1128, found 171.1128. 
Rf = 0.33 (5% EtOAc/hexane). 
 
 
7-Methoxy-7-methyl-8-oxa-5,6-diazaspiro[3.4]oct-5-ene (313): Following the general 
procedure for oxadiazoline synthesis using cyclobutanone (2.80 g, 40.0 mmol), purified by 
silica gel column chromatography (eluent: pentane → 20% Et2O/pentane) provided the title 
compound as a volatile colourless oil (3.01 g, 19.3 mmol, 48%). 
 
1
H NMR (600 MHz, CDCl3): δ 2.93 (s, 3 H, H1), 2.59 – 2.49 (m, 3 H, H5/H7), 2.44 – 2.37 
(m, 1 H, H5/H7), 2.28 – 2.17 (m, 1 H, H6a), 1.98 – 1.88 (m, 1 H, H6b), 1.59 (s, 3 H, H2). 
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13
C NMR (150 MHz, CDCl3): δ 133.7 (C3), 119.0 (C4), 50.0 (C1), 33.6 (C5/C7), 33.5 
(C5/C7), 23.3 (C2), 11.9 (C6). 
FTIR (νmax, cm
-1
): 2999 (w), 2945 (w), 2837 (w), 1563 (w), 1460 (w), 1438 (w), 1419 (w), 
1379 (m), 1275 (m), 1246 (m), 1204 (s), 1182 (s), 1148 (s), 1110 (m), 1066 (s), 1052 (s), 959 
(m), 910 (s), 869 (m), 821 (w), 768 (w). 
HRMS (ESI): calculated for C7H13N2O2 [M+H]
+
 157.0972, found 157.0974. 
Rf = 0.73 (30% EtOAc/hexane). 
 
 
5'-Methoxy-5'-methyl-3,4-dihydro-1H,5'H-spiro[naphthalene-2,2'-[1,3,4]oxadiazole] 
(314): Following the general procedure for oxadiazoline synthesis using 2-tetralone (6.50 g, 
44.5 mmol), purified by silica gel column chromatography (eluent: hexane → 5% 
EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers (1:1) 
as a red viscous oil (9.01 g, 38.8 mmol, 87%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.23 – 7.15 (m, 3 H, H8, H9 and H10), 7.13 – 7.05 (m, 1 H, 
H11), 3.48 (d, J = 16.9 Hz, 0.5 H, H13a of diastereomer A), 3.35 (d, J = 16.7 Hz, 0.5 H, 
H13a of diastereomer B), 3.19 and 3.18 (two s, 3 H, H1), 3.17 – 3.02 (m, 2 H, H6), 2.96 (d,   
J = 16.9 Hz, 0.5 H, H13b of diastereomer A), 2.73 (d, J = 16.7 Hz, 0.5 H, H13b of 
diastereomer B), 2.42 (ddd, J = 13.4, 9.5, 6.1 Hz, 0.5 H, H5a of diastereomer B), 2.27 – 2.20 
(m, 0.5 H, H5a of diastereomer A), 2.03 – 1.96 (m, 0.5 H, H5b of diastereomer B), 1.86 – 
1.79 (m, 0.5 H, H5b of diastereomer A), 1.71 and 1.70 (two s, 3 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 135.08 and 135.05 (C7), 133.59 and 133.57 (C3), 132.5 
(C12), 129.1 (C11), 128.77 and 128.76 (C8), 126.67 and 126.65 (C9), 126.46 and 126.44 
(C10), 120.8 and 120.7 (C4), 50.7 (C1), 37.8 and 36.9 (C13), 31.9 and 30.7 (C6), 27.0 and 
26.7 (C5), 23.91 and 23.88 (C2). 
FTIR (νmax, cm
-1
): 3000 (w), 2941 (w), 2836 (w), 1573 (w), 1497 (w), 1454 (w), 1435 (w), 
1377 (m), 1344 (w), 1299 (w), 1227 (m), 1200 (s), 1156 (s), 1136 (m), 1118 (m), 1089 (m), 
1050 (s), 1003 (w), 968 (m), 906 (s), 869 (m), 849 (w), 832 (w), 775 (w). 
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HRMS (ESI): calculated for C13H17N2O2 [M+H]
+
 233.1285, found 233.1293. 
Rf = 0.27 (5% EtOAc/hexane). 
 
 
5'-Methoxy-5'-methyl-5'H-spiro[adamantane-2,2'-[1,3,4]oxadiazole] (315): Following the 
general procedure for oxadiazoline synthesis using 2-adamantanone (6.01 g, 40.0 mmol), 
purified by silica gel column chromatography (eluent: hexane → 10% EtOAc/hexane) 
provided the title compound as a white crystalline solid (7.55 g, 31.9 mmol, 80%), m.p. 70-
72 °C (lit. m.p.
221
 72 °C). Data are consistent with a reported example.
221 
 
1
H NMR (600 MHz, CDCl3): δ 3.07 (s, 3 H, H1), 2.65 – 2.60 (m, 1 H, H6/H10/H12/H13), 
2.48 – 2.43 (m, 1 H, H6/H10/H12/H13), 2.10 – 2.04 (m, 2 H, H7/H9, H6/H10/H12/H13), 
2.04 – 1.99 (m, 1 H, H6/H10/H12/H13), 1.92 – 1.86 (m, 2 H, H6/H10/H12/H13), 1.85 – 1.76 
(m, 4 H, H5/H11, H7/H9, H8), 1.76 – 1.68 (m, 2 H, H6/H10/H12/H13), 1.61 (s, 3 H, H2), 
1.55 – 1.51 (m, 1 H, H5/H11). 
13
C NMR (150 MHz, CDCl3): δ 131.7 (C3), 125.3 (C4), 50.3 (C1), 38.3 (C5/C11), 37.3 (C8), 
36.5 (C5/C11), 35.2 (C6/C10/C12/C13), 35.1 (C6/C10/C12/C13), 34.5 (C6/C10/C12/C13), 
34.1 (C6/C10/C12/C13), 27.4 (C7/C9), 26.7 (C7/C9), 24.4 (C2). 
FTIR (νmax, cm
-1
): 2998 (w), 2937 (m), 2908 (s), 2854 (m), 1575 (w), 1468 (w), 1451 (m), 
1433 (w), 1375 (m), 1363 (w), 1351 (w), 1280 (w), 1247 (m), 1222 (m), 1196 (s), 1155 (m), 
1109 (s), 1092 (m), 1059 (s), 1022 (m), 999 (w), 948 (w), 911 (s), 880 (m), 859 (m), 839 (w), 
801 (w), 779 (w), 764 (w). 
HRMS (ESI): calculated for C13H21N2O2 [M+H]
+
 237.1598, found 237.1590. 
Rf = 0.48 (10% EtOAc/hexane). 
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2-Cyclopropyl-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole (316): Following 
the general procedure for oxadiazoline synthesis using cyclopropyl methyl ketone (3.36 g, 
40.0 mmol), purified by silica gel column chromatography (eluent: hexane → 10% 
EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers (1:1) 
as a colourless oil (4.74 g, 27.8 mmol, 70%). Compound has been prepared previously,
39
 but 
NMR spectra were recorded in C6D6. 
 
1
H NMR (600 MHz, CDCl3): δ 3.27 and 3.17 (two s, 3 H, H1), 1.68 and 1.62 (two s, 3 H, 
H2), 1.58 and 1.40 (two s, 3 H, H8), 1.33 – 1.23 (m, 1 H, H5), 0.73 – 0.66 (m, 0.5 H, H6/H7), 
0.63 – 0.46 (m, 3 H, H6/H7), 0.38 – 0.32 (m, 0.5 H, H6/H7). 
13
C NMR (150 MHz, CDCl3): δ 133.3 and 133.1 (C3), 122.2 and 122.1 (C4), 51.1 and 50.8 
(C1), 23.0 and 22.66 (C2), 22.70 and 22.66 (C8), 18.3 and 17.5 (C5), 2.4 and 1.5 (C6/C7), 
1.7 and 1.6 (C6/C7).  
FTIR (νmax, cm
-1
): 2998 (w), 2945 (w), 2837 (w), 1575 (w), 1456 (w), 1376 (m), 1230 (m), 
1195 (m), 1144 (s), 1105 (m), 1055 (s), 1027 (m), 968 (m), 930 (m), 908 (m), 885 (m), 870 
(m), 840 (w), 822 (w), 786 (w), 757 (w). 
HRMS (ESI): calculated for C8H15N2O2 [M+H]
+
 171.1128, found 171.1130. 
Rf = 0.54 (10% EtOAc/hexane). 
 
 
2-(But-3-en-1-yl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole (317): Following 
the general procedure for oxadiazoline synthesis using 5-hexen-2-one (3.93 g, 40.0 mmol), 
purified by silica gel column chromatography (eluent: hexane → 10% EtOAc/hexane) 
provided the title compound as an inseparable mixture of diastereomers (1.5:1) as a 
colourless oil (4.92 g, 26.7 mmol, 67%). 
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1
H NMR (600 MHz, CDCl3): δ 5.89 – 5.73 (m, 1 H, H7), 5.08 – 4.95 (m, 2 H, H8), 3.17 and 
3.16 (two s, 3 H, H1), 2.39 – 2.29 (m, 0.4 H, H6a of diastereomer A), 2.28 – 2.12 (m, 1 H, 
H6b of diastereomer A, H6a of diastereomer B), 2.11 – 2.00 (m, 1 H, H5a of diastereomer A, 
H6b of diastereomer B), 1.93 (ddd, J = 13.9, 11.5, 5.1 Hz, 0.6 H, H5a of diastereomer B), 
1.79 – 1.70 (m, 1 H, H5b of diastereomers A and B), 1.66 and 1.63 (two s, 3 H, H2), 1.55 and 
1.44 (two s, 3 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 137.5 and 137.3 (C7), 133.4 and 133.2 (C3), 122.3 and 
122.1 (C4), 115.34 and 115.30 (C8), 50.80 and 50.75 (C1), 37.6 and 36.8 (C5), 28.2 and 28.0 
(C6), 23.4 and 22.6 (C2), 22.5 and 22.4 (C9). 
FTIR (νmax, cm
-1
): 2999 (w), 2946 (w), 1643 (w), 1574 (w), 1455 (w), 1376 (m), 1226 (m), 
1190 (m), 1150 (s), 1055 (m), 978 (w), 907 (s), 869 (m). 
HRMS (ESI): calculated for C9H17N2O2 [M+H]
+
 185.1285, found 185.1280. 
Rf = 0.33 (5% EtOAc/hexane). 
 
 
2-(2,2-Dimethylpent-4-yn-1-yl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole 
(318): Following the general procedure for oxadiazoline synthesis using 4,4-dimethylhept-6-
yn-2-one (1.38 g, 10.0 mmol), purified by silica gel column chromatography (eluent: hexane 
→ 5% EtOAc/hexane) provided the title compound as an inseparable mixture of 
diastereomers (1:1) as a colourless oil (1.82 g, 8.1 mmol, 81%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.18 and 3.15 (two s, 3 H, H1), 2.30 – 2.16 (m, 2.5 H, H5a 
of diastereomer A and H9), 2.05 (d, J = 14.8 Hz, 0.5 H, H5a of diastereomer B), 1.99 (t, J = 
2.6 Hz, 1 H, H11), 1.67 and 1.61 (two s, 3 H, H2), 1.66 (d, J = 14.8 Hz, 0.5 H, H5b of 
diastereomer A), 1.59 and 1.47 (two s, 3 H, H12), 1.54 (d, J = 14.8 Hz, 0.5 H, H5b of 
diastereomer B), 1.17 and 1.16 (two s, 3 H, H7/H8), 1.114 and 1.107 (two s, 3 H, H7/H8). 
13
C NMR (150 MHz, CDCl3): δ 134.3 and 133.8 (C3), 122.6 and 122.4 (C4), 82.2 and 82.1 
(C10), 70.85 and 70.83 (C11), 51.1 and 50.7 (C1), 47.1 and 46.8 (C5), 33.9 and 33.8 (C6), 
33.7 and 33.4 (C9), 28.6 and 28.5 (C7/C8), 28.4 and 28.3 (C7/C8), 24.4 and 24.1 (C12), 23.5 
and 22.8 (C2). 
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FTIR (νmax, cm
-1
): 3296 (w, alkyne CH), 2964 (m), 2838 (w), 1718 (w), 1577 (w), 1456 (m), 
1376 (m), 1195 (s), 1153 (s), 1081 (m), 1056 (s), 1020 (w), 995 (w), 959 (m), 914 (m), 882 
(m), 858 (m), 763 (w). 
HRMS (ESI): calculated for C12H21N2O2 [M+H]
+
 225.1598, found 225.1602. 
Rf = 0.22 (5% EtOAc/hexane). 
 
 
3-Methoxy-3-methyl-4,9,12-trioxa-1,2-diazadispiro[4.2.4
8
.2
5
]tetradec-1-ene (319): 
Following the general procedure for oxadiazoline synthesis using 1,4-cyclohexanedione 
monoethylene acetal (3.12 g, 20.0 mmol), purified by silica gel column chromatography 
(eluent: 20% EtOAc/hexane) provided the title compound as a white crystalline solid (3.94 g, 
16.3 mmol, 81%), m.p. 57-58 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 3.98 (s, 4 H, H8 and H9), 3.11 (s, 3 H, H1), 2.34 – 2.26 (m, 
1 H, H5/H6/H10/H11), 2.18 – 2.11 (m, 1 H, H5/H6/H10/H11), 2.04 – 1.92 (m, 2 H, 
H5/H6/H10/H11), 1.91 – 1.84 (m, 2 H, H5/H6/H10/H11), 1.80 – 1.74 (m, 1 H, 
H5/H6/H10/H11), 1.63 (s, 3 H, H2), 1.59 – 1.52 (m, 1 H, H5/H6/H10/H11). 
13
C NMR (150 MHz, CDCl3): δ 133.0 (C3), 120.8 (C4), 107.6 (C7), 64.7 (C8/C9), 64.6 
(C8/C9), 50.6 (C1), 32.4 (C5/C6/C10/C11), 31.7 (C5/C6/C10/C11), 31.6 (C5/C6/C10/C11), 
31.2 (C5/C6/C10/C11), 23.9 (C2). 
FTIR (νmax, cm
-1
): 2941 (w), 2888 (w), 1572 (w), 1439 (w), 1375 (m), 1337 (w), 1299 (w), 
1263 (w), 1233 (m), 1200 (m), 1169 (m), 1158 (m), 1107 (s), 1074 (w), 1055 (m), 1034 (s), 
995 (m), 968 (m), 947 (m), 921 (m), 906 (s), 864 (w), 854 (w), 766 (w). 
HRMS (ESI): calculated for C11H19N2O4 [M+H]
+
 243.1339, found 243.1329. 
Rf = 0.31 (20% EtOAc/hexane). 
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Diethyl ((5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)phosphonate 
(320): Following the general procedure for oxadiazoline synthesis using diethyl (2-
oxopropyl)phosphonate (3.88 g, 20.0 mmol), purified by silica gel column chromatography 
(eluent: hexane → 60% EtOAc/hexane) provided the title compound as an inseparable 
mixture of diastereomers (1.5:1) as a pale yellow oil (3.33 g, 11.9 mmol, 59%). 
 
1
H NMR (600 MHz, CDCl3): δ 4.21 – 4.09 (m, 4 H, H6 and H8), 3.16 and 3.15 (two s, 3 H, 
H1), 2.55 (dd, J = 20.0, 15.3 Hz, 0.4 H, H5a of diastereomer A), 2.42 (dd, J = 19.4, 15.5 Hz, 
0.6 H, H5a of diastereomer B), 2.09 (dd, J = 19.2, 15.3 Hz, 0.4 H, H5b of diastereomer A), 
1.97 (dd, J = 19.1, 15.5 Hz, 0.6 H, H5b of diastereomer B), 1.77 and 1.669 (two s, 3 H, H10), 
1.673 and 1.65 (s, 3 H, H2), 1.36 – 1.30 (m, 6 H, H7 and H9). 
13
C NMR (150 MHz, CDCl3): δ 135.2 and 135.1 (C3), 118.7 and 118.5 (d, J = 2.9 Hz; d, J = 
2.3 Hz, C4), 62.42 and 62.26 (d, J = 6.3 Hz; d, J = 6.4 Hz, C6/C8), 62.15 and 62.11 (d, J = 
6.4 Hz; d, J = 6.4 Hz, C6/C8), 50.9 and 50.8 (C1), 35.3 and 34.7 (d, J = 142.5 Hz; d, J = 
142.6 Hz, C5), 23.8 and 22.9 (C2), 23.43 and 23.42 (d, J = 4.3 Hz; d, J = 2.0 Hz, C10), 16.54 
and 16.50 (d, J = 6.4 Hz; d, J = 6.4 Hz, C7 and C9). 
31
P NMR (245 MHz, CDCl3): δ 23.4 and 23.2 (two s, 1 P, C5-P). 
FTIR (νmax, cm
-1
): 2987 (w), 1740 (w), 1576 (w), 1444 (w), 1379 (w), 1243 (m), 1202 (m), 
1157 (m), 1098 (w), 1049 (s), 1020 (s), 958 (s), 912 (m), 881 (w), 835 (w), 795 (m). 
HRMS (ESI): calculated for C10H22N2O5P [M+H]
+
 281.1261, found 281.1265.  
Rf = 0.20 (60% EtOAc/hexane). 
 
 
8-(Propan-2-ylidene)-1,4-dioxaspiro[4.5]decane: To a suspension of 
isopropyltriphenylphosphonium bromide (9.40 g, 24.4 mmol, 1 equiv.) and sodium hydride 
(1.17 g, 29.3 mmol, 1.2 equiv., 60% dispersion in mineral oil) in anhydrous DMSO (15 mL) 
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was heated at 50 °C until formation of a red solution. A solution of 1,4-cyclohexanedione 
monoethylene acetal (3.81 g, 24.4 mmol) in anhydrous DMSO (15 mL) was then added to the 
reaction mixture and stirred further at 50 °C for 16 h. The mixture was cooled to r.t., 
quenched with water (15 mL) then extracted with Et2O (3 × 25 mL). The combined organic 
extracts were dried (MgSO4), evaporated under reduced pressure and purified by silica gel 
column chromatography (eluent: 5% EtOAc/hexane) to provide the title compound as a 
colourless oil (1.57 g, 8.6 mmol, 35%). Data are consistent with a reported example.
222 
 
1
H NMR (600 MHz, CDCl3): δ 3.95 (s, 4 H, H1), 2.32 – 2.25 (m, 4 H, H4), 1.67 (s, 6 H, H7), 
1.65 – 1.61 (m, 4 H, H3). 
13
C NMR (150 MHz, CDCl3): δ 129.4 (C5), 122.0 (C6), 109.2 (C2), 64.4 (C1), 35.8 (C3), 
26.9 (C4), 20.3 (C7). 
FTIR (νmax, cm
-1
): 2994 (m), 2877 (m), 1445 (w), 1364 (w), 1343 (w), 1280 (w), 1233 (w), 
1136 (m), 1109 (s), 1070 (m), 1036 (m), 995 (w), 944 (m), 909 (m), 865 (w), 770 (w). 
HRMS (ESI): calculated for C11H19O2 [M+H]
+
 183.1380, found 183.1381. 
Rf = 0.15 (5% EtOAc/hexane). 
 
 
4-(Propan-2-ylidene)cyclohexan-1-one: To a suspension of silica gel (3.4 g) in CH2Cl2 
(10 mL) was added 15% aqueous H2SO4 (0.6 mL) and stirred for 5 min. 8-(propan-2-
ylidene)-1,4-dioxaspiro[4.5]decane (1.50 g, 8.23 mmol) was added and the mixture stirred at 
r.t. for 2 h. The silica was filtered off, washed with CH2Cl2 (25 mL) and the filtrate 
evaporated under reduced pressure. The residue was purified by silica gel column 
chromatography (eluent: 10% EtOAc/hexane) to provide the title compound as a colourless 
oil (0.819 g, 5.93 mmol, 72%). Data are consistent with a reported example.
222
 
 
1
H NMR (600 MHz, CDCl3): δ 2.58 – 2.49 (m, 4 H, H3), 2.43 – 2.36 (m, 4 H, H2), 1.71 (s, 
6 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 213.2 (C1), 126.3 (C4), 125.0 (C5), 40.5 (C2), 27.1 (C3), 
20.4 (C6). 
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FTIR (νmax, cm
-1
): 2912 (w), 2858 (w), 1715 (s, C=O), 1442 (w), 1376 (w), 1342 (w), 1300 
(w), 1233 (w), 1167 (w), 1129 (w), 946 (w), 909 (w), 811 (w), 765 (w). 
HRMS (ESI): calculated for C9H15O [M+H]
+
 139.1117, found 139.1115. 
Rf = 0.33 (10% EtOAc/hexane). 
 
 
2,2-Dimethyl-1-oxaspiro[2.5]octan-6-one: To a solution of 4-(propan-2-
ylidene)cyclohexan-1-one (0.819 g, 5.93 mmol, 1 equiv.) in CH2Cl2 (40 mL) was added m-
CPBA (2.25 g, 6.52 mmol, 50% purity) in three portions at 0 °C and the mixture warmed to 
r.t. and stirred further for 2 h. The mixture was filtered to remove precipitated m-
chlorobenzoic acid, washed on the filter with CH2Cl2 (2 × 15 mL), then the filtrate washed 
with saturated aqueous Na2CO3 solution (25 mL). The aqueous layer was extracted with 
CH2Cl2 (3 × 25 mL) and the combined organic extracts were dried (MgSO4), evaporated 
under reduced pressure and purified by silica gel column chromatography (eluent: 30% 
EtOAc/hexane) to provide the title compound as a white amorphous solid (0.734 g, 4.76 
mmol, 80%), m.p. 50-52 °C (lit. m.p.
223
 50-51 °C). Data are consistent with a reported 
example.
223 
 
1
H NMR (600 MHz, CDCl3): δ 2.65 – 2.56 (m, 2 H, H2a), 2.44 – 2.36 (m, 2 H, H2b), 2.10 – 
2.02 (m, 2 H, H3a), 1.99 – 1.91 (m, 2 H, H3b), 1.40 (s, 6 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 210.7 (C1), 64.1 (C4), 63.4 (C5), 38.6 (C2), 29.3 (C3), 21.1 
(C6). 
FTIR (νmax, cm
-1
): 2965 (w), 2923 (w), 1717 (s, C=O), 1435 (w), 1378 (w), 1340 (w), 1308 
(w), 1233 (w), 1124 (w), 1000 (w), 955 (w), 890 (w), 869 (w). 
HRMS (ESI): calculated for C9H14O2Na [M+Na]
+
 177.0886, found 177.0893. 
Rf = 0.31 (30% EtOAc/hexane). 
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9-Methoxy-2,2,9-trimethyl-1,10-dioxa-7,8-diazadispiro[2.2.4
6
.2
3
]dodec-7-ene (321): To a 
solution of 2,2-dimethyl-1-oxaspiro[2.5]octan-6-one (0.734 g, 4.76 mmol, 1 equiv.) in MeOH 
(20 mL) was added acetic hydrazide (0.388 g, 5.24 mmol, 1.1 equiv.). The mixture was 
stirred at r.t. for 2 h, then cooled to 0 °C. (Diacetoxy)iodobenzene (1.69 g, 5.24 mmol, 
1.1 equiv.) was added portionwise, then the mixture stirred further at this temperature for 1 h. 
The mixture was evaporated under reduced pressure and the residue purified by silica gel 
column chromatography (eluent: 20% EtOAc/hexane) to provide the title compound as an 
inseparable mixture of diastereomers (1:1) as a white amorphous solid (1.03 g, 4.29 mmol, 
90%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.15 and 3.14 (two s, 3 H, H1), 2.48 (td, J = 12.7, 4.4 Hz, 
0.5 H, H5a of diastereomer A), 2.35 (td, J = 12.7, 4.4 Hz, 0.5 H, H12a of diastereomer A), 
2.18 – 2.11 (m, 0.5 H, H6a of diastereomer B), 2.11 – 1.94 (m, 2.5 H, H6/H11 of 
diastereomer A, H11a of diastereomer B, H12 of diastereomer B), 1.94 – 1.79 (m, 3 H, 
H6/H11 of diastereomer A, H5 of diastereomer B, H6b of diastereomer B, H11b of 
diastereomer B), 1.75 – 1.68 (m, 0.5 H, H5b of diastereomer A), 1.67 and 1.66 (two s, 3 H, 
H2), 1.48 – 1.42 (m, 0.5 H, H12b of diastereomer A), 1.42 and 1.38 (two s, 3 H, H9/H10), 
1.41 and 1.37 (two s, 3 H, H9/H10). 
13
C NMR (150 MHz, CDCl3): δ 133.1 and 133.0 (C3), 121.1 and 120.8 (C4), 64.8 and 64.3 
(C7), 63.0 and 62.9 (C8), 50.73 and 50.70 (C1), 33.7 and 32.2 (C5/C12), 32.4 and 31.1 
(C5/C12), 27.7 and 26.8 (C6/C11), 27.6 and 26.7 (C6/C11), 24.0 and 23.9 (C2), 20.9 and 
20.7 (C9 and C10). 
FTIR (νmax, cm
-1
): 2953 (m), 1574 (w), 1439 (m), 1378 (m), 1359 (w), 1225 (m), 1201 (s), 
1157 (m), 1102 (s), 1056 (s), 1003 (w), 979 (w), 954 (w), 907 (s), 889 (m), 871 (m), 770 (w). 
HRMS (ESI): calculated for C12H20N2O3Na [M+Na]
+
 263.1366, found 263.1361. 
Rf = 0.40 (20% EtOAc/hexane). 
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2-(Furan-2-ylmethyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole (322): 
Following the general procedure for oxadiazoline synthesis using 2-furylacetone (2.48 g, 
20.0 mmol), purified by silica gel column chromatography (eluent: hexane → 10% 
EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers (2:1) 
as an orange oil (3.36 g, 16.0 mmol, 80%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 (d, J = 1.3 Hz, 0.33 H, H9 of diastereomer A), 7.32 (d, 
J = 1.3 Hz, 0.67 H, H9 of diastereomer B), 6.35 – 6.31 (m, 0.33 H, H8 of diastereomer A), 
6.31 – 6.26 (m, 0.67 H, H8 of diastereomer B), 6.22 (d, J = 3.1 Hz, 0.33 H, H7 of 
diastereomer A), 6.11 (d, J = 3.2 Hz, 0.67 H, H7 of diastereomer B), 3.33 (d, J = 15.2 Hz, 
0.33 H, H5a of diastereomer A), 3.21 – 3.14 (m, 1.33 H, H5 of diastereomer B), 3.13 and 
3.12 (two s, 3 H, H1), 3.05 (d, J = 15.2 Hz, 0.33 H, H5b of diastereomer A), 1.63 and 1.34 
(two s, 3 H, H2), 1.60 and 1.44 (two s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 149.2 and 149.0 (C6), 142.2 and 142.1 (C9), 134.5 and 
134.1 (C3), 121.3 and 120.5 (C4), 110.73 and 110.71 (C8), 109.3 and 109.1 (C7), 50.8 and 
50.7 (C1), 37.1 and 36.4 (C5), 23.4 and 22.3 (C2), 22.8 (C10). 
FTIR (νmax, cm
-1
): 2990 (w), 2945 (w), 1597 (w), 1573 (w), 1505 (w), 1455 (w), 1377 (m), 
1188 (m), 1146 (s), 1089 (m), 1054 (s), 1012 (m), 968 (m), 939 (m), 907 (s), 886 (w), 865 
(m), 835 (w), 812 (w). 
HRMS (ESI): calculated for C10H15N2O3 [M+H]
+
 211.1077, found 211.1076. 
Rf = 0.33 (10% EtOAc/hexane). 
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3-Methoxy-3-methyl-8-(pyrimidin-2-yl)-4-oxa-1,2,8-triazaspiro[4.5]dec-1-ene (323): 
Following the general procedure for oxadiazoline synthesis using 1-(pyrimidin-2-
yl)piperidin-4-one (0.98 g, 5.5 mmol), purified by silica gel column chromatography (eluent: 
hexane → 30% EtOAc/hexane) provided the title compound as a white crystalline solid 
(1.25 g, 4.7 mmol, 86%), m.p. 96-98 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 8.32 (d, J = 4.8 Hz, 2 H, H8 and H10), 6.51 (t, J = 4.8 Hz, 
1 H, H9), 4.44 – 4.33 (m, 2 H, H6/H11), 3.87 – 3.80 (m, 2 H, H6/H11), 3.15 (s, 3 H, H1), 
2.23 – 2.16 (m, 1 H, H5/H12), 2.07 – 2.00 (m, 1 H, H5/H12), 1.79 – 1.72 (m, 1 H, H5/H12), 
1.68 (s, 3 H, H2), 1.59 – 1.53 (m, 1 H, H5/H12). 
13
C NMR (150 MHz, CDCl3): δ 161.5 (C7), 158.0 (C8 and C10), 133.3 (C3), 120.3 (C4), 
110.2 (C9), 50.8 (C1), 41.12 (C6/C11), 41.07 (C6/C11), 34.2 (C5/C12), 33.1 (C5/C12), 23.9 
(C2). 
FTIR (νmax, cm
-1
): 2999 (w), 2962 (w), 2865 (w), 1585 (s), 1548 (s), 1499 (s), 1456 (m), 
1394 (w), 1365 (s), 1307 (w), 1262 (m), 1232 (m), 1201 (m), 1157 (m), 1132 (m), 1118 (m), 
1096 (m), 1054 (m), 984 (w), 950 (w), 930 (m), 907 (m), 865 (w), 798 (m), 782 (w). 
HRMS (ESI): calculated for C12H18N5O2 [M+H]
+
 264.1455, found 264.1465. 
Rf = 0.44 (30% EtOAc/hexane). 
 
 
3-(5-Methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazol-2-yl)propan-1-ol (324): 
Following the general procedure for oxadiazoline synthesis using 5-hydroxy-2-pentanone 
(4.09 g, 40.0 mmol), purified by silica gel column chromatography (eluent: hexane → 40% 
5. Experimental (Appendix) 
284 
 
EtOAc/hexane) provided the title compound as an inseparable mixture of diastereomers 
(1.4:1) as a colourless oil (4.07 g, 21.6 mmol, 54%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.73 – 3.63 (m, 2 H, H7), 3.18 and 3.17 (two s, 3 H, H1), 
2.12 – 1.51 (m, 5 H, H5, H6 and OH), 1.68 and 1.64 (two s, 3 H, H2), 1.57 and 1.46 (two s, 
3 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 133.4 and 133.3 (C3), 122.4 and 122.3 (C4), 62.59 and 
62.56 (C7), 50.9 and 50.8 (C1), 34.9 and 34.1 (C5), 27.2 and 27.0 (C6), 23.4 and 22.8 (C2), 
22.5 and 22.3 (C8). 
FTIR (νmax, cm
-1
): 3431 (br w, OH), 2990 (w), 2945 (w), 1574 (w), 1455 (w), 1377 (m), 
1197 (s), 1150 (s), 1102 (w), 1053 (s), 1024 (s), 963 (w), 907 (s), 868 (m). 
HRMS (ESI): calculated for C8H16N2O3Na [M+Na]
+
 211.1053, found 211.1055. 
Rf = 0.26 (40% EtOAc/hexane). 
 
 
3-Methoxy-3-methyl-4-oxa-8-thia-1,2-diazaspiro[4.5]dec-1-ene 8,8-dioxide (325): To a 
solution of 3-methoxy-3-methyl-4-oxa-8-thia-1,2-diazaspiro[4.5]dec-1-ene (1.01 g, 5.0 mmol, 
1 equiv.) in CH2Cl2 (25 mL) was added m-CPBA (3.97 g, 11.5 mmol, 2.3 equiv., 50% purity) 
in four portions at r.t. and the mixture stirred further for 3 h. The mixture was filtered to 
remove precipitated m-chlorobenzoic acid, washed on the filter with CH2Cl2 (2 × 15 mL), 
then the filtrate washed with saturated aqueous Na2CO3 solution (50 mL). The organic phase 
was dried (MgSO4), evaporated under reduced pressure and purified by silica gel column 
chromatography (eluent: 40% EtOAc/hexane) to provide the title compound as a white 
amorphous solid (1.13 g, 4.83 mmol, 97%), m.p. 122-123 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 3.36 – 3.23 (m, 4 H, H6 and H7), 3.20 (s, 3 H, H1), 2.80 
(ddd, J = 14.6, 10.8, 3.9 Hz, 1 H, H5/H8), 2.74 – 2.64 (m, 1 H, H5/H8), 2.17 – 2.10 (m, 1 H, 
H5/H8), 1.98 – 1.90 (m, 1 H, H5/H8), 1.70 (s, 3 H, H2). 
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13
C NMR (150 MHz, CDCl3): δ 134.9 (C3), 117.3 (C4), 51.2 (C1), 48.2 (C6/C7), 48.1 
(C6/C7), 32.8 (C5/C8), 32.0 (C5/C8), 23.1 (C2). 
FTIR (νmax, cm
-1
): 2989 (w), 2944 (w), 1576 (w), 1436 (w), 1402 (w), 1382 (w), 1358 (w), 
1337 (m), 1298 (s), 1225 (m), 1203 (m), 1133 (s), 1087 (s), 1051 (m), 1012 (w), 950 (m), 930 
(w), 903 (m), 852 (s), 768 (w). 
HRMS (ESI): calculated for C8H15N2O4S [M+H]
+
 235.0747, found 235.0750. 
Rf = 0.33 (40% EtOAc/hexane). 
 
 
2-(3-Bromopropyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole (326): To a 
solution of 3-(5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazol-2-yl)propan-1-ol (324) 
(0.941 g, 5.0 mmol, 1 equiv.) in CH2Cl2 (25 mL) at r.t. was added carbon tetrabromide 
(1.99 g, 6.0 mmol, 1.2 equiv.) then triphenylphosphine (1.57 g, 6.0 mmol, 1.2 equiv.) in three 
portions. The mixture was further stirred for 1 h, evaporated under reduced pressure and the 
residue purified by silica gel column chromatography (eluent: 5% EtOAc/hexane) to provide 
the title compound as inseparable diastereomers (1.4:1) as a colourless oil (0.991 g, 
3.95 mmol, 79%). 
 
1
H NMR (600 MHz, CDCl3): δ 3.49 – 3.39 (m, 2 H, H7), 3.20 and 3.18 (two s, 3 H), 2.20 – 
1.76 (m, 4 H, H5 and H6), 1.68 and 1.64 (two s, 3 H, H2), 1.56 and 1.44 (two s, 3 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 133.7 and 133.5 (C3), 121.9 and 121.7 (C4), 51.0 and 50.8 
(C1), 36.8 and 36.2 (C5), 33.4 and 33.2 (C7), 27.3 and 27.2 (C6), 23.3 and 22.68 (C2), 22.70 
and 22.4 (C8). 
FTIR (νmax, cm
-1
): 2990 (w), 2943 (w), 2837 (w), 1574 (w), 1455 (w), 1377 (m), 1298 (w), 
1264 (w), 1239 (m), 1196 (s), 1152 (s), 1089 (m), 1053 (s), 1003 (w), 975 (w), 909 (s), 869 
(m), 835 (w), 767 (w). 
HRMS (ESI): calculated for C8H16N2O2Br [M+H]
+
 251.0390, found 251.0378. 
Rf = 0.22 (5% EtOAc/hexane). 
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3-(5-Methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazol-2-yl)propanal (327): To a 
solution of oxalyl chloride (1.28 mL, 15.0 mmol, 1.5 equiv.) in anhydrous CH2Cl2 (15 mL) at 
-78 °C was added slowly dropwise a solution of DMSO (1.56 mL, 22.0 mmol, 2.2 equiv.) in 
anhydrous CH2Cl2 (15 mL), keeping the internal temperature below -60 °C. The mixture was 
stirred further for 5 min. A solution of 3-(5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazol-2-yl)propan-1-ol (324) (1.88 g, 10.0 mmol, 1 equiv.) in anhydrous CH2Cl2 (15 mL) 
was added slowly dropwise and stirred further for 15 min. Triethylamine (6.9 mL, 50.0 mmol, 
5 equiv.) was then added, stirred at -78 °C for 30 min, warmed to r.t. and quenched with 
water (40 mL). The organic layer was separated and the aqueous layer extracted with CH2Cl2 
(3 × 25 mL). The combined organic extracts were washed with saturated aqueous NH4Cl 
solution (50 mL), dried (MgSO4) and evaporated under reduced pressure. The residue was 
purified by silica gel column chromatography (eluent: 30% EtOAc/hexane) to provide the 
title compound as inseparable diastereomers (1.4:1) as a pale yellow oil (1.36 g, 7.3 mmol, 
73%). 
 
1
H NMR (600 MHz, CDCl3): δ 9.81 – 9.75 (m, 1 H, H7), 3.21 and 3.20 (two s, 3 H, H1), 
2.73 (dddd, J = 18.3, 9.7, 5.7, 0.6 Hz, 0.4 H, H6a of diastereomer A), 2.62 (dddd, J = 18.3, 
9.7, 5.7, 0.8 Hz, 0.4 H, H6b of diastereomer A), 2.58 – 2.46 (m, 1.2 H, H6 of diastereomer B), 
2.33 – 2.25 (m, 0.4 H, H5a of diastereomer A), 2.25 – 2.18 (m, 0.6 H, H5a of diastereomer B), 
2.11 – 2.01 (m, 1 H, H5b of diastereomer A and B), 1.68 and 1.64 (two s, 3 H, H2), 1.55 and 
1.44 (two s, 3 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 200.6 and 200.5 (C7), 133.8 and 133.5 (C3), 121.46 and 
121.45 (C4), 51.1 and 50.9 (C1), 38.5 and 38.3 (C6), 30.3 and 29.6 (C5), 23.0 and 22.3 (C2), 
22.9 and 22.5 (C8). 
FTIR (νmax, cm
-1
): 2989 (w), 2943 (w), 2837 (w), 1723 (s, C=O), 1574 (w), 1455 (w), 1415 
(w), 1378 (m), 1191 (s), 1147 (s), 1101 (m), 1053 (s), 1023 (m), 961 (w), 908 (s), 867 (m). 
HRMS (ESI): calculated for C8H15N2O3 [M+H]
+
 187.1077, found 187.1072. 
Rf = 0.43 (30% EtOAc/hexane). 
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5.4.2. Synthetic procedures and characterisation for protodeboronative cross-couplings 
 
General procedure for protodeboronative coupling: A solution of the appropriate 
oxadiazoline (1.0 mmol, 2 equiv.), boronic acid (0.5 mmol, 1.0 equiv.) and DIPEA (0.17 mL, 
1.0 mmol, 2 equiv.) in CH2Cl2 (10 mL) was pumped at a flow rate of 0.125 mL min
-1
 through 
a Vapourtec UV-150 photochemical reactor (10 mL reactor volume, FEP tubing) held at 
10 °C and the reactor output was monitored using a FlowIR
®
 device (SiComp head, 2100-
2000 cm
-1
 and 1750-1700 cm
-1
). After 80 min once the reaction mixture has fully been taken 
up by the pump, the input was swapped to CH2Cl2 solvent. When the FlowIR
®
 showed that 
the reaction plug was exiting the output stream (by monitoring the MeOAc C=O stretch at 
1750-1700 cm
-1
), the reaction plug was directed into a sealed vial containing TBAF (1.5 mL, 
1.5 mmol, 3.0 equiv., 1.0 M in THF) and stirred for 16 h. The mixture was then evaporated 
under reduced pressure, the residue redissolved in EtOAc (5 mL) and filtered through a pad 
of Celite, eluting with EtOAc. The filtrate was evaporated under reduced pressure and 
purified by silica gel column chromatography. 
 
 
4-(4-Chlorophenyl)tetrahydro-2H-pyran (332): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) provided the title 
compound as a colourless oil (69.9 mg, 0.355 mmol, 71%). Data are consistent with a 
reported example.
224 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.4 Hz, 2 H, H2), 7.15 (d, J = 8.4 Hz, 2 H, H3), 
4.17 – 4.00 (m, 2 H, H7a), 3.52 (td, J = 11.5, 2.7 Hz, 2 H, H7b), 2.73 (tt, J = 11.4, 4.5 Hz, 
1 H, H5), 1.85 – 1.68 (m, 4 H, H6a and H6b). 
13
C NMR (150 MHz, CDCl3): δ 144.4 (C4), 132.0 (C1), 128.7 (C2), 128.2 (C3), 68.7 (C7), 
41.1 (C5), 34.0 (C6). 
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FTIR (νmax, cm
-1
): 2938 (m), 2842 (m), 2757 (w), 1493 (m), 1466 (w), 1442 (w), 1430 (w), 
1386 (m), 1365 (w), 1303 (w), 1263 (w), 1237 (m), 1197 (w), 1129 (m), 1089 (s), 1013 (s), 
980 (m), 911 (w), 896 (m), 838 (m), 824 (m), 792 (m). 
HRMS (ESI): calculated for C11H14OCl [M+H]
+
 197.0728, found 197.0737.  
Rf = 0.39 (10% EtOAc/hexane). 
 
 
3-(4-Chlorophenyl)tetrahydrofuran (333): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,7-dioxa-1,2-diazaspiro[4.4]non-1-
ene (304) (0.172 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) provided the title 
compound as a colourless oil (53.2 mg, 0.291 mmol, 58%). 
 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.5 Hz, 2 H, H2), 7.18 (d, J = 8.5 Hz, 2 H, H3), 
4.11 (dd, J = 8.5, 7.6 Hz, 1 H, H8a), 4.05 (td, J = 8.4, 4.6 Hz, 1 H, H7a), 3.94 – 3.87 (m, 1 H, 
H7b), 3.69 (dd, J = 8.5, 7.2 Hz, 1 H, H8b), 3.42 – 3.32 (m, 1 H, H5), 2.41 – 2.31 (m, 1 H, 
H6a), 1.99 – 1.92 (m, 1 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 141.5 (C4), 132.3 (C1), 128.8 (C2), 128.7 (C3), 74.7 (C8), 
68.5 (C7), 44.5 (C5), 34.8 (C6). 
FTIR (νmax, cm
-1
): 2971 (w), 2938 (w), 2861 (w), 1493 (s), 1452 (w), 1413 (w), 1362 (w), 
1181 (w), 1091 (s), 1055 (s), 1014 (s), 970 (w), 903 (m), 822 (s). 
HRMS (ESI): calculated for C10H12OCl [M+H]
+
 183.0571, found 183.0573. 
Rf = 0.29 (10% EtOAc/hexane). 
 
 
4-(4-Chlorophenyl)tetrahydro-2H-thiopyran (334): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4-oxa-8-thia-1,2-diazaspiro[4.5]dec-
1-ene (305) (0.202 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
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purified by silica gel column chromatography (eluent: 2% EtOAc/hexane) provided the title 
compound as a white crystalline solid (53.2 mg, 0.291 mmol, 58%), m.p. 69-70 °C (lit. 
m.p.
225
 70-71 °C). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.4 Hz, 2 H, H2), 7.12 (d, J = 8.4 Hz, 2 H, H3), 
2.87 – 2.79 (m, 2 H, H7a), 2.72 – 2.66 (m, 2 H, H7b), 2.50 (tt, J = 12.5, 3.1 Hz, 1 H, H5), 
2.15 – 2.07 (m, 2 H, H6a), 1.82 (qd, J = 12.5, 3.2 Hz, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 145.4 (C4), 132.0 (C1), 128.7 (C2), 128.3 (C3), 43.9 (C5), 
35.2 (C6), 29.3 (C7). 
FTIR (νmax, cm
-1
): 2926 (w), 2904 (w), 2841 (w), 1596 (w), 1493 (s), 1441 (w), 1428 (w), 
1409 (w), 1306 (w), 1269 (m), 1174 (w), 1093 (s), 1013 (m), 985 (w), 952 (m), 902 (w), 825 
(s), 783 (m). 
HRMS (ESI): calculated for C11H14SCl [M+H]
+
 213.0499, found 213.0497. 
Rf = 0.19 (2% EtOAc/hexane). 
 
 
3-(4-Chlorophenyl)tetrahydrothiophene (335): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4-oxa-7-thia-1,2-diazaspiro[4.4]non-
1-ene (306) (0.188 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 2% EtOAc/hexane) provided the title 
compound as a white crystalline solid (59.4 mg, 0.299 mmol, 60%), m.p. 42-44 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.5 Hz, 2 H, H2), 7.22 (d, J = 8.5 Hz, 2 H, H3), 
3.35 – 3.26 (m, 1 H, H5), 3.15 (dd, J = 10.5, 6.8 Hz, 1 H, H8a), 3.00 – 2.94 (m, 2 H, H7a and 
H7b), 2.86 (dd, J = 10.5, 9.6 Hz, 1 H, H8b), 2.42 – 2.35 (m, 1 H, H6a), 2.06 – 1.97 (m, 1 H, 
H6b). 
13
C NMR (150 MHz, CDCl3): δ 140.7 (C4), 132.5 (C1), 128.8 (C2), 128.5 (C3), 49.1 (C5), 
38.1 (C6), 37.7 (C8), 30.9 (C7). 
FTIR (νmax, cm
-1
): 2932 (w), 2860 (w), 1493 (s), 1456 (w), 1437 (w), 1410 (w), 1262 (w), 
1211 (w), 1091 (m), 1014 (m), 886 (w), 865 (w), 824 (m). 
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HRMS (ESI): calculated for C10H12SCl [M+H]
+
 199.0343, found 199.0345. 
Rf = 0.38 (2% EtOAc/hexane). 
 
 
3-(4-Chlorophenyl)thietane (336): Following the general procedure for protodeboronative 
coupling using 7-methoxy-7-methyl-8-oxa-2-thia-5,6-diazaspiro[3.4]oct-5-ene (307) (0.174 g, 
1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel 
column chromatography (eluent: 2% EtOAc/hexane) provided the title compound as a 
colourless oil (38.9 mg, 0.211 mmol, 42%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.31 (d, J = 8.5 Hz, 2 H, H2), 7.23 (d, J = 8.5 Hz, 2 H, H3), 
4.52 (qn, J = 9.0 Hz, 1 H, H5), 3.53 (t, J = 9.0 Hz, 2 H, H6a), 3.36 (t, J = 9.0 Hz, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 142.6 (C4), 132.8 (C1), 128.9 (C2), 127.4 (C3), 44.6 (C5), 
33.1 (C6). 
FTIR (νmax, cm
-1
): 2977 (w), 2938 (w), 2860 (w), 1595 (w), 1492 (s), 1451 (w), 1409 (w), 
1326 (w), 1236 (w), 1174 (m), 1091 (s), 1014 (s), 941 (w), 908 (w), 846 (m), 816 (s). 
HRMS (ESI): calculated for C9H10SCl [M+H]
+
 185.0186, found 185.0179. 
Rf = 0.33 (2% EtOAc/hexane). 
 
 
tert-Butyl 4-(4-chlorophenyl)piperidine-1-carboxylate (337): Following the general 
procedure for protodeboronative coupling using tert-butyl 3-methoxy-3-methyl-4-oxa-1,2,8-
triazaspiro[4.5]dec-1-ene-8-carboxylate (308) (0.285 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a colourless 
gum (124.4 mg, 0.421 mmol, 84%). Data are consistent with a reported example.
24 
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1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.12 (d, J = 8.5 Hz, 2 H, H3), 
4.23 (br s, 2 H, H7a), 2.78 (br s, 2 H, H7b), 2.61 (tt, J = 12.2, 3.5 Hz, 1 H, H5), 1.78 (br d, 
J = 12.8 Hz, 2 H, H6a), 1.62 – 1.52 (br m, 2 H, H6b), 1.47 (s, 9 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 154.9 (C8), 144.3 (C4), 132.0 (C1), 128.7 (C2), 128.2 (C3), 
79.6 (C9), 45.5 – 43.4 (br, C7), 42.2 (C5), 33.2 (br, C6), 28.6 (C10). 
FTIR (νmax, cm
-1
): 2976 (w), 2934 (w), 2853 (w), 1687 (s, C=O), 1493 (m), 1466 (m), 1445 
(m), 1420 (m), 1365 (m), 1320 (w), 1294 (w), 1276 (m), 1230 (s), 1161 (s), 1123 (m), 1091 
(m), 1012 (m), 987 (w), 933 (w), 908 (w), 884 (w), 862 (w), 824 (m), 769 (w). 
HRMS (ESI): calculated for C16H22NO2ClNa [M+Na]
+
 318.1231, found 318.1229.  
Rf = 0.30 (10% EtOAc/hexane). 
 
 
tert-Butyl 3-(4-chlorophenyl)pyrrolidine-1-carboxylate (338): Following the general 
procedure for protodeboronative coupling using tert-butyl 3-methoxy-3-methyl-4-oxa-1,2,7-
triazaspiro[4.4]non-1-ene-7-carboxylate (309) (0.271 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a colourless 
gum (84.6 mg, 0.300 mmol, 60%). Data are consistent with a reported example.
226 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.3 Hz, 2 H, H2), 7.15 (two superimposed d 
from rotamers, J = 8.3 Hz, 2 H, H3), 3.88 – 3.79 (m, 0.5 H, H8a of rotamer A), 3.79 – 3.72 
(m, 0.5 H, H8a of rotamer B), 3.66 – 3.58 (m, 0.5 H, H7a of rotamer B), 3.57 – 3.49 (m, 
0.5 H, H7a of rotamer A), 3.44 – 3.34 (m, 1 H, H7b of rotamers A and B), 3.34 – 3.25 (m, 
1.5 H, H5 of rotamers A and B, H8b of rotamer A), 3.22 (t, J = 9.9 Hz, 0.5 H, H8b of rotamer 
B), 2.30 – 2.18 (m, 1 H, H6a of rotamers A and B), 1.99 – 1.87 (m, 1 H, H6b of rotamers A 
and B), 1.47 and 1.46 (two superimposed s from rotamers, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 154.6 (C9), 140.1 (C4), 132.6 (C1), 128.8 (C2), 128.5 (C3), 
79.4 (C10), 52.6 and 51.8 (rotameric, C8), 45.9 and 45.6 (rotameric, C7), 43.8 and 42.9 
(rotameric, C5), 33.4 and 32.5 (rotameric, C6), 28.6 (C11). 
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FTIR (νmax, cm
-1
): 2976 (w), 2880 (w), 1688 (s, C=O), 1494 (m), 1478 (w), 1454 (w), 1399 
(s), 1365 (s), 1342 (w), 1254 (w), 1164 (s), 1122 (s), 1092 (s), 1014 (m), 984 (w), 922 (w), 
879 (m), 826 (m), 772 (m). 
HRMS (ESI): calculated for C15H20NO2ClNa [M+Na]
+
 304.1075, found 304.1063.  
Rf = 0.22 (10% EtOAc/hexane). 
 
 
tert-Butyl 3-(4-chlorophenyl)azetidine-1-carboxylate (339): Following the general 
procedure for protodeboronative coupling using tert-butyl 7-methoxy-7-methyl-8-oxa-2,5,6-
triazaspiro[3.4]oct-5-ene-2-carboxylate (310) (0.257 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 20% 
EtOAc/hexane) provided the title compound as a colourless gum (70.9 mg, 0.265 mmol, 
53%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.30 (d, J = 8.5 Hz, 2 H, H2), 7.23 (d, J = 8.5 Hz, 2 H, H3), 
4.31 (t, J = 8.7 Hz, 2 H, H6a), 3.97 – 3.87 (dd, J = 8.7, 6.0 Hz, 2 H, H6b), 3.68 (tt, J = 8.7, 
6.0 Hz, 1 H, H5), 1.45 (s, 9 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 156.4 (C7), 140.8 (C4), 132.7 (C1), 128.9 (C2), 128.3 (C3), 
79.8 (C8), 57.2 and 56.0 (br, C6), 33.0 (C5), 28.5 (C9). 
FTIR (νmax, cm
-1
): 2976 (w), 2887 (w), 1697 (s, C=O), 1494 (m), 1478 (w), 1457 (w), 1390 
(s), 1365 (s), 1338 (m), 1297 (w), 1250 (w), 1129 (s), 1093 (s), 1060 (w), 1014 (m), 967 (w), 
909 (w), 859 (w), 821 (m), 773 (m). 
HRMS (ESI): calculated for C14H18NO2ClNa [M+Na]
+
 290.0918, found 290.0910. 
Rf = 0.43 (20% EtOAc/hexane). 
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1-Chloro-4-cyclohexylbenzene (340): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.5]dec-1-ene 
(311) (0.184 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: hexane) provided the title compound 
as a colourless oil (71.9 mg, 0.369 mmol, 74%). Data are consistent with a reported 
example.
227 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.4 Hz, 2 H, H2), 7.15 (d, J = 8.4 Hz, 2 H, H3), 
2.54 – 2.44 (m, 1 H, H5), 1.91 – 1.81 (m, 4 H, H6a and H7a), 1.80 – 1.73 (m, 1 H, H8a), 1.46 
– 1.34 (m, 4 H, H6b and H7b), 1.32 – 1.20 (m, 1 H, H8b). 
13
C NMR (150 MHz, CDCl3): δ 146.6 (C4), 131.4 (C1), 128.5 (C2), 128.3 (C3), 44.1 (C5), 
34.6 (C6), 26.9 (C7), 26.2 (C8). 
FTIR (νmax, cm
-1
): 2923 (m), 2851 (m), 1492 (m), 1448 (m), 1409 (w), 1351 (w), 1262 (w), 
1178 (w), 1090 (m), 1014 (m), 1000 (w), 892 (w), 818 (s), 775 (w). 
HRMS (ESI): calculated for C12H16Cl [M+H]
+
 195.0935, found 195.0941. 
Rf = 0.76 (hexane). 
 
 
1-Chloro-4-cyclopentylbenzene (341): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.4]non-1-ene 
(312) (0.170 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: hexane) provided the title compound 
as a colourless oil (52.0 mg, 0.288 mmol, 58%). Data are consistent with a reported 
example.
155 
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1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.4 Hz, 2 H, H2), 7.17 (d, J = 8.4 Hz, 2 H, H3), 
3.01 – 2.90 (m, 1 H, H5), 2.10 – 2.01 (m, 2 H, H6a), 1.86 – 1.75 (m, 2 H, H7a), 1.74 – 1.62 
(m, 2 H, H7b), 1.60 – 1.49 (m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 145.1 (C4), 131.3 (C1), 128.6 (C3), 128.4 (C2), 45.5 (C5), 
34.7 (C6), 25.6 (C7). 
FTIR (νmax, cm
-1
): 2953 (m), 2870 (m), 1597 (w), 1493 (s), 1451 (w), 1337 (w), 1179 (w), 
1091 (s), 1014 (m), 947 (w), 818 (s). 
HRMS (ESI): calculated for C11H14Cl [M+H]
+
 181.0779, found 181.0784. 
Rf = 0.75 (hexane). 
  
 
1-Chloro-4-cyclobutylbenzene (342): Following the general procedure for 
protodeboronative coupling using 7-methoxy-7-methyl-8-oxa-5,6-diazaspiro[3.4]oct-5-ene 
(313) (0.156 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: hexane) provided the title compound 
as a colourless oil (46.0 mg, 0.276 mmol, 55%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.4 Hz, 2 H, H2), 7.14 (d, J = 8.4 Hz, 2 H, H3), 
3.51 (qn, J = 8.7 Hz, 1 H, H5), 2.40 – 2.30 (m, 2 H, H6a), 2.16 – 2.07 (m, 2 H, H6b), 2.07 – 
1.97 (m, 1 H, H7a), 1.90 – 1.82 (m, 1 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 144.8 (C4), 131.4 (C1), 128.4 (C2), 127.8 (C3), 39.9 (C5), 
29.9 (C6), 18.3 (C7). 
FTIR (νmax, cm
-1
): 2964 (m), 2940 (m), 2863 (w), 1596 (w), 1491 (m), 1445 (w), 1399 (w), 
1333 (w), 1243 (w), 1091 (s), 1014 (m), 916 (w), 872 (w), 820 (s), 752 (w).  
HRMS (ESI): calculated for C10H12Cl [M+H]
+
 167.0622, found 167.0617. 
Rf = 0.78 (hexane). 
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2-(4-Chlorophenyl)-1,2,3,4-tetrahydronaphthalene (343): Following the general procedure 
for protodeboronative coupling using 5'-methoxy-5'-methyl-3,4-dihydro-1H,5'H-
spiro[naphthalene-2,2'-[1,3,4]oxadiazole] (314) (0.232 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: hexane) provided the title compound as a pale brown amorphous 
solid (116.2 mg, 0.479 mmol, 96%), m.p. 93-94 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.30 (d, J = 8.4 Hz, 2 H, H2), 7.21 (d, J = 8.4 Hz, 2 H, H3), 
7.17 – 7.07 (m, 4 H, H9, H10, H11 and H12), 3.06 – 2.84 (m, 5 H, H5, H7 and H14), 2.15 – 
2.09 (m, 1 H, H6a), 1.96 – 1.87 (m, 1 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 145.2 (C4), 136.4 (C8/C13), 136.2 (C8/C13), 132.0 (C1), 
129.14 (C9/C10/C11/C12), 129.09 (C9/C10/C11/C12), 128.7 (C2), 128.4 (C3), 126.0 
(C9/C10/C11/C12), 125.9 (C9/C10/C11/C12), 40.3 (C5), 37.7 (C14), 30.5 (C6), 29.7 (C7). 
FTIR (νmax, cm
-1
): 3019 (w), 2924 (w), 2836 (w), 1599 (w), 1579 (w), 1492 (s), 1451 (m), 
1436 (m), 1410 (w), 1344 (w), 1297 (w), 1216 (s), 1180 (w), 1108 (w), 1088 (m), 1056 (w), 
1036 (w), 1014 (m), 951 (w), 924 (w), 890 (w), 837 (w), 818 (s), 797 (w). 
HRMS (ESI): calculated for C16H16Cl [M+H]
+
 243.0935, found 243.0934. 
Rf = 0.47 (hexane). 
 
 
2-(4-Chlorophenyl)adamantane (344): Following the general procedure for 
protodeboronative coupling using 5'-methoxy-5'-methyl-5'H-spiro[adamantane-2,2'-
[1,3,4]oxadiazole] (315) (0.236 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: hexane) provided the title 
compound as a colourless oil (91.0 mg, 0.369 mmol, 74%). 
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1
H NMR (600 MHz, CDCl3): δ 7.29 (appears s, 4 H, H2 and H3), 2.97 (br s, 1 H, H5), 2.44 
(br s, 2 H, H6), 2.05 – 1.97 (m, 3 H, H10 and H11a), 1.94 (br d, J = 11.1 Hz, 2 H, H11b), 
1.83 – 1.76 (m, 5 H, H7a, H8 and H9), 1.57 (br d, J = 12.2 Hz, 2 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 143.0 (C4), 130.9 (C1), 128.4 (C2/C3), 128.3 (C2/C3), 46.5 
(C5), 39.2 (C11), 37.9 (C9), 32.0 (C7), 31.2 (C6), 28.1 (C10), 27.8 (C8). 
FTIR (νmax, cm
-1
): 2902 (s), 2849 (m), 1594 (w), 1568 (w), 1493 (s), 1469 (w), 1450 (m), 
1400 (w), 1355 (w), 1342 (w), 1329 (w), 1282 (w), 1227 (w), 1208 (w), 1092 (m), 1070 (w), 
1040 (w), 1013 (m), 971 (m), 950 (w), 913 (w), 870 (w), 851 (m), 832 (m), 818 (m), 784 (m), 
761 (m). 
HRMS (ESI): calculated for C16H20Cl [M+H]
+
 247.1248, found 247.1256. 
Rf = 0.70 (hexane). 
 
 
1-Chloro-4-(1-cyclopropylethyl)benzene (345): Following the general procedure for 
protodeboronative coupling using 2-cyclopropyl-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole (316) (0.236 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: hexane) provided the title 
compound as a colourless oil (78.0 mg, 0.432 mmol, 86%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.28 (d, J = 8.4 Hz, 2 H, H2), 7.20 (d, J = 8.4 Hz, 2 H, H3), 
2.04 – 1.93 (m, 1 H, H5), 1.33 (d, J = 7.1 Hz, 3 H, H9), 0.96 – 0.87 (m, 1 H, H6), 0.61 – 0.54 
(m, 1 H, H7/H8), 0.48 – 0.40 (m, 1 H, H7/H8), 0.25 – 0.18 (m, 1 H, H7/H8), 0.17 – 0.11 (m, 
1 H, H7/H8). 
13
C NMR (150 MHz, CDCl3): δ 145.9 (C4), 131.6 (C1), 128.5 (C2/C3), 128.4 (C2/C3), 44.2 
(C5), 21.6 (C9), 18.6 (C6), 4.8 (C7/C8), 4.4 (C7/C8). 
FTIR (νmax, cm
-1
): 3077 (w), 3000 (w), 2964 (w), 2875 (w), 1492 (s), 1454 (w), 1428 (w), 
1410 (w), 1370 (w), 1282 (w), 1168 (w), 1091 (s), 1036 (w), 1014 (s), 973 (w), 926 (m), 822 
(s), 791 (w), 753 (w). 
HRMS (ESI): calculated for C11H14Cl [M+H]
+
 181.0779, found 181.0783. 
Rf = 0.69 (hexane). 
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1-Chloro-4-(hex-5-en-2-yl)benzene (346): Following the general procedure for 
protodeboronative coupling using 2-(but-3-en-1-yl)-5-methoxy-2,5-dimethyl-2,5-dihydro-
1,3,4-oxadiazole (317) (0.184 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: hexane) provided the title 
compound as a colourless oil (86.6 mg, 0.445 mmol, 89%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.4 Hz, 2 H, H2), 7.12 (d, J = 8.4 Hz, 2 H, H3), 
5.78 (ddt, J = 16.9, 10.2, 6.6 Hz, 1 H, H8), 5.00 – 4.93 (m, 2 H, H9), 2.74 – 2.66 (m, 1 H, H5), 
2.02 – 1.89 (m, 2 H, H7), 1.71 – 1.60 (m, 2 H, H6), 1.23 (d, J = 7.0 Hz, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 145.9 (C4), 138.6 (C8), 131.6 (C1), 128.6 (C2/C3), 128.5 
(C2/C3), 114.7 (C9), 38.9 (C5), 37.5 (C6), 31.9 (C7), 22.3 (C10). 
FTIR (νmax, cm
-1
): 2960 (w), 2925 (w), 1641 (w), 1493 (m), 1456 (w), 1411 (w), 1376 (w), 
1344 (w), 1300 (w), 1180 (w), 1094 (m), 1014 (m), 993 (w), 910 (m), 826 (s), 788 (w), 760 
(w). 
HRMS (ESI): calculated for C12H16Cl [M+H]
+
 195.0935, found 195.0935. 
Rf = 0.72 (hexane). 
 
 
1-Chloro-4-(4,4-dimethylhept-6-yn-2-yl)benzene (347): Following the general procedure 
for protodeboronative coupling using 2-(2,2-dimethylpent-4-yn-1-yl)-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-oxadiazole (318) (0.224 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 
hexane) provided the title compound as a colourless oil (100.2 mg, 0.427 mmol, 85%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.24 (d, J = 8.5 Hz, 2 H, H2), 7.15 (d, J = 8.5 Hz, 2 H, H3), 
2.86 – 2.78 (m, 1 H, H5), 2.02 (dd, J = 16.4, 2.8 Hz, 1 H, H10a), 1.97 (t, J = 2.8 Hz, 1 H, 
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H12), 1.93 (dd, J = 16.4, 2.8 Hz, 1 H, H10b), 1.79 (dd, J = 14.3, 8.6 Hz, 1 H, H6a), 1.63 (dd, 
J = 14.3, 4.2 Hz, 1 H, H6b), 1.22 (d, J = 7.0 Hz, 3 H, H13), 0.89 (s, 3 H, H8/H9), 0.85 (s, 3 H, 
H8/H9). 
13
C NMR (150 MHz, CDCl3): δ 147.5 (C4), 131.4 (C1), 128.6 (C2/C3), 128.5 (C2/C3), 82.6 
(C11), 70.2 (C12), 48.9 (C6), 36.2 (C5), 34.2 (C7), 32.4 (C10), 27.5 (two superimposed s, C8 
and C9), 26.0 (C13). 
FTIR (νmax, cm
-1
): 3307 (w, alkyne CH), 2959 (m), 2926 (w), 1493 (m), 1470 (m), 1454 (w), 
1410 (w), 1388 (w), 1367 (w), 1263 (w), 1179 (w), 1097 (m), 1014 (m), 825 (s), 771 (w). 
HRMS (ESI): calculated for C15H20Cl [M+H]
+
 232.1248, found 232.1243. 
Rf = 0.35 (hexane). 
 
 
8-(4-Chlorophenyl)-1,4-dioxaspiro[4.5]decane (348): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,9,12-trioxa-1,2-
diazadispiro[4.2.4
8
.2
5
]tetradec-1-ene (319) (0.242 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
EtOAc/hexane) provided the title compound as a white crystalline solid (113.6 mg, 
0.449 mmol, 90%), m.p. 82-84 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.5 Hz, 2 H, H2), 7.16 (d, J = 8.5 Hz, 2 H, H3), 
3.98 (s, 4 H, H9 and H10), 2.53 (tt, J = 12.0, 3.4 Hz, 1 H, H5), 1.89 – 1.80 (m, 4 H, H6a and 
H7a), 1.80 – 1.71 (m, 2 H, H6b), 1.71 – 1.64 (m, 2 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 145.1 (C4), 131.7 (C1), 128.5 (C2), 128.3 (C3), 108.5 (C8), 
64.45 (C9/C10), 64.44 (C9/C10), 42.8 (C5), 35.2 (C7), 31.6 (C6). 
FTIR (νmax, cm
-1
): 2938 (m), 2880 (m), 1493 (m), 1445 (w), 1410 (w), 1371 (w), 1335 (w), 
1241 (w), 1172 (w), 1132 (m), 1102 (s), 1035 (m), 1014 (m), 926 (m), 867 (w), 827 (m). 
HRMS (ESI): calculated for C14H18O2Cl [M+H]
+
 253.0990, found 253.0991.  
Rf = 0.27 (10% EtOAc/hexane). 
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Diethyl (2-(4-chlorophenyl)propyl)phosphonate (349): Following the general procedure 
for protodeboronative coupling using diethyl ((5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazol-2-yl)methyl)phosphonate (320) (0.280 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 2% 
MeOH/CH2Cl2) provided the title compound as a colourless oil (92.8 mg, 0.319 mmol, 64%). 
Data are consistent with a reported example.
228 
 
1
H NMR (600 MHz, CDCl3): δ 7.25 (d, J = 8.5 Hz, 2 H, H2), 7.14 (d, J = 8.5 Hz, 2 H, H3), 
4.03 – 3.86 (m, 4 H, H8 and H10), 3.23 – 3.14 (m, 1 H, H5), 2.08 – 1.94 (m, 2 H, H6), 1.34 
(d, J = 7.0 Hz, 3 H, H7), 1.23 (t, J = 7.1 Hz, 3 H, H9/H11), 1.19 (t, J = 7.1 Hz, 3 H, H9/H11). 
13
C NMR (150 MHz, CDCl3): δ 145.2 (d, J = 11.4 Hz, C4), 132.1 (C1), 128.7 (C2), 128.2 
(C3), 61.5 (d, J = 6.6 Hz, C8/C10), 61.4 (d, J = 6.5 Hz, C8/C10), 34.4 (d, J = 139.0 Hz, C6), 
34.3 (d, J = 3.6 Hz, C5), 23.7 (d, J = 10.1 Hz, C7), 16.5 (d, J = 6.1 Hz, C9/C11), 16.4 (d, J = 
6.1 Hz, C9/C11). 
31
P NMR (245 MHz, CDCl3): δ 29.6 (s, 1 P, C6-P). 
FTIR (νmax, cm
-1
): 2981 (w), 2906 (w), 1493 (w), 1456 (w), 1411 (w), 1392 (w), 1243 (m), 
1163 (w), 1095 (m), 1052 (s), 1023 (s), 955 (s), 826 (m), 789 (m), 759 (w).  
HRMS (ESI): calculated for C13H21O3PCl [M+H]
+
 291.0911, found 291.0922. 
Rf = 0.12 (2% MeOH/CH2Cl2). 
 
 
4-(4-Chlorophenyl)tetrahydro-2H-thiopyran 1,1-dioxide (350): Following the general 
procedure for protodeboronative coupling using 3-methoxy-3-methyl-4-oxa-8-thia-1,2-
diazaspiro[4.5]dec-1-ene 8,8-dioxide (325) (0.234 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 50% 
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EtOAc/hexane) provided the title compound as a white crystalline solid (73.6 mg, 
0.301 mmol, 60%), m.p. 208-210 °C (lit. m.p.
225
 208-209 °C). 
 
1
H NMR (600 MHz, CDCl3): δ 7.30 (d, J = 8.4 Hz, 2 H, H2), 7.16 (d, J = 8.4 Hz, 2 H, H3), 
3.18 – 3.09 (m, 4 H, H7a and H7b), 2.77 (tt, J = 12.3, 3.1 Hz, 1 H, H5), 2.43 – 2.30 (m, 2 H, 
H6a), 2.23 – 2.14 (m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 141.7 (C4), 132.9 (C1), 129.1 (C2), 128.1 (C3), 51.5 (C7), 
41.7 (C5), 31.4 (C6). 
FTIR (νmax, cm
-1
): 2932 (w), 1495 (m), 1409 (w), 1342 (m), 1287 (s), 1245 (m), 1171 (w), 
1122 (s), 1090 (m), 1050 (w), 1013 (w), 987 (w), 950 (w), 896 (w), 853 (w), 825 (m), 797 
(w). 
HRMS (ESI): calculated for C11H14O2SCl [M+H]
+
 245.0398, found 245.0392. 
Rf = 0.44 (50% EtOAc/hexane). 
 
 
6-(4-Chlorophenyl)-2,2-dimethyl-1-oxaspiro[2.5]octane (351): Following the general 
procedure for protodeboronative coupling using 9-methoxy-2,2,9-trimethyl-1,10-dioxa-7,8-
diazadispiro[2.2.4
6
.2
3
]dodec-7-ene (321) (0.240 g, 1.0 mmol) and 4-chlorophenylboronic acid 
(329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
Et2O/hexane) provided the title compound as separable diastereomers (1:1) as a white 
crystalline solids (A: 47.2 mg, 0.188 mmol; B: 54.8 mg, 0.219 mmol; combined yield 81%), 
m.p. 91-92 °C for diastereomer A and m.p. 80-82 °C for diastereomer B. 
 
Diastereomer A: 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H, H2), 7.17 (d, J = 8.5 Hz, 2 H, H3), 
2.62 – 2.53 (m, 1 H, H5), 1.94 – 1.85 (m, 2 H, H6a), 1.85 – 1.74 (m, 4 H, H6b and H7a), 1.75 
– 1.64 (m, 2 H, H7b), 1.34 (s, 6 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 145.4 (C4), 131.8 (C1), 128.6 (C2), 128.3 (C3), 65.1 (C8), 
63.0 (C9), 43.2 (C5), 31.6 (C6), 30.3 (C7), 20.7 (C10). 
FTIR (νmax, cm
-1
): 2926 (m), 1493 (s), 1441 (w), 1377 (m), 1274 (w), 1222 (w), 1178 (w), 
1126 (m), 1094 (s), 1073 (m), 1013 (m), 970 (w), 926 (w), 880 (w), 862 (m), 827 (s). 
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HRMS (ESI): calculated for C15H19OClNa [M+Na]
+
 273.1017, found 273.1010.  
Rf = 0.37 (10% Et2O/hexane). 
 
Diastereomer B: 
1
H NMR (600 MHz, CDCl3): δ 7.26 (d, J = 8.5 Hz, 2 H), 7.16 (d, J = 8.5 Hz, 2 H), 2.64 (tt, 
J = 12.1, 3.6 Hz, 1 H, H5), 2.05 – 1.97 (m, 2 H, H6a), 1.85 (td, J = 13.4, 3.5 Hz, 2 H, H7a), 
1.81 – 1.74 (m, 2 H, H7b), 1.58 – 1.46 (m, 2 H, H6b), 1.40 (s, 6 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 144.7 (C4), 131.9 (C1), 128.6 (C2), 128.2 (C3), 66.3 (C8), 
62.5 (C9), 43.2 (C5), 33.6 (C6), 31.5 (C7), 21.0 (C10). 
FTIR (νmax, cm
-1
): 3005 (w), 2979 (w), 2921 (m), 2856 (m), 1492 (m), 1470 (w), 1412 (w), 
1377 (m), 1214 (w), 1168 (w), 1120 (m), 1087 (m), 1060 (w), 1015 (m), 985 (w), 896 (w), 
857 (m), 821 (s). 
HRMS (ESI): calculated for C15H19OClNa [M+Na]
+
 273.1017, found 273.1012. 
Rf = 0.21 (10% Et2O/hexane). 
 
 
1-(5-Bromopentan-2-yl)-4-chlorobenzene (352): Following the general procedure for 
protodeboronative coupling using 2-(3-bromopropyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-
1,3,4-oxadiazole (326) (0.251 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: hexane) provided the title 
compound as a colourless oil (42.2 mg, 0.161 mmol, 32%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 (d, J = 8.4 Hz, 2 H, H2), 7.11 (d, J = 8.4 Hz, 2 H, H3), 
3.41 – 3.28 (m, 2 H, H8), 2.74 – 2.65 (m, 1 H, H5), 1.86 – 1.62 (m, 4 H, H6 and H7), 1.25 (d, 
J = 7.0 Hz, 3 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 145.4 (C4), 131.8 (C1), 128.7 (C2), 128.4 (C3), 39.0 (C5), 
36.8 (C6), 33.9 (C8), 31.0 (C7), 22.5 (C9). 
FTIR (νmax, cm
-1
): 2961 (m), 2927 (w), 1596 (w), 1493 (m), 1455 (m), 1411 (w), 1377 (w), 
1295 (w), 1245 (w), 1214 (w), 1091 (m), 1013 (m), 946 (w), 824 (s), 787 (w), 769 (w). 
HRMS (ESI): calculated for C11H15BrCl [M+H]
+
 261.0040, found 261.0045. 
Rf = 0.32 (hexane). 
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2-(2-(4-Chlorophenyl)propyl)furan (353): Following the general procedure for 
protodeboronative coupling using 2-(furan-2-ylmethyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-
1,3,4-oxadiazole (322) (0.210 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: hexane) provided the title 
compound as an orange oil (72.0 mg, 0.326 mmol, 65%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.31 – 7.28 (m, 1 H, H10), 7.26 (d, J = 8.5 Hz, 2 H, H2), 
7.11 (d, J = 8.5 Hz, 2 H, H3), 6.24 (dd, J = 3.1, 1.9 Hz, 1 H, H9), 5.88 (d, J = 3.1 Hz, 1 H, 
H8), 3.17 – 3.09 (m, 1 H, H5), 2.89 (dd, J = 14.9, 7.0 Hz, 1 H, H6a), 2.83 (dd, J = 14.9, 
7.8 Hz, 1 H, H6b), 1.27 (d, J = 7.0 Hz, 3 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 154.3 (C7), 145.0 (C4), 141.1 (C10), 131.9 (C1), 128.6 (C2), 
128.4 (C3), 110.2 (C9), 106.4 (C8), 38.8 (C5), 36.9 (C6), 21.5 (C11). 
FTIR (νmax, cm
-1
): 2964 (w), 2930 (w), 1795 (w), 1597 (w), 1493 (s), 1455 (w), 1411 (w), 
1376 (w), 1210 (w), 1146 (m), 1093 (s), 1012 (s), 933 (m), 883 (w), 824 (s), 767 (w). 
HRMS (ESI): calculated for C13H14OCl [M+H]
+
 221.0728, found 221.0734. 
Rf = 0.47 (hexane). 
 
 
2-(4-(4-Chlorophenyl)piperidin-1-yl)pyrimidine (354): Following the general procedure 
for protodeboronative coupling using 3-methoxy-3-methyl-8-(pyrimidin-2-yl)-4-oxa-1,2,8-
triazaspiro[4.5]dec-1-ene (323) (0.263 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) 
(78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 20% 
EtOAc/hexane) provided the title compound as a white crystalline solid (77.4 mg, 
0.283 mmol, 57%), m.p. 88-90 °C. 
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1
H NMR (600 MHz, CDCl3): δ 8.31 (d, J = 4.7 Hz, 2 H, H9), 7.26 (d, J = 8.4 Hz, 2 H, H2), 
7.14 (d, J = 8.4 Hz, 2 H, H3), 6.46 (t, J = 4.7 Hz, 1 H, H10), 4.97 – 4.88 (m, 2 H, H7a), 2.94 
(td, J = 12.7, 2.4 Hz, 2 H, H7b), 2.77 (tt, J = 12.7, 3.5 Hz, 1 H, H5), 1.94 – 1.87 (m, 2 H, 
H6a), 1.65 (qd, J = 12.7, 4.2 Hz, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 161.7 (C8), 157.9 (C9), 144.5 (C4), 132.0 (C1), 128.7 (C2), 
128.3 (C3), 109.6 (C10), 44.5 (C7), 42.6 (C5), 33.2 (C6). 
FTIR (νmax, cm
-1
): 3026 (w), 2991 (w), 2934 (w), 2849 (w), 1584 (s), 1545 (m), 1493 (s), 
1459 (m), 1446 (m), 1410 (w), 1393 (w), 1361 (s), 1306 (w), 1273 (w), 1239 (w), 1180 (w), 
1094 (w), 1012 (w), 979 (m), 947 (w), 827 (w), 796 (m). 
HRMS (ESI): calculated for C15H17N3Cl [M+H]
+
 274.1106, found 274.1116.   
Rf = 0.24 (20% EtOAc/hexane). 
 
 
4-(4-Bromophenyl)tetrahydro-2H-pyran (355): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 4-bromophenylboronic acid (100.4 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) provided the title 
compound as a white amorphous solid (82.9 mg, 0.344 mmol, 69%), m.p. 72-74 °C (lit. 
m.p.
164
 61-62 °C). Data are consistent with a reported example.
164 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.4 Hz, 2 H, H2), 7.10 (d, J = 8.4 Hz, 2 H, H3), 
4.12 – 4.03 (m, 2 H, H7a), 3.51 (td, J = 11.5, 2.8 Hz, 2 H, H7b), 2.72 (tt, J = 11.4, 4.5 Hz, 
1 H, H5), 1.83 – 1.70 (m, 4 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 144.9 (C4), 131.7 (C2), 128.6 (C3), 120.1 (C1), 68.4 (C7), 
41.2 (C5), 33.9 (C6). 
FTIR (νmax, cm
-1
): 2963 (w), 2939 (m), 2915 (m), 2871 (w), 2841 (m), 1590 (w), 1490 (m), 
1440 (w), 1428 (w), 1408 (w), 1383 (m), 1300 (w), 1295 (w), 1263 (w), 1250 (w), 1236 (m), 
1199 (w), 1126 (s), 1085 (s), 1075 (m), 1020 (m), 1008 (m), 979 (m), 910 (w), 896 (m), 837 
(m), 819 (s). 
HRMS (ESI): calculated for C11H14OBr [M+H]
+
 241.0223, found 241.0226.   
Rf = 0.25 (10% EtOAc/hexane). 
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4-(4-(Trifluoromethyl)phenyl)tetrahydro-2H-pyran (356): Following the general 
procedure for protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and 4-(trifluoromethyl)phenylboronic 
acid (95.0 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
EtOAc/hexane) provided the title compound as a colourless oil (78.0 mg, 0.339 mmol, 68%). 
Data are consistent with a reported example.
229 
 
1
H NMR (600 MHz, CDCl3): δ 7.57 (d, J = 8.2 Hz, 2 H, H3), 7.34 (d, J = 8.2 Hz, 2 H, H4), 
4.16 – 4.04 (m, 2 H, H8a), 3.54 (td, J = 11.7, 2.3 Hz, 2 H, H8b), 2.83 (tt, J = 11.8, 4.0 Hz, 
1 H, H6), 1.91 – 1.72 (m, 4 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 149.9 (C5), 128.8 (q, J = 32.3 Hz, C2), 127.2 (C4), 125.6 (q, 
J = 3.8 Hz, C3), 124.4 (q, J = 271.8 Hz, C1), 68.3 (C8), 41.6 (C6), 33.8 (C7). 
19
F NMR (376 MHz, CDCl3): δ -62.4 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 2939 (w), 2845 (w), 1619 (w), 1468 (w), 1444 (w), 1420 (w), 1387 (w), 
1324 (s), 1259 (w), 1239 (w), 1190 (w), 1162 (m), 1116 (s), 1098 (s), 1086 (m), 1068 (s), 
1016 (m), 982 (w), 955 (w), 913 (w), 896 (w), 837 (m), 802 (w), 761 (w). 
HRMS (ESI): calculated for C12H14F3O [M+H]
+
 231.0991, found 231.0984. 
Rf = 0.21 (10% EtOAc/hexane). 
 
 
4-(Tetrahydro-2H-pyran-4-yl)benzonitrile (357): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 4-cyanophenylboronic acid (73.5 mg, 0.5 mmol), purified 
by silica gel column chromatography (eluent: 20% EtOAc/hexane) provided the title 
compound as a white amorphous solid (52.7 mg, 0.281 mmol, 56%), m.p. 58-60 °C. 
Compound has been prepared previously,
229
 but NMR spectra were recorded in acetone-d6. 
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1
H NMR (600 MHz, CDCl3): δ 7.59 (d, J = 8.3 Hz, 2 H, H3), 7.31 (d, J = 8.3 Hz, 2 H, H4), 
4.11 – 4.04 (m, 2 H, H8a), 3.51 (td, J = 11.5, 2.7 Hz, 2 H, H8b), 2.81 (tt, J = 11.5, 4.4 Hz, 
1 H, H6), 1.84 – 1.70 (m, 4 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 151.2 (C5), 132.5 (C3), 127.7 (C4), 119.0 (C1), 110.3 (C2), 
68.1 (C8), 41.8 (C6), 33.5 (C7). 
FTIR (νmax, cm
-1
): 2939 (m), 2842 (m), 2226 (m, C≡N), 1608 (m), 1505 (m), 1467 (w), 1443 
(m), 1417 (w), 1387 (m), 1292 (w), 1265 (w), 1239 (m), 1200 (w), 1179 (w), 1124 (s), 1100 
(m), 1084 (s), 1018 (m), 982 (m), 913 (w), 895 (m), 838 (s), 808 (m). 
HRMS (ESI): calculated for C12H14NO [M+H]
+
 188.1070, found 188.1086. 
Rf = 0.22 (20% EtOAc/hexane). 
 
 
Methyl 4-(tetrahydro-2H-pyran-4-yl)benzoate (358): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 4-methoxycarbonylphenylboronic acid (90.0 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: 5% Et2O/CH2Cl2) provided 
the title compound as a white crystalline solid (63.4 mg, 0.306 mmol, 61%), m.p. 71-72 °C 
(lit. m.p.
159
 74-75 °C). Data are consistent with a reported example.
159 
 
1
H NMR (600 MHz, CDCl3): δ 7.98 (d, J = 8.3 Hz, 2 H, H4), 7.29 (d, J = 8.3 Hz, 2 H, H5), 
4.08 (dd, J = 11.5, 4.2 Hz, 2 H, H9a), 3.90 (s, 3 H, H1), 3.53 (td, J = 11.5, 2.3 Hz, 2 H, H9b), 
2.81 (tt, J = 11.8, 4.0 Hz, 1 H, H7), 1.88 – 1.73 (m, 4 H, H8). 
13
C NMR (150 MHz, CDCl3): δ 167.1 (C2), 151.2 (C6), 130.0 (C4), 128.4 (C3), 126.9 (C5), 
68.3 (C9), 52.1 (C1), 41.8 (C7), 33.7 (C8). 
FTIR (νmax, cm
-1
): 2964 (w), 2933 (w), 2907 (w), 2853 (w), 1719 (s, C=O), 1610 (w), 1573 
(w), 1440 (m), 1415 (w), 1390 (w), 1362 (w), 1289 (m), 1278 (m), 1236 (w), 1198 (w), 1180 
(w), 1168 (w), 1130 (w), 1110 (m), 1097 (m), 1082 (m), 1018 (m), 978 (w), 962 (w), 915 (w), 
894 (w), 858 (w), 842 (w), 825 (w), 764 (m). 
HRMS (ESI): calculated for C13H17O3 [M+H]
+
 221.1172, found 221.1179. 
Rf = 0.38 (5% Et2O/CH2Cl2). 
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N-(3-(Tetrahydro-2H-pyran-4-yl)phenyl)acetamide (359): Following the general 
procedure for protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and 3-acetamidophenylboronic acid (89.5 
mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 5% MeOH/CH2Cl2) 
provided the title compound as an off-white amorphous solid (96.9 mg, 0.442 mmol, 88%), 
m.p. 128-131 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.58 (br s, 1 H, NH), 7.41 (s, 1 H, H8), 7.35 (d, J = 8.0 Hz, 
1 H, H4), 7.28 – 7.21 (m, 1 H, H5), 6.96 (d, J = 7.6 Hz, 1 H, H6), 4.06 (dd, J = 11.3, 3.5 Hz, 
2 H, H11a), 3.51 (td, J = 11.3, 2.4 Hz, 2 H, H11b), 2.73 (tt, J = 11.6, 4.2 Hz, 1 H, H9), 2.16 (s, 
3 H, H1), 1.85 – 1.70 (m, 4 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 168.6 (C2), 147.0 (C7), 138.3 (C3), 129.2 (C5), 122.7 (C6), 
118.4 (C8), 118.0 (C4), 68.4 (C11), 41.6 (C9), 34.0 (C10), 24.7 (C1). 
FTIR (νmax, cm
-1
): 3290 (w, NH), 2938 (m), 2845 (m), 1668 (s, C=O), 1611 (s), 1594 (m), 
1555 (s), 1490 (m), 1442 (m), 1372 (m), 1303 (m), 1259 (m), 1238 (m), 1130 (m), 1084 (m), 
1015 (m), 980 (w), 917 (w), 869 (w), 824 (w), 791 (w). 
HRMS (ESI): calculated for C13H18NO2 [M+H]
+
 220.1332, found 220.1328. 
Rf = 0.27 (5% MeOH/CH2Cl2). 
 
 
1-(1-Cyclopropylethyl)-4-methoxybenzene (360): Following a modified version of the 
general procedure for protodeboronative coupling using 2-cyclopropyl-5-methoxy-2,5-
dimethyl-2,5-dihydro-1,3,4-oxadiazole (316) (0.236 g, 1.0 mmol) and 4-
methoxyphenylboronic acid (76.0 mg, 0.5 mmol) – the output of the reactor was heated in the 
sealed vial at 75 °C for 16 h. Purification by silica gel column chromatography (eluent: 2% 
EtOAc/hexane) provided the title compound as a colourless oil (49.0 mg, 0.278 mmol, 56%). 
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1
H NMR (600 MHz, CDCl3): δ 7.20 (d, J = 8.6 Hz, 2 H, H4), 6.87 (d, J = 8.6 Hz, 2 H, H3), 
3.81 (s, 3 H, H1), 2.02 – 1.92 (m, 1 H, H6), 1.33 (d, J = 7.1 Hz, 3 H, H10), 0.97 – 0.87 (m, 
1 H, H7), 0.59 – 0.51 (m, 1 H, H8a), 0.48 – 0.40 (m, 1 H, H9a), 0.24 – 0.12 (m, 2 H, H8b and 
H9b). 
13
C NMR (150 MHz, CDCl3): δ 157.9 (C2), 139.6 (C5), 127.9 (C4), 113.7 (C3), 55.4 (C1), 
43.8 (C6), 21.8 (C10), 18.9 (C7), 4.7 (C8/C9), 4.4 (C8/C9). 
FTIR (νmax, cm
-1
): 3076 (w), 2998 (w), 2959 (w), 2934 (w), 2835 (w), 1612 (w), 1584 (w), 
1510 (s), 1455 (w), 1442 (w), 1428 (w), 1369 (w), 1333 (w), 1303 (w), 1288 (w), 1268 (w), 
1241 (s), 1178 (m), 1111 (w), 1073 (w), 1030 (m), 1015 (m), 972 (w), 925 (w), 830 (m), 806 
(m), 769 (w). 
HRMS (ESI): calculated for C12H17O [M+H]
+
 177.1274, found 177.1266. 
Rf = 0.37 (2% EtOAc/hexane). 
 
 
4-(o-Tolyl)tetrahydro-2H-pyran (361): Following a modified version of the general 
procedure for protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and o-tolylboronic acid (68.0 mg, 
0.5 mmol) – the output of the reactor was heated in the sealed vial at 75 °C for 16 h. 
Purification by silica gel column chromatography (eluent: 5% EtOAc/hexane) provided the 
title compound as a colourless oil (60.9 mg, 0.346 mmol, 69%). Data are consistent with a 
reported example.
229 
 
1
H NMR (600 MHz, CDCl3): δ 7.27 – 7.20 (m, 2 H, H5 and H6), 7.18 (d, J = 6.9 Hz, 1 H, 
H3), 7.15 – 7.11 (m, 1 H, H4), 4.12 (dd, J = 11.8, 4.4 Hz, 2 H, H10a), 3.58 (td, J = 11.8, 1.9 
Hz, 2 H, H10b), 3.00 (tt, J = 12.0, 3.6 Hz, 1 H, H8), 2.38 (s, 3 H, H1), 1.90 – 1.80 (m, 2 H, 
H9a), 1.74 – 1.67 (m, 2 H, H9b). 
13
C NMR (150 MHz, CDCl3): δ 143.8 (C7), 135.2 (C2), 130.5 (C3), 126.5 (C5), 126.1 (C4), 
125.6 (C6), 68.8 (C10), 37.5 (C8), 33.3 (C9), 19.4 (C1). 
FTIR (νmax, cm
-1
): 3020 (w), 2944 (m), 2840 (m), 1605 (w), 1493 (m), 1462 (m), 1442 (w), 
1386 (m), 1367 (w), 1297 (w), 1257 (w), 1235 (m), 1217 (w), 1173 (w), 1132 (m), 1121 (m), 
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1091 (m), 1052 (w), 1021 (m), 1011 (m), 980 (m), 940 (w), 895 (m), 834 (m), 809 (w), 779 
(w), 750 (s). 
HRMS (ESI): calculated for C12H17O [M+H]
+
 177.1274, found 177.1277. 
Rf = 0.22 (5% EtOAc/hexane). 
 
 
3-(Tetrahydro-2H-pyran-4-yl)pyridine (362): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 3-pyridinylboronic acid (61.5 mg, 0.5 mmol), purified by 
silica gel column chromatography (eluent: 5% MeOH/CH2Cl2) provided the title compound 
as a yellow oil (24.6 mg, 0.151 mmol, 30%). Compound has been prepared previously,
229
 but 
NMR spectra were recorded in acetone-d6.  
 
1
H NMR (600 MHz, CDCl3): δ 8.51 (br s, 1 H, H5), 8.47 (d, J = 3.9 Hz, 1 H, H1), 7.55 (dt, J 
= 7.9, 1.8 Hz, 1 H, H3), 7.28 – 7.24 (m, 1 H, H2), 4.12 – 4.07 (m, 2 H, H8a), 3.54 (td, J = 
11.7, 2.4 Hz, 2 H, H8b), 2.80 (tt, J = 11.8, 4.2 Hz, 1 H, H6), 1.87 – 1.74 (m, 4 H, H7). 
13
C NMR (150 MHz, CDCl3): δ 148.9 (C5), 147.9 (C1), 141.0 (C4), 134.3 (C3), 123.7 (C2), 
68.3 (C8), 39.2 (C6), 33.7 (C7). 
FTIR (νmax, cm
-1
): 2938 (m), 2846 (m), 1576 (w), 1480 (w), 1443 (w), 1426 (m), 1388 (m), 
1275 (w), 1263 (w), 1239 (m), 1182 (w), 1126 (s), 1098 (m), 1085 (s), 1050 (w), 1020 (s), 
982 (m), 895 (m), 840 (m), 812 (w). 
HRMS (ESI): calculated for C10H14NO [M+H]
+
 164.1070, found 164.1062. 
Rf = 0.37 (5% MeOH/CH2Cl2). 
 
 
4-(Thiophen-2-yl)tetrahydro-2H-pyran (363): Following the general procedure for 
protodeboronative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-
ene (303) (0.186 g, 1.0 mmol) and 2-thienylboronic acid (64.0 mg, 0.5 mmol), purified by 
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silica gel column chromatography (eluent: 30% CH2Cl2/hexane) provided the title compound 
as a colourless oil (32.3 mg, 0.192 mmol, 38%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.15 (dd, J = 5.1, 1.1 Hz, 1 H, H1), 6.95 (dd, J = 5.1, 3.5 Hz, 
1 H, H2), 6.85 – 6.82 (m, 1 H, H3), 4.08 – 4.02 (m, 2 H, H7a), 3.52 (td, J = 11.8, 2.1 Hz, 2 H, 
H7b), 3.07 (tt, J = 11.8, 3.9 Hz, 1 H, H5), 1.97 – 1.92 (m, 2 H, H6a), 1.87 – 1.79 (m, 2 H, 
H6b). 
13
C NMR (150 MHz, CDCl3): δ 150.2 (C4), 126.8 (C2), 122.8 (C1), 122.3 (C3), 68.1 (C7), 
36.7 (C5), 35.1 (C6). 
FTIR (νmax, cm
-1
): 2937 (m), 2842 (m), 1533 (w), 1466 (w), 1442 (m), 1387 (m), 1311 (w), 
1257 (m), 1240 (m), 1125 (s), 1088 (s), 1015 (m), 981 (m), 879 (m), 852 (m), 821 (m). 
HRMS (ESI): calculated for C9H13OS [M+H]
+
 169.0682, found 169.0682. 
Rf = 0.24 (30% CH2Cl2/hexane). 
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5.4.3. Synthetic procedures and characterisation for oxidative cross-couplings 
 
General procedure for oxidative coupling: A solution of the appropriate oxadiazoline 
(1.0 mmol, 2 equiv.), boronic acid (0.5 mmol, 1.0 equiv.) and DIPEA (0.17 mL, 1.0 mmol, 
2 equiv.) in CH2Cl2 (10 mL) was pumped at a flow rate of 0.125 mL min
-1
 through a 
Vapourtec UV-150 photochemical reactor (10 mL reactor volume, FEP tubing) held at 10 °C 
and the reactor output was monitored using a FlowIR
®
 device (SiComp head, 2100-2000 cm
-1
 
and 1750-1700 cm
-1
). After 80 min once the reaction mixture has fully been taken up by the 
pump, the input was swapped to CH2Cl2 solvent. When the FlowIR
®
 showed that the reaction 
plug was exiting the output stream (by monitoring the MeOAc C=O stretch at 1750-        
1700  cm
-1
), the reaction plug was directed into a round-bottomed flask and stirred for 16 h 
under air. The mixture was then evaporated under reduced pressure and the residue purified 
by silica gel column chromatography.   
 
 
4-(4-Chlorophenyl)tetrahydro-2H-pyran-4-ol (331): Following the general procedure for 
oxidative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-ene (303) 
(0.186 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by 
silica gel column chromatography (eluent: 40% EtOAc/hexane) provided the title compound 
as a white crystalline solid (80.6 mg, 0.378 mmol, 76%), m.p. 69-71 °C (lit. m.p.
230
 77-78 °C). 
Data are consistent with a reported example.
230 
 
1
H NMR (600 MHz, CDCl3): δ 7.41 (d, J = 8.8 Hz, 2 H, H2), 7.33 (d, J = 8.8 Hz, 2 H, H3), 
3.89 (td, J = 11.8, 2.1 Hz, 2 H, H7a), 3.86 – 3.81 (m, 2 H, H7b), 2.14 – 2.06 (m, 2 H, H6a), 
1.99 (br s, 1 H, OH), 1.67 – 1.60 (m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 146.8 (C4), 133.1 (C1), 128.7 (C3), 126.1 (C2), 70.5 (C5), 
63.9 (C7), 38.8 (C6). 
FTIR (νmax, cm
-1
): 3399 (br m, OH), 2955 (m), 2871 (m), 1595 (w), 1494 (m), 1467 (w), 
1388 (m), 1302 (w), 1238 (m), 1222 (w), 1125 (m), 1095 (s), 1033 (m), 1013 (s), 965 (w), 
915 (w), 826 (s), 798 (w). 
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HRMS (ESI): calculated for C11H13O2ClNa [M+Na]
+
 235.0496, found 235.0505. 
Rf = 0.28 (40% EtOAc/hexane). 
 
 
3-(4-Chlorophenyl)tetrahydrofuran-3-ol (370): Following the general procedure for 
oxidative coupling using 3-methoxy-3-methyl-4,7-dioxa-1,2-diazaspiro[4.4]non-1-ene (304) 
(0.172 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by 
silica gel column chromatography (eluent: 40% EtOAc/hexane) provided the title compound 
as a colourless oil (57.0 mg, 0.287 mmol, 57%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.6 Hz, 2 H, H2), 7.33 (d, J = 8.6 Hz, 2 H, H3), 
4.19 (td, J = 8.8, 7.0 Hz, 1 H, H7a), 4.10 (td, J = 8.8, 3.5 Hz, 1 H, H7b), 3.93 (dd, J = 9.5, 
1.3 Hz, 1 H, H8a), 3.84 (d, J = 9.5 Hz, 1 H, H8b), 2.56 (br s, 1 H, OH), 2.37 (dt, J = 13.1, 8.8 
Hz, 1 H, H6a), 2.24 (dddd, J = 13.1, 7.0, 3.5, 1.3 Hz, 1 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 140.9 (C4), 133.5 (C1), 128.7 (C3), 126.9 (C2), 81.6 (C5), 
80.5 (C8), 68.1 (C7), 42.2 (C6). 
FTIR (νmax, cm
-1
): 3386 (br m, OH), 2955 (w), 2882 (w), 1599 (w), 1493 (m), 1440 (w), 
1400 (w), 1359 (w), 1252 (w), 1136 (m), 1094 (s), 1057 (s), 1013 (s), 976 (m), 923 (m), 892 
(m), 823 (s), 775 (m). 
HRMS (ESI): calculated for C10H11O2ClNa [M+Na]
+
 221.0340, found 221.0334. 
Rf = 0.28 (40% EtOAc/hexane). 
 
 
4-(4-Chlorophenyl)tetrahydro-2H-thiopyran-4-ol (371): Following the general procedure 
for oxidative coupling using 3-methoxy-3-methyl-4-oxa-8-thia-1,2-diazaspiro[4.5]dec-1-ene 
(305) (0.202 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 30% Et2O/hexane) provided the title 
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compound as an off-white crystalline solid (95.2 mg, 0.416 mmol, 83%), m.p. 88-90 °C (lit. 
m.p.
230
 86-87 °C). Data are consistent with a reported example.
230 
 
1
H NMR (600 MHz, CDCl3): δ 7.40 (d, J = 8.7 Hz, 2 H, H2), 7.32 (d, J = 8.7 Hz, 2 H, H3), 
3.24 – 3.12 (m, 2 H, H7a), 2.51 – 2.42 (m, 2 H, H7b), 2.18 – 2.08 (m, 2 H, H6a), 2.02 – 1.94 
(m, 2 H, H6b), 1.60 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 147.7 (C4), 133.0 (C1), 128.6 (C3), 125.9 (C2), 71.9 (C5), 
39.6 (C6), 24.2 (C7). 
FTIR (νmax, cm
-1
): 3428 (br m, OH), 2916 (m), 1596 (w), 1494 (s), 1424 (m), 1399 (w), 1304 
(w), 1275 (m), 1227 (m), 1179 (w), 1136 (w), 1095 (s), 1067 (s), 1027 (w), 1013 (s), 968 (s), 
927 (s), 881 (w), 827 (s), 777 (w). 
HRMS (ESI): calculated for C11H13OSClNa [M+Na]
+
 251.0268, found 251.0270. 
Rf = 0.22 (30% Et2O/hexane). 
 
 
3-(4-Chlorophenyl)tetrahydrothiophen-3-ol (372): Following the general procedure for 
oxidative coupling using 3-methoxy-3-methyl-4-oxa-7-thia-1,2-diazaspiro[4.4]non-1-ene 
(306) (0.188 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), 
purified by silica gel column chromatography (eluent: 30% Et2O/hexane) provided the title 
compound as a colourless oil (62.6 mg, 0.292 mmol, 58%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.47 (d, J = 8.6 Hz, 2 H, H2), 7.33 (d, J = 8.6 Hz, 2 H, H3), 
3.20 (d, J = 11.6 Hz, 1 H, H8a), 3.13 (td, J = 10.5, 7.0 Hz, 1 H, H7a), 3.05 (ddd, J = 10.5, 7.7, 
2.5 Hz, 1 H, H7b), 2.96 (dd, J = 11.6, 1.4 Hz, 1 H, H8b), 2.71 (br s, 1 H, OH), 2.33 – 2.23 (m, 
2 H, H6). 
13
C NMR (150 MHz, CDCl3): δ 141.1 (C4), 133.5 (C1), 128.6 (C3), 126.8 (C2), 83.5 (C5), 
45.5 (C8), 43.4 (C6), 29.0 (C7). 
FTIR (νmax, cm
-1
): 3418 (br w, OH), 2938 (w), 1706 (w), 1596 (w), 1493 (m), 1427 (w), 
1400 (m), 1358 (m), 1269 (w), 1208 (m), 1176 (w), 1093 (s), 1065 (w), 1035 (s), 1013 (s), 
984 (w), 957 (m), 935 (m), 822 (s). 
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HRMS (ESI): calculated for C10H11OSClNa [M+Na]
+
 237.0111, found 237.0110. 
Rf = 0.29 (30% Et2O/hexane). 
 
 
3-(4-Chlorophenyl)thietan-3-ol (373): Following the general procedure for oxidative 
coupling using 7-methoxy-7-methyl-8-oxa-2-thia-5,6-diazaspiro[3.4]oct-5-ene (307) (0.174 g, 
1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel 
column chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a 
yellow oil (20.0 mg, 0.100 mmol, 20%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.63 (d, J = 8.6 Hz, 2 H, H2), 7.38 (d, J = 8.6 Hz, 2 H, H3), 
3.59 (s, 4 H, H6), 2.86 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 143.1 (C4), 134.0 (C1), 128.9 (C3), 125.9 (C2), 78.8 (C5), 
42.8 (C6). 
FTIR (νmax, cm
-1
): 3365 (br w, OH), 2987 (w), 2939 (w), 2850 (w), 1682 (w), 1598 (w), 
1575 (w), 1491 (m), 1426 (w), 1400 (w), 1368 (w), 1304 (w), 1265 (w), 1212 (m), 1175 (m), 
1127 (w), 1092 (m), 1053 (m), 1013 (m), 954 (m), 880 (w), 826 (s), 771 (w). 
HRMS (ESI): calculated for C9H9OSClNa [M+Na]
+
 222.9955, found 222.9948. 
Rf = 0.21 (10% EtOAc/hexane). 
 
 
tert-Butyl 4-(4-chlorophenyl)-4-hydroxypiperidine-1-carboxylate (374): Following the 
general procedure for oxidative coupling using tert-butyl 3-methoxy-3-methyl-4-oxa-1,2,8-
triazaspiro[4.5]dec-1-ene-8-carboxylate (308) (0.285 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: 20% → 30% EtOAc/hexane) provided the title compound as a 
colourless gum (125.1 mg, 0.401 mmol, 80%). 
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1
H NMR (600 MHz, CDCl3): δ 7.40 (d, J = 8.7 Hz, 2 H, H2), 7.31 (d, J = 8.7 Hz, 2 H, H3), 
3.99 (br s, 2 H, H7a), 3.20 (br s, 2 H, H7b), 2.02 (br s, 1 H, OH), 1.93 (br s, 2 H, H6a), 1.72 – 
1.66 (m, 2 H, H6b), 1.46 (s, 9 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 155.0 (C8), 146.8 (C4), 133.1 (C1), 128.6 (C3), 126.2 (C2), 
79.8 (C9), 71.4 (C5), 40.7 – 38.9 (br, C7), 38.5 – 37.6 (br, C6), 28.6 (C10). 
FTIR (νmax, cm
-1
): 3431 (br w, OH), 2975 (w), 2927 (w), 1662 (s, C=O), 1479 (m), 1425 (m), 
1392 (m), 1366 (m), 1319 (w), 1277 (m), 1248 (m), 1216 (m), 1163 (s), 1138 (m), 1093 (m), 
1029 (m), 1013 (m), 958 (w), 909 (m), 861 (m), 824 (m), 795 (w), 769 (m). 
HRMS (ESI): calculated for C16H22NO3ClNa [M+Na]
+
 334.1180, found 334.1193. 
Rf = 0.14 (20% EtOAc/hexane). 
 
 
tert-Butyl 3-(4-chlorophenyl)-3-hydroxypyrrolidine-1-carboxylate (375): Following the 
general procedure for oxidative coupling using tert-butyl 3-methoxy-3-methyl-4-oxa-1,2,7-
triazaspiro[4.4]non-1-ene-7-carboxylate (309) (0.271 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: 60% Et2O/hexane) provided the title compound as a colourless gum 
(82.2 mg, 0.276 mmol, 55%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.41 and 7.39 (two d from rotamers, J = 8.6 Hz, 2 H, H2), 
7.31 (two superimposed d from rotamers, J = 8.6 Hz, 2 H, H3), 3.72 – 3.45 (m, 4 H, H7 and 
H8), 2.90 and 2.88 (two br s from rotamers, 1 H, OH), 2.31 – 2.07 (m, 2 H, H6), 1.44 and 
1.43 (two s from rotamers, 9 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 154.9 and 154.7 (rotameric, C9), 141.7 and 141.6 
(rotameric, C4), 133.6 (C1), 128.7 (C3), 126.9 (C2), 80.2 and 79.4 (C5), 79.8 (C10), 59.7 and 
58.9 (C8), 45.2 and 44.7 (C7), 39.9 and 39.0 (C6), 28.6 (C11). 
FTIR (νmax, cm
-1
): 3405 (br w, OH), 2978 (w), 2892 (w), 1668 (s, C=O), 1493 (w), 1478 (w), 
1416 (s), 1367 (m), 1254 (w), 1170 (m), 1136 (s), 1094 (m), 1015 (w), 924 (w), 878 (w), 827 
(m), 757 (w). 
HRMS (ESI): calculated for C15H20NO3ClNa [M+Na]
+
 320.1024, found 320.1025. 
Rf = 0.27 (60% Et2O/hexane). 
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tert-Butyl 3-(4-chlorophenyl)-3-hydroxyazetidine-1-carboxylate (376): Following the 
general procedure for oxidative coupling using tert-butyl 7-methoxy-7-methyl-8-oxa-2,5,6-
triazaspiro[3.4]oct-5-ene-2-carboxylate (310) (0.257 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 30% 
EtOAc/hexane) provided the title compound as a white amorphous solid (60.3 mg, 0.213 
mmol, 43%), m.p. 128-131 °C (lit. m.p.
231
 139.0-140.6 °C). Data are consistent with a 
reported example.
231 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.7 Hz, 2 H, H2), 7.34 (d, J = 8.7 Hz, 2 H, H3), 
4.15 (s, 4 H, H6), 3.65 (br s, 1 H, OH), 1.44 (s, 9 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 156.6 (C7), 142.1 (C4), 133.7 (C1), 128.8 (C3), 126.2 (C2), 
80.3 (C8), 70.8 (C5), 65.5 – 63.5 (br, C6), 28.5 (C9). 
FTIR (νmax, cm
-1
): 3372 (br w, OH), 2978 (w), 2882 (w), 1675 (s, C=O), 1493 (m), 1478 (m), 
1416 (s), 1367 (s), 1250 (m), 1160 (s), 1119 (m), 1094 (m), 1013 (m), 936 (w), 860 (w), 826 
(w), 772 (w). 
HRMS (ESI): calculated for C14H18NO3ClNa [M+Na]
+
 306.0867, found 306.0855. 
Rf = 0.38 (30% EtOAc/hexane). 
 
 
1-(4-Chlorophenyl)cyclohexan-1-ol (377): Following the general procedure for oxidative 
coupling using 3-methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.5]dec-1-ene (311) (0.184 g, 
1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel 
column chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a white 
crystalline solid (82.2 mg, 0.390 mmol, 78%), m.p. 74-76 °C (lit. m.p.
232
 77 °C). Data are 
consistent with a reported example.
233 
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1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.7 Hz, 2 H, H2), 7.30 (d, J = 8.7 Hz, 2 H, H3), 
1.82 – 1.72 (m, 7 H, H6, H7a and H8a), 1.69 (br s, 1 H, OH), 1.67 – 1.60 (m, 2 H, H7b), 1.36 
– 1.21 (m, 1 H, H8b). 
13
C NMR (150 MHz, CDCl3): δ 148.1 (C4), 132.5 (C1), 128.4 (C3), 126.3 (C2), 73.0 (C5), 
38.9 (C6), 25.5 (C8), 22.2 (C7). 
FTIR (νmax, cm
-1
): 3380 (br m, OH), 2933 (s), 2857 (m), 1595 (w), 1494 (m), 1448 (m), 
1399 (w), 1257 (w), 1209 (w), 1174 (w), 1134 (w), 1095 (m), 1011 (m), 973 (m), 903 (w), 
849 (w), 821 (s).  
HRMS (ESI): calculated for C12H15OClNa [M+Na]
+
 233.0704, found 233.0700. 
Rf = 0.24 (10% EtOAc/hexane). 
 
 
1-(4-Chlorophenyl)cyclopentan-1-ol (378): Following the general procedure for oxidative 
coupling using 3-methoxy-3-methyl-4-oxa-1,2-diazaspiro[4.5]dec-1-ene (312) (0.184 g, 
1.0  mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel 
column chromatography (eluent: 10% EtOAc/hexane) provided the title compound as a 
colourless oil (63.5 mg, 0.323 mmol, 65%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.42 (d, J = 8.6 Hz, 2 H, H2), 7.30 (d, J = 8.6 Hz, 2 H, H3), 
2.03 – 1.92 (m, 6 H, H6 and H7a), 1.88 – 1.78 (m, 2 H, H7b), 1.68 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 145.7 (C4), 132.6 (C1), 128.4 (C3), 126.7 (C2), 83.2 (C5), 
42.1 (C6), 24.0 (C7). 
FTIR (νmax, cm
-1
): 3365 (br w, OH), 2964 (m), 2874 (w), 1597 (w), 1492 (m), 1450 (w), 
1399 (w), 1323 (w), 1295 (w), 1178 (w), 1093 (s), 1039 (w), 1012 (s), 1003 (s), 960 (w), 904 
(w), 882 (w), 824 (s). 
HRMS (ESI): calculated for C11H13OClNa [M+Na]
+
 219.0547, found 219.0554. 
Rf = 0.21 (10% EtOAc/hexane). 
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1-(4-Chlorophenyl)cyclobutan-1-ol (379): Following the general procedure for oxidative 
coupling using 7-methoxy-7-methyl-8-oxa-5,6-diazaspiro[3.4]oct-5-ene (313) (0.156 g, 
1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel 
column chromatography (eluent: 20% EtOAc/hexane) provided the title compound as a 
colourless oil (60.9 mg, 0.333 mmol, 67%). Data are consistent with a reported example.
234 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.6 Hz, 2 H, H2), 7.33 (d, J = 8.6 Hz, 2 H, H3), 
2.55 – 2.48 (m, 2 H, H6a), 2.39 – 2.32 (m, 2 H, H6b), 2.14 (br s, 1 H, OH), 2.06 – 1.98 (m, 
1 H, H7a), 1.73 – 1.64 (m, 1 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 144.9 (C4), 133.1 (C1), 128.6 (C3), 126.6 (C2), 76.7 (C5), 
37.1 (C6), 13.0 (C7). 
FTIR (νmax, cm
-1
): 3341 (br w, OH), 2988 (w), 2940 (w), 1599 (w), 1493 (m), 1423 (w), 
1399 (w), 1282 (w), 1244 (m), 1181 (w), 1133 (m), 1093 (s), 1067 (w), 1032 (w), 1012 (s), 
957 (w), 890 (w), 828 (s). 
HRMS (ESI): calculated for C10H11OClNa [M+Na]
+
 205.0391, found 205.0400. 
Rf = 0.29 (20% EtOAc/hexane). 
 
 
2-(4-Chlorophenyl)-1,2,3,4-tetrahydronaphthalen-2-ol (380): Following the general 
procedure for oxidative coupling using 5'-methoxy-5'-methyl-3,4-dihydro-1H,5'H-
spiro[naphthalene-2,2'-[1,3,4]oxadiazole] (314) (0.232 g, 1.0 mmol) and 4-
chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column 
chromatography (eluent: 30% Et2O/hexane) provided the title compound as a colourless gum 
(92.3 mg, 0.357 mmol, 71%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.46 (d, J = 8.6 Hz, 2 H, H2), 7.33 (d, J = 8.6 Hz, 2 H, H3), 
7.21 – 7.08 (m, 4 H, H9, H10, H11 and H12), 3.29 (d, J = 16.9 Hz, 1 H, H14a), 3.15 – 3.05 
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(m, 1 H, H7a), 3.01 (d, J = 16.9 Hz, 1 H, H14b), 2.79 (dt, J = 17.1, 5.3 Hz, 1 H, H7b), 2.27 – 
2.18 (m, 1 H, H6a), 2.11 – 2.04 (m, 1 H, H6b), 2.01 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 146.3 (C4), 135.3 (C8/C13), 134.2 (C8/C13), 133.0 (C1), 
129.5 (C9/C10/C11/C12), 129.0 (C9/C10/C11/C12), 128.5 (C3), 126.5 (C2), 126.4 
(C9/C10/C11/C12), 126.2 (C9/C10/C11/C12), 72.4 (C5), 43.8 (C14), 35.5 (C6), 26.4 (C7). 
FTIR (νmax, cm
-1
): 3367 (br w, OH), 3061 (w), 3019 (w), 2921 (w), 2845 (w), 1596 (w), 
1583 (w), 1494 (m), 1453 (w), 1433 (w), 1398 (w), 1346 (w), 1317 (w), 1298 (w), 1243 (w), 
1175 (w), 1092 (m), 1077 (m), 1037 (w), 1013 (m), 964 (m), 908 (m), 876 (w), 853 (w), 816 
(s), 762 (m). 
HRMS (ESI): calculated for C16H15OClNa [M+Na]
+
 281.0704, found 281.0713. 
Rf = 0.31 (30% Et2O/hexane). 
 
 
1-(4-Chlorophenyl)-1-cyclopropylethan-1-ol (382): Following the general procedure for 
oxidative coupling using 2-cyclopropyl-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole (316) (0.170 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: 10% EtOAc/hexane) 
provided the title compound as a colourless oil (82.8 mg, 0.421 mmol, 84%). Data are 
consistent with a reported example.
235 
 
1
H NMR (600 MHz, CDCl3): δ 7.46 (d, J = 8.6 Hz, 2 H, H2), 7.30 (d, J = 8.6 Hz, 2 H, H3), 
1.63 (br s, 1 H, OH), 1.46 (s, 3 H, H9), 1.22 (tt, J = 8.3, 5.6 Hz, 1 H, H6), 0.58 – 0.49 (m, 1 H, 
H7a), 0.49 – 0.35 (m, 3 H, H7b and H8). 
13
C NMR (150 MHz, CDCl3): δ 146.7 (C4), 132.6 (C1), 128.2 (C3), 126.8 (C2), 73.1 (C5), 
28.6 (C9), 23.0 (C6), 2.2 (C7/C8), 1.2 (C7/C8). 
FTIR (νmax, cm
-1
): 3419 (br w, OH), 3085 (w), 3009 (w), 2978 (w), 1597 (w), 1489 (m), 
1455 (w), 1400 (w), 1368 (w), 1227 (w), 1175 (w), 1091 (s), 1043 (m), 1012 (s), 952 (w), 
925 (m), 897 (m), 828 (s). 
HRMS (ESI): calculated for C11H13OClNa [M+Na]
+
 219.0547, found 219.0546. 
Rf = 0.23 (10% EtOAc/hexane). 
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2-(4-Chlorophenyl)hex-5-en-2-ol (383): Following the general procedure for oxidative 
coupling using 2-(but-3-en-1-yl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-oxadiazole (317) 
(0.184 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 0.5 mmol), purified by 
silica gel column chromatography (eluent: 10% EtOAc/hexane) provided the title compound 
as a colourless oil (97.5 mg, 0.463 mmol, 93%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.36 (d, J = 8.6 Hz, 2 H, H2), 7.30 (d, J = 8.6 Hz, 2 H, H3), 
5.84 – 5.72 (m, 1 H, H8), 5.00 – 4.94 (m, 1 H, H9trans), 4.93 (d, J = 10.3 Hz, 1 H, H9cis), 2.10 
– 1.97 (m, 1 H, H7a), 1.95 – 1.84 (m, 4 H, H6, H7b and OH), 1.54 (s, 3 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 146.3 (C4), 138.6 (C8), 132.5 (C1), 128.4 (C3), 126.5 (C2), 
114.9 (C9), 74.6 (C5), 43.1 (C6), 30.5 (C10), 28.6 (C7). 
FTIR (νmax, cm
-1
): 3406 (br w, OH), 2976 (w), 2930 (w), 1641 (w), 1598 (w), 1490 (m), 
1452 (w), 1397 (w), 1373 (w), 1304 (w), 1219 (w), 1093 (s), 1013 (s), 996 (w), 934 (w), 910 
(m), 881 (w), 829 (s). 
HRMS (ESI): calculated for C12H15OClNa [M+Na]
+
 233.0704, found 233.0699. 
Rf = 0.26 (10% EtOAc/hexane). 
 
 
2-(4-Chlorophenyl)-4,4-dimethylhept-6-yn-2-ol (384): Following the general procedure for 
oxidative coupling using 2-(2,2-dimethylpent-4-yn-1-yl)-5-methoxy-2,5-dimethyl-2,5-
dihydro-1,3,4-oxadiazole (318) (0.224 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) 
(78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
EtOAc/hexane) provided the title compound as a colourless oil (104.4 mg, 0.416 mmol, 83%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.40 (d, J = 8.7 Hz, 2 H, H2), 7.28 (d, J = 8.7 Hz, 2 H, H3), 
2.20 (dd, J = 16.5, 2.7 Hz, 1 H, H10a), 2.04 (t, J = 2.7 Hz, 1 H, H12), 1.99 (s, 2 H, H6), 1.943 
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(br s, 1 H, OH), 1.940 (dd, J = 16.5, 2.7 Hz, 1 H, H10b), 1.54 (s, 3 H, H13), 0.87 (s, 3 H, 
H8/H9), 0.76 (s, 3 H, H8/H9). 
13
C NMR (150 MHz, CDCl3): δ 146.8 (C4), 132.2 (C1), 128.2 (C3), 126.6 (C2), 83.3 (C11), 
75.2 (C5), 70.9 (C12), 52.6 (C6), 34.9 (C13), 34.5 (C7), 32.8 (C10), 29.4 (C8/C9), 28.7 
(C8/C9). 
FTIR (νmax, cm
-1
): 3429 (br w, OH), 3304 (w, alkyne CH), 2961 (w), 2927 (w), 1598 (w), 
1491 (m), 1471 (w), 1425 (w), 1398 (w), 1367 (w), 1265 (w), 1174 (w), 1093 (m), 1075 (m), 
1013 (s), 946 (w), 923 (w), 829 (s).  
HRMS (ESI): calculated for C15H19OClNa [M+Na]
+
 273.1017, found 273.1020. 
Rf = 0.28 (10% EtOAc/hexane). 
 
 
8-(4-Chlorophenyl)-1,4-dioxaspiro[4.5]decan-8-ol (385): Following the general procedure 
for oxidative coupling using 3-methoxy-3-methyl-4,9,12-trioxa-1,2-
diazadispiro[4.2.4
8
.2
5
]tetradec-1-ene (319) (0.242 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
EtOAc/CH2Cl2) provided the title compound as a white crystalline solid (111.1 mg, 
0.413 mmol, 83%), m.p. 158-160 °C (lit m.p.
236
 147-149 °C). Data are consistent with a 
reported example.
237 
 
1
H NMR (600 MHz, CDCl3): δ 7.45 (d, J = 8.6 Hz, 2 H, H2), 7.30 (d, J = 8.6 Hz, 2 H, H3), 
4.02 – 3.93 (m, 4 H, H9/H10), 2.17 – 2.04 (m, 4 H, H6a and H7a), 1.81 – 1.75 (m, 2 H, H6b), 
1.72 – 1.66 (m, 2 H, H7b), 1.64 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 147.2 (C4), 132.8 (C1), 128.5 (C3), 126.2 (C2), 108.4 (C8), 
72.4 (C5), 64.5 (C9/C10), 64.4 (C9/C10), 36.7 (C6), 30.8 (C7). 
FTIR (νmax, cm
-1
): 3459 (br w, OH), 2931 (m), 2884 (w), 1493 (m), 1435 (w), 1398 (w), 
1369 (w), 1251 (w), 1216 (w), 1181 (w), 1145 (w), 1096 (s), 1034 (m), 1013 (m), 987 (m), 
943 (m), 889 (w), 826 (m), 772 (w). 
HRMS (ESI): calculated for C14H17O3ClNa [M+Na]
+
 291.0758, found 291.0768. 
Rf = 0.23 (10% EtOAc/CH2Cl2). 
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Diethyl (2-(4-chlorophenyl)-2-hydroxypropyl)phosphonate (386): Following the general 
procedure for oxidative coupling using diethyl ((5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazol-2-yl)methyl)phosphonate (320) (0.280 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 35% 
EtOAc/60% hexane/5% MeOH) provided the title compound as a colourless oil (92.6 mg, 
0.302 mmol, 60%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.40 (d, J = 8.6 Hz, 2 H, H2), 7.29 (d, J = 8.6 Hz, 2 H, H3), 
5.03 (s, 1 H, OH), 4.13 – 3.96 (m, 2 H, H8/H10), 3.79 – 3.69 (m, 1 H, H8/H10), 3.55 – 3.46 
(m, 1 H, H8/H10), 2.40 (dd, J = 17.5, 15.5 Hz, 1 H, H6a), 2.29 (t, J = 16.5, 15.5 Hz, 1 H, 
H6b), 1.58 (d, J = 2.1 Hz, 3 H, H7), 1.30 (t, J = 7.1 Hz, 3 H, H9/H11), 1.02 (t, J = 7.1 Hz, 
3 H, H9/H11). 
13
C NMR (150 MHz, CDCl3): δ 145.9 (d, J = 7.3 Hz, C4), 132.7 (C1), 128.2 (C3), 126.5 
(C2), 71.8 (d, J = 4.9 Hz, C5), 61.9 (d, J = 6.4 Hz, C8/C10), 61.8 (d, J = 6.5 Hz, C8/C10), 
39.6 (d, J = 135.6 Hz, C6), 32.5 (d, J = 14.1 Hz, C7), 16.4 (d, J = 6.2 Hz, C9/C11), 16.2 (d, J 
= 6.1 Hz, C9/C11). 
31
P NMR (245 MHz, CDCl3): δ 28.5 (s, 1 P, C6-P). 
FTIR (νmax, cm
-1
): 3386 (br w, OH), 2981 (w), 2932 (w), 2908 (w), 1491 (w), 1443 (w), 
1394 (w), 1369 (w), 1218 (m), 1164 (w), 1093 (m), 1049 (s), 1025 (s), 964 (m), 912 (w), 833 
(m), 782 (w). 
HRMS (ESI): calculated for C13H20O4PClNa [M+Na]
+
 329.0680, found 329.0678. 
Rf = 0.36 (35% EtOAc/60% hexane/5% MeOH). 
 
 
4-(4-Chlorophenyl)-4-hydroxytetrahydro-2H-thiopyran 1,1-dioxide (387): Following the 
general procedure for oxidative coupling using 3-methoxy-3-methyl-4-oxa-8-thia-1,2-
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diazaspiro[4.5]dec-1-ene 8,8-dioxide (325) (0.234 g, 1.0 mmol) and 4-chlorophenylboronic 
acid (329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 20% 
→ 40% EtOAc/CH2Cl2) provided the title compound as a white crystalline solid (90.8 mg, 
0.348 mmol, 70%), m.p. 196-198 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.43 (d, J = 8.7 Hz, 2 H, H2), 7.37 (d, J = 8.7 Hz, 2 H, H3), 
3.58 (td, J = 13.8, 3.5 Hz, 2 H, H7a), 3.00 – 2.91 (m, 2 H, H7b), 2.68 (td, J = 14.5, 2.6 Hz, 
2 H, H6a), 2.18 – 2.10 (m, 2 H, H6b), 1.78 (br s, 1 H, OH). 
13
C NMR (150 MHz, CDCl3): δ 144.6 (C4), 134.2 (C1), 129.1 (C3), 125.8 (C2), 70.6 (C5), 
47.3 (C7), 37.1 (C6). 
FTIR (νmax, cm
-1
): 3404 (br m, OH), 1595 (w), 1485 (m), 1433 (w), 1393 (m), 1363 (w), 
1334 (m), 1284 (s), 1272 (s), 1243 (w), 1224 (w), 1193 (w), 1172 (m), 1119 (s), 1093 (m), 
1068 (s), 1023 (m), 1013 (m), 984 (w), 968 (m), 931 (s), 878 (w), 853 (w), 823 (s). 
HRMS (ESI): calculated for C11H13O3SClNa [M+Na]
+
 283.0166, found 283.0170. 
Rf = 0.34 (20% EtOAc/CH2Cl2). 
 
 
6-(4-Chlorophenyl)-2,2-dimethyl-1-oxaspiro[2.5]octan-6-ol (388): Following the general 
procedure for oxidative coupling using 9-methoxy-2,2,9-trimethyl-1,10-dioxa-7,8-
diazadispiro[2.2.4
6
.2
3
]dodec-7-ene (321) (0.240 g, 1.0 mmol) and 4-chlorophenylboronic acid 
(329) (78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 30% 
EtOAc/hexane) provided the title compound as separable diastereomers (1:1) as a white 
crystalline solids (A: 55.5 mg, 0.208 mmol; B: 60.3 mg, 0.226 mmol; combined yield 87%), 
m.p. 168-171 °C for diastereomer A and m.p. 156-159 °C for diastereomer B. 
 
Diastereomer A: 
1
H NMR (600 MHz, CDCl3): δ 7.45 (d, J = 8.6 Hz, 2 H, H2), 7.30 (d, J = 8.6 Hz, 2 H, H3), 
2.20 (td, J = 13.5, 3.6 Hz, 2 H, H7a), 2.12 (td, J = 13.5, 3.6 Hz, 2 H, H6a), 1.84 – 1.79 (m, 
2 H, H6b), 1.78 (br s, 1 H, OH), 1.55 – 1.49 (m, 2 H, H7b), 1.35 (s, 6 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 147.5 (C4), 132.8 (C1), 128.5 (C3), 126.2 (C2), 72.5 (C5), 
65.1 (C8), 63.3 (C9), 36.4 (C6), 25.8 (C7), 20.7 (C10). 
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FTIR (νmax, cm
-1
): 3390 (br m, OH), 2928 (m), 1735 (w), 1489 (w), 1432 (w), 1379 (m), 
1313 (w), 1245 (m), 1195 (m), 1133 (w), 1095 (s), 1036 (m), 1011 (m), 988 (m), 961 (m), 
903 (w), 889 (w), 849 (s), 833 (m), 817 (s), 756 (w). 
HRMS (ESI): calculated for C15H19O2ClNa [M+Na]
+
 289.0966, found 289.0960. 
Rf = 0.38 (30% EtOAc/hexane). 
 
Diastereomer B: 
1
H NMR (600 MHz, CDCl3): δ 7.44 (d, J = 8.6 Hz, 2 H, H2), 7.31 (d, J = 8.6 Hz, 2 H, H3), 
2.26 – 2.15 (m, 2 H, H7a), 1.98 – 1.88 (m, 5 H, H6 and OH), 1.62 – 1.56 (m, 2 H, H7b), 1.39 
(s, 6 H, H10). 
13
C NMR (150 MHz, CDCl3): δ 146.5 (C4), 133.0 (C1), 128.5 (C3), 126.4 (C2), 72.2 (C5), 
66.1 (C8), 62.5 (C9), 38.3 (C6), 26.9 (C7), 20.9 (C10). 
FTIR (νmax, cm
-1
): 3426 (br m, OH), 2938 (m), 1710 (w), 1491 (s), 1474 (m), 1377 (s), 1241 
(m), 1174 (w), 1118 (m), 1095 (s), 1064 (s), 1033 (m), 1013 (s), 993 (m), 961 (s), 900 (m), 
853 (m), 827 (s). 
HRMS (ESI): calculated for C15H19O2ClNa [M+Na]
+
 289.0966, found 289.0967. 
Rf = 0.21 (30% EtOAc/hexane). 
 
 
5-Bromo-2-(4-chlorophenyl)pentan-2-ol (389): Following the general procedure for 
oxidative coupling using 2-(3-bromopropyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole (326) (0.251 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: 20% EtOAc/hexane) 
provided the title compound as a yellow oil (99.0 mg, 0.357 mmol, 87%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.35 (d, J = 8.7 Hz, 2 H, H2), 7.30 (d, J = 8.7 Hz, 2 H, H3), 
3.39 – 3.29 (m, 2 H, H8), 1.97 – 1.82 (m, 3 H, H6 and H7a), 1.76 (br s, 1 H, OH), 1.72 – 1.63 
(m, 1 H, H7b), 1.56 (s, 3 H, H9). 
13
C NMR (150 MHz, CDCl3): δ 145.9 (C4), 132.7 (C1), 128.5 (C3), 126.4 (C2), 74.2 (C5), 
42.7 (C6), 34.3 (C8), 30.8 (C9), 27.6 (C7). 
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FTIR (νmax, cm
-1
): 3422 (br w, OH), 2967 (w), 1598 (w), 1490 (m), 1453 (w), 1397 (w), 
1373 (w), 1293 (w), 1254 (m), 1202 (w), 1163 (w), 1093 (s), 1013 (s), 956 (w), 889 (w), 831 
(s), 767 (w). 
HRMS (ESI): calculated for C11H14OBrClNa [M+Na]
+
 298.9809, found 298.9823. 
Rf = 0.34 (20% EtOAc/hexane). 
 
 
2-(4-Chlorophenyl)-1-(furan-2-yl)propan-2-ol (390): Following the general procedure for 
oxidative coupling using 2-(furan-2-ylmethyl)-5-methoxy-2,5-dimethyl-2,5-dihydro-1,3,4-
oxadiazole (322) (0.210 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) (78.2 mg, 
0.5 mmol), purified by silica gel column chromatography (eluent: 30% Et2O/CH2Cl2) 
provided the title compound as an orange gum (90.2 mg, 0.381 mmol, 76%). 
 
1
H NMR (600 MHz, CDCl3): δ 7.37 (d, J = 8.6 Hz, 2 H, H2), 7.31 (d, J = 1.9 Hz, 1 H, H10), 
7.29 (d, J = 8.6 Hz, 2 H, H3), 6.26 (dd, J = 3.0, 1.9 Hz, 1 H, H9), 5.97 (d, J = 3.0 Hz, 1 H, 
H8), 3.13 (d, J = 15.0 Hz, 1 H, H6a), 3.08 (d, J = 15.0 Hz, 1 H, H6b), 2.45 (br s, 1 H, OH), 
1.54 (s, 3 H, H11). 
13
C NMR (150 MHz, CDCl3): δ 151.6 (C7), 145.8 (C4), 142.0 (C10), 132.7 (C1), 128.3 (C3), 
126.4 (C2), 110.5 (C9), 108.6 (C8), 74.0 (C5), 42.7 (C6), 29.7 (C11). 
FTIR (νmax, cm
-1
): 3429 (br w, OH), 2974 (w), 2910 (w), 1596 (w), 1490 (m), 1455 (w), 
1400 (w), 1376 (w), 1266 (w), 1179 (m), 1147 (m), 1090 (s), 1012 (s), 951 (m), 935 (m), 885 
(w), 856 (m), 828 (s). 
HRMS (ESI): calculated for C13H13O2ClNa [M+Na]
+
 259.0496, found 259.0485. 
Rf = 0.21 (10% EtOAc/hexane). 
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4-(4-Chlorophenyl)-1-(pyrimidin-2-yl)piperidin-4-ol (391): Following the general 
procedure for oxidative coupling using 3-methoxy-3-methyl-8-(pyrimidin-2-yl)-4-oxa-1,2,8-
triazaspiro[4.5]dec-1-ene (323) (0.263 g, 1.0 mmol) and 4-chlorophenylboronic acid (329) 
(78.2 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 30% 
Et2O/CH2Cl2) provided the title compound as a colourless gum (83.3 mg, 0.287 mmol, 57%). 
 
1
H NMR (600 MHz, CDCl3): δ 8.30 (d, J = 4.8 Hz, 2 H, H9), 7.41 (d, J = 8.6 Hz, 2 H, H2), 
7.31 (d, J = 8.6 Hz, 2 H, H3), 6.47 (t, J = 4.8 Hz, 1 H, H10), 4.72 – 4.64 (m, 2 H, H7a), 3.39 
(td, J = 13.1, 2.6 Hz, 2 H, H7b), 2.07 (br s, 1 H, OH), 2.02 (td, J = 13.4, 4.8 Hz, 2 H, H6a), 
1.84 – 1.76 (m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 161.6 (C8), 157.9 (C9), 146.8 (C4), 133.1 (C1), 128.6 (C3), 
126.2 (C2), 109.7 (C10), 71.8 (C5), 40.0 (C7), 38.1 (C6). 
FTIR (νmax, cm
-1
): 3361 (br w, OH), 3027 (w), 2998 (w), 2950 (w), 2920 (w), 2868 (w), 
1584 (s), 1546 (s), 1493 (s), 1456 (s), 1392 (m), 1362 (s), 1306 (m), 1272 (m), 1254 (m), 
1238 (w), 1215 (m), 1177 (w), 1132 (w), 1091 (m), 1027 (m), 1012 (m), 980 (s), 923 (m), 
825 (s), 794 (s). 
HRMS (ESI): calculated for C15H17N3OCl [M+H]
+
 290.1055, found 290.1053. 
Rf = 0.22 (30% Et2O/CH2Cl2). 
 
 
4-(4-Bromophenyl)tetrahydro-2H-pyran-4-ol (392): Following the general procedure for 
oxidative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-diazaspiro[4.5]dec-1-ene (303) 
(0.186 g, 1.0 mmol) and 4-bromophenylboronic acid (100.4 mg, 0.5 mmol), purified by silica 
gel column chromatography (eluent: 40% EtOAc/hexane) provided the title compound as a 
white crystalline solid (91.0 mg, 0.354 mmol, 71%), m.p. 114-116 °C. Data are consistent 
with a reported example.
238 
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1
H NMR (600 MHz, CDCl3): δ 7.48 (d, J = 8.7 Hz, 2 H, H2), 7.34 (d, J = 8.7 Hz, 2 H, H3), 
3.88 (td, J = 11.9, 2.0 Hz, 2 H, H7a), 3.85 – 3.79 (m, 2 H, H7b), 2.13 (br s, 1 H, OH), 2.12 – 
2.04 (m, 2 H, H6a), 1.65 – 1.58 (m, 2 H, H6b). 
13
C NMR (150 MHz, CDCl3): δ 147.3 (C4), 131.6 (C2), 126.5 (C3), 121.2 (C1), 70.5 (C5), 
63.8 (C7), 38.7 (C6). 
FTIR (νmax, cm
-1
): 3399 (br m, OH), 2954 (m), 2869 (m), 1589 (w), 1492 (m), 1388 (m), 
1302 (w), 1237 (m), 1221 (w), 1126 (s), 1103 (s), 1073 (m), 1033 (s), 1009 (s), 965 (w), 915 
(w), 821 (s), 799 (w). 
HRMS (ESI): calculated for C11H13O2BrNa [M+Na]
+
 278.9991, found 278.9994. 
Rf = 0.22 (40% EtOAc/hexane). 
 
 
4-(4-(Trifluoromethyl)phenyl)tetrahydro-2H-pyran-4-ol (393): Following the general 
procedure for oxidative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and 4-(trifluoromethyl)phenylboronic 
acid (95.0 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 40% 
EtOAc/hexane) provided the title compound as a white crystalline solid (85.9 mg, 
0.349 mmol, 70%), m.p. 82-84 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.65 – 7.58 (m, 4 H, H3 and H4), 3.95 – 3.89 (m, 2 H, H8a), 
3.89 – 3.83 (m, 2 H, H8b), 2.21 – 2.10 (m, 2 H, H7a), 2.03 (br s, 1 H, OH), 1.69 – 1.60 (m, 
2 H, H7b). 
13
C NMR (150 MHz, CDCl3): δ 152.1 (q, J = 0.9 Hz, C5), 129.5 (q, J = 32.4 Hz, C2), 125.5 
(q, J = 3.7 Hz, C3), 125.1 (C4), 124.2 (q, J = 272.0 Hz, C1), 70.8 (C6), 63.8 (C8), 38.7 (C7). 
19
F NMR (376 MHz, CDCl3): δ -62.5 (s, 3 F, F1). 
FTIR (νmax, cm
-1
): 3402 (br w, OH), 2958 (w), 2873 (w), 1618 (w), 1469 (w), 1409 (w), 
1389 (w), 1324 (s), 1303 (m), 1239 (w), 1224 (w), 1164 (m), 1106 (s), 1071 (s), 1034 (m), 
1016 (m), 966 (w), 918 (w), 835 (s), 799 (w), 777 (w). 
HRMS (ESI): calculated for C12H13F3O2Na [M+Na]
+
 269.0760, found 269.0752. 
Rf = 0.28 (40% EtOAc/hexane). 
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Methyl 4-(4-hydroxytetrahydro-2H-pyran-4-yl)benzoate (394): Following the general 
procedure for oxidative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and 4-methoxycarbonylphenylboronic 
acid (90.0 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 50% 
EtOAc/hexane) provided the title compound as a white crystalline solid (36.4 mg, 
0.154 mmol, 31%), m.p. 97-98 °C. 
 
1
H NMR (600 MHz, CDCl3): δ 7.99 (d, J = 8.6 Hz, 2 H, H4), 7.54 (d, J = 8.6 Hz, 2 H, H5), 
3.94 – 3.89 (m, 2 H, H9a), 3.88 (s, 3 H, H1), 3.85 (dd, J = 11.3, 5.0 Hz, 2 H, H9b), 2.34 (br s, 
1 H, OH), 2.14 (td, J = 13.2, 5.0 Hz, 2 H, H8a), 1.64 (d, J = 13.2 Hz, 2 H, H8b). 
13
C NMR (150 MHz, CDCl3): δ 167.0 (C2), 153.3 (C6), 129.9 (C4), 128.9 (C3), 124.7 (C5), 
70.8 (C7), 63.8 (C9), 52.3 (C1), 38.6 (C8). 
FTIR (νmax, cm
-1
): 3420 (br w, OH), 2954 (w), 2870 (w), 1722 (s, C=O), 1610 (w), 1575 (w), 
1436 (m), 1407 (w), 1387 (w), 1281 (s), 1239 (w), 1224 (w), 1192 (w), 1104 (s), 1035 (w), 
1018 (m), 967 (w), 917 (w), 856 (w), 840 (m), 773 (m). 
HRMS (ESI): calculated for C13H16O4Na [M+Na]
+
 259.0941, found 259.0945. 
Rf = 0.30 (50% EtOAc/hexane). 
 
 
N-(3-(4-Hydroxytetrahydro-2H-pyran-4-yl)phenyl)acetamide (395): Following the 
general procedure for oxidative coupling using 3-methoxy-3-methyl-4,8-dioxa-1,2-
diazaspiro[4.5]dec-1-ene (303) (0.186 g, 1.0 mmol) and 3-acetamidophenylboronic acid 
(89.5 mg, 0.5 mmol), purified by silica gel column chromatography (eluent: 10% 
MeOH/CH2Cl2) provided the title compound as a white flaky solid (62.3 mg, 0.265 mmol, 
53%), m.p. 128-130 °C. 
 
5. Experimental (Appendix) 
328 
 
1
H NMR (600 MHz, MeOD-d4): δ 7.68 (t, J = 1.8 Hz, 1 H, H8), 7.45 (ddd, J = 7.9, 1.8, 
1.1 Hz, 1 H, H4), 7.29 (t, J = 7.8 Hz, 1 H, H5), 7.27 – 7.23 (m, 1 H, H6), 3.93 (td, J = 11.5, 
2.0 Hz, 2 H, H11a), 3.81 (dd, J = 11.5, 4.7 Hz, 2 H, H11b), 2.16 – 2.06 (m, 2 H, H10a), 2.12 
(s, 3 H, H1), 1.68 – 1.63 (m, 2 H, H10b). 
13
C NMR (150 MHz, MeOD-d4): δ 171.7 (C2), 150.9 (C7), 139.8 (C3), 129.7 (C5), 121.6 
(C6), 119.8 (C4), 117.9 (C8), 71.1 (C9), 65.0 (C11), 39.7 (C10), 23.8 (C1). 
FTIR (νmax, cm
-1
): 3388 (br m, OH), 3299 (m, NH), 2957 (m), 2872 (w), 1665 (s, C=O), 
1610 (s), 1592 (m), 1553 (s), 1489 (s), 1428 (s), 1372 (m), 1302 (s), 1263 (m), 1239 (m), 
1185 (w), 1125 (m), 1095 (s), 1041 (m), 1017 (m), 984 (w), 963 (w), 928 (w), 884 (w), 855 
(w), 833 (m), 791 (m). 
HRMS (ESI): calculated for C13H17NO3Na [M+Na]
+
 258.1101, found 258.1110. 
Rf = 0.33 (10% MeOH/CH2Cl2). 
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5.4.4. Synthetic procedure and characterisation for boroxine 396 
 
 
2,4,6-Tris(4-chlorophenyl)-1,3,5,2,4,6-trioxatriborinane (396): A suspension of 4-
chlorophenylboronic acid (329) (0.782 g, 5.0 mmol) in toluene was heated under reflux with 
equipped Dean-Stark apparatus for 2 h. The reaction mixture was then evaporated under 
reduced pressure to provide the title compound as a white crystalline solid (0.692 g, 5.0 mmol 
w.r.t. monomer, 99%), m.p. 286-288 °C (lit. m.p.
239
 284-286 °C). Data are consistent with a 
reported example.
239 
 
1
H NMR (600 MHz, CD2Cl2): δ 8.17 (d, J = 8.3 Hz, 2 H, H3), 7.52 (d, J = 8.3 Hz, 2 H, H2). 
1
H NMR (600 MHz, CDCl3): δ 8.14 (d, J = 8.3 Hz, 2 H, H3), 7.49 (d, J = 8.3 Hz, 2 H, H2). 
13
C NMR (150 MHz, CDCl3): δ 139.5 (C1), 137.1 (C3), 128.6 (C2). (C4 broadened by 
quadrupolar relaxation with boron). 
FTIR (νmax, cm
-1
): 1654 (w), 1593 (m), 1563 (w), 1451 (w), 1396 (s), 1363 (s), 1340 (s), 
1306 (s), 1256 (m), 1174 (m), 1102 (m), 1085 (s), 1014 (m), 969 (w), 953 (w), 822 (m), 776 
(m). 
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